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Abstract 
 
 
Background: Vitamin D has attracted considerable academic and clinical attention 
over the last two decades. However, the epidemiology of symptomatic vitamin D 
deficiency in UK children is poorly characterised, and the impact of the recent interest 
on paediatric clinical practice has not been explored. 
 
Methods: A systematic review of the global incidence of symptomatic vitamin D 
deficiency in children was undertaken. A prospective surveillance study was conducted 
across the UK and Ireland to determine the incidence of hypocalcaemic seizures 
secondary to vitamin D deficiency in children. Cohort studies were undertaken to 
examine temporal trends in the diagnosis of vitamin D deficiency among children in 
clinical practice in the UK, and investigate healthcare expenditure related to vitamin D 
testing and prescribing in primary care. 
 
Results: Four higher quality studies, from high-income countries with predominantly 
Caucasian populations, provided a pooled annual incidence estimate for symptomatic 
vitamin D deficiency of 3.4 per 100,000 children. The annual incidence of 
hypocalcaemic seizures secondary to vitamin D deficiency in the UK and Ireland was 
3.5 per million children aged 0-15 years, with male infants from South Asian and black 
ethnic backgrounds at greatest risk. There was a 15-fold increase in the diagnosis of 
vitamin D deficiency among children in UK clinical practice between 2008-2014. Older 
age (≥10 years), non-white ethnicity, and social deprivation were associated with 
higher rates of diagnosis. Healthcare expenditure on vitamin D tests and prescriptions 
for children in primary care increased 13-fold between 2008-2014, with national costs 
in England estimated at £4.3 million in 2014. 
 
Conclusion: Considered in the context of the existing literature, these studies suggest 
that vitamin D deficiency may be over-tested and over-diagnosed, yet under-prevented, 
among children in the UK. These findings have implications for public health policy, 
clinical practice and health service delivery, and inform areas for future research. 
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1.1 Introduction 
 
Vitamin D plays an important role in bone metabolism and calcium homeostasis, and 
its deficiency can cause various clinical complications in children including rickets and 
hypocalcaemia. Vitamin D has attracted considerable clinical and academic interest 
over the last two decades. In relation to child health, there are concerns that clinical 
complications of vitamin D deficiency have increased in frequency among children in 
high-income countries such as the UK, USA, and Australia (Ahmed et al, 2011; 
Allgrove, 2004; Holick, 2006; Robinson et al, 2006; Shaw & Pal, 2002). In the UK, this 
has generated criticism of national public health policy regarding the prevention of 
vitamin D deficiency (Davies & Shaw, 2011; Högler, 2015; Hyppönen & Boucher, 
2010), and prompted the Department of Health to commission a review of the Healthy 
Start vitamin programme (Lemer, 2013; NICE, 2015). However, these concerns have 
largely been based upon anecdotal reports and local case series, and quantitative 
evaluation of the epidemiology of symptomatic vitamin D deficiency has been limited.  
 
There has also been considerable debate and controversy regarding the possibility that 
vitamin D may have clinically relevant physiological activity beyond its established role 
in calcium and bone metabolism, and that vitamin D deficiency may increase the risk of 
various non-musculoskeletal diseases (SACN, 2016; Theodoratou et al, 2014). As 
vitamin D has attracted increasing attention, large increases in vitamin D testing and 
prescribing have been reported in adult practice over the last decade, with significant 
associated healthcare costs (Bilinski & Boyages, 2012; 2013; HSCIC, 2005; 2015b). 
However, the influence of the increased interest in vitamin D on paediatric clinical 
practice has not been explored.  
 
 
 
1.2 Aims and Objectives 
 
The overall aims of this research were to investigate the epidemiology of symptomatic 
vitamin D deficiency in children, explore temporal trends in the diagnosis of vitamin D 
deficiency in clinical practice, and examine healthcare expenditure related to vitamin D 
testing and prescribing in children. 
 
 
  
Chapter 1. Introduction 
 29 
The main research objectives were: 
 
1. To systematically review the published literature on the incidence of 
symptomatic vitamin D deficiency in children worldwide. 
 
2. To estimate the incidence of hypocalcaemic seizures secondary to vitamin D 
deficiency in children in the UK and Ireland, both overall and stratified for 
demographic characteristics. 
 
3. To describe the clinical characteristics, biochemical profile, clinical 
management, and clinical outcomes in children who develop hypocalcaemic 
seizures secondary to vitamin D deficiency. 
 
4. To determine rates of diagnosis of vitamin D deficiency among children in UK 
clinical practice between 2000 and 2014, and examine differences in 
diagnosis by socio-demographic characteristics. 
 
5. To examine the recording of symptoms, in primary care health records, among 
children diagnosed with vitamin D deficiency. 
 
6. To estimate healthcare costs arising from vitamin D testing and prescribing in 
primary care for children in the UK. 
 
 
 
1.3 Outline of the Thesis 
 
The subsequent chapters contained in this thesis are summarised below: 
 
Chapter 2: This background chapter summarises current understanding regarding the 
influence of vitamin D on children’s health, from a UK perspective. 
 
Chapter 3: This chapter describes a systematic literature review undertaken to explore 
the incidence of symptomatic vitamin D deficiency in children worldwide, and 
investigate differences in incidence by demographic factors. 
 
Chapter 4: This chapter describes a prospective surveillance study undertaken across 
the UK and Ireland, using the British Paediatric Surveillance Unit reporting system, 
investigating the incidence of hypocalcaemic seizures secondary to vitamin D 
deficiency in children. 
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Chapter 5: This chapter describes a cohort study, using electronic healthcare records 
from UK primary care held in The Health Improvement Network (THIN) database, 
which examines longitudinal trends in the diagnosis of vitamin D deficiency in children, 
and explores differences in diagnosis by socio-demographic factors. 
 
Chapter 6: This chapter describes a cohort study, using the THIN primary care 
database, which examines longitudinal trends in healthcare expenditure arising from 
vitamin D testing and prescribing in children in primary care. 
 
Chapter 7: In the discussion chapter, the main findings from the work described in 
chapters 3 to 6 are summarised, the implications of these research findings for clinical 
practice and public health policy are discussed, and recommendations for future 
research are made. 
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Chapter 2 
 
 
Background: Vitamin D in Relation to Child 
Health in the UK   
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2.1 Introduction 
 
This chapter summarises the state of current understanding regarding vitamin D 
biology and the influence of vitamin D on children’s health, from a UK perspective. 
 
 
 
2.2 Vitamin D Biology 
 
The term vitamin D refers to a group of secosteroid compounds (organic compounds 
that are structurally related to steroids with a cleavage in one of the four carbon atom 
rings) that are precursors of the active hormone 1,25-dihydroxyvitamin D, which plays 
an important role in bone metabolism and calcium homeostasis (Allgrove, 2015). 
Vitamin D exists in two main forms: vitamin D3 (colecalciferol) and vitamin D2 
(ergocalciferol). They are collectively referred to as vitamin D or calciferol. 
 
The main natural source of vitamin D is endogenous production in the skin, upon 
exposure to sunlight. Ultraviolet B radiation in the wavelength range of 280 to 315 nm 
penetrates the skin and converts 7-dehydrocholesterol to a precursor of vitamin D3 
(Allgrove, 2015; SACN, 2016). Few food sources naturally contain significant amounts 
of vitamin D. Vitamin D3 is found in oily fish, fish oils and egg yolk, whilst vitamin D2 
can be obtained in small quantities from wild mushrooms (Misra et al, 2008; SACN, 
2016). Certain food products are artificially fortified with vitamin D. In the United 
Kingdom (UK), infant formula milk and some margarines, cereals, and yoghurts are 
fortified. In the USA and Canada cow’s milk is also fortified. 
 
Both vitamin D3 and vitamin D2 follow a two-step metabolic pathway to generate the 
biologically active hormone 1,25-dihydroxyvitamin D, as summarised in Figure 2.1 
(Allgrove, 2015; Basatemur et al, 2015; SACN, 2016). The first step involves 
hydroxylation in the liver to form 25-hydroxyvitamin D (25-OH-D). This is the major 
circulating form of vitamin D, and is the best available measure of an individual’s 
vitamin D status (SACN, 2016). The second hydroxylation step is catalysed by the 
enzyme 1α-hydroxylase, to form 1,25-dihydroxyvitamin D. This is the main regulatory 
step in the vitamin D metabolic pathway. The principal site of 1α-hydroxylase activity is 
the kidney, however the enzyme is active in numerous other tissues where it is 
believed to have a paracrine role. The activity of 1α-hydroxylase is stimulated by 
parathyroid hormone (PTH), and inhibited by 1,25-dihydroxyvitamin D creating a 
negative feedback loop. 
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1,25-dihydroxyvitamin D acts via the vitamin D receptor, a member of the superfamily 
of nuclear receptors, to modify gene transcription. The main function of 1,25-
dihydroxyvitamin D is to regulate calcium and phosphate metabolism and homeostasis, 
which in turn is essential for ensuring normal neuronal and muscular function and 
adequate bone mineralisation. The classical actions of 1,25-dihydroxyvitamin D are to 
Skin 
7-dehydrocholesterol 
Sunlight 
Vitamin D3 
Vitamin D3 and 
vitamin D2 
Vitamin D3 and 
vitamin D2 
Small intestine Liver 
25-hydroxyvitamin D 
Parathyroid 
hormone 
+ 
24,25-dihydroxyvitamin D 
(inactive metabolite) 
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Decreased 
renal excretion 
of calcium 
Bone resorption 
to maintain 
serum calcium 
Increased intestinal 
absorption of calcium 
and phosphate 
+ 
Low serum 
calcium  
+ 
Dietary intake 
1,25-dihydroxyvitamin D 
Figure 2.1  Overview of vitamin D metabolism.a 
a Figure adapted from Crawford et al (2006). 
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increase intestinal absorption of calcium and phosphate, decrease renal excretion of 
calcium, and stimulate osteoclast mediated calcium resorption from the skeleton and 
promote bone remodelling. 
 
 
 
2.3 Clinical Consequences of Vitamin D Deficiency in Children 
 
 
2.3.1 Pathophysiology 
 
In the early stages of vitamin D deficiency, impaired intestinal absorption of calcium 
causes hypocalcaemia (low serum calcium levels), which may or may not be 
symptomatic (Allgrove & Shaw, 2015; Shaw & Mughal, 2013a). The hypocalcaemia in 
turn stimulates parathyroid hormone (PTH) secretion, which acts to: i) reduce renal 
calcium excretion, ii) increase renal phosphate excretion, iii) stimulate renal 1α-
hydroxylase activity resulting in increased 1,25-dihydroxyvitamin D production, and iv) 
stimulate calcium release from the bone by promoting osteoclast activity (Allgrove, 
2015). This secondary hyperparathyroidism acts to normalise serum calcium levels, 
however the combination of hypophosphataemia (low serum phosphate levels) and 
increased osteoclast activity results in demineralisation of the bone. In growing children 
this results in rickets, a childhood metabolic bone disease caused by under-
mineralisation of the growing bone before the epiphyses (growth plates) have closed. 
After the growth plates have fused, in older children and adults, the term osteomalacia 
is used to describe the demineralisation of bone at sites of bone remodelling. 
 
In the later stages of vitamin D deficiency, 25-OH-D levels fall to the extent that there is 
insufficient substrate for 1,25-dihydroxyvitamin D synthesis. The PTH response is then 
no longer able to maintain normal serum calcium levels, and hypocalcaemia occurs. 
Hypocalcaemia lowers the threshold for nerve and muscle cell depolarisation, causing 
neuromuscular irritability. Vitamin D deficiency is also thought to adversely affect 
skeletal muscle function, although it is not clear whether this effect is a direct result of 
1,25-dihydroxyvitamin D action on myocytes, or is an indirect effect of 
hypophosphataemia and hypocalcaemia (Reid, 2016). 
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2.3.2 Clinical Presentation 
 
In children, vitamin D deficiency can present clinically with symptoms or signs related 
to the skeletal effects of rickets and osteomalacia, with symptoms arising from muscle 
weakness, or with sequelae of hypocalcaemia, as summarised in Table 2.1 (Dimitri & 
Bishop, 2007; Shaw & Mughal, 2013a). The classical long-bone deformities of rickets 
are typically seen in infants and toddlers once they are mobilising and weight bearing. 
Adolescents often present with vague symptoms of musculoskeletal aches and pains 
and muscle weakness. Hypocalcaemic symptoms tend to present either in young 
children in the first two years of life, or in adolescents. 
 
Table 2.1  Clinical features with which vitamin D deficiency can present in children. 
Clinical features Additional notes 
Skeletal features  
• Long bone deformities  Bowing deformities affect weight-bearing limbs, with forearm 
deformities occurring in crawling infants, and bow legs 
(genu varum) or knock knees (genu valgum) seen in 
walking children. 
• Swelling of the joints and 
costochondral junctions 
Caused by deposition of excessive cartilage, typically 
involving the wrist and ankle joints. Swelling of the 
costochondral junctions results in a ‘string of beads’ 
appearance on the anterior rib cage (termed rickety rosary). 
• Cranial signs Include frontal bossing of the skull, delayed fontanelle 
closure, and craniotabes (softening of the skull bones which 
are depressible upon pressure, seen in infants). 
• Kyphoscoliosis Pathological curvature of the spine. 
• Poor growth  
• Musculoskeletal pain Thought to be the cause of irritability seen in infants with 
rickets. Causes non-specific limb pains in older children. 
• Pathological fractures The under-mineralised bone may predispose to fractures. 
• Dental features Delayed tooth eruption and enamel hypoplasia (which 
increases the risk of dental caries). 
Muscle weakness  
• Proximal myopathy May present with difficulty in climbing stairs, or gait 
disturbance. 
• Delayed motor milestones For example, delay in walking. 
Hypocalcaemia  
• Seizures  
• Tetany Generalised involuntary muscle contractions, or localised to 
the hands and feet (carpopedal spasm). 
• Cardiac complications Include prolongation of the QT interval, arrhythmias, and 
cardiomyopathy that presents with cardiac failure and can 
be fatal. 
• Stridor Due to laryngospasm. 
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There are various causes of rickets, vitamin D deficiency being the most common 
aetiology in regions of the world where the majority of countries have high-income 
economies (Europe, North America, Australasia). In low- and middle-income countries, 
particularly in Africa and Asia, dietary calcium deficiency is a common cause of rickets 
(Creo et al, 2017; Mughal, 2011; Prentice, 2013). Inadequate calcium intake has also 
been reported to be a contributing factor in cases of rickets reported from high-income 
countries such as the USA (DeLucia et al, 2003). Rickets can also be caused by rare 
genetic defects affecting the vitamin D metabolic pathway or phosphate metabolism 
(Dimitri & Bishop, 2007; Mughal, 2011). 
 
The biochemical profile seen in children with vitamin D deficiency rickets includes a low 
25-OH-D level, raised PTH, and raised alkaline phosphatase (ALP). Serum phosphate 
levels are normal or elevated in early stages of vitamin D deficiency, but subsequently 
become low when the secondary hyperparathyroid response is established (Allgrove & 
Shaw, 2015). Calcium levels can be low or normal depending on the stage of vitamin D 
deficiency (see section 2.3.1). The classical radiological signs of rickets are cupping, 
fraying, and widening of the metaphysis at the ends of the long bones. Other 
radiological features that may be seen include generalised osteopenia, and a 
periosteal reaction along the diaphysis (shaft) of the bone. 
 
 
2.3.3 Treatment 
 
Symptomatic vitamin D deficiency is treated with either colecalciferol or ergocalciferol, 
which are most commonly given as a once daily oral dose over a treatment course of 
between 1 to 3 months. Doses of between 1,000 to 10,000 International Units (IU) per 
day are used depending on the age of the child, and various different dosing guidelines 
exist internationally (Misra et al, 2008; Munns et al, 2016; RCPCH, 2013). As an 
alternative strategy to daily dosing, vitamin D deficiency can be treated with a large 
dose of calciferol given as a single dose, or in divided doses over a short period of 
time. This is known as stoss therapy (from the German for “push”), and typically 
involves the administration of doses between 100,000 to 600,000 IU, either orally or by 
intramuscular injection (Misra et al, 2008; Munns et al, 2016). This approach can be 
particularly useful in situations of poor compliance with medication, however concerns 
exist regarding a risk of adverse effects, with case reports of markedly elevated 25-OH-
D levels, hypercalcaemia, hypercalciuria, and nephrocalcinosis following large 
treatment doses in children (Vogiatzi et al, 2014).  
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Activated analogues of vitamin D, such as alfacalcidol (1α-hydroxycolecalciferol) and 
calcitriol (1,25-dihydroxyvitamin D), are not routinely recommended in the treatment of 
primary vitamin D deficiency (Allgrove & Shaw, 2015; Elder & Bishop, 2014). They are 
ineffective at replenishing vitamin D stores, and require closer monitoring as their use 
carries a risk of hypercalcaemia. However, they may be used in the acute phase when 
there is clinically significant hypocalcaemia secondary to vitamin D deficiency, until 
calcium levels have normalised (Arundel & Shaw, 2015; Munns et al, 2006). They are 
also indicated in situations where there is impaired vitamin D metabolism, such as 
renal impairment, liver disease, or genetic defects affecting the vitamin D or phosphate 
metabolic pathways, and in hypoparathyroidism (Allgrove & Shaw, 2015). 
 
Children who are hypocalcaemic at presentation require calcium replacement in 
addition to vitamin D, and this may also be considered in children with normal serum 
calcium but a low dietary calcium intake (Shaw & Mughal, 2013a). Most children make 
a full recovery following appropriate treatment, however residual skeletal deformities 
may remain in some cases. 
 
Evidence is limited regarding the management of asymptomatic children with an 
incidental finding of biochemical vitamin D deficiency (defined as a 25-OH-D level <25 
nmol/l in the UK, see section 2.4 below). Some sources recommend a course of 
treatment dose vitamin D as described above for symptomatic deficiency (Arundel & 
Shaw, 2015; Misra et al, 2008), whilst others advise low-dose maintenance 
supplements (400 to 800 IU per day) and lifestyle advice regarding safe sun exposure 
(Shaw & Mughal, 2013b). 
 
 
2.3.4 Bone Mass Accrual 
 
Peak bone mass is attained in early adulthood, with 90% of adult bone mineral content 
achieved by the end of adolescence, and the greatest increase in bone mass occurring 
between 12 to 17 years of age (Lewis & Laing, 2015; Winzenberg & Jones, 2013). 
Peak bone mass is considered to be an important determinant of the risk of 
osteoporotic fractures in later life (Shaw & Mughal, 2013a). It has been suggested that 
vitamin D deficiency may impair bone mass accrual during childhood, and adversely 
affect peak bone mass. However, evidence from randomised controlled trials is 
inconsistent (Lewis & Laing, 2015). A systematic review of placebo-controlled 
randomised controlled trials found no overall effect of vitamin D supplementation on 
bone mineral content in children (Winzenberg et al, 2011). However, in planned 
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subgroup analysis limited to individuals with low baseline 25-OH-D levels (defined as 
<35 nmol/l), vitamin D supplementation was associated with higher total body bone 
mineral content. The authors suggested that it is unlikely that vitamin D 
supplementation is beneficial in increasing bone density in vitamin D replete children, 
however in those with suboptimal vitamin D status supplementation may have clinically 
useful benefits for skeletal health. 
 
 
 
2.4 Definition of Vitamin D Deficiency 
 
Vitamin D status is defined on the basis of serum 25-hydroxyvitamin D (25-OH-D) 
levels, as this is the major circulating form of vitamin D and reflects both endogenous 
synthesis and dietary intake. However, the extent to which 25-OH-D levels reflect how 
well the physiological requirements of the body for vitamin D are being met is unclear, 
and 25-OH-D levels do not correlate well with health outcomes such as rickets (SACN, 
2016). As a result of this uncertainty, the choice of 25-OH-D thresholds considered to 
represent deficiency and sufficiency are controversial and vary internationally across 
different guidelines and reports. 
 
In the UK, the British Paediatric and Adolescent Bone Group, the Royal College of 
Paediatrics and Child Health (RCPCH), and the National Osteoporosis Society all 
recommend the following thresholds for the interpretation of serum 25-OH-D levels in 
children (Arundel et al, 2012; Arundel & Shaw, 2015; RCPCH, 2013): 
 
 25-OH-D <25 nmol/l: Deficiency 
 25-OH-D 25-50 nmol/l: Insufficiency / may be inadequate in some people 
 25-OH-D >50 nmol/l: Sufficiency 
 
The UK Scientific Advisory Committee on Nutrition (SACN) considers the 25-OH-D 
threshold of 25 nmol/l as the level below which the risk of poor musculoskeletal health 
is increased (SACN, 2016). This threshold for vitamin D deficiency is based on the 
observation that 25-OH-D levels are <25 nmol/l in the majority of reported cases of 
symptomatic vitamin D deficiency in children (e.g. rickets or hypocalcaemia). However, 
several case series have reported symptomatic vitamin D deficiency in children with 
higher 25-OH-D levels between 25 to 50 nmol/l (Ahmed et al, 2011; Sharma et al, 
2009; Wheeler et al, 2015). Furthermore, the 25-OH-D cut-off of <25 nmol/l is not a 
clinical threshold diagnostic of disease, as the majority of children with 25-OH-D levels 
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<25 nmol/l are asymptomatic and do not exhibit any clinical or biochemical features of 
rickets. The British Paediatric and Adolescent Bone Group acknowledges that the 
evidence base underpinning the choice of 25-OH-D thresholds in children and 
adolescents is limited (Arundel et al, 2012). Internationally, definitions of vitamin D 
deficiency vary across different guidelines, as summarised in Table 2.2. The 
interpretation of serum 25-OH-D levels is further complicated by the variability in results 
obtained using different laboratory assay methods (Lai et al, 2010; SACN, 2016).  
 
 
Table 2.2  Definitions of vitamin D status used in international guidelines. 
Guidelines 25-OH-D Thresholds 
- US Institute of Medicine (IOM, 2011) 
- International paediatric consensus 
recommendations (Munns et al, 2016) 
- French Society of Paediatrics  
(Vidailhet et al, 2012) 
<30 nmol/l:  severe deficiency 
30-50 nmol/l:  moderate deficiency 
>50 nmol/l:  sufficiency 
- European Society for Pediatric 
Gastroenterology, Hepatology, and Nutrition 
(Braegger et al, 2013) 
<25 nmol/l:  severe deficiency 
>50 nmol/l:  sufficiency 
- American Academy of Pediatrics  
(Wagner & Greer, 2008) 
<50 nmol/l:  deficiency 
>50 nmol/l:  sufficiency 
- Australia and New Zealand paediatric 
consensus recommendations  
(Munns et al, 2006) 
<12.5 nmol/l:  severe deficiency 
12.5-25 nmol/l:  moderate deficiency 
25-50 nmol/l:  mild deficiency 
>50 nmol/l:  sufficiency 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D 
 
 
 
2.5 Determinants of Vitamin D Status 
 
The main natural source of vitamin D is endogenous production in the skin upon 
exposure to sunlight, as there are few natural food sources. Exposure to sunlight is 
therefore an important determinant of 25-OH-D status. At latitudes above 
approximately 40° from the equator, ultraviolet B radiation of the appropriate 
wavelength required to facilitate cutaneous vitamin D synthesis is only present at 
limited times during the middle of the day, during certain months of the year (Prentice, 
2008). In the UK (which is at a latitude of 50–60° North), exposure to ultraviolet 
radiation effective for vitamin D synthesis is minimal during the winter months, and 
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seasonal differences in population 25-OH-D levels have been observed (SACN, 2016). 
Lifestyle factors and disabilities can limit outdoor activity, and restrict sunlight exposure. 
Excessive sunscreen use can also impair cutaneous vitamin D synthesis. 
 
Ethnicity is an important determinant of vitamin D status (Mithal et al, 2009). The skin 
pigment melanin absorbs ultraviolet radiation. Therefore, individuals with darker 
coloured skin (brown or black) produce less vitamin D that people with lighter skin 
tones, when exposed to a constant dose of ultraviolet B radiation (Prentice, 2008; 
SACN, 2016). Cultural or religious clothing practices involving covering of most of the 
skin surface area limit sunlight exposure.  Examples include traditional clothing worn by 
girls and women from some Muslim communities, such as the hijab (covering the body 
and head) and niqab (also covering the face). Furthermore, in certain cultures, for 
example some South and East Asian communities, people avoid sunlight exposure 
because fair skin is considered to be associated with beauty (Chen et al, 2017). 
 
Although there are few natural dietary sources of vitamin D, the regular consumption of 
food products artificially fortified with vitamin D, fish liver oils, or vitamin D supplements 
can have a substantial influence on vitamin D status. Setting recommendations for 
dietary reference values for vitamin D is complicated by the ability of humans to 
synthesise vitamin D endogenously through exposure to sunlight. However, the UK 
Scientific Advisory Committee on Nutrition has set a reference nutrient intake (RNI) for 
vitamin D of 400 IU (10 micrograms) per day for all people in the general population 
aged 4 years and above (SACN, 2016). The RNI was derived by estimating the 
average intake that is required for the majority (97.5%) of the population to maintain 
serum 25-OH-D levels ≥25 nmol/l. There was insufficient data available to derive an 
RNI for children under 4 years of age, however SACN recommended a ‘safe intake’ of 
between 340 to 400 IU (8.5 to 10 micrograms) per day for infants under 1 year of age, 
and 400 IU per day for children aged from 1 year up to 4 years. It was not possible for 
SACN to quantify and take account of sunlight exposure when setting the dietary 
reference values, because of the wide range of factors that affect endogenous vitamin 
D synthesis. Hence, the RNI was calculated under the assumption of minimal exposure 
to ultraviolet B radiation through sunlight (as is the case in winter months in the UK). 
The dietary reference values refer to intake from all dietary sources: natural food 
sources, fortified foods (including infant formula milk), and supplements. Based on data 
from the National Diet and Nutrition Survey conducted between 2008 to 2012, mean 
dietary intakes of vitamin D (including from supplements) among children in the UK 
were between only 24% to 27% of the RNI / ‘safe intake’ values recommended by 
SACN (Bates et al, 2014). 
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Various medical conditions can interfere with vitamin D absorption or metabolism. In 
renal disease, reduced activity of 1α-hydroxylase can impair the conversion of 25-OH-
D to its active metabolite 1,25-dihydroxyvitamin D. In liver disease, the hydroxylation of 
calciferol to 25-OH-D may be impaired, and conditions associated with cholestasis 
(impaired bile flow from the liver into the intestine) can interfere with the gastrointestinal 
absorption of vitamin D. Other conditions associated with gastrointestinal 
malabsorption can also predispose to vitamin D deficiency, for example cystic fibrosis, 
coeliac disease, and inflammatory bowel disease. Obesity is associated with lower 25-
OH-D levels, and it has been suggested that excessive adipose tissue may act as a 
sink for vitamin D, reducing its bioavailability (Prentice, 2008). Polymorphisms in genes 
involved in the vitamin D metabolic pathway are also likely to influence 25-OH-D status 
(Dastani et al, 2013). 
 
The vitamin D status of newborns is directly dependent upon the vitamin D status of 
their mothers during pregnancy. 25-OH-D readily crosses the placenta, and 25-OH-D 
levels in umbilical cord blood (which represents vitamin D status in the newborn) have 
been shown to be between 80% to 100% of maternal 25-OH-D levels (Thandrayen & 
Pettifor, 2012). 
 
 
 
2.6 Historical Context in the UK 
 
Prior to 1900 rickets was widespread throughout urban parts of the UK, due to 
atmospheric pollution from coal fires, overcrowded housing conditions, and poor diets 
related to poverty (Hardy, 2003). In the late 19th and early 20th centuries the beneficial 
effects of sunlight exposure and cod liver oil ingestion on the prevention and treatment 
of rickets were identified (Elder & Bishop, 2014). The incidence of rickets declined 
dramatically from the 1920’s onwards due to improved living conditions, a reduction in 
atmospheric pollution, distribution of cod liver oil to pregnant women and young 
children, and the practice of outdoor ‘airing’ of infants (Bivins, 2007). 
During the Second World War, mandatory fortification of certain food products with 
vitamin D was introduced, including dried milk, infant cereals, and margarine. However, 
reports of cases of infantile hypercalcaemia in the 1950’s, attributed to excessive 
fortification of baby milks and food with vitamin D, resulted in food fortification policy 
being reversed (Bivins, 2007; Stewart et al, 1964). From the 1960’s reports were 
published of rickets returning among South Asian immigrant communities (Bivins, 
2007; Ford et al, 1972; Ford et al, 1976), and local public health campaigns were 
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developed to prevent rickets through the distribution of vitamin D supplements to high-
risk groups (Dunnigan et al, 1981). In the 1990’s the teratogenicity of excessive vitamin 
A intake was recognized, and cod-liver oil was no longer recommended or provided to 
pregnant women, without provision being made for alternative vitamin D 
supplementation in pregnancy (Hyppönen & Boucher, 2010). 
 
 
 
2.7 Contemporary Epidemiology of Childhood Vitamin D 
Deficiency in the UK 
 
When considering the epidemiology of vitamin D deficiency, biochemical deficiency 
(defined on the basis of serum 25-OH-D levels) needs to be distinguished from 
symptomatic complications of vitamin D deficiency. The majority of children with low 
25-OH-D levels are asymptomatic and do not exhibit any clinical or biochemical 
features of rickets or hypocalcaemia. 
 
 
2.7.1 Biochemical Vitamin D Status 
 
A number of cross-sectional studies have investigated biochemical vitamin D status, 
determined using serum 25-OH-D levels, in healthy children in the UK (Table 2.3). 
Using the 25-OH-D thresholds recommended by the British Paediatric and Adolescent 
Bone Group and the RCPCH (see section 2.4), it is clear that a substantial proportion 
of the paediatric population have vitamin D levels that are considered to be suboptimal. 
The prevalence of vitamin D deficiency (25-OH-D <25 nmol/l) reported by the studies 
varied widely between 1.6% to 34%, depending on the ethnicity and age of 
participants, and the prevalence of vitamin D insufficiency (25-OH-D 25-50 nmol/l) 
varied between 29% to 85%. 
 
25-OH-D levels exhibit a strong seasonal variation in UK children, with higher levels 
seen in summer and autumn months compared to winter and spring (Absoud et al, 
2011; Farrar et al, 2016; Tolppanen et al, 2012). Vitamin D levels are considerably 
lower in children from non-white compared to white ethnic backgrounds (Absoud et al, 
2011; Tolppanen et al, 2012). 
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Table 2.3  Studies investigating biochemical vitamin D status in UK children. 
Study Study date 
Sample 
size 
Participant 
characteristics 
% of children with 25-OH-
D below specified levels 
Bates et al 
(2014) 
2008 to 
2012 
802 Age: 1.5 to 18 years  
 
Ethnicity not 
reported 
25-OH-D <25 nmol/l: 
- age 1.5 to 3 years: 7.5% 
- age 4 to 10 years: 14% 
- age 11 to 18 years: 22% 
Das et al 
(2006) 
2003 51 Age: 14 to 16 years 
 
Ethnicity: 
- 27% white 
- 73% non-white 
 
All female 
25-OH-D <12.5 nmol/l: 17% 
 
25-OH-D <30 nmol/l: 73% 
Tolppanen et al 
(2012) 
1998 to 
2005 
7,560 Age: 7 to 13 years 
 
Ethnicity: 
- 95% white 
- 5% non-white 
25-OH-D <25 nmol/l: 1.6% 
 
25-OH-D <50 nmol/l: 29% 
Absoud et al 
(2011) 
1997 to 
1998 
1,102 Age: 4 to 18 years 
 
Ethnicity: 
- 91% white 
- 9% non-white 
25-OH-D <50 nmol/l: 
- white: 30% 
- non-white: 85% 
 
Lawson & 
Thomas (1999) 
1996 618 Age: 1.5 to 2.5 years 
 
Ethnicity: 
- 45% Indian 
- 32% Pakistani 
- 22% Bangladeshi 
25-OH-D <25 nmol/l: 
- Indian: 25% 
- Pakistani: 34% 
- Bangladeshi: 20% 
 
25-OH-D <50 nmol/l: 
- Indian: 70% 
- Pakistani: 81% 
- Bangladeshi: 69% 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D 
 
 
2.7.2 Symptomatic Vitamin D Deficiency 
 
Over the last two decades, anecdotal observations have raised concerns that the 
number of children presenting to healthcare services in the UK with symptomatic 
vitamin D deficiency has been increasing (Allgrove, 2004; Davies & Shaw, 2011; Shaw 
& Pal, 2002). However, there is limited data available regarding the epidemiology of 
symptomatic vitamin D deficiency among children in the UK. Most of the existing 
studies have been retrospective single- or multi-centre case series, without 
denominator data available for the calculation of incidence (Table 2.4). 
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Table 2.4  Studies investigating symptomatic vitamin D deficiency in UK children. 
Study Study  design 
Time 
period Setting Summary of main results 
El-Fakhri et al 
(2013) 
Prospective 
surveillance 
study 
Sept 2009 
to August 
2011 
Scotland 109 children age 0-16 years with 
symptomatic VDD reported by 
paediatricians. 38% presented 
with bowed legs, 25% with bone 
pain. 
Ahmed et al 
(2011) 
Retrospective 
case series 
2002 to 
2008 
Royal Hospital 
for Sick 
Children, 
Glasgow 
160 children aged 0-14 years 
identified with symptomatic VDD. 
40% presented with bowed legs, 
12% with seizures. 
Sharma et al 
(2009) 
Retrospective 
case series 
Jan 2006 
to June 
2008 
4 London 
hospitals 
74 infants (age <1 year) 
identified with symptomatic VDD. 
27% presented with 
hypocalcaemic seizures. 
Maiya et al 
(2008) 
Retrospective 
case series 
2000 to 
2006 
4 paediatric 
cardiology 
centres in 
South East 
England 
16 infants identified with 
hypocalcaemia and dilated 
cardiomyopathy secondary to 
VDD. 3 died. 
Callaghan et al 
(2006) 
Prospective 
surveillance 
study 
May 2000 
to April 
2001 
West Midlands 24 children aged 0-4 years with 
symptomatic VDD reported by 
paediatricians. 46% presented 
with bowed legs, 25% with 
seizures, 17% with gross motor 
delay. Overall annual incidence 
of 7.5 per 100,000 children. 
Ladhani et al 
(2004) 
Retrospective 
case series 
1996 to 
2001 
4 London 
hospitals 
65 children aged 0-16 years 
identified with symptomatic VDD. 
55% presented with 
musculoskeletal signs, 45% with 
symptoms of hypocalcaemia. 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; VDD, vitamin D deficiency. 
 
 
 
The only study to report a reliable incidence estimate is a regional prospective 
surveillance study conducted in the West Midlands, which involved active case 
reporting by paediatricians (Callaghan et al, 2006). 24 cases of symptomatic vitamin D 
deficiency were identified between May 2000 and April 2001 in children aged 0 to 4 
years, equating to an annual incidence of 7.5 per 100,000 children (confidence interval 
not reported). However, regional differences in ethnic demography limit the 
generalisability of the findings, as the West Midlands has a higher South Asian 
population than the national average: 12.3% compared to 6.7% nationally in England 
and Wales, among children aged 0 to 4 years in the 2001 Census (ONS, 2001). 
National data is lacking regarding the health burden caused by symptomatic vitamin D 
deficiency among children in the UK. 
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In all of the studies reporting symptomatic vitamin D deficiency among UK children 
(Table 2.4), the vast majority of cases (>90%) were from either South Asian, African-
Caribbean, or Middle Eastern ethnic minority backgrounds. 
 
 
 
2.8 UK Public Health Policy Regarding the Prevention of Vitamin D 
Deficiency 
 
UK public health policy regarding the prevention of vitamin D deficiency is based upon 
the recommendation of vitamin D supplementation for high-risk population groups, 
including young children and pregnant women. Department of Health (DoH) guidance 
regarding vitamin D supplementation changed recently, following the publication of 
updated recommendations for vitamin D intake issued by the Scientific Advisory 
Committee on Nutrition (SACN, 2016). The population groups for whom vitamin D 
supplementation is recommended, in previous and current DoH guidance, are 
summarised in Table 2.5 (DoH, 2009; 2016). Following the updated SACN guidance, 
vitamin D supplements are now recommended from birth rather than 6 months for 
breastfed infants. 
 
However, evidence suggests that the implementation of these recommendations has 
not been effective. In most regions of the country supplements for children and 
pregnant women are only provided free of charge to low-income families who qualify 
for the Healthy Start scheme. Healthy Start is a UK-wide, means tested, statutory 
scheme which provides food vouchers (that can be used to obtain milk, fruit and 
vegetables, and infant formula milk) and coupons for multivitamin supplements to 
pregnant women and mothers who are in receipt of income-related state benefits or 
child tax credits (with an annual family income of £16,190 or less) (McGee & Shaw, 
2013). Pregnant women under the age of 18 are also eligible for the scheme, 
regardless of whether or not they receive benefits (Filby et al, 2015). The Healthy Start 
vitamin tablets for pregnant and lactating women contain vitamin D (400 IU), vitamin C, 
and folic acid. The Healthy Start vitamin drops for children contain vitamin D (300 IU in 
the recommended daily dose of 5 drops), vitamin A, and vitamin C. In a limited number 
of areas, local programmes have been introduced with universal provision of Healthy 
Start vitamins for all pregnant women and children (Moy et al, 2012). 
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Table 2.5  Population groups for whom vitamin D supplementation is recommended, in 
previous and current DoH guidance. 
DoH guidance between 2007 and 2016 Current DoH guidance 
• Children aged from 6 months to 5 years 
who drink less than 500ml of formula milk 
per day. Supplements were 
recommended from 1 month of age for 
breastfed infants if there was doubt about 
the mother’s use of vitamin supplements 
during pregnancy or breastfeeding. 
Recommended supplement of 280 to 340 
IU per day. 
• Infants from birth to 1 year of age, unless 
they are taking ≥500ml of formula milk per 
day. Recommended supplement of 340 to 
400 IU per day. 
• Children aged between 1 to 4 years. 
Recommended supplement of 400 IU per 
day. 
• Pregnant and breastfeeding women. 
Recommended supplement of 400 IU per 
day. 
• Pregnant and breastfeeding women. 
Recommended supplement of 400 IU per 
day. 
• People aged ≥65 years. Recommended 
supplement of 400 IU per day. 
• All people aged 5 years or older advised to 
consider taking a supplement of 400 IU 
per day during the autumn and winter. 
People from minority ethnic groups with 
dark skin advised to consider taking a 
supplement of 400 IU per day throughout 
the year. 
• People with limited sunlight exposure. 
Recommended supplement of 400 IU per 
day. 
• People with limited sunlight exposure. 
Recommended supplement of 400 IU per 
day. 
Abbreviations: DoH, Department of Health; IU, International Units 
References: DoH (2009; 2016) 
 
 
 
Uptake rates for Healthy Start vitamins among eligible families have been reported to 
be very low (<10%) across the country (Jessiman et al, 2013; Moonan et al, 2012). The 
overall use of vitamin supplements, whether Healthy Start or other brands, by young 
children in the general population is also low. In the national Infant Feeding Survey 
conducted between 2010 to 2011, 9% of breastfed infants were receiving vitamin drops 
at the age of six weeks, and 11% at four to six months of age (McAndrew et al, 2012). 
14% of all children aged eight to ten months were receiving vitamin drops. In the 
National Diet and Nutrition Survey conducted between 2008 to 2012, the proportion of 
children reported to have used multivitamin supplements or cod liver oil at any point in 
the preceding year was 16% at age 1.5 to 3 years, 22% at age 4 to 10 years, and 18% 
at age 11 to 18 years (Bates et al, 2014). 
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Knowledge regarding the DoH recommendations for vitamin D supplementation among 
various groups of health professionals involved in the care of pregnant women and 
young children, as well as among parents, has been shown to be limited (Cleghorn, 
2006; Jain et al, 2011; Sharma et al, 2011; Zipitis et al, 2011). Reasons that have been 
suggested for the poor uptake of Healthy Start vitamins include poor accessibility with 
limited distribution points for the vitamins, a lack of awareness among eligible families, 
and poor promotion of the scheme by healthcare professionals (Jessiman et al, 2013). 
 
An alternative approach to supplementation for improving the vitamin D status of the 
population is the fortification of food products. Fortification of infant formula milk with 
vitamin D is mandatory across Europe and North America (SACN, 2016). In Canada, 
the fortification of milk and margarine with vitamin D is mandatory, whilst in the US 
almost all milk and most cereals are fortified on a voluntary basis. In the UK, most 
margarines and fat spreads, and some cereals, but not milk, are fortified on a voluntary 
basis. Although food fortification has been shown to be effective in increasing dietary 
vitamin D intake and population vitamin D levels in randomised controlled trials (Black 
et al, 2012), historical reports of toxicity arising from over-fortification highlight the need 
for careful regulation and monitoring of such approaches (Blank et al, 1995). 
 
 
 
2.9 Recent Academic and Clinical Interest in Vitamin D 
 
 
2.9.1 Proposed Extra-Skeletal Roles of Vitamin D 
 
Over the last two decades, there has been extensive research and interest regarding 
the possibility that vitamin D may have clinically relevant physiological activity beyond 
its established role in calcium and bone metabolism, and that vitamin D deficiency may 
have a role in the development of numerous extra-skeletal diseases. This has also 
generated considerable interest and coverage in the general media (Sattar et al, 2012). 
 
The vitamin D receptor is expressed in many tissue and cell types, beyond those that 
mediate the classical actions of 1,25-dihydroxyvitamin D in calcium and bone 
metabolism (the kidney, intestine, and bone) (Rosen et al, 2012). In vitro studies have 
demonstrated that 1,25-dihydroxyvitamin D can influence cell differentiation and cell 
proliferation, and modulate immune responses under experimental conditions (Rosen 
et al, 2012). Numerous observational studies, the majority of which involve adult 
populations, have suggested associations between lower 25-OH-D levels and 
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increased risk of a wide range of medical conditions including various cancers, 
cardiovascular disease, asthma and other atopic disorders, autoimmune conditions 
such as multiple sclerosis and diabetes mellitus, and infectious diseases such as 
Tuberculosis and acute respiratory tract infections (SACN, 2016; Theodoratou et al, 
2014). However, for many of the health outcomes investigated, studies are conflicting 
and associations are inconsistent. Systematic reviews of randomised controlled trials 
(RCTs), largely involving elderly participants, have suggested that vitamin D 
supplementation may reduce overall mortality risk (Bjelakovic et al, 2014; Chowdhury 
et al, 2014). A recent meta-analysis of individual participant data from RCTs suggested 
a small protective effect of vitamin D supplementation against the risk of developing 
acute respiratory tract infections (Martineau et al, 2017). However, for most of the 
conditions reported to be associated with 25-OH-D levels in observational studies, 
adequately powered RCTs investigating the effect of vitamin D supplementation on 
disease prevention or treatment are either lacking or provide null results (SACN, 2016; 
Theodoratou et al, 2014). 
 
Fewer RCTs have been conducted investigating the effect of vitamin D on non-skeletal 
outcomes in children. High-dose colecalciferol given every 3 months did not reduce the 
risk of lower respiratory tract infections or diarrhoeal illness in infants recruited to a 
large placebo-controlled RCT in Afghanistan (Aluisio et al, 2013; Manaseki-Holland et 
al, 2012). A weekly dose of 1,400 IU of colecalciferol did not reduce hospital 
admissions, clinic attendance, or mortality during the first 6 months of life among low-
birthweight (<2.5 kg) infants recruited to a large placebo-controlled RCT in India 
(Kumar et al, 2011). A systematic review identified few trials investigating the effect of 
vitamin D supplementation on asthma control in children, with inconclusive results 
(Fares et al, 2015). 
 
There are various possible explanations why the associations seen in observational 
studies may be misleading (Harvey & Cooper, 2012; Reid, 2016). Observed 
associations may be due to reverse causation; illness may cause reduced physical 
activity and exposure to sunlight, and it has also been proposed that systemic 
inflammation may itself reduce 25-OH-D levels (Reid et al, 2011; Waldron et al, 2013). 
Associations may be confounded by factors such as body mass index, and publication 
bias may distort the balance of the literature in favour of positive findings. The UK 
Scientific Advisory Committee on Nutrition and the US Institute of Medicine have 
concluded that, at present, convincing evidence does not exist for a beneficial effect of 
vitamin D on non-musculoskeletal health outcomes (IOM, 2011; SACN, 2016). 
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2.9.2 Vitamin D Testing and Treatment in Clinical Practice 
 
In addition to the growth in academic research and media interest in vitamin D, there is 
also evidence that vitamin D has attracted increasing attention in clinical practice over 
the last decade. In England, overall NHS expenditure on vitamin D prescriptions 
dispensed by community pharmacies has more than tripled from £28 million in 2004 to 
£92 million in 2014 (HSCIC, 2005; 2015b). Individual hospital biochemistry 
departments in the UK have reported large increases in requests for vitamin D tests; a 
10-fold increase was seen at the Homerton Hospital in East London between 2006 to 
2010 (Kotta et al, 2015), and a 2-fold increase at the Glasgow Royal Infirmary between 
2008 to 2010 (Sattar et al, 2012). In Australia, national rates of 25-OH-D testing 
increased over 50-fold from 59 tests per 100,000 people in 2001 to 3,648 tests per 
100,000 people in 2011, whilst in the Ontario province of Canada there was a 25-fold 
increase in testing between 2004 to 2010, with large associated increases in 
healthcare expenditure (Bilinski & Boyages, 2012; 2013). Although large increases in 
vitamin D testing and treatment have been reported in adult practice, trends in the 
diagnosis of vitamin D deficiency have not been specifically investigated in children, 
either in the UK or internationally. 
 
  
  50 
  51 
Chapter 3 
 
 
The Global Incidence of Symptomatic Vitamin D 
Deficiency in Children: A Systematic Review 
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3.1 Introduction 
 
Over the last two decades, reports have raised concerns that clinical complications of 
vitamin D deficiency, such as rickets and hypocalcaemia, have increased in frequency 
among children in developed countries (Allgrove, 2004; Davies & Shaw, 2011; Holick, 
2006; Robinson et al, 2006; Shaw & Pal, 2002). However, the majority of studies 
investigating symptomatic vitamin D deficiency in children are limited to single and 
multi-centre case series, which are not derived from defined populations, and therefore 
lack the denominator data required to calculate incidence or prevalence estimates. 
Systematic reviews have been undertaken to investigate biochemical vitamin D status, 
assessed using serum 25-hydroxyvitamin D (25-OH-D) levels, in populations worldwide 
(Hilger et al, 2014; Saraf et al, 2016). However, the epidemiology of symptomatic 
vitamin D deficiency in children has not been systematically reviewed. This chapter 
describes a systematic literature review and meta-analysis undertaken to explore the 
incidence of symptomatic vitamin D deficiency in children worldwide, and investigate 
differences in incidence by demographic factors. 
 
 
 
3.2 Aims and Objectives 
 
 
3.2.1 Review Aims 
 
The overall aim was to systematically review studies which report the contemporary 
incidence of symptomatic vitamin D deficiency among children worldwide. 
 
 
3.2.2 Review Objectives 
  
i) To investigate the incidence of symptomatic vitamin D deficiency in children 
worldwide, between 1990 to 2016. 
 
ii) To investigate differences in the incidence of symptomatic vitamin D 
deficiency in children by ethnicity, age, and sex. 
 
iii) To investigate temporal trends in the incidence of symptomatic vitamin D 
deficiency in children, between 1990 to 2016. 
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3.3 Methods 
 
 
3.3.1 Research Question 
 
The primary research question for the systematic review, which was used as the basis 
upon which to develop the search strategy, was: What is the contemporary incidence 
of symptomatic vitamin D deficiency in children worldwide? Symptomatic vitamin D 
deficiency was defined as one or more of the recognised clinical complications or 
symptoms that can be caused by vitamin D deficiency in children, including rickets and 
hypocalcaemia (see chapter 2.3.2). 
 
 
3.3.2 Measures of Disease Frequency 
 
The most commonly used measures of disease frequency fall into two broad 
categories: prevalence and incidence (Hennekens & Buring, 1987). Prevalence 
quantifies the proportion of people within a population who have a certain disease 
(existing cases) at a given point, or during a specified period, in time. In contrast, 
measures of incidence describe how often new cases of a disease occur within a 
population during a given period of time. 
 
There are two main types of incidence measures: incidence risk and incidence rate. 
Incidence risk quantifies the proportion of individuals at risk of developing a disease 
who develop the disease during a certain time period. The denominator in the 
calculation is the number of people at risk of developing the disease at the start of the 
time period (the total population at risk): 
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Incidence risk is also referred to in the literature as cumulative incidence or incidence 
proportion. In the calculation of incidence risk an assumption is made that the entire 
population at risk is followed-up, and remains at risk, throughout the whole of the study 
time period. In contrast, incidence rate quantifies the frequency of occurrence of new 
cases of a disease in a population in relation to the total person-time at risk during the 
study time period, allowing for varying time-periods of follow-up between individuals: 
 
Chapter 3. Systematic Review 
 54 
!"#$%&"#&	(36&	 = 		,-./&(	01	"&2	#3)&)	01	3	%$)&3)&	%-($"4	3	4$5&"	6$.&	7&($0%;0639	7&()0"– 6$.&	36	($)*	%-($"4	6ℎ&	7&($0% 	
 
As the research objective for this review was concerned with exploring the frequency of 
occurrence of symptomatic vitamin D deficiency in populations of children worldwide, it 
was limited to studies reporting estimates of incidence. Studies reporting prevalence 
were not included, as prevalence is influenced not only by the risk of developing a 
condition but also by factors which determine the duration of illness, such as access to 
healthcare. 
 
 
3.3.3 Study Inclusion and Exclusion Criteria 
 
Studies were considered eligible for inclusion if they met all of the following inclusion 
criteria: 
 
i) The study reported symptomatic vitamin D deficiency as an outcome (defined 
as one or more of the recognised clinical complications or symptoms that can 
be caused by vitamin D deficiency in children, including rickets and 
hypocalcaemia). 
 
ii) An estimate for incidence rate or incidence risk (also known as cumulative 
incidence or incidence proportion) was given, or sufficient information was 
provided from which to calculate an incidence estimate. 
 
iii) The data was drawn from a general population of children, or a sample of the 
general population, in a defined geographical area. 
 
iv) The study reported original research. 
 
 
Studies were excluded if they met any of the following exclusion criteria: 
 
i) The outcome reported was biochemical vitamin D deficiency identified through 
the screening of asymptomatic individuals, or the distribution of vitamin D 
levels in a population, as opposed to symptomatic vitamin D deficiency. 
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ii) The data was not drawn from a general population of children, for example 
where the study population was limited to children with a co-morbidity (for 
example renal disease) or to children receiving healthcare services (for 
example patients in intensive care units, or attending outpatient clinics). 
 
iii) The study did not include children (age <18 years), or if the study population 
included both adults and children the data provided did not allow incidence 
estimates to be calculated separately for children. 
 
iv) The study reported data covering a time period prior to 1990. The intention 
was to investigate contemporary data, considered to be informative regarding 
the current epidemiology of symptomatic vitamin D deficiency in children. 
 
v) Duplicate reports of the same data. Where multiple publications presented 
identical or overlapping data, the most comprehensive and informative version 
of the study was included and the other related papers were excluded. 
 
vi) The study full-text was not obtainable through the University College London 
libraries, the British Library, the M25 Consortium of Academic Libraries 
(http://www.m25lib.ac.uk), online, or following e-mail request sent to the 
corresponding author. 
 
There was no specific restriction by study type or design, other than that the study 
methodology had to allow the derivation of an incidence estimate. In the case of 
interventional studies, only incidence estimates from a control or no-intervention study 
arm were included. There was no restriction by geographical location or language. 
 
 
3.3.4 Search Strategy 
 
The following bibliographic databases were searched to identify relevant published 
literature: MEDLINE, EMBASE, PsycINFO, CINAHL, Web of Science, and Global 
Health. An initial search was carried out on 30th October 2014, and included studies 
published from 1st January 1990 onwards. An updated search was carried out on 2nd 
April 2017, and included studies published between 1st January 2014 and 31st 
December 2016. The reference lists of studies that met the inclusion criteria, and of 
relevant review articles (identified by the search or already known to the author), were 
also hand-searched to identify additional relevant work. A summary of the search terms 
used as the basis for the search strategy across databases was as follows: 
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 Concept 1:  ‘vitamin d deficiency’, rickets, osteomalacia,  
 ‘hypovitaminosis D’, OR ‘avitaminosis D’ 
 
AND 
 
 Concept 2:  incidence, prevalence, OR epidemiolog* 1 
 
AND 
 
 Concept 3: child*, infant*, infancy, neonat*, newborn*, baby, babies, toddler*, 
adolescen*, teenage*, ‘young person*’, ‘young people*’, youth, 
paediatric*, pediatric*, kid*, OR juvenile* 
 
The search term for prevalence was included so that papers reporting a prevalence 
estimate could be reviewed, to ensure that the epidemiological terminology was 
correctly used and that the study did not in fact contain an estimate of incidence. The 
detailed search terms used for each of the bibliographic databases are described in 
appendix C. Search strategies were designed such that searches of database subject 
headings as well as free-text searches were included for each search term of interest. 
 
 
3.3.5 Study Selection and Data Extraction 
 
The search results from each of the databases were imported into the EndNote X7 
software package (Clarivate Analytics), and duplicate records were identified and 
removed. The titles and abstracts of all remaining references were screened, and any 
articles that were clearly not relevant to the study question or did not meet the study 
inclusion criteria were excluded at this stage. For articles written in a language other 
than English, Google Translate (https://translate.google.co.uk) was used to translate 
the text to English. The full text was obtained for all articles that were deemed to be 
potentially relevant at the title and abstract review stage, and the full text was analysed 
to determine study eligibility based on the pre-determined criteria (see section 3.3.3). 
For each study deemed eligible for inclusion, a standardised data collection form was 
used to extract information regarding study characteristics, methodology, participant 
characteristics, relevant outcomes, and indicators of the quality of study reporting and 
design (see Tables 3.1 & 3.3). 
 
                                               
1 The symbol * represents truncation of a search term, to identify all words starting with a 
particular combination of letters. For example, the search term epidemiolog* will find references 
containing the words epidemiology and epidemiological. 
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3.3.6 Critical Appraisal of Included Studies 
 
Studies included in the systematic review were critically appraised to assess their 
methodological quality, the quality of study reporting, and the risk of bias influencing 
the incidence estimates. Whilst a number of guidelines for the critical evaluation of 
prevalence studies have been published (Boyle, 1998; Hoy et al, 2012; Loney et al, 
1998), no quality-assessment tools have been developed specifically for studies 
reporting disease incidence. Therefore, the criteria used to assess study quality and 
risk of bias were developed ad hoc specifically for this study. 
 
A list of quality indicators for study reporting and methodology, considered to be 
relevant for the assessment of studies investigating the incidence of symptomatic 
vitamin D deficiency, was compiled (Table 3.1). This list was developed with reference 
to existing guidelines for the reporting of observational epidemiological studies 
(Vandenbroucke et al, 2007), published guidelines for the appraisal of prevalence 
studies (Boyle, 1998; Hoy et al, 2012; Loney et al, 1998), and previously published 
systematic reviews of disease incidence (Ferris et al, 2017; Tibazarwa et al, 2008). As 
there are no validated diagnostic criteria available for clinical complications of vitamin D 
deficiency, such as rickets, the use of accepted diagnostic criteria could not be 
included as a study quality indicator.  
 
The risk of bias in study results (i.e. the internal validity of included studies) was 
assessed by considering three sources of systematic error that were considered to be 
of particular relevance to studies of disease incidence; the risk of case 
misclassification, the risk of case under-ascertainment, and inaccuracy in the 
estimation of the population at risk (denominator). The risk of systematic error arising 
from each of these sources was graded as low, moderate, or high, using criteria 
developed specifically for this study described in Table 3.2. The external validity of 
included studies was also assessed by considering the generalisability of the study 
results to the national population (see Table 3.2). 
 
A subgroup of studies considered to be of higher overall methodological quality 
included those in which: i) the risk of case misclassification was moderate or low, ii) the 
risk of case-under-ascertainment was moderate or low, iii) the reliability of the 
population at risk estimate was moderate or high, and iv) the generalisability to the 
national population was moderate or high. 
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Table 3.1  Quality indicators for study reporting and methodology. 
Quality indicator Additional notes 
• Is the study population clearly defined?  
• Does the study population represent 
either an entire population survey, or a 
random sample taken from the general 
population?  
Not true if the study population represents a 
convenience based sample of the general 
population (e.g. individuals registered with a 
particular healthcare provider). 
• Are the study inclusion and exclusion 
criteria clearly specified? 
 
• Is the study time period clearly 
specified? 
 
• Is the case definition clearly specified?  
• Does the case definition include an 
assessment of vitamin D status? 
Considered important to reduce the risk of case 
misclassification, as clinical complications such 
as rickets can have causes other than vitamin D 
deficiency (e.g. dietary calcium deficiency). 
• Did case ascertainment or validation 
involve clinical assessment or review 
of medical notes? 
Not true for studies where case status was 
defined entirely on the basis of diagnostic codes 
in healthcare / administrative databases. 
• Response rate Only applicable for studies involving primary 
data collection (as opposed to secondary 
analysis of existing datasets). 
• Were multiple sources used for case 
ascertainment? 
In the case of surveillance studies, was there 
more than one source of case reporting? In the 
case of database studies, was more than one 
database used to identify cases? 
• Is there a method for excluding cases 
originating from outside of the study 
population? 
E.g. temporary residents or travellers from 
outside the population used as the denominator 
in the calculation of incidence. 
• Is there a method for excluding pre-
existing (prevalent) cases? 
Is it explicitly stated that only new cases / cases 
diagnosed within the study period were 
included? 
• Is there a method for avoidance of 
duplicate counting / reporting of 
cases? 
In surveillance studies, were patient identifiers 
collected to distinguish duplicate reports? In 
studies ascertaining cases from multiple 
databases, were they linked or did the authors 
have access to patient identifiers? 
• Are 95% confidence intervals for the 
incidence estimate reported, or can 
they be derived? 
Confidence intervals could be derived if the 
number of incident cases, size of the 
denominator population, and study duration 
were reported.  
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Table 3.2  Assessment domains for risk of bias and external validity of included studies. 
Domain Grading criteria 
1. Risk of case 
misclassification 
Considered HIGH risk if any of the following: 
- No case definition provided (unless the clinical presentation of 
cases is reported and is consistent with symptomatic vitamin D 
deficiency in ≥80%, when the risk is considered moderate). 
- Case status not verified by review of medical notes or clinical 
assessment (based entirely upon diagnostic codes in healthcare / 
administrative databases). 
 
Considered MODERATE risk if any of the following: 
- 25-OH-D status not included in case definition, or not reported as 
being low among the majority of included cases (<50 nmol/l in 
≥80% of cases). 
- Children with predisposing chronic diseases (e.g. renal or liver 
disease, GI malabsorption) not excluded. Risks inclusion of cases 
where vitamin D deficiency is not the primary aetiology. 
- Case definition not clear. 
2. Risk of case 
under-
ascertainment 
Considered HIGH risk if any of the following: 
- Only includes children admitted to hospital (inpatients). 
- Cases ascertained by retrospective clinician survey (as opposed to 
prospective surveillance). 
- Response rate <70% (if applicable). 
- Method of case ascertainment not described. 
 
Considered MODERATE risk if any of the following: 
- Only includes children presenting to secondary care (inpatient and 
outpatient), not primary care. 
- Single source of case reporting for surveillance studies. 
- Response rate ≥70%, but <80% (if applicable). 
- Only includes cases with confirmed radiographic evidence of rickets 
(children diagnosed without radiographic evaluation will be missed). 
3. Reliability of the 
population at risk 
estimate 
Considered to be HIGH if derived from reliable population estimates for 
a defined geographical area (e.g. census statistics), or if the study 
involved a research cohort of known size. The denominator estimate 
should also match in time with the period of case identification. 
 
Considered to be LOW or MODERATE if the estimate is derived from 
data sources other than reliable population estimates, or if the time 
period for the population estimate does not match the period of case 
identification. Decision between grading of LOW or MODERATE based 
upon a subjective assessment of the risk of significant inaccuracy in the 
estimate of the population at risk. 
4. Generalisability to 
the national 
population 
Considered HIGH for national studies that cover the entire target 
population within the country. 
 
Considered MODERATE for regional studies that include the entire 
target population within a large / high-level administrative area (e.g. a 
state in the USA, or a county in the UK). 
 
Considered LOW if the study population is not representative of the 
general population of children within a geographical region (e.g. it is 
limited to a single ethnic group, or to individuals registered with a 
particular healthcare provider), or for local studies that are limited to a 
relatively small geographical area (e.g. a single city, or a low-level 
administrative region). 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; GI, gastrointestinal. 
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3.3.7 Data Synthesis and Analysis 
 
Some of the included studies reported incidence estimates over a time period other 
than 1 year, in which case an annual incidence estimate was derived by dividing the 
reported incidence estimate by the duration of the study period in years. Incidence 
estimates were re-calculated per 100,000 children or person-years at risk, if not 
originally reported as such. 
 
If a 95% confidence interval (CI) for the incidence estimate was not reported, but the 
relevant numerator and denominator values for the calculation of incidence were 
provided, a 95% confidence interval was calculated using the exact Poisson method. 
 
One included study did not report an appropriately derived incidence estimate, but 
provided the number of incident cases of symptomatic vitamin D deficiency in a defined 
population for which a reliable population estimate was publicly available from an 
external source (El-Fakhri et al, 2013). In this case, an annual incidence risk estimate 
was calculated by dividing the total number of cases over the entire study period by the 
population estimate at the mid-point of the study, then further dividing by the duration 
of the study period in years. A 95% confidence interval for the incidence risk estimate 
was calculated using the exact Poisson method. 
 
Incidence estimates from the included studies were displayed graphically using forest 
plots. Due to considerable heterogeneity among the included studies with respect to 
clinical and methodological aspects (see section 3.4.8), the estimation of pooled 
summary estimates was limited to studies considered to be of higher overall 
methodological quality (see section 3.3.6), and by necessity to studies for which 95% 
confidence intervals around incidence estimates were available. Random-effects 
models were used to calculate pooled incidence risk estimates, using the metan 
command in Stata (Sterne, 2009). Statistical evidence of heterogeneity between 
studies was assessed using chi-squared tests and the I2 statistic (Higgins et al, 2003). 
The number of included studies was not sufficient to perform subgroup analysis to 
investigate possible sources of heterogeneity (calculation of pooled incidence 
estimates in strata of key variables such as geographical region or demographic 
characteristics of the study population), or meta-regression to examine and test 
differences in incidence rates in relation to socio-demographic factors. 
 
Statistical and graphical analyses were performed using Stata MP version 14.2 
(StataCorp, USA). 
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3.4 Results 
 
3.4.1 Literature Search 
 
After the removal of duplicates, the literature search yielded a total of 8,299 citations 
(Figure 3.1). Following the initial screening of study titles and abstracts, 276 studies 
were selected for review of the full text. A further 9 potentially relevant studies for full 
text review were identified from the reference lists of included studies and relevant 
review articles. Following full text review, 13 studies that met the systematic review 
eligibility criteria were identified and included. One of these studies represents the 
publication of original data arising from work contributing to this thesis, and is described 
in full in chapter 4 (Basatemur & Sutcliffe, 2015). 
 
A prospective national surveillance study undertaken in Australia between January 
2006 to July 2007, in which the reported outcome was the incidence of vitamin D 
deficiency rickets among children age 0 to 15 years, was excluded following review of 
the full text (Munns et al, 2012). Although the stated outcome was a clinical 
complication of vitamin D deficiency, the large majority of cases (>80%, exact number 
not provided) were identified through routine screening of vitamin D status undertaken 
at services such as refugee health clinics. The study case definition did not require the 
presence of any symptoms or signs attributable to vitamin D deficiency, and could be 
met on the basis of biochemical findings alone: i) serum 25-OH-D ≤50 nmol/l and ii) 
either a raised serum alkaline phosphatase level or radiological features of rickets. The 
study was therefore excluded, as the majority of cases represented biochemical 
vitamin D deficiency identified through the screening of asymptomatic individuals. 
 
 
3.4.2 Characteristics of Included Studies 
 
Six of the studies reported data from Europe, 5 from North America, 1 from Asia, and 1 
from New Zealand (Table 3.3). Five studies had national coverage, whilst eight were 
regional or local studies. The study methodology involved retrospective analysis of 
healthcare administrative data or hospital records in 7 studies, prospective surveillance 
through clinician reporting in 5 studies, and follow-up of children recruited to a non-
randomised controlled trial in 1 study. The study outcome was stated as rickets in 9 
studies, symptomatic vitamin D deficiency in 3 studies, and hypocalcaemic seizures 
secondary to vitamin D deficiency in 1 study. However, a number of the studies in 
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which the stated outcome was rickets also included children presenting with 
hypocalcaemic symptoms (Beck-Nielsen et al, 2009a; Thacher et al, 2013; Ward et al, 
2007; Wheeler et al, 2015), making distinction difficult between studies reporting an 
incidence estimate specifically for rickets and those reporting an overall incidence 
estimate for any presentation of symptomatic vitamin D deficiency. Twelve studies 
reported an incidence risk estimate, whilst one study reported an incidence rate. 
Figure 3.1  Flow diagram outlining study selection and exclusion.  
Records identified from searches of 
bibliographic databases: 
 
- MEDLINE:  n = 4,300 
- EMBASE:  n = 4,901 
- PsycINFO:  n = 47 
- CINAHL Plus: n = 2,481 
- Web of Science: n = 1,494 
- Global Health: n = 720 
Duplicate Records: 
n = 5,644 
Titles and abstracts screened: 
n = 8,299 
Excluded after screening 
of title or abstract: 
n = 8,023 
Full text articles assessed for eligibility: 
n = 276 
Excluded after full text review: 
n = 272 
 
- Not an original study:   n = 165 
- Data pre-1990:   n = 3 
- Paediatric data not provided:  n = 5 
- Outcome not symptomatic VDD: n = 15 
- Case series (no denominator):  n = 40 
- Selected cohort of children: a  n = 15 
- Duplicate data published elsewhere: n = 8 
- Prevalence (not incidence) reported:  n = 21 
Articles for full text 
review identified 
through hand-
searching: 
n = 9 
Eligible studies meeting the inclusion criteria 
and included in the systematic review: 
n = 13 
Abbreviations: VDD, vitamin D deficiency. 
a The data was not drawn from a general population of children, for example where the study 
population was limited to children with a co-morbidity or those receiving healthcare services. 
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Table 3.3  Characteristics and design of included studies with overall incidence rates, grouped by continent. 
Study a Country & region 
Study 
duration 
Setting, 
population and 
age group 
Study design & source 
of case ascertainment 
Exclusion 
criteria 
Stated outcome and case 
definition 
Source & size of 
denominator 
data 
No. of 
cases 
Outcome measure, 
incidence estimate, 
& 95% CI 
Europe 
Callaghan, 
2006 
England 
 
West 
Midlands 
1 year, 
from May 
2000 to 
April 2001 
Setting: Secondary 
care (inpatient and 
outpatient) 
 
Population: 
General population 
 
Age: 0–4 years 
Prospective surveillance 
study of paediatricians in 
the West Midlands 
 
Active case reporting by 
paediatricians every 
month 
Prematurity 
Outcome: Symptomatic 
vitamin D deficiency 
 
Case definition: 
1) Radiographic signs of 
rickets (fraying or splaying at 
end or a long bone) 
OR 
2) Hypocalcaemic convulsion 
thought to be caused by VDD 
Source: 
Population 
statistics from 
2001 census 
 
Size: N/A 
24 
Incidence risk 
 
7.5 per 100,000 
children per year 
 
95% CI: N/A 
Beck-
Nielsen, 
2009 
Denmark 
 
Southern 
Denmark 
11 years, 
from 1995 
to 2005 
Setting: Secondary 
care (inpatient and 
outpatient) 
 
Population: 
General population 
 
Age: 0–14 years 
Analysis of healthcare 
administrative data 
(Danish National Patient 
Registry and hospital 
registers) 
 
Cases identified using 
ICD-8 (265, 265.0, 265.1, 
265.9, 273.4) and ICD-10 
(E55, E55.0, E55.9, 
E64.3, E83.3) codes for 
VDD & rickets 
Renal 
insufficiency, 
renal tubular 
acidosis, liver / 
bile duct 
disease, 
genetic 
syndromes, 
medically 
induced 
rickets 
Outcome: Nutritional rickets 
 
Case definition: 
1) 25-OH-D <25nmol/l and at 
least one of: raised ALP, 
raised PTH, or low Ca2+ b 
AND 
2) Clinical or radiological 
signs of rickets c 
AND 
3) Rickets healed following 
treatment with vitamin D 
Source: 
Population 
estimates from 
Statistics 
Denmark 
 
Size: 246,972 
(average yearly 
population size 
between 1995-
2005) 
78 
Incidence risk 
 
2.9 per 100,000 
children per year 
 
95% CI: 2.3 to 3.6 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; ALP, alkaline phosphatase; Ca2+, calcium; CI, confidence interval; ICD, International Classification of Diseases; N/A, not available; PTH, 
parathyroid hormone; VDD, vitamin D deficiency. 
a First author, year of publication 
b Where a 25-OH-D level was not available, cases included if at least one of the following present: raised ALP, raised PTH, or low Ca2+ 
c In infants and young children, clinical signs of rickets defined as one of: craniotabes, rachitic rosary, Harrison groove, enlargement of wrists knees or ankles, bowing of weight bearing 
extremeties, or hypocalcaemic seizures. In adolescents, clinical signs defined as one of: enlargement of writsts, knees or ankles, bowing of legs, muscle weakness, pain of lower limbs 
or in the back, or hypocalcaemic seizures. Radiological signs defined as widening of growth plates with irregularity and cupping of their metaphyseal borders. 
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Table 3.3  continued. 
Study a Country & region 
Study 
duration 
Setting, 
population and 
age group 
Study design & source 
of case ascertainment Exclusion criteria 
Stated outcome and 
case definition 
Source & size of 
denominator 
data 
No. of 
cases 
Outcome measure, 
incidence estimate, 
& 95% CI 
Europe (continued) 
Moy, 
2012 
England 
 
Part of 
inner-city 
Birmingham 
(Heart of 
Birmingham 
Primary 
Care Trust 
catchment 
area) 
2 x 1-year 
periods: 
 
1) Jan to 
Dec 2005 
 
2) March 
2009 to 
Feb 2010 
Setting: Secondary 
care (inpatient and 
outpatient) 
 
Population: 
General population 
resident in the 
Primary Care Trust 
catchment area 
 
Age: 0–4 years 
Retrospective analysis of 
medical records from 3 
hospitals, before & after 
an intervention to 
increase vitamin D 
supplement uptake. 
 
Cases identified by 
medical record review of 
all children with a 25-
OH-D record <25 nmol/l 
Chronic renal or 
hepatic disease, 
incidental finding of 
low 25-OH-D in an 
asymptomatic child 
Outcome: Symptomatic 
vitamin D deficiency 
 
Case definition: 
1) 25-OH-D <25 nmol/l 
AND 
2) Diagnosis of rickets, 
hypocalcaemic seizure, or 
muscle weakness (clinical 
outcomes not further 
defined) 
Source: 
Population 
statistics from 
2001 census 
 
Size: N/A 
2005: 
29 
 
2009-
2010: 
12 
Incidence risk 
 
Jan to Dec 2005: 
120 per 100,000 
children per year 
 
March 2009 to Feb 
2010: 49 per 100,000 
children per year 
 
95% CIs: N/A 
El-Fakhri, 
2013 
Scotland 
 
National 
study 
2 years, 
from 
Sept. 
2009 to 
August 
2011 
Setting: Secondary 
care (inpatient and 
outpatient) 
 
Population: 
General population 
 
Age: 0–16 years 
Prospective surveillance 
study using the Scottish 
Paediatric Surveillance 
Unit network 
 
Active case reporting by 
paediatricians every 
month 
Osteopenia of 
prematurity, genetic 
or drug-induced 
rickets, liver 
disease, chronic 
renal insufficiency, 
malabsorption, 
thalassaemia 
Outcome: Symptomatic 
vitamin D deficiency 
 
Case definition: Symptoms 
or signs related to vitamin 
D deficiency or 
hypocalcaemia (not 
specified) 
Source: Mid-
2010 national 
population 
estimate (Office 
for National 
Statistics) b 
 
Size: 981,072 
109 
Incidence risk 
 
5.6 per 100,000 
children per year b 
 
95% CI: 4.6 to 6.7 
Goldacre, 
2014 
England 
 
National 
study 
5 years, 
from 2007 
to 2011 
Setting: Hospital 
admissions data 
(inpatient 
secondary care) 
 
Population: 
General population 
 
Age: 0–14 years 
Analysis of healthcare 
administrative data 
(Hospital Episode 
Statistics) 
 
Cases identified using 
ICD-10 code for ‘active 
rickets’ 
None 
Outcome: Rickets 
 
Case definition: Record of 
ICD-10 code E55.0 (‘active 
rickets’) 
Source: Not 
stated, but likely  
to be national 
population 
estimates 
 
Size: N/A 
Not 
stated 
Incidence risk - 
directly standardised 
to European standard 
population using 5-
year age groups 
 
3.16 per 100,000 
children per year 
 
95% CI: 3.00 to 3.33 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; CI, confidence interval; ICD, International Classification of Diseases; N/A, not available. 
a First author, year of publication 
b A national incidence estimate was not reported by the authors, but has been calculated using the number of incident cases reported in the paper alongside publicly available national 
population estimates for Scotland from the Office for National Statistics (ONS, 2013c). 
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Table 3.3  continued. 
Study a Country & region 
Study 
duration 
Setting, 
population and 
age group 
Study design & source 
of case ascertainment Exclusion criteria 
Stated outcome and case 
definition 
Source & size 
of denominator 
data 
No. of 
cases 
Outcome measure, 
incidence estimate, 
& 95% CI 
Europe (continued) 
Basatemur, 
2015 
UK & 
Ireland 
 
National 
study 
2 years, 
from 
Sept. 
2011 to 
Sept. 
2013 
Setting: Secondary 
care (inpatient and 
outpatient) 
 
Population: 
General population 
 
Age: 0–15 years 
Prospective surveillance 
study using the British 
Paediatric Surveillance 
Unit network 
 
Active case reporting by 
paediatricians every 
month 
Alternative cause of 
seizures present at 
time of event, chronic 
renal disease, total 
parenteral nutrition, 
liver disease, 
malabsorption, 
inherited disorder of 
vitamin D metabolism. 
Outcome: Hypocalcaemic 
seizure secondary to VDD 
 
Case definition: 
1) Clinical seizure 
AND 
2) Serum Ca2+ <2.0 mmol/l 
AND 
3) 25-OH-D <50 nmol/l 
Source: 2012 
national 
population 
estimates from 
the ONS and 
CSO 
 
Size: 
13,037,071 
92 
Incidence risk 
 
0.35 per 100,000 
children per year 
 
95% CI: 0.28 to 0.43 
North America 
CDC, 
2001 
USA 
 
Georgia 
18 
months, 
from Jan 
1997 to 
June 
1999 
Setting: Hospital 
admissions data 
(inpatient 
secondary care) 
 
Population: 
General population 
resident in Georgia 
 
Age: 6 months to 5 
years 
Retrospective analysis of 
discharge records from 
hospitals in Georgia 
 
Cases identified using 
ICD-9 codes for rickets 
(268.0), vitamin D 
deficiency (268.9), or 
osteomalacia (268.2) 
Congenital or genetic 
aetiology, premature 
birth, chronic diseases 
(N/S) 
Outcome: Vitamin D 
deficiency rickets 
 
Case definition: 
1) 25-OH-D level below lab 
reference range (N/S) 
AND 
2) Radiographic signs: 
osteopenia, growth plate 
widening, fraying/cupping of 
metaphysis, craniomalacia 
Source: 
Population 
census data for 
the State of 
Georgia 
 
Size: N/A 
6 
Incidence risk 
 
0.3 per 100,000 
children per year 
 
95% CI: N/A 
Ward, 
2007 
Canada 
 
National 
Study 
2 years, 
from July 
2002 to 
June 
2004 
Setting: Secondary 
care (inpatient and 
outpatient) 
 
Population: 
General population 
 
Age: 0–18 years 
Prospective surveillance 
study using the Canadian 
Paediatric Surveillance 
Program network 
 
Active case reporting by 
paediatricians every 
month 
Liver disease, total 
parenteral nutrition, 
renal insufficiency, 
genetic disorder of 
vitamin D metabolism, 
fat malabsorption 
Outcome: Vitamin D 
deficiency rickets 
 
Case definition:  
No definition of rickets 
specified. Serum 25-OH-D 
<27.5 nmol/l specified as an 
inclusion criteria. 
Source: 2003 
national 
population 
estimates from 
Statistics 
Canada 
 
Size: N/A 
104 
Incidence risk 
 
2.9 per 100,000 
children per year 
 
95% CI: 2.2 to 3.7 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; Ca2+, calcium; CDC, Centers for Disease Control and Prevention; CI, confidence interval; CSO, Central Statistics Office Ireland; ICD, 
International Classification of Diseases; N/A, not available; N/S, not specified; ONS, Office for National Statistics; VDD, vitamin D deficiency 
a First author, year of publication 
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Table 3.3  continued. 
Study a Country & region 
Study 
duration 
Setting, population 
and age group 
Study design & source of 
case ascertainment 
Exclusion 
criteria 
Stated outcome and 
case definition 
Source & size of 
denominator 
data 
No. of 
cases 
Outcome measure, 
incidence estimate, 
& 95% CI 
North America (continued) 
Thacher, 
2013 
USA 
 
Olmsted 
County, 
Minnesota 
2 x 10-
year 
periods: 
1990 to 
1999, 
and 
2000 to 
2009 
Setting: Primary  
and secondary  
care 
 
Population: General 
population resident 
in Olmsted county 
 
Age: 0–2 years 
Analysis of linked healthcare 
administrative data (Rochester 
Epidemiology Project) 
 
Cases identified using codes 
for: rickets, vitamin D 
deficiency, osteomalacia, genu 
varum/valgum, tetany, 
craniotabes, hypocalcaemia, 
angulation, hypocalcaemic 
seizure, chest deformity 
Inherited / genetic 
cause of rickets, 
renal tubular 
disorders, renal 
insufficiency, 
tumor-induced 
osteomalacia, 
hypophosphatasia 
Outcome: Nutritional 
rickets 
 
Case definition: 
Radiographic 
interpretation consistent 
with rickets (not 
specified) and no 
evidence of non-
nutritional causes of 
rickets 
Source: 
Rochester 
Epidemiology 
Project cohort 
population 
 
Size: N/A 
1990-
1999: 
2 
 
2000-
2009: 
14 
Incidence rate 
 
1990-1999: 3.7 per 
100,000 person-
years 
95% CI: N/A 
 
2000-2009: 24.1 per 
100,000 person-
years 
95% CI: N/A 
Millette, 
2014 
Canada 
 
Quebec 
2 
separate 
1-year 
periods: 
2004 & 
2009 
Setting: Primary  
and secondary care 
 
Population: Children 
covered by a public 
medication 
insurance plan 
 
Age: 0–6 years   
Analysis of linked data from 2 
healthcare administrative 
databases and the state birth 
registry (the Quebec 
Pregnancy Cohort) 
 
Cases identified using ICD 
codes for rickets or vitamin D 
deficiency. 
Inherited forms of 
rickets, renal 
failure, born at 
<37 or >42 weeks 
gestation, child or 
mother taking 
calcitriol 
Outcome: Rickets 
 
Case definition: Record 
of ICD-9 code 268 or 
ICD-10 code E55 
Source: Quebec 
Pregnancy  
Cohort population 
 
Size: 
2004: ~100,000 
2009: ~83,000 
2004: 
3 
 
2009: 
6 
Incidence risk 
 
2004: 3.0 per 
100,000 children 
95% CI: 0.6 to 8.8 
 
2009: 7.2 per 
100,000 children 
95% CI: 2.7 to 15.7 
Singleton, 
2015 
USA 
 
Alaska 
15 
years, 
from 
1999 to 
2013 
Setting: Inpatient 
and outpatient data 
from health facilities 
for Alaska native 
people 
 
Population: Alaska 
native (American 
Indian) children 
 
Age: 0–9 years   
Analysis of healthcare 
administrative data (Indian 
Health Service National 
Patient Information Reporting 
System [IHS]). 
 
Cases identified using ICD- 
9 codes for rickets (268.1, 
268.0) & vitamin D deficiency 
(268.9), and lab records for 
25-OH-D <37.5 nmol/l. 
Rickets 
associated with 
hepatic disease or 
malabsorption 
Outcome: Nutritional 
rickets 
 
Case definition: 
1) 25-OH-D <37.5 nmol/l 
AND 
2) Recorded clinical or 
radiographic signs 
consistent with rickets 
(not specified) 
Source: The IHS 
user population, 
calculated as the 
number of 
individuals who 
received any IHS-
funded care in the 
preceding 3 
years. 
 
Size: N/A 
16 
Incidence risk 
 
4.2 per 100,000 
children per year 
 
95% CI: N/A 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; CI, confidence interval; ICD, International Classification of Diseases; N/A, not available. 
a First author, year of publication 
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Table 3.3  continued. 
Study a Country & region 
Study 
duration 
Setting, population 
and age group 
Study design & source of 
case ascertainment Exclusion criteria 
Stated outcome and 
case definition 
Source & size of 
denominator data 
No. of 
cases 
Outcome measure, 
incidence estimate, 
& 95% CI 
Asia 
Beser, 
1994 
Turkey 
 
Akcaabat 
district (in 
Trabzon 
province, 
northeast 
Turkey) 
12 
months 
follow-up 
per child, 
during 
the 
period 
1990-
1992 
Setting: Control arm 
of intervention study 
 
Population: Children 
from 21 villages 
attached to a single 
health centre 
 
Age: 3 to 36 months 
Non-randomised study of 
vitamin D supplementation 
vs no intervention. 
 
Physical examination by 
study investigators and 
unspecified biochemical and 
radiological tests, 12 months 
after recruitment 
Rickets present at 
baseline 
Outcome: Rickets 
 
Case definition: None.  
Source: Number of 
children in no 
intervention arm of 
the study 
 
Size: 369 
14 
Incidence risk 
 
3,800 per 100,000 
children (3.8%) 
 
95% CI: 2,074 to 
6,366 
Oceania 
Wheeler, 
2015 
New 
Zealand 
 
National 
study 
3 years, 
from July 
2010 to 
June 
2013 
Setting: Secondary 
care (inpatient and 
outpatient) 
 
Population: General 
population 
 
Age: 0–14 years   
Prospective surveillance 
study using the New Zealand 
Paediatric Surveillance Unit 
network 
 
Active case reporting by 
paediatricians every month 
Fat malabsorption, 
liver disease, renal 
insufficiency, 
genetic forms of 
rickets, total 
parenteral nutrition 
Outcome: Vitamin D 
Deficiency Rickets 
 
Case definition: 
1) 25-OH-D <50 nmol/l 
AND 
2) Elevated ALP or 
radiological signs of 
rickets 
Source: National 
census data for 
2013 (Statistics 
New Zealand) 
 
Size: 870,378 
58 
Incidence risk 
 
2.2 per 100,000 
children per year  
 
95% CI: 1.4 to 3.5 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; ALP, alkaline phosphatase; CI, confidence interval. 
a First author, year of publication 
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3.4.3 Summary of Included Studies 
 
A summary of the study design and overall incidence rates reported by each of the 
included studies is given in Table 3.3. Assessment of the quality of study reporting and 
design is shown in Table 3.4. Assessment of the risk of bias, generalisability to the 
national population, and a description of the key limitations for each study is given in 
Table 3.5. A brief discussion of each of the included studies, grouped by geographical 
region, is given below. 
 
 
3.4.3.1 Europe 
 
Five studies were conducted in the United Kingdom (3 in England, 1 in Scotland, and 1 
study across the UK and Ireland), and one in Denmark. 
 
A prospective surveillance study in the West Midlands region of England, involving 
active case reporting by paediatricians, identified 24 cases of symptomatic vitamin D 
deficiency among children aged 0 to 4 years presenting to secondary care over a one 
year period between May 2000 to April 2001 (Callaghan et al, 2006). Children met the 
case criteria if they had radiographic features of rickets or presented with a 
hypocalcaemic seizure where the most likely cause was considered to be vitamin D 
deficiency by the treating clinician. This equated to an overall annual incidence risk of 
7.5 per 100,000 children aged 0 to 4 years. The incidence risk was considerably higher 
among children from South Asian (38 per 100,000) and black (95 per 100,000) ethnic 
backgrounds than among those of white ethnic origin (0.4 per 100,000). Confidence 
intervals around the incidence estimates were not reported, and would be expected to 
be relatively wide given the small number of cases. Case ascertainment was limited to 
children presenting to secondary care, and there was a non-response rate of 24% for 
requests to report cases. Although vitamin D status was not explicitly incorporated into 
the case definition, the authors state that all included children exhibited a biochemical 
profile consistent with vitamin D deficiency, without elaborating further. Regional 
differences in ethnic demography limit the generalisability of the findings to the UK as a 
whole: the West Midlands has a higher South Asian population than the national 
average (12.3% compared to 6.7% nationally in England & Wales, among children 
aged 0 to 4 years in the 2001 Census) (ONS, 2001). 
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Table 3.4  Assessment of the quality of study reporting and methodology for included studies. 
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Basatemur, 
2015 Yes Yes Yes Yes Yes Yes Yes 93% No Yes Yes Yes Reported 
Beck-Nielsen, 
2009 Yes Yes Yes Yes Yes Yes Yes N/A Yes Yes Yes Yes Derived 
Beser, 
1994 Yes No Yes Yes No No Yes 98.6% No Yes Yes Yes Derived 
Callaghan, 
2006 Yes Yes Yes Yes Yes No Yes 76% No No Unclear Yes No 
CDC, 
2001 Yes Yes Partial Yes Partial 
Threshold 
not specified Yes N/A No Yes Unclear Yes No 
El-Fakhri, 
2013 Yes Yes Yes Yes No No Yes 
Not 
reported No Unclear Yes Yes Derived 
Goldacre, 
2014 Yes Yes Yes Yes Yes No No N/A No No Yes Yes Reported 
Millette, 
2014 Yes No Partial Yes Yes No No N/A Yes Yes Yes Yes Derived 
Moy, 
2012 Yes Yes Yes Yes Partial Yes Yes N/A No Yes Yes Yes No 
Singleton, 
2015 Yes No Yes Yes Partial Yes Yes N/A Yes Yes Yes Yes No 
Thacher, 
2013 Yes Yes Yes Yes Partial No Yes N/A Yes Yes Yes Yes No 
Ward, 
2007 Yes Yes Yes Yes No Yes Yes 84.5% No Yes Yes Yes Reported 
Wheeler, 
2015 Yes Yes Yes Yes Yes Yes Yes 92% No Unclear Yes Yes Reported 
Abbreviations: N/A, not applicable. 
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Table 3.5  Assessment of the risk of bias, external generalisability, and summary of the main limitations for included studies. 
Study Risk of case misclassification 
Risk of case under-
ascertainment 
Reliability of population 
at risk estimate 
Generalisability to 
national population Notes regarding study limitations 
Basatemur, 
2015 Low Moderate High High 
- Single source of case ascertainment 
- Case status could not be ascertained for 7% of case reports 
Beck-
Nielsen, 
2009 
Low Moderate High Moderate 
- Only includes cases presenting to secondary care 
- Cases ascertained using only diagnostic codes in administrative databases 
- Regional study 
Beser, 
1994 High Low High Low 
- No case definition for rickets specified, left to study investigator judgement 
- High risk that case inclusion was based on non-specific clinical signs  
- Assessment of vitamin D status not incorporated in the case definition 
- No exclusion of children with predisposing chronic diseases 
- Small study size, and large statistical uncertainty in incidence estimate 
- Covers a limited geographical region 
Callaghan, 
2006 Moderate Moderate High Moderate 
- No exclusion of children with predisposing chronic diseases 
- Assessment of vitamin D status not incorporated in the case definition 
- Not explicitly stated that prevalent cases were excluded 
- Single source of case ascertainment 
- Only includes cases presenting to secondary care (paediatricians) 
- Non-response rate of 24% 
- Regional study 
- Confidence intervals not reported and cannot be derived 
CDC, 
2001 Moderate High High Moderate 
- 25-OH-D level considered low not defined 
- Not explicitly stated that prevalent cases were excluded 
- Only includes cases requiring hospital admission 
- Cases ascertained using only diagnostic codes in administrative databases 
- Case inclusion limited to children with confirmed radiographic signs 
- Regional study 
- Confidence intervals not reported and cannot be derived 
El-Fakhri, 
2013 Moderate Moderate High 
a High a 
- Clinical symptoms / signs used to determine case inclusion not defined 
- Assessment of vitamin D status not incorporated in the case definition 
- Only includes cases presenting to secondary care (paediatricians) 
- Single source of case ascertainment 
Goldacre, 
2014 High High High High 
- Cases ascertained using only diagnostic codes in administrative databases 
- Case status not verified by review of medical notes 
- Assessment of vitamin D status not incorporated in the case definition 
- No exclusion of children with predisposing chronic diseases 
- Only includes cases requiring hospital admission 
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Table 3.5  continued. 
Study Risk of case misclassification  
Risk of case under-
ascertainment  
Reliability of population 
at risk estimate 
Generalisability to 
national population Notes regarding study limitations 
Millette, 
2014 High Moderate High Low 
- Cases ascertained using only diagnostic codes in administrative databases 
- Case status not verified by review of medical notes 
- Assessment of vitamin D status not incorporated in the case definition 
- Study population limited to individuals eligible for a public medical insurance 
plan – may not be representative of the general population 
- Small number of cases & large statistical uncertainty in incidence estimate 
Moy, 
2012 Low Moderate Moderate Low 
- Clinical outcomes used to determine case inclusion not fully defined 
- Only includes cases with 25-OH-D <25 nmol/l, children with higher 25-OH-D 
levels or who received treatment prior to testing will be excluded 
- Only includes cases presenting to secondary care 
- Estimate for population at risk does not match study time period 
- Covers a limited geographical region, with a marked difference in ethnic 
demography compared to the national population. 
- Confidence intervals not reported and cannot be derived 
Singleton, 
2015 Moderate Moderate Low Low 
- High risk that denominator data does not accurately reflect the population at-
risk; derived from users of healthcare services, not true population estimates 
- Limited to a single ethnic group (American Indian Alaska native) 
- Limited to cases treated at Indian Health Service funded providers 
- Confidence intervals not reported and cannot be derived 
- Clinical signs of rickets used to determine case inclusion not defined 
Thacher, 
2013 High High High Low 
- Assessment of vitamin D status not incorporated in the case definition 
- Radiological signs of rickets used to determine case inclusion not defined 
- Case inclusion limited to children with confirmed radiographic features of 
rickets, any cases diagnosed without radiographic evaluation not included 
- Covers a limited geographical region 
- Confidence intervals not reported and cannot be derived 
Ward, 
2007 Moderate Moderate High High 
- No case definition of rickets specified, left to individual clinician judgement. 
- Single source of case ascertainment 
- Only includes cases presenting to secondary care (paediatricians) 
Wheeler, 
2015 Low Moderate High High 
- Single source of case ascertainment 
- Only includes cases presenting to secondary care (paediatricians)  
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; CDC, Centers for Disease Control and Prevention; ICD, International Classification of Diseases. 
a Assessment relates to the calculation of incidence performed using national population estimates for Scotland available from the Office for National statistics, not to the analyses 
reported in the paper. 
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A local study in inner-city Birmingham, a city in the West Midlands region of England, 
investigated the incidence of symptomatic vitamin D deficiency in children presenting to 
secondary care, before and after a local public health initiative in 2005 to provide 
universal free of charge vitamin D supplements to pregnant and lactating women and 
children aged under 5 years (Moy et al, 2012). Cases were identified through the 
retrospective analysis of medical records from 3 local hospitals. Children met the case 
criteria if aged 0 to 4 years, with a 25-OH-D level <25 nmol/l, and a clinical diagnosis of 
either rickets, hypocalcaemic seizure or muscle weakness. 29 cases were identified in 
2005, and 12 cases in a separate 12-month period between March 2009 to February 
2010. This equated to an annual incidence risk of 120 per 100,000 children aged 0 to 4 
years in 2005, and 49 per 100,000 children in 2009-2010. However, caution must be 
taken in drawing conclusions about temporal trends from this data, as confidence 
intervals were not provided and incidence was reported from two distinct 1-year time 
periods as opposed to continuous time-trend data. The authors report that 75% of the 
population of inner-city Birmingham were from ethnic minority groups (compared to 9% 
nationally across England and Wales in 2001), which prevents generalisability of the 
results to the national population, and is the most likely explanation for the incidence 
figures being considerably higher than those reported by other studies in Europe and 
North America (Table 3.3). The ethnic origin of cases was not reported. 
 
A prospective surveillance study in Scotland, involving active case reporting by 
paediatricians on a monthly basis, identified 109 cases of symptomatic vitamin D 
deficiency among children aged 0 to 16 years presenting to secondary care over a two 
year period between September 2009 to August 2011 (El-Fakhri et al, 2013). Clinicians 
were asked to report children with symptoms or signs related to vitamin D deficiency or 
hypocalcaemia, however an important limitation of the study was the absence of a 
case definition for validation of reported cases. Information about clinical presentation 
was available for 90% of cases (n=98), of whom 85% (n=83) had a presentation 
consistent with symptomatic vitamin D deficiency (bone deformity, gait abnormality, 
bone pain, fracture, or hypocalcaemic seizure). Although the surveillance had national 
coverage, the authors did not report national incidence estimates. They attempted to 
derive separate incidence estimates for the two major cities in Scotland (Glasgow and 
Edinburgh), where the majority of cases (90%) had been reported from (82 from 
Glasgow, 16 from Edinburgh). They used population estimates for children resident in 
these cities as the denominator for the calculations, and reported incidence estimates 
of 80 per 100,000 children aged 0 to 16 in Glasgow, and 19 per 100,000 children in 
Edinburgh. However, it is unlikely that children who receive secondary care in hospitals 
in these cities will be restricted to children who reside there, as children who live 
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outside of Glasgow or Edinburgh could be referred to these hospitals for specialist 
care. Data regarding area of residence or postcode was not collected, and therefore 
the city-based incidence estimates may include cases from outside the denominator 
populations. Furthermore, the ethnic demography of Glasgow and Edinburgh differs 
considerably from that of Scotland as a whole; nationally 5.6% of children aged 0 to 17 
years were of non-white ethnicity in the 2011 Scottish census, compared to 11.6% of 
children in Edinburgh and 17.9% of children in Glasgow (NRS, 2014). The authors do 
not provide an explanation for why they reported city-based rather than national 
incidence estimates. For the purpose of this systematic review, the number of incident 
cases reported nationally (as stated in the paper) was used alongside mid-2010 
national population estimates available from the Office for National Statistics (ONS, 
2013c), to derive an annual incidence risk estimate of 5.6 per 100,000 children aged 0 
to 16 across Scotland (95% CI: 4.6 to 6.7). Case ascertainment was limited to children 
presenting to secondary care, and the response rate from clinicians for requests to 
report cases was not reported. Data regarding serum 25-OH-D level was missing for 
24% of cases. Among cases with data available, 25-OH-D levels were ≤25 nmol/l for 
83%, between 26-50 nmol/l for 14%, and >50 nmol/l for 2%. 53% of cases were of 
South Asian ethnic origin, 26% African, 9% Middle Eastern, and 9% white. 
 
An analysis of routinely collected Hospital Episode Statistics data in England identified 
hospital admissions among children in which the coded diagnosis was ‘active rickets’ 
(Goldacre et al, 2014). Following direct standardisation by age to the European 
Standard Population, the annual incidence risk between 2007 to 2011 was reported to 
be 3.16 per 100,000 children aged 0 to 14 (95% CI: 3.00 to 3.33). An important 
limitation of the study is that only cases admitted to hospital as inpatients were 
ascertained, whilst many children with rickets will be managed as outpatients. The risk 
of case misclassification was considered to be high as case status was determined 
using administrative codes only with no validation of case status through review of 
medical records, and children with predisposing chronic conditions or inherited causes 
of rickets were not excluded. Among cases for whom ethnicity data was available, 33% 
were reported to be of South Asian origin, 33% black, and 32% white, although the 
authors acknowledged that the overall recording of ethnicity data was poor. 
 
A prospective surveillance study of hypocalcaemic seizures secondary to vitamin D 
deficiency, undertaken across the UK and Ireland between September 2011 to 
September 2013, is described in full in chapter 4 (Basatemur & Sutcliffe, 2015). The 
overall annual incidence risk was 0.35 per 100,000 children aged 0 to 15 years (95% 
CI: 0.28 to 0.43). 
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A retrospective cohort study in Southern Denmark used diagnostic codes for vitamin D 
deficiency and rickets to identify children with possible nutritional rickets from hospital 
records and a national healthcare administrative database (the Danish National Patient 
Registry), which included both inpatient and outpatient data (Beck-Nielsen et al, 
2009a). The medical records of potential cases were reviewed, and children were 
included if they met a clearly described case definition that required biochemical as 
well as clinical or radiographic evidence of symptomatic vitamin D deficiency, and 
clinical improvement following treatment with vitamin D (see Table 3.3). Seventy-eight 
children met the case criteria over an 11-year period between 1995 to 2005, 
corresponding to an overall annual incidence risk of 2.9 per 100,000 children aged 0 to 
14 years (95% CI: 2.3 to 3.6). The incidence risk among children from immigrant 
backgrounds was considerably higher than the overall incidence, at 60 per 100,000 
children aged 0 to 14 years (95% CI: 41 to 84). The incidence risk was also higher 
among younger children aged 0 to 2 years, at 5.8 per 100,000 children (95% CI: 4.0 to 
8.3), than the overall incidence among children aged 0 to 14 years. Case 
ascertainment was limited to children managed in secondary care. 
 
 
3.4.3.2 North America 
 
Three studies were conducted in the United States of America, and two in Canada. 
 
A retrospective analysis of hospital discharge records in the US state of Georgia 
identified 6 children aged between 6 months to 5 years who were admitted to hospital 
with vitamin D deficiency rickets over an 18 month period between January 1997 to 
June 1999 (CDC, 2001). Children met the case criteria if they had a serum 25-OH-D 
level below the local laboratory reference range (not specified) and radiographic signs 
of rickets. This equated to an annual incidence risk of 0.3 per 100,000 children aged 
between 6 months to 5 years. Insufficient information was provided to derive a 
confidence interval around the incidence estimate, however this would be expected to 
be wide given the small number of cases. A major limitation of the study was that only 
cases admitted to hospital as inpatients were ascertained, whilst many children with 
rickets would be expected to be managed as outpatients. Case ascertainment was also 
limited to children who had radiographic features of rickets, therefore any children 
diagnosed on the basis of clinical and biochemical features alone, without radiographic 
evaluation, would not have been included. The ethnic origin of cases was not reported. 
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A local retrospective cohort study conducted in Olmsted County in the US state of 
Minnesota, which had a total population of 145,225 in 2009, investigated the incidence 
of nutritional rickets among children aged 0 to 2 years, using data held in the 
Rochester Epidemiology Project (Thacher et al, 2013). The database contains linked 
medical records from 2 large integrated health systems, which between them cover 
98% of all primary and secondary health care services for Olmsted County residents. 
Children were included as cases if they had radiographic evidence of rickets, in the 
absence of non-nutritional causes of rickets (predisposing chronic medical conditions 
and inherited causes of rickets). Two cases were identified between 1990 to 1999, and 
14 cases between 2000 to 2009. This equated to an annual incidence rate of 3.7 per 
100,000 person-years between 1990 to 1999, and 24.1 per 100,000 person-years 
between 2000 to 2009. Confidence intervals around the incidence estimates were not 
reported, and would be expected to be wide given the small numbers of cases, limiting 
conclusions that can be drawn regarding temporal trends. However, the authors 
speculate that an increase in the non-white, particularly Somali, immigrant population 
in the region during the study period may be a contributing factor to changing incidence 
over time. A strength of the study was the ascertainment of cases from both primary 
and secondary care. However, case ascertainment was limited to children who had 
radiographic features of rickets, therefore any children diagnosed on the basis of 
clinical and biochemical features alone, without radiographic evaluation, would not 
have been included. Vitamin D status was not incorporated into the case definition, and 
the range of serum 25-OH-D values reported among cases was wide (10 to 137 
nmol/l), suggesting that an alternative aetiology to vitamin D deficiency (for example 
dietary calcium deficiency) may have been responsible in some cases. 59% of cases 
were of black ethnic origin, with 24% white, and 12% of mixed ethnic origin. 
 
A retrospective cohort study in the US state of Alaska investigated the incidence of 
nutritional rickets among Alaska native American Indian children, using data held in the 
Indian Health Service (IHS) National Patient Information Reporting System (NIPRS) 
database (Singleton et al, 2015). The NIPRS contains data regarding all inpatient and 
outpatient activity in healthcare facilities for people of Alaska native American Indian 
origin. Children aged between 0 to 9 years met the case criteria if they had a serum 25-
OH-D level <37.5 nmol/l, and either clinical features or radiographic signs consistent 
with rickets. 16 cases were identified over a 15-year study period between 1999 to 
2013. The authors calculated an annual incidence risk of 4.2 per 100,000 children aged 
0 to 9 years, however a confidence interval around this estimate was not provided. The 
denominator estimates used for the population at risk in each year are likely to be 
unreliable, as they were based on the numbers of children who had used IHS-funded 
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healthcare services in the preceding 3 years rather than true population estimates. The 
results are not generalisable to the general population, as the study was limited to 
children from a single ethnic group. 
 
A national prospective surveillance study in Canada, involving active case reporting by 
paediatricians on a monthly basis, identified 104 cases of vitamin D deficiency rickets 
among children aged 0 to 18 years presenting to secondary care over a 2-year period 
between July 2002 to June 2004 (Ward et al, 2007). This equated to an annual 
incidence risk of 2.9 per 100,000 children aged 0 to 18 years. Children were included if 
they had a serum 25-OH-D level <27.5 nmol/l. A clear case definition for rickets was 
not provided, however >90% of cases were reported to have a clinical presentation 
consistent with symptomatic vitamin D deficiency (skeletal deformity, hypocalcaemic 
seizure, delayed developmental milestones, fracture, failure to thrive, or muscle 
weakness). Annual incidence estimates were stratified by age group as follows: 9 per 
100,000 children aged <1 year (95% CI: 6 to 12), 12 per 100,000 children aged 1 to 2 
years (95% CI: 8 to 16), and 0.3 per 100,000 children aged 3 to 7 years (95% CI: 0.1 to 
0.7). Case ascertainment was limited to children presenting to secondary care. 33% of 
cases were of black ethnic origin, 25% from First Nations or Inuit indigenous 
backgrounds, 14% Middle Eastern, and 11% Caucasian. 
 
A retrospective cohort study in the Canadian province of Quebec reported the 
incidence of rickets among children covered by a public medication insurance plan, in 
two separate 1-year periods (2004 and 2009) (Millette et al, 2014). This programme 
covered approximately 30% of pregnant women in Quebec and their children, 
encompassing recipients of social assistance and individuals without private insurance. 
Data for the cohort was held in the Quebec Pregnancy Cohort, which links birth and 
death registration data with two healthcare administrative databases containing 
information regarding diagnoses made in primary and secondary care. Cases were 
defined as children aged 0 to 6 years with a diagnostic code for vitamin D deficiency or 
rickets. Three cases were identified in 2004, and 6 cases in 2009. This equated to an 
annual incidence estimate of 3.0 per 100,000 children aged 0 to 6 years in 2004 (95% 
CI: 0.6 to 8.8), and 7.2 per 100,000 children in 2009 (95% CI: 2.7 to 15.7). The study 
had a number of significant limitations. The risk of case misclassification was 
considered to be high as case status was determined using administrative codes only, 
with no validation of case status through review of medical records. In view of the small 
numbers of cases, there is a large degree of statistical uncertainty around the 
incidence estimates. The vitamin D status of cases was not reported. The study 
population was a selected subgroup, rather than a random sample, of the general 
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population. The study population has been shown to have a lower average socio-
economic position than the general population of Quebec, and the ethnic distribution of 
the population was not reported. The generalisability of the results to the national 
population is therefore questionable. The ethnic origin of cases was not reported. 
 
 
3.4.3.3 Asia 
 
A non-randomised interventional study, undertaken in the Trabzon province of 
northeast Turkey between 1990 to 1992, reported the incidence of rickets among 
children aged between 3 to 36 months who either received vitamin D supplementation 
(400 International Units per day) or no intervention for 12 months (Beser & Cakmakci, 
1994). Children were recruited from 21 villages in a single district. Those found to have 
signs of rickets on physical examination at baseline were excluded. The investigators 
reported that 14 children out of 369 (3.8%) in the control arm of the study had signs of 
rickets on physical examination when followed-up at 12 months. This equates to an 
annual incidence risk of 3,800 per 100,000 children aged 3 to 36 months (95% CI: 
2,074 to 6,366). A major limitation of the study was the absence of a case definition for 
the outcome, which was left to the investigators judgement. The authors did not report 
the clinical features of rickets among the cases identified during follow-up. However, 
they did report the most common symptoms and signs which prompted a diagnosis of 
rickets among children at baseline, which were: teeth disorders, craniotabes, delayed 
fontanelle closure, sweating of the head, and restlessness. None of these symptoms 
are specific for rickets, and the relevance of symptoms such as sweating of the head 
and restlessness are questionable. The authors state that suspected cases had 
laboratory and radiological investigations performed, but provide no further details of 
the investigations undertaken or the results. There is a very high risk of case 
misclassification, as children are likely to have been given a diagnosis of rickets on the 
basis of non-specific and vague clinical features. 
 
 
3.4.3.4 Oceania 
 
A national prospective surveillance study in New Zealand, involving active case 
reporting by paediatricians on a monthly basis, identified 58 cases of vitamin D 
deficiency rickets among children aged 0 to 14 years presenting to secondary care 
over a 3-year period between July 2010 to June 2013 (Wheeler et al, 2015). Children 
met the case criteria if they had a serum 25-OH-D level <50 nmol/l, and either an 
elevated serum alkaline phosphatase level or radiographic features of rickets. This 
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equated to an overall annual incidence risk of 2.2 per 100,000 children aged 0 to 14 
years (95% CI: 1.4 to 4.5). The majority of included cases presented with clinical 
features consistent with symptomatic vitamin D deficiency (skeletal deformity, poor 
growth, motor delay, hypocalcaemic seizures or tetany, bone pain, or cardiomyopathy). 
However, in approximately 10% of cases the diagnosis was made as an incidental 
finding, or following sibling screening. Incidence was considerably higher in younger 
children aged 0 to 2 years (10.5 per 100,000 children per year, 95% CI: 6.7 to 16.6) 
than in older children aged 3 to 14 years (0.1 per 100,000 children per year, 95% CI: 
0.02 to 1.0). Case ascertainment was limited to children presenting to secondary care. 
The ethnicity of affected children was not reported. 
 
 
3.4.4 Methodological Quality of Included Studies 
 
Assessment of the quality of study reporting and design is shown in Table 3.4. 
Assessment of the risk of bias, generalisability to the national population, and a 
description of the key limitations for each study is given in Table 3.5. 
Six of the thirteen studies were considered to be at high risk of bias influencing the 
reported incidence estimates, due to either a high risk of misclassification of cases 
(Beser & Cakmakci, 1994; Goldacre et al, 2014; Millette et al, 2014; Thacher et al, 
2013), a high risk of case under-ascertainment (CDC, 2001; Goldacre et al, 2014; 
Thacher et al, 2013), or low reliability of the population at risk estimate (Singleton et al, 
2015). Five of the thirteen studies were considered to have low generalisability to the 
national population, either because they were local studies covering a low-level 
administrative region (Beser & Cakmakci, 1994; Moy et al, 2012; Thacher et al, 2013), 
or because the study population was a selected group that was unlikely to be 
representative of the general population in that region (Millette et al, 2014; Singleton et 
al, 2015). 
 
Six of the thirteen studies were considered to be of higher overall methodological 
quality (Basatemur & Sutcliffe, 2015; Beck-Nielsen et al, 2009a; Callaghan et al, 2006; 
El-Fakhri et al, 2013; Ward et al, 2007; Wheeler et al, 2015). These studies were 
considered not to be at high risk of bias, and to have moderate or high generalisability 
to the national population. 
 
Confidence intervals around the incidence estimates were only reported in four of the 
thirteen studies (Basatemur & Sutcliffe, 2015; Goldacre et al, 2014; Ward et al, 2007; 
Wheeler et al, 2015), whilst sufficient information was available to derive confidence 
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intervals in a further four studies (Beck-Nielsen et al, 2009a; Beser & Cakmakci, 1994; 
El-Fakhri et al, 2013; Millette et al, 2014). For the remaining five studies, insufficient 
information was provided for the calculation of confidence intervals (Callaghan et al, 
2006; CDC, 2001; Moy et al, 2012; Singleton et al, 2015; Thacher et al, 2013). 
 
 
3.4.5 Overall Incidence Data 
 
Studies reporting a stated outcome of rickets or symptomatic vitamin D deficiency were 
considered together, as a number of the studies in which the stated study outcome was 
rickets also included children presenting with hypocalcaemic symptoms (Beck-Nielsen 
et al, 2009a; Thacher et al, 2013; Ward et al, 2007; Wheeler et al, 2015). The UK study 
specifically investigating hypocalcaemic seizures secondary to vitamin D deficiency 
was considered separately (Basatemur & Sutcliffe, 2015). 
 
3.4.5.1 Studies Reporting an Outcome of Rickets or Symptomatic Vitamin D 
Deficiency 
 
Figure 3.2 displays the incidence estimates from each of the included studies, with the 
exception of the small Turkish interventional study by Beser & Cakmakci (1994) which 
was excluded from the forest plot for purposes of clarity. The annual incidence risk for 
rickets reported by this study (3,800 per 100,000 children aged 3 to 36 months, 95% 
CI: 2,074 to 6,366) was over 30-fold higher than the next highest incidence estimate. 
As discussed in section 3.4.3.3, the risk of case misclassification in the Turkish study 
was considered to be very high, in view of the absence of a case definition and the 
diagnosis of rickets on the basis of non-specific and questionable symptoms and signs. 
Among the other included studies, annual incidence estimates for rickets or 
symptomatic vitamin D deficiency varied widely between 0.3 to 120 per 100,000 
children. 
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Figure 3.2  Forest plot of incidence estimates for rickets or symptomatic vitamin D 
deficiency, grouped by country of origin.a 
 
Abbreviations: CDC, Centers for Disease Control and Prevention; CI, confidence interval; m, months; N/A, 
not available; PYAR, person-years at risk; yrs, years. 
a Overall incidence estimates from all included studies reporting an outcome of rickets or symptomatic 
vitamin D deficiency, with the exception of the study by Beser & Cakmakci (1994) which was excluded for 
purposes of clarity. The study time period and age of included children is also displayed for each study. 
Where studies report separate incidence estimates for more than one time period, each time period is 
displayed as a separate line. Estimates represent an annual incidence risk per 100,000 children for all 
studies, with the exception of Thacher et al (2013) where the estimates represent an incidence rate per 
100,000 person-years at risk. Incidence estimates are represented by circles where 95% confidence 
intervals are not available. 
 
 
When only the five studies considered to be of higher methodological quality were 
considered (see section 3.4.4), there was substantially less variation in reported 
incidence (Figure 3.3). Among these studies, annual incidence risk estimates for rickets 
or symptomatic vitamin D deficiency ranged from 2.2 to 7.5 per 100,000 children.  
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Figure 3.3  Forest plot of incidence risk estimates for rickets or symptomatic vitamin D 
deficiency, restricted to studies of higher methodological quality.a 
 
Abbreviations: CI, confidence interval; N/A, not available; yrs, years. 
a Overall annual incidence risk estimates from studies considered to be of higher methodological quality 
(see section 3.4.4), grouped by country of origin. The study time period and age of included children is 
also displayed for each study. Incidence estimates are represented by circles where 95% confidence 
intervals are not available. 
 
 
After exclusion of the study by Callaghan et al (2006), which did not provide a 95% 
confidence interval, the pooled annual incidence risk estimate across the remaining 
four higher quality studies was 3.37 per 100,000 children (95% CI: 2.15 to 4.60) (Figure 
3.4). The meta-analysis indicated a high level of statistical heterogeneity between the 
studies’ incidence estimates (I2 = 88%). 
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Figure 3.4  Forest plot of the incidence of rickets or symptomatic vitamin D deficiency, 
restricted to studies of higher methodological quality, with a pooled summary estimate.a 
 
Abbreviations: CI, confidence interval; yrs, years. 
a Analysis restricted to studies which provided a 95% confidence interval around the incidence estimate, 
and to studies considered to be of higher methodological quality (see section 3.4.4). A random-effects 
model was used to calculate the pooled incidence risk estimate. 
 
 
3.4.5.2 Studies Investigating Hypocalcaemic Seizures Secondary to Vitamin D 
Deficiency 
 
The single study which specifically investigated hypocalcaemic seizures secondary to 
vitamin D deficiency reported an overall incidence risk estimate of 0.35 per 100,000 
children aged 0 to 15 years (95% CI: 0.28 to 0.43) (Basatemur & Sutcliffe, 2015). This 
study is described in full in chapter 4. 
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3.4.6 Differences in Incidence by Socio-Demographic Factors 
 
 
3.4.6.1 Age 
 
Four studies, all considered to be of higher methodological quality, reported incidence 
risk estimates stratified by age group (Basatemur & Sutcliffe, 2015; Beck-Nielsen et al, 
2009a; Ward et al, 2007; Wheeler et al, 2015). The incidence of rickets or symptomatic 
vitamin D deficiency was consistently reported to be significantly higher among young 
children aged ≤2 years compared to older children aged ≥3 years (Table 3.6). The 
incidence of hypocalcaemic seizures secondary to vitamin D deficiency was 
considerably higher among infants aged <1 year compared to older children. 
 
 
Table 3.6  Studies reporting age-stratified incidence estimates for symptomatic vitamin 
D deficiency. 
Study Location Age group Annual incidence risk per 100,000 children (95% CI) 
Study outcome - symptomatic vitamin D deficiency: 
Beck-Nielsen, 2009 Southern Denmark 
0 – 2 years 5.8  (4.0 – 8.3) 
0 – 14 years (overall) 2.9  (2.3 – 3.6) 
Ward, 2007 Canada 
0 – 1 year 9  (6 – 12) 
1 – 2 years 12  (8 – 16) 
3 – 7 years 0.3  (0.1 – 0.7) 
Wheeler, 2015 New Zealand 
0 – 2 years 10.5  (6.7 – 16.6) 
3 – 14 years 0.1  (0.02 – 1.0) 
Study outcome - hypocalcaemic seizures secondary to vitamin D deficiency: 
Basatemur, 2015 UK & Ireland 
<1 year 4.5  (3.6 – 5.6) 
1 – 2 years 0.2  (0.08 – 0.4) 
3 – 10 years No cases reported 
11 – 15 years 0.06  (0.02 – 0.1) 
Abbreviations: CI, confidence interval. 
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3.4.6.2 Ethnicity 
 
Four studies reported incidence estimates stratified by ethnicity, shown in Table 3.7 
(Basatemur & Sutcliffe, 2015; Beck-Nielsen et al, 2009a; Callaghan et al, 2006; 
Thacher et al, 2013). All four studies were conducted among populations of majority 
white (Caucasian) ethnicity. Two studies reported stratified incidence estimates among 
children from minority ethnic groups, but not among children of white ethnicity (Beck-
Nielsen et al, 2009a; Thacher et al, 2013). Across all four studies, incidence estimates 
for symptomatic vitamin D deficiency were considerably higher among children from 
minority ethnic groups (black, Asian, and Middle Eastern) when compared to white 
children or overall incidence estimates. However, confidence intervals around the 
incidence estimates were only available in two of the studies (Basatemur & Sutcliffe, 
2015; Beck-Nielsen et al, 2009a), limiting the conclusions that can be drawn from the 
data. 
 
 
Table 3.7  Studies reporting incidence estimates for symptomatic vitamin D deficiency 
stratified by ethnicity. 
Study Location Outcome Age Ethnic origin 
Annual incidence risk 
per 100,000 children 
(95% CI) 
Beck-Nielsen, 
2009 
Southern 
Denmark 
Symptomatic 
vitamin D 
deficiency 
0 – 14 
years 
Middle East 85  (53 – 129) 
Africa 59  (22 – 129) 
Asia 18  (2.2 – 66) 
Overall 2.9  (2.3 – 3.6) 
Callaghan, 
2006 
West 
Midlands, 
UK 
Symptomatic 
vitamin D 
deficiency 
0 – 4 
years 
White 0.4  (N/A) 
South Asian 38  (N/A) 
Black 95  (N/A) 
Basatemur, 
2015 
UK & 
Ireland 
Hypocalcaemic 
seizures 
0 – 15 
years 
White 0.04  (0.02 – 0.09) 
South Asian 2.6  (1.9 – 3.4) 
Black 2.1  (1.3 – 3.2) 
Mixed & other 0.37  (0.12 –0.88) 
Study Location Outcome Age Ethnic origin 
Incidence rate per 
100,000 person-years 
(95% CI) 
Thacher,  
2013 
 
(study period 
2000-2009) 
Olmsted 
County, 
Minnesota, 
USA 
Symptomatic 
vitamin D 
deficiency 
0 – 2 
years 
Black 220  (N/A) 
Overall 24.1  (N/A) 
Abbreviations: CI, confidence interval; N/A, not available. 
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3.4.6.3 Sex 
 
One study reported incidence estimates stratified by sex (Basatemur & Sutcliffe, 2015), 
with the incidence of hypocalcaemic seizures secondary to vitamin D deficiency 
reported to be 4-fold higher in males (0.57 per 100,000 boys aged 0 to 15 years, 95% 
CI: 0.45 to 0.71) compared to females (0.13 per 100,000 girls aged 0 to 15 years, 95% 
CI: 0.07 to 0.20). 
 
 
3.4.7 Temporal Trends in Incidence 
 
Three studies reported incidence estimates over separate time periods, shown in Table 
3.8 (Millette et al, 2014; Moy et al, 2012; Thacher et al, 2013). Millette et al (2014) 
reported an increase in the annual incidence of rickets among children aged ≤6 years 
in Quebec from 3.0 per 100,000 children in 2004, to 7.2 per 100,000 children in 2009. 
However, these estimates were based on very small numbers of cases with widely 
overlapping confidence intervals, and incidence was reported from two distinct 1-year 
time periods as opposed to continuous time-trend data, preventing any conclusions 
being drawn about temporal trends in incidence. 
 
Thacher et al (2013) reported an increase in the incidence of rickets among children 
aged ≤2 years in Olmsted County, Minnesota, USA from 1990-1999 (3.7 per 100,000 
person years) to 2000-2009 (24.1 per 100,000 person years). However, caution must 
be taken in drawing conclusions about temporal trends from this data, as confidence 
intervals were not provided and would be expected to be wide given the small number 
of cases in each time period (2 in 1990-999, 14 in 2000-2009). 
 
Moy et al (2012) reported a decrease in the incidence of symptomatic vitamin D 
deficiency among children aged ≤4 years in inner-city Birmingham, UK following a local 
public health initiative in 2005 to provide universal free of charge vitamin D 
supplements to pregnant and lactating women and children aged under 5 years. The 
annual incidence risk decreased from 120 per 100,000 children in 2005, to 49 per 
100,000 children in 2009-2010. However, caution must be taken in drawing 
conclusions about temporal trends from this data, as confidence intervals were not 
provided and incidence was reported from two distinct 1-year time periods as opposed 
to continuous time-trend data. 
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Table 3.8  Studies reporting incidence estimates for symptomatic vitamin D deficiency 
over separate time periods. 
Study Location Age Time period Annual incidence risk per 100,000 children (95% CI) 
Millette, 
2014 
Quebec, 
Canada 
0 – 6 
years 
2004 3.0  (0.6 – 8.8) 
2009 7.2  (2.7 – 15.7) 
Moy,  
2012 
Inner-city 
Birmingham, 
UK 
0 – 4 
years 
2005 120  (N/A) 
2009 – 2010 49  (N/A) 
Study Location Age Time period Incidence rate per 100,000 person-years (95% CI) 
Thacher, 
2013 
Olmsted 
County, 
Minnesota, 
USA 
0 – 2 
years 
1990 – 1999 3.7  (N/A) 
2000 – 2009 24.1  (N/A) 
Abbreviations: CI, confidence interval; N/A, not available. 
 
 
3.4.8 Sources of Heterogeneity 
 
There were considerable differences among the included studies with respect to 
various important clinical and methodological characteristics, such as: the age of 
included children, the ethnic composition of study populations, whether or not children 
with underlying chronic conditions that predispose to vitamin D deficiency were 
excluded, differences in the setting from which cases were identified (e.g. both 
outpatient and inpatient, or inpatient only), differences in case definitions for the 
outcome, and differences in methods of data collection (e.g. prospective surveillance 
study, or retrospective analysis of healthcare administrative database). The number of 
included studies was not sufficient for subgroup analysis or meta-regression to be 
undertaken to further investigate possible sources of heterogeneity. 
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3.5 Discussion 
 
3.5.1 Summary of Results and Comparison with Existing Studies 
 
The systematic review identified 13 studies reporting data concerning the incidence of 
symptomatic vitamin D deficiency in children. The majority of the studies originated 
from Europe and North America, and data was scarce to non-existent from Asia, Africa, 
and South America. There was considerable heterogeneity among the included studies 
with respect to the study populations, clinical and methodological characteristics, and 
the assessed risk of bias. There was a wide variation in reported annual incidence 
estimates, ranging between 0.3 to 3,800 per 100,000 children. 
 
Among the subset of studies considered to have a lower risk of bias, and which 
included all presentations of symptomatic vitamin D deficiency as the outcome, there 
was substantially less variation in annual incidence estimates, which ranged between 
2.2 to 7.5 per 100,000 children. A summary estimate for the annual incidence of 
symptomatic vitamin D deficiency, derived from four studies considered to be of higher 
methodological quality, was 3.37 per 100,000 children (95% CI: 2.15 to 4.60). The 
studies included in the meta-analysis all originated from high-income countries with 
populations of predominantly Caucasian (white) ethnicity (Canada, Denmark, New 
Zealand, and Scotland), and were similar in respect to the age range of included 
children (between 0-14 to 0-18 years). However, the pooled incidence estimate should 
be interpreted with caution, given the high level of statistical heterogeneity observed (I2 
= 88%). 
 
One study specifically investigated the incidence of hypocalcaemic seizures secondary 
to vitamin D deficiency in the UK and Ireland, reporting an annual incidence estimate of 
0.35 per 100,000 children aged 0 to 15 years (95% CI: 0.28 to 0.43) (Basatemur & 
Sutcliffe, 2015). This study is described in full in chapter 4. 
 
Few studies have examined differences in the incidence of symptomatic vitamin D 
deficiency by children’s socio-demographic characteristics. Data from three studies 
suggests that the incidence of symptomatic vitamin D deficiency overall is considerably 
higher among younger children aged ≤2 years (annual incidence estimates between 
5.8 to 12 per 100,000 children) compared to older children aged ≥3 years (annual 
incidence estimates between 0.1 to 0.3 per 100,000 children). The incidence of 
hypocalcaemic seizures secondary to vitamin D deficiency was >20-fold higher in 
infants under 1 year of age compared to older children. The limited data available 
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regarding ethnic differences in the incidence of symptomatic vitamin D deficiency 
suggests that it is considerably higher among children from black, Asian, and Middle 
Eastern ethnic groups when compared to white children or overall incidence estimates 
from predominantly Caucasian populations. No studies have examined differences in 
the overall incidence of symptomatic vitamin D deficiency in children by gender, 
however the incidence of hypocalcaemic seizures secondary to vitamin D deficiency 
was 4-fold higher in boys compared to girls in results from a single study. There is 
insufficient data to draw any conclusions regarding temporal trends in the incidence of 
symptomatic vitamin D deficiency in children over the last 25 years. 
 
As far as it has been possible to identify, this is the first systematic review to 
specifically investigate the incidence of symptomatic vitamin D deficiency in children. 
Both systematic and narrative reviews have been published which broadly explore the 
epidemiology, aetiology and clinical presentation of nutritional rickets worldwide (Creo 
et al, 2017; Prentice, 2013; Thacher et al, 2006). In contrast to the systematic review 
described in the chapter, these reviews were not focused on disease incidence, but 
also included studies which reported disease prevalence, as well case series which did 
not provide any measures of disease frequency. Although a considerably larger 
number of studies were included in these reviews, their findings were summarised very 
briefly, and there was no critical appraisal or quality assessment of the included 
studies. These reviews included prevalence studies from regions of the world for which 
incidence data was scare or non-existent, such as Africa, Asia, and the Middle East. 
However, dietary calcium deficiency is an important cause of rickets in developing 
countries, and few studies from these regions included biochemical assessment to help 
distinguish the relative contribution of vitamin D deficiency and calcium deficiency in 
the aetiology of rickets. 
 
 
3.5.2 Study Strengths and Limitations 
 
A comprehensive search of the published literature was undertaken using multiple 
bibliographic databases. However, a limitation of the search strategy was that 
unpublished material or ‘grey literature’ was not specifically sought. The reporting of the 
systematic review followed the MOOSE guidelines for meta-analysis of observational 
studies in epidemiology (Stroup et al, 2000). Included studies were critically appraised 
for indicators of methodological quality, and for assessment of the risk of bias. 
However, as no established or validated tool exists for the quality assessment of 
studies of disease incidence, the assessment criteria for study quality and risk of bias 
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were constructed in an ad hoc manner specifically for this study. A limitation of the 
review methodology was that study assessment and selection was undertaken by a 
single researcher, as opposed to independent double screening by at least two 
investigators as recommended by published guidelines (Liberati et al, 2009). 
 
The methodological quality of included studies was variable, with seven of the thirteen 
included studies (54%) considered to have either a high risk of bias or poor 
generalisability to the national population. The considerable heterogeneity between 
studies limited the ability to synthesise results across settings. Factors contributing to 
this heterogeneity include the lack of accepted diagnostic criteria for the outcome, 
which resulted in wide variation in the case definitions used by different studies, and 
differences in the demographic characteristics of different study populations (e.g. in 
terms of age and ethnicity). The studies included in the systematic review originated 
almost entirely from high-income countries with predominantly Caucasian populations, 
restricting the relevance of the findings to similar settings. Few studies reported 
incidence estimates stratified by socio-demographic factors, limiting the ability to 
investigate differences in incidence by age, sex, and ethnicity. The number of included 
studies was not sufficient to perform subgroup analysis or meta-regression to further 
investigate possible sources of heterogeneity, or differences in incidence rates in 
relation to socio-demographic factors. There was also insufficient data available to 
draw any conclusions regarding temporal trends in incidence.  
 
 
3.5.3 Conclusion 
 
Overall, symptomatic vitamin D deficiency is relatively uncommon among children from 
high-income countries with populations of predominantly Caucasian ethnicity. The 
more reliable annual incidence estimates available from such settings range between 
2.2 to 7.5 per 100,000 children. The limited evidence available suggests that 
symptomatic vitamin D deficiency is considerably more frequent (by between 1 to 2 
orders of magnitude) among younger children aged ≤2 years compared to older 
children aged ≥3 years, and among children from black, Asian, and Middle Eastern 
ethnic minority groups compared to children from white ethnic backgrounds. Although 
anecdotal reports and local case series have raised concerns that symptomatic vitamin 
D deficiency may have increased in frequency among children in high-income countries 
in recent decades, there is insufficient epidemiological data available to draw any 
conclusions regarding temporal trends in incidence over the last 25 years. There is a 
lack of data regarding the incidence of symptomatic vitamin D deficiency among 
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children from regions such as Africa, Asia, the Middle East, and South America. The 
implications of the work described in this chapter, with respect to public health and 
future research, are further discussed in the final chapter of the thesis. 
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Chapter 4 
 
 
Hypocalcaemic Seizures Secondary to Vitamin D 
Deficiency in Children: A Prospective, 
Population-Based Surveillance Study in the 
United Kingdom and Ireland 
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4.1 Introduction 
 
Over the last two decades, anecdotal reports have raised concerns that increasing 
numbers of children are presenting to healthcare services in the United Kingdom (UK) 
with clinical complications of vitamin D deficiency (Allgrove, 2004; Davies & Shaw, 
2011; Shaw & Pal, 2002). However, existing studies investigating symptomatic vitamin 
D deficiency among children in the UK have either been single- or multi-centre case 
series, without denominator data available for the calculation of incidence, or regional 
studies with limited generalisability to the national population (see chapter 2.7.2). The 
systematic review described in chapter 3 identified that no previous studies have 
reported incidence estimates for any of the clinical complications of vitamin D 
deficiency at the national level in the UK. This chapter describes a prospective 
surveillance study undertaken across the UK and Ireland, using the British Paediatric 
Surveillance Unit (BPSU) reporting system, investigating the incidence of 
hypocalcaemic seizures secondary to vitamin D deficiency in children. 
 
 
 
4.2 Background 
 
 
4.2.1 The British Paediatric Surveillance Unit 
 
The British Paediatric Surveillance Unit (BPSU) was established in 1986, with the remit 
of facilitating research into rare childhood diseases. It has national coverage across the 
UK and Republic of Ireland, and uses an active method of surveillance with case 
reporting by consultant paediatricians and associate specialist paediatricians who have 
their own case load. In 2009, approximately 94% of all consultant paediatricians in the 
UK and Ireland participated in the BPSU reporting system (Knowles et al, 2012). 
 
Each month all participating paediatricians are mailed or emailed a reporting card from 
the BPSU, known as the ‘Orange Card’. The reporting card lists the conditions under 
surveillance, along with the reporting case criteria for each of the conditions. Recipients 
are asked to indicate the number of relevant cases that they have seen within the past 
month, or state that they have nothing to report, before returning the card to the BPSU. 
Follow-up reminders are sent to paediatricians who do not return their reporting cards. 
Response rates to BPSU reporting cards are high, with 95.3% of reporting cards 
returned in 2013 (BPSU, 2014). On receiving a case report, BPSU staff inform the 
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relevant study team, who send the reporting clinician a short data collection form to 
obtain case details. The BPSU methodology is summarised in Figure 4.1. 
 
Researchers collect limited patient identifiable data in order to identify duplicate 
reports. However patient consent is not sought, as doing so would reduce case 
ascertainment and risk selection bias if certain groups of patients were more likely to 
refuse consent (Verity & Nicoll, 2002). Regulatory approval for the collection of patient 
identifiable data without consent, for research purposes, is obtained from the 
Confidentiality Advisory Group (CAG) at the NHS Health Research Authority, under 
section 251 of the NHS Act 2006. Prior to 2013, this responsibility of the CAG was 
undertaken by the National Information Governance Board for Health and Social Care 
(NIGB). 
 
 
 
Figure 4.1  The British Paediatric Surveillance Unit methodology. 
 
Key: A The BPSU reporting card is sent to paediatricians every month. B Paediatricians return 
the reporting card to the BPSU office, to report the number of cases that they have seen in the 
preceding month, or to state that they have no cases to report. C BPSU staff inform researchers 
of paediatricians who have reported cases. D Researchers send reporting paediatricians a 
questionnaire to collect case details. E For some studies, cases may also be ascertained from 
alternative sources, for example laboratory surveillance systems, national death registration 
data, or surveillance systems involving reporting by other groups of specialist clinicians 
(Knowles et al, 2006). Figure adapted from Knowles et al. (2012). 
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4.2.2 Rationale for Investigating Hypocalcaemic Seizures Secondary to Vitamin 
D Deficiency Using the BPSU Methodology 
 
In order to be appropriate for investigation using the BPSU reporting system, 
conditions must be relatively rare and should be principally managed by paediatricians 
(as opposed to being managed in primary care or by other specialties). At the time of 
the design of this study, the BPSU eligibility criteria stated that conditions ‘should have 
an expected incidence in the UK of no more than 300 cases per year’, so as not to 
exceed the unit’s administrative capacity (Knowles et al, 2010). 
 
It was considered that symptomatic vitamin D deficiency in its entirety may not to be 
suitable for investigation using the BPSU methodology, for two reasons. Firstly, it was 
predicted that the incidence may exceed 300 cases per year in children in the UK and 
Ireland. The incidence of symptomatic vitamin D deficiency in children aged 0 to 4 
years in the West Midlands had previously been estimated at 7.5 per 100,000 children 
per year (Callaghan et al, 2006). Based on mid-2010 population estimates of 4.22 
million children aged between 0 to 4 years in the UK and Republic of Ireland (CSO, 
2014; ONS, 2013c), an incidence rate of 7.5 per 100,000 would equate to an estimated 
316 cases per year nationally in this age group alone. Although one would expect 
incidence rates for symptomatic vitamin D deficiency to be lower nationally than in the 
West Midlands, due to the large South Asian population resident in this region, further 
cases would be expected among older children aged 5 years and above. 
 
Secondly, health professionals who do not participate in BPSU surveillance may 
manage certain presentations of vitamin D deficiency. Less severe presentations of 
rickets or osteomalacia with non-specific musculoskeletal pain or muscle weakness, 
particularly in older children, may be managed in primary care. Children with skeletal 
deformities secondary to rickets may be referred to orthopaedic surgeons rather than 
paediatricians (Naseem et al, 2011). This could result in under-ascertainment of cases 
with musculoskeletal manifestations of vitamin D deficiency. 
 
However, the BPSU reporting system was considered to be suitable for investigation of 
the most common acute presentation of vitamin D deficiency: hypocalcaemic seizures 
(see chapter 2.3.2 and 2.7.2). In the UK, the care of children with hypocalcaemic 
seizures is likely to be managed almost exclusively by paediatricians. The incidence of 
hypocalcaemic seizures secondary to vitamin D deficiency was predicted not to exceed 
the recommended capacity of BPSU studies. In Callaghan and colleagues (2006) 
survey of West Midlands paediatricians, 6 out of the reported 25 cases (25%) 
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presented with hypocalcaemic seizures, equating to an estimated annual incidence of 
1.88 per 100,000 children age between 0 to 4 years. Using mid-2010 population 
estimates (CSO, 2014; ONS, 2013c), this gives an estimate of 79 cases per year in the 
UK and Ireland in this age group. A relatively small number of additional cases would 
be expected in older children; previous case series have reported that the majority 
(76% to 85%) of children with hypocalcaemic presentations of vitamin D deficiency are 
less than 3 years of age (Ladhani et al, 2004; Robinson et al, 2006). 
 
 
 
4.3 Aims and Objectives 
 
 
4.3.1 Study Aims 
 
The overall aim of this study was to describe the epidemiology in the UK of one of the 
acute clinical presentations of vitamin D deficiency in children, hypocalcaemic seizures. 
 
 
4.3.2 Study Objectives 
  
i) To estimate the overall incidence of hypocalcaemic seizures secondary to 
vitamin D deficiency in children in the UK and Ireland, and the incidence 
stratified by sex, age and ethnicity. 
 
ii) To describe the demographic and clinical characteristics of affected children. 
 
iii) To summarise the biochemical profile, and other investigation results, in 
affected children. 
 
iv) To describe the clinical management of affected children. 
 
v) To determine the clinical outcomes in affected children. 
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4.4 Methods 
 
 
4.4.1 Study Design 
 
This was a prospective national surveillance study, using the British Paediatric 
Surveillance Unit reporting system (see section 4.2.1). 
 
 
4.4.2 Study Surveillance Period 
 
Surveillance of hypocalcaemic seizures secondary to vitamin D deficiency was 
conducted for a 2-year period, between September 2011 and September 2013, during 
which the condition was listed on the monthly BPSU reporting card (the ‘Orange Card’). 
 
 
4.4.3 Correspondence with Reporting Clinicians 
 
The study team was informed of all case notifications for the study by BPSU staff on a 
weekly basis, and provided with contact details for the paediatricians who reported the 
cases. Reporting clinicians were subsequently contacted by both post and email, with a 
cover letter (see appendix D.1) thanking them for reporting the case and politely 
requesting them to complete an attached data collection form (see appendix D.2), in 
order to confirm case status and obtain demographic and clinical details regarding the 
case. A reminder letter and email was sent to paediatricians who did not return the 
data collection form within three to four weeks of the initial request. If reporting 
clinicians did not respond within a further three weeks of the reminder letter, they were 
contacted by telephone (a minimum of three attempts on separate days). 
 
 
4.4.4 Case Definition 
 
A surveillance case definition was used to provide case reporting criteria for 
paediatricians, and a narrower analytic case definition was used to subsequently 
confirm case status. Separate surveillance and analytic case definitions were used to 
simplify the reporting criteria, and thus minimise any under-reporting of cases arising 
from uncertainty or complexity regarding the reporting criteria. The surveillance case 
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definition, which was included on the monthly BPSU reporting card, is shown in Box 
4.1: 
 
 
 
The 25-hydroxyvitamin D (25-OH-D) cut-off of 50 nmol/l represents the level below 
which vitamin D status is defined as ‘insufficient’ in UK paediatric guidelines, although 
the evidence base underpinning 25-OH-D thresholds is limited (see chapter 2.4) 
(Arundel et al, 2012; Arundel & Shaw, 2015; RCPCH, 2013). Severe manifestations of 
vitamin D deficiency, such a frank rickets and hypocalcaemic symptoms, are generally 
thought to occur with 25-OH-D levels below 25 nmol/l, which is defined as ‘deficiency’ 
in UK guidance (Pearce & Cheetham, 2010; Shaw & Mughal, 2013a). However, a 
number of case series have reported that children with symptomatic vitamin D 
deficiency, including those with hypocalcaemic presentations, can have 25-OH-D levels 
in the ‘insufficient’ range of 25-50 nmol/l (Ahmed et al, 2011; Sharma et al, 2009; 
Wheeler et al, 2015). Therefore, the cut-off of <50 nmol/l was chosen for the study 
case definition, as opposed to <25 nmol/l, in order to minimise the risk of case under-
ascertainment. 
 
  
Any child under 16 years of age who develops a suspected seizure* in the 
presence of BOTH of the following biochemical criteria: 
 
 1. Low serum corrected calcium: <2.0 mmol/l 
 2. Low serum 25-hydroxyvitamin D level: <50 nmol/l (<20 ng/ml) 
 
Excluding children with a history of a previous confirmed hypocalcaemic 
seizure due to vitamin D deficiency (prior to this presentation). 
 
*Include cases where the event is felt to most likely represent a true seizure, as 
opposed to another paroxysmal event. A seizure can be defined as a 
paroxysmal, time-limited change in motor activity and/or behaviour that results 
from abnormal electrical activity in the brain. 
 
Box 4.1  Surveillance case definition. 
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The analytic case definition was identical to the surveillance case definition, with the 
addition of the following exclusion criteria: 
 
i) Presence of an alternative cause of seizures (other than hypocalcaemia) at 
the time of the event. 
 
ii) Presence of an underlying pathology that can cause secondary vitamin D 
deficiency, by interfering with vitamin D absorption or metabolism. 
 
Information regarding the above exclusion criteria was obtained using the data 
collection form (see appendix D.2). The presence or absence of the following 
conditions that can cause seizures was specifically sought in the data collection form; 
central nervous system infection (meningitis or encephalitis), central nervous system 
ischaemic or haemorrhagic events (intracranial haemorrhage, cerebral infarction, or 
hypoxic ischaemic encephalopathy), hypoglycaemia, severe hypernatraemia (>155 
nmol/l) or hyponatraemia (<125 nmol/l), epilepsy, drug withdrawal, and inborn errors of 
metabolism. The presence or absence of the following conditions that can cause 
secondary vitamin D deficiency was specifically sought in the data collection form; 
chronic renal disease, liver disease, gastrointestinal disease with malabsorption, 
conditions necessitating total parenteral nutrition, and inherited disorders of vitamin D 
metabolism. 
 
Cases that met the analytic case definition were defined as ‘confirmed’ cases. During 
data collection, a number of cases were reported in which serum 25-OH-D 
measurements were unavailable, because blood samples taken at presentation were 
insufficient for analysis. However, the working diagnosis in all of these cases was that 
of a hypocalcaemic seizure secondary to vitamin D deficiency. Excluding these cases 
would have resulted in case under-ascertainment. Therefore, such cases were defined 
as ‘probable’ cases if they otherwise met the analytic case definition, and if one or 
more of the following additional features suggestive of metabolic bone disease 
secondary to vitamin D deficiency were present: 
 
i) High serum alkaline phosphatase (ALP), according to local laboratory 
reference range. 
 
ii) High serum parathyroid hormone (PTH), according to local laboratory 
reference range. 
 
iii) Radiological features suggestive of rickets, as reported by the clinician. 
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4.4.5 Data Collection Form 
 
The data collection form was designed to take no longer than 10 to 15 minutes to 
complete, so as not to impose an excessive burden on reporting clinicians. 
Participation in the BPSU reporting system is voluntary, and paediatricians who report 
cases do not receive any incentive for doing so. Requesting clinicians to complete a 
longer or more time consuming questionnaire would risk compromising return rates. 
 
The data collection form was designed to only request information that was likely to be 
readily available in the clinical case notes, i.e. information that would be documented 
as part of routine clinical care. Paediatricians would generally be expected to complete 
the questionnaire some time, typically weeks to months, after the child had presented. 
Therefore, they were not expected to have access to the child or their family to clarify 
specific study questions. 
 
Feedback on the design and content of the data collection form was requested from a 
convenience sample of 14 consultant paediatricians, of whom 8 responded. Their 
comments were incorporated into the final questionnaire design. 
 
The data collection form requested details regarding the demographics, clinical 
presentation, co-morbidities, investigation results, and clinical management of cases. 
See appendix D.2 for a copy of the data collection form. Information regarding ethnicity 
was collected using the UK Census 2001 categories (ONS, 2001). Gestational age was 
categorised using the World Health Organisation definitions of prematurity (Blencowe 
et al, 2012). The following patient identifiable data was collected in order to identify 
duplicate reports; NHS number, local hospital number, date of birth, sex, and district 
level partial postcode. 
 
 
4.4.6 Population Estimates 
 
Population estimates from the Office for National Statistics (ONS) for the UK, and the 
Central Statistics Office (CSO) for the Republic of Ireland, were used to estimate the 
population at risk for the calculation of incidence. For the calculation of overall 
incidence, and incidence stratified by age and sex, mid-2012 population estimates from 
the ONS (2013b) and 2012 population estimates from the CSO (2014) were used, as 
this represents the study midpoint. Population data stratified by ethnicity was only 
available for children aged between 0 to 14 years in England, Wales, and Republic of 
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Ireland, using 2011 census population estimates (CSO, 2012; ONS, 2013a). 
Population estimates stratified by ethnicity were not available for Scotland or Northern 
Ireland. 
 
 
4.4.7 Statistical Analysis 
 
Analyses were primarily descriptive. Data were summarised using means and standard 
deviations (SD) for approximately normally distributed data, and using medians and 
interquartile ranges (IQR) for non-normally distributed data. Annual incidence estimates 
were calculated as follows: 
 
 number of cases during the study period ÷ (population at risk x 2) 
 
95% confidence intervals (CI) around incidence estimates were calculated using the 
exact Poisson method. Differences in biochemical test parameters by age and sex 
were examined using independent t-tests for normally distributed data, and Wilcoxon 
rank sum tests for non-normally distributed data. Analyses were performed using Stata 
SE version 13.1 (StataCorp, USA). 
 
 
4.4.8 Ethical Approval 
 
Ethical approval for the study was obtained from the London Central Research Ethics 
Committee (reference 11/LO/0838, see appendix B.1). Approval for the collection of 
patient identifiable data without consent was obtained from the Ethics and 
Confidentiality Committee of the National Information Governance Board for Health 
and Social Care (NIGB), under Section 251 of the NHS Act 2006 (reference ECC/ 
BPSU/6-02(FT7)/2011, see appendix B.2). Following a two-stage scientific review 
process, the study was approved for inclusion in the BPSU reporting system by the 
BPSU Executive Committee (see appendix B.3). 
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4.5 Results 
 
 
4.5.1 Status of Reported Cases 
 
There were 137 case notifications in total during the study period, of which 82 were 
confirmed cases and 10 were probable cases (Figure 4.2).1 There were 18 duplicate 
notifications, and 18 cases were reported in error or did not meet the case criteria. It 
was not possible to ascertain case status for 9 notifications (7%), either because the 
reporting consultants were unable to recall the patient’s identifiers and locate the case 
notes (n=6), or because they were not contactable or did not return the data collection 
form despite several reminders (n=3). The 92 confirmed and probable cases were 
included for the subsequent analyses. 
 
  
                                               
1 The data collection form for one case was returned by the clinician 2 years after the initial case 
report, following publication of the results of the study in The Journal of Clinical Endocrinology 
and Metabolism (see appendix A.1). Therefore, the number of confirmed cases included in the 
analyses reported in the published paper is one less (81) than described in this thesis. 
82 
Confirmed Cases 
10 
Probable Cases 
18 
Erroneous reports / did 
not meet case criteria a 
18 
Duplicate notifications  
137  
Case Notifications 
128 
Case status ascertained 
9 
Lost to follow-up  
Figure 4.2  Flow diagram of case notifications. 
a 7 cases occurred prior to the study surveillance period, 3 had tetany rather than seizures, 2 did 
not have a serum 25-OH-D available and did not meet the criteria for a probable case, 1 was 
age 17 years at the time of the seizure, 1 had a previous hypocalcaemic seizure due to vitamin 
D deficiency, 1 was an overseas patient not resident in the UK, and 1 child was known to have 
velocardiofacial syndrome and hypoparathyroidism which was an alternative explanation for the 
hypocalcaemia. In 2 cases, the paediatrician did not intend to report a case for the study (the 
notification was in error). 
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4.5.2 Demographic Characteristics 
 
Demographic characteristics of the included cases are shown in Table 4.1. There was 
a marked difference in the number of cases by sex, with 83% being male. Cases fell 
into two distinct age groups; 95% of cases were young children aged between 0 and 2 
years (n=87), and the remaining 5% (n=5) were adolescents aged between 11 and 15 
years (Figure 4.3). The majority of cases were infants less than 1 year of age (87%), 
and a significant proportion of cases were neonates below 1 month of age (26%). 
 
 
 
Table 4.1  Demographic characteristics of cases. 
Country (n=92) n  (%) 
 England 83  (90%) 
 Scotland 3  (3%) 
 Wales 1  (1%) 
 Northern Ireland 2  (2%) 
 Republic of Ireland 3  (3%) 
Sex (n=92) n  (%) 
 Male 76  (83%) 
 Female 16  (17%) 
Ethnicity (n=92) n  (%) 
 Any white background 11  (12%) 
 Pakistani 35  (38%) 
 Indian 11  (12%) 
 Other South Asiana 8  (9%) 
 Black (African / Caribbean / other) 22  (24%) 
 Mixed & other ethnicityb 5  (5%) 
Age in months at presentation (n=92) Median  (IQR) 
 5.5  (0.9–8.0) 
Gestation at birth (n=84) n  (%) 
 ≥ 37 weeks 77  (92%) 
 32 – 36 weeks 6  (7%) 
 < 28 weeks 1  (1%) 
Abbreviations: IQR, interquartile range. 
a 3 Bangladeshi, 2 Afghan, 3 unspecified Asian background. 
b 2 children with mixed ethnicity, 1 Libyan, 1 Iranian, and 1 Iraqi. 
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Figure 4.3  Distribution of cases by age. 
 
 
 
The majority of cases were from ethnic groups known to be at high risk of vitamin D 
deficiency; 59% (n=54) were of South Asian ethnicity and 24% (n=22) were black. 12% 
(n=11) came from a white background. Data regarding gestational age at birth was 
missing for 8 cases (9%). Among cases with data available for gestational age, the 
majority (92%) were born at term (≥37 weeks gestation). 6 children (7%) were 
moderate to late preterm (32 to 36 weeks gestation), and one case (1%) was extremely 
preterm (<28 weeks). 
 
 
4.5.3 Seasonal Variation in Presentation 
 
There was a marked seasonal pattern in presentation, with 74% of cases occurring 
between November to April (Figure 4.4). 
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Figure 4.4  Distribution of cases by calendar month. 
 
 
 
 
4.5.4 Incidence Estimates 
 
The estimated annual incidence of hypocalcaemic seizures secondary to vitamin D 
deficiency was 3.53 per million children aged 0 to 15 years (95% CI: 2.84 to 4.33). 
Incidence was significantly greater in males compared to females, in infants compared 
to older children, and in children of South Asian or black ethnicity compared to children 
from white ethnic backgrounds (Table 4.2). 
 
Population estimates stratified by ethnicity are not available by single year of age. 
However, approximate population estimates for infants (under 1 year of age) stratified 
by ethnicity can be derived for England, Wales and Republic of Ireland by applying the 
ethnicity distribution for children aged 0 to 4 years in the 2011 census (CSO, 2012; 
ONS, 2013a) to overall population estimates for infants in 2012 (CSO, 2014; ONS, 
2013b). This gives estimated incidence of 30.9 per 100,000 South Asian infants (95% 
CI: 22.6 to 41.2), 26.9 per 100,000 black infants (95% CI: 16.7 to 41.2), and 0.32 per 
100,000 white infants (95% CI: 0.09 to 0.81). 
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Table 4.2  Annual incidence estimates: overall and stratified by sex, age, and ethnicity. 
 Number of cases a 
Population 
estimate 
Annual incidence per million 
(95% CI) 
All children age <16 years 92 13,037,071 b 3.53  (2.84–4.33)  
Stratified by sex    
 Male 76 6,673,852 b 5.69  (4.49–7.13) 
 Female 16 6,363,219 b 1.26  (0.72–2.04) 
Stratified by age    
 < 1 year 80 890,510 b 44.9  (35.6–55.9) 
 1 – 2 years 7 1,745,821 b 2.00  (0.81–4.13) 
 3 – 10 years 0 6,430,876 b - 
 11 – 15 years 5 3,969,864 b 0.63  (0.20–1.47) 
Stratified by ethnicity c    
 White 8 8,674,415 d 0.46  (0.20–0.91) 
 South Asian 52 998,463 d 26.0  (19.4–34.1) 
 Black 21 507,205 d 20.7  (12.8–31.6) 
 Mixed & other 5 662,816 d 3.77  (1.22–8.80) 
a Number of confirmed and probable cases over the 2-year study period 
b Mid-2012 population estimates for children aged 0 to 15 years in England, Wales, Scotland, 
Northern Ireland, & Republic of Ireland. 
c Analysis stratified by ethnicity only includes children aged 0 to 14 years in England, Wales & 
Republic of Ireland (n=86), as population estimates by ethnicity are not available for children in 
Scotland and Northern Ireland, or for children aged 15 years in the Republic of Ireland. 
d Mid-2011 population estimates for children aged 0 to 14 years in England, Wales, & Republic 
of Ireland. 
 
 
 
4.5.5 Risk Factors for Vitamin D Deficiency 
 
Information regarding type of feeding was available for 98% of children under 1 year of 
age (Table 4.3). Although most cases were exclusively breastfed (55%), 15 (19%) were 
exclusively formula milk fed. 14 of these 15 (93%) were neonates under one month of 
age. Information regarding whether or not the mother was veiled / covered was 
available for 77% of cases. Of these, 46% of mothers were reported to have some 
degree of veiling / covering (either full length or a head scarf). There was a substantial 
proportion of missing data regarding maternal use of vitamin D supplements during 
pregnancy (38% missing) and breastfeeding (26% missing). Among cases age <2 
years, 8% (n=4) of mothers were reported to have taken vitamin D supplements during 
pregnancy. Information regarding the preparation of vitamin D was available for 2 of 
these cases (Adcal D3 in one, non-specified multivitamin in the other), however the 
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dose was not available for either case. Among cases who were breastfed, 6% of 
mothers were reported to be taking vitamin D supplements at the time of presentation. 
Information regarding the preparation and dose of vitamin D was not available in any of 
these cases. 
 
 
Table 4.3  Risk factors for vitamin D deficiency among cases. 
 n  (%) 
Diet if age <1 year (n=78) a  
 Exclusively breast fed 43  (55%) 
 Formula milk 15  (19%) 
 Mixed breast milk & formula 7  (9%) 
 Weaned onto solids 13  (17%) 
Mother veiled / covered (n=71)  
 Yes 33  (46%) 
 No 38  (54%) 
If child aged <2 years, did the mother take vitamin D supplements 
during pregnancy (n=53) b  
 Yes 4  (8%) 
 No 49  (92%) 
If child breastfed, was mother taking vitamin D supplements (n=52) c  
 Yes 3  (6%) 
 No 49  (94%) 
a Total number of cases aged <1 year = 80. Data missing for 2 cases. All children age ≥1 
year were weaned onto solids. 
b Total number of cases aged <2 years = 85. Data missing for 32 cases. 
c 22 cases reported as not breastfeeding. Number of cases with data missing = 18.  
 
 
 
4.5.6 Clinical Characteristics 
 
61% of cases had multiple seizures (Table 4.4). In the majority of children, seizure 
duration was less than 5 minutes (60%), with more prolonged seizures lasting ≥10 
minutes in 20% of cases. 80% of children did not have any other clinical features of 
vitamin D deficiency, whilst 15% exhibited features of rickets. 
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Table 4.4  Clinical characteristics of cases. 
Number of seizures (n=92) n  (%) 
 1 36  (39%) 
 2 – 5 37  (40%) 
 > 5 19  (21%) 
Duration of longest seizure in minutes (n=85) Median  (IQR) 
  3 (2–7) 
Other clinical manifestations of vitamin D deficiency (n=92) n  (%) 
 None 74  (80%) 
 Rickets a 14  (15%) 
 Stunted growth 4  (4%) 
 Fracture 1  (1%) 
 Muscular cramps & paraesthesia 1  (1%) 
Abbreviations: IQR, interquartile range. 
a Skeletal features reported included bowed legs, joint swelling, ricketary rosary, and 
craniotabes. 
 
 
 
4.5.7 Investigations 
 
Serum biochemistry results are shown in Table 4.5. Where available, serum 25-OH-D 
levels were <25 nmol/l in 87% of children, and between 25-50 nmol/l in 13%. Median 
ALP and PTH levels were above normal, whilst the mean phosphate was at the upper 
end of the normal range. Exploration of the relationship between age and serum 
biochemistry using scatterplots suggested that neonates (age <1 month) exhibited 
lower ALP and PTH levels, and higher phosphate levels, than older children (Figure 
4.5). These differences were statistically significant (Table 4.6). There were no 
significant differences in serum biochemistry between males and females, although the 
analysis is limited by small numbers of females resulting in wide confidence intervals in 
this group (Table 4.7). Where the maternal 25-OH-D level was available (48% of 
cases), it was <25 nmol/l in 72% and between 25-50 nmol/l in 26% of cases. 
Radiographs were performed in 30 cases (33%), of which 23 were reported to have 
features of rickets present (77%). Electrocardiograms were performed in 40 cases 
(43%), of which 16 were reported to have a prolonged QT interval (40%). 
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Table 4.5  Investigation results. 
Serum biochemistry a Median  (IQR) 
 25-hydroxyvitamin D (nmol/l)  (n=82) 11.1  (8.0–19.2) 
 Alkaline phosphatase (iu/l)  (n=90) 683  (452–1,003) 
 Parathyroid hormone (pmol/l)  (n=73) 21.3  (9.0–36.6) 
 Mean  (SD) 
 Corrected calcium (mmol/l)  (n=92) 1.42  (0.21) 
 Phosphate (mmol/l)  (n=87) 2.13  (0.75) 
Maternal 25-OH-D (nmol/l)  (n=43) Median  (IQR) 
  18.5  (12.0–27.9) 
X-ray of a long bone  (n=30) n  (%) 
 Signs of rickets present 23  (77%) 
Electrocardiogram  (n=40) n  (%) 
 Prolonged QT interval present 16  (40%) 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; ALP, alkaline phosphatase; IQR, interquartile 
range; PTH, parathyroid hormone; SD, standard deviation. 
a Reference ranges vary by lab. Indicative reference values from University College London 
Hospital are as follows. ALP: upper limit of normal varies with age, between 250-460 iu/l. PTH: 
1.6-6.9 pmol/l. Calcium: 2.15-2.55 mmol/l. Phosphate: age 10d to 2yr = 1.45-2.16 mmol/l, age 
2yr to 13yr = 1.45-1.78 mmol/l. 
  
 
 
Table 4.6  Differences in serum biochemistry between neonates and older children. 
 
  
Test  (units) (n) Age <1 month Age >1 month  
 Median  (95% CI) Median  (95% CI) p-value a 
25-OH-D (nmol/l)  (n=82) 20.1  (13.9–25.9) 10.3  (10–11.6) <0.001 
ALP (iu/l)  (n=90) 351  (256–406) 820  (725–928) <0.001 
PTH (pmol/l)  (n=73) 5.9  (2.8–8.6) 27.4  (21.8–33.1) <0.001 
 Mean  (95% CI) Mean  (95% CI) p-value b 
Co. Ca2+ (mmol/l)  (n=92) 1.54  (1.44–1.63) 1.38  (1.33–1.43) 0.002 
Phosphate (mmol/l)  (n=87) 2.97  (2.71–3.24) 1.83  (1.70–1.97) <0.001 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; ALP, alkaline phosphatase; CI, confidence 
interval; Co. Ca2+, corrected calcium; PTH, parathyroid hormone; SD, standard deviation. 
a p-value for no difference using Wilcoxon rank sum test. 
b p-value for no difference using independent t-test. 
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Figure 4.5  Scatterplots of serum biochemistry by age.a 
 
  
a Graphs limited to cases age 0-2 years, for purposes of clarity. 
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Table 4.7  Differences in serum biochemistry by sex. 
 
 
 
4.5.8 Clinical Management and Outcomes 
 
97% of cases were admitted to hospital, for a median duration of 3 days (IQR: 2 – 5). 
Approximately half of the children (51%) were given acute treatment in order to 
terminate a seizure or prevent seizure recurrence; 44% received intravenous calcium 
gluconate, and 27% received anticonvulsant medication (Table 4.8). 79 children (87%) 
were given vitamin D replacement as either colecalciferol or ergocalciferol, with 10 
(11%) given single high-dose (stoss) therapy (administered intramuscularly in 8 cases 
and orally in 2 cases). 12 children (13%) received alfacalcidol, whilst 3 children (3%) 
were reported to have received vitamin D replacement only in the form of Abidec or 
Dalivit multivitamin preparations.  
 
Among children who received colecalciferol or ergocalciferol, information regarding the 
dose prescribed was available for 71% of cases. The dose prescribed was in 
accordance with the dosage recommendations by age from the British National 
Formulary for Children (BNFc) in 69% of cases (BNFc, 2014). A lower dose than that 
recommended in the BNFc was prescribed in 23%, and a higher dose in 8%. 
 
None of the children died. One case had sequelae at the time of discharge (a burn 
from extravasation of intravenous calcium gluconate). 
  
Test  (units) (n) Male Female  
 Median  (95% CI) Median  (95% CI) p-value a 
25-OH-D (nmol/l) (n=82) 11.1 (10.0–14.6) 14.2  (9.1–28.5) 0.15 
ALP (iu/l) (n=90) 718  (585–820) 529  (246–1,097) 0.34 
PTH (pmol/l) (n=73) 21.3  (14.7–26.7) 27.7  (2.9–42.1) 0.82 
 Mean  (95% CI) Mean  (95% CI) p-value b 
Co. Ca2+ (mmol/l) (n=92) 1.43  (1.38–1.47) 1.39  (1.25–1.53) 0.55 
Phosphate (mmol/l) (n=87) 2.10  (1.93–2.67) 2.30  (1.76–2.84) 0.37 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; ALP, alkaline phosphatase; CI, confidence 
interval;  Co. Ca2+, corrected calcium; PTH, parathyroid hormone; SD, standard deviation. 
a p-value for no difference using Wilcoxon rank sum test. 
b p-value for no difference using independent t-test. 
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Table 4.8  Clinical management. 
 n  (%) 
Acute treatment to terminate / prevent seizures  (n=90)  
 None 44  (49%) 
 Intravenous calcium gluconate 40  (44%) 
 Anticonvulsant: Any 24  (27%) 
  Benzodiazepine 13  (14%) 
  Phenobarbitone 11  (12%) 
  Phenytoin 5  (6%) 
Vitamin D replacement therapy  (n=91)  
 Colecalciferol or ergocalciferol 79  (87%) 
 Alfacalcidol 12  (13%) 
 Multivitamin preparation (Abidec or Dalivit) 11  (12%) 
 Adcal D3 2  (2%) 
 
 
 
 
4.6 Discussion 
 
 
4.6.1 Summary of Results and Comparison with Existing Studies 
 
This chapter describes the first study in the UK to report national incidence estimates 
for any of the clinical manifestations of vitamin D deficiency. There were 92 confirmed 
and probable cases of hypocalcaemic seizures secondary to vitamin D deficiency 
during the 2-year study period, equating to an overall annual incidence of 3.53 per 
million children aged 0 to 15 years (95% CI: 2.84 to 4.33). As described in chapter 
2.7.2, most previous studies of symptomatic vitamin D deficiency in children in the UK 
have been single or multi-centre case series, with the exception of two regional 
prospective studies (Callaghan et al, 2006; El-Fakhri et al, 2013). Although based on 
small numbers of cases, incidence estimates for hypocalcaemic seizures due to 
vitamin D deficiency can be derived from the results of these studies, and are broadly 
similar to the national incidence estimates described in this chapter. Six cases of 
hypocalcaemic convulsions secondary to vitamin D deficiency were reported during the 
1-year study period (May 2000 to April 2001) of the West Midlands study by Callaghan 
et al. (2006), equating to an annual incidence estimate of 1.88 per 100,000 children 
aged 0 to 4 years (confidence intervals not reported, but would be expected to be 
relatively wide given the small number of cases). There were 87 cases in this age 
group in the BPSU study, equating to an annual incidence of 1.00 per 100,000 children 
aged 0 to 4 years (95% CI: 0.80 to 1.23). Regional differences in ethnic demography 
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are the most likely explanation for incidence estimates being higher in the West 
Midlands study: in the 2011 census 7.3% of children aged 0 to 4 years in England & 
Wales were of Indian, Pakistani or Bangladeshi ethnic origin, compared to 13.6% in the 
West Midlands (ONS, 2013a). In the Scottish Paediatric Surveillance Unit study, 4 
cases of hypocalcaemic seizures were reported during the 2-year study period 
between September 2009 to August 2011 (El-Fakhri et al, 2013). Although the authors 
do not report incidence estimates based on their results, using mid-2010 population 
estimates for Scotland (ONS, 2013c), an incidence estimate of 2.18 per million children 
aged 0 to 15 years (95% CI: 0.59 to 5.58) can be derived. 
 
Internationally, incidence estimates for hypocalcaemic seizures due to vitamin D 
deficiency in children can be derived from the results of prospective national studies in 
Canada (Ward et al, 2007) and New Zealand (Wheeler et al, 2015), both of which used 
similar methods to the BPSU system with active surveillance of paediatricians. In the 2-
year Canadian study (July 2002 to June 2004), the annual incidence of symptomatic 
vitamin D deficiency presenting to paediatricians was reported to be 2.9 per 100,000 
children aged 0 to 17 years (95% CI: 2.2 to 3.7) (Ward et al, 2007). 19% of cases 
(n=20) presented with hypocalcaemic seizures, thus the annual incidence for this 
complication of vitamin D deficiency can be estimated at 5.5 per million children aged 0 
to 17 years (95% CI: 3.4 to 8.6). In the New Zealand study, 8 children presented with 
hypocalcaemic seizures during the 3-year study period (July 2010 to June 2013) from 
an estimated population of 870,378 children below 15 years of age (Wheeler et al, 
2015). Thus, an annual incidence of 3.06 per million children aged 0 to 14 years (95% 
CI: 1.32 to 6.04) can be calculated. There were 91 cases in this age group in the BPSU 
study, equating to an annual incidence of 3.73 per million children aged 0 to 14 years 
(95% CI: 3.00 to 4.58). In summary, national estimates for the incidence of 
hypocalcaemic seizures secondary to vitamin D deficiency among children in Canada 
and New Zealand are comparable to those for the UK described in this chapter. 
 
The results of this study are consistent with previous reports in identifying children from 
South Asian and Black ethnic groups as being at highest risk of symptomatic vitamin D 
deficiency (Ahmed et al, 2011; Callaghan et al, 2006; El-Fakhri et al, 2013; Ladhani et 
al, 2004; Sharma et al, 2009). However, although rare, cases of severe vitamin D 
deficiency also occur in children from white ethnic backgrounds. Of the 11 cases with 
white ethnicity, two were adolescents with autistic spectrum disorders and restricted 
diets, one 2-year-old had multiple allergies and a restricted diet, and the remaining 8 
were aged between 0 to 2 years without co-morbidities. 
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The age distribution of cases observed in this study is consistent with previous reports, 
which suggest that vitamin D deficiency presents with hypocalcaemic symptoms in two 
distinct age groups; infants aged between 0 to 2 years (the majority of cases) and 
adolescents (Ahmed et al, 2011; Ladhani et al, 2004). These age groups have been 
shown to correlate with periods of rapid growth, and it has been suggested that higher 
metabolic demand for calcium during periods of rapid bone growth may increase 
susceptibility for the development of hypocalcaemia (Ladhani et al, 2004). 
 
Although most infants under 1 year of age were either exclusively breastfed or on 
mixed feeds, 15 cases were exclusively formula milk fed (19%). Almost all of the 
formula milk fed children were neonates under one month of age (n=14). Maternal 
vitamin D levels were available for 10 of these 14 cases, 70% of which were deficient 
(<25 nmol/L) and 30% insufficient (25-50 nmol/L). These results suggest that the 
vitamin D content of formula milk alone is not sufficient to prevent severe 
manifestations of vitamin D deficiency in neonates born to mothers with suboptimal 
vitamin D status during pregnancy. The vitamin D status of newborns is known to be 
directly dependent upon the vitamin D status of mothers during pregnancy 
(Thandrayen & Pettifor, 2012). 
 
There was an unexpected male predominance in cases of 82%. However, a similar 
finding has been reported in two previous case series of hypocalcaemic seizures. A 
Turkish study of 93 infants aged between 1 to 24 months with hypocalcaemic seizures 
due to suspected rickets reported that 71% of cases were male (Bicakci, 2007). In a 
case series from the United States of 78 term neonates (age <31 days) with ‘transient 
hypocalcaemia’, 72% were male (Thomas et al, 2012). Cases in the American study 
exhibited suboptimal serum 25-OH-D levels (median 35 nmol/L), low magnesium levels 
(median 0.58 mmol/L), and inappropriately normal PTH levels (median 4.8 pmol/L). 
The authors proposed a synergistic role for transient hypoparathyroidism, vitamin D 
deficiency, and hypomagnesaemia in the aetiology of transient neonatal 
hypocalcaemia. The study was not able to explore reasons for the observed sex 
difference, however the authors hypothesised whether the explanation could involve 
gender-specific differences in neonatal vitamin D levels, PTH secretion, dietary calcium 
absorption, or an increased susceptibility of males to hypocalcaemic seizures. Case 
series of children with symptomatic vitamin D deficiency, including other manifestations 
such as rickets, have reported inconsistent results regarding gender. Some studies 
have reported a male predominance of between 55 – 64% (El-Fakhri et al, 2013; 
Robinson et al, 2006; Sharma et al, 2009), whilst other studies have reported equal 
numbers by sex (Ladhani et al, 2004; Ward et al, 2007). Studies investigating serum 
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25-OH-D levels in healthy neonates (Camargo et al, 2010), infants & toddlers (Gordon 
et al, 2008), and older children (Absoud et al, 2011; Mansbach et al, 2009) have not 
found any significant sex differences in vitamin D status. Thus, gender-specific 
differences in vitamin D levels do not appear to be the explanation for the observed 
male predominance in cases. In this study, the male predominance was present in both 
neonates (79%) and older children (84%). There was no significant difference in PTH 
levels between males and females (Table 4.7), suggesting that gender-specific 
differences in PTH response, or susceptibility to transient neonatal hypoparathyroidism, 
do not explain the observed male predominance in cases. Males have been reported to 
exhibit higher bone mineral content than females during early childhood (age 0 to 36 
months) (Kalkwarf et al, 2014). Therefore, one possible hypothesis for the observed 
male predominance in cases is that that there may be gender-specific differences in 
metabolic calcium demand during periods of rapid bone growth, predisposing males to 
develop hypocalcaemia in the presence of vitamin D deficiency. 
 
Median ALP and PTH levels were elevated, as is expected in the presence of 
metabolic bone disease due to vitamin D deficiency. However, phosphate levels were 
not depressed as is expected in vitamin D deficiency rickets, a finding previously 
reported in children with hypocalcaemic presentations of vitamin D deficiency (Ladhani 
et al, 2004). This is likely to be due to presentation in the early stage of vitamin D 
deficiency before a secondary hyperparathyroid response has been established or, as 
some authors have suggested, it may reflect PTH resistance in later stages of 
deficiency (Ladhani et al, 2004; Misra et al, 2008). 
 
There were significant differences in serum biochemistry between cases presenting in 
the neonatal period and those presenting after 1 month of age. Older children generally 
exhibited an appropriate secondary hyperparathyroid response to the hypocalcaemia, 
with high PTH levels. In contrast, neonates exhibited lower PTH levels, with only 44% 
reported to have a PTH level ≥7.0 pmol/L. Neonates also exhibited lower ALP and 
higher phosphate levels compared to older children. These differences suggest that an 
inability of some neonates to mount an appropriate PTH response, possibly due to a 
transient neonatal hypoparathyroidism, may predispose this age group to a higher risk 
of developing hypocalcaemia in the presence of vitamin D deficiency. 
 
There was a marked seasonal pattern in occurrence, with the majority of cases 
reported in and around the winter months, between late autumn (November) to early 
spring (April). This corresponds to periods in the year when levels of ultraviolet 
radiation from sunlight are at their lowest in the UK (DEFRA, 2016). Similar findings 
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have been reported by previous case series from Australia (Robinson et al, 2006) and 
Turkey (Cesur et al, 2011), in which hypocalcaemic presentations of vitamin D 
deficiency in children were predominantly seen in winter and spring. Whilst also 
reporting a seasonal pattern in the presentation of children with hypocalcaemic 
symptoms secondary to vitamin D deficiency, a case series from three London 
hospitals between 1996 to 2001 suggested that the peak occurs between March to July 
(spring to mid-summer), although the number of cases was relatively small (n=29) 
(Ladhani et al, 2004). 
 
In the majority of cases, seizures were brief and self-terminating. Clinical outcomes 
were good, with no deaths reported. In a minority of cases (13%), it was reported that 
children did not receive vitamin D replacement in the form of treatment doses of 
colecalciferol or ergocalciferol, as recommended by national and international 
guidelines (Misra et al, 2008; RCPCH, 2013). 5 children received alfacalcidol only, 3 
received a multivitamin (Abidec) only (at a dose of 0.6 ml/day, which equates to 400 
units of ergocalciferol), and 2 cases received both alfacalcidol and Abidec. Among 
children who did receive colecalciferol or ergocalciferol, and for whom dosage 
information was available, 23% received a lower dose than recommended in the BNFc 
(2014). A surveillance study of symptomatic vitamin D deficiency in Scotland also 
reported considerable variation in management, with one third of cases receiving 
suboptimal doses of vitamin D in the form of multivitamin preparations (El-Fakhri et al, 
2013). 
 
 
4.6.2 Study Strengths 
 
The main strength of this study is the use of an established active surveillance system, 
with national coverage and consistently high response rates. A high proportion (~94%) 
of consultant paediatricians across the UK and Republic of Ireland participate in the 
BPSU reporting system (Knowles et al, 2012), therefore the results are nationally 
representative. The BPSU has a consistently high completion rate for reporting cards, 
providing some reassurance that the extent of any under-reporting of cases is unlikely 
to be large. Between 2011 and 2013, return rates for the BPSU ‘Orange Card’ ranged 
from 91.4% to 95.3% (BPSU, 2013; 2014). 
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4.6.3 Study Limitations 
 
This study is limited to one acute presentation of vitamin D deficiency, rather than 
investigating symptomatic vitamin D deficiency in children more broadly. Hence, the 
results do not indicate the overall health burden in children caused by symptomatic 
vitamin D deficiency. The rationale behind choosing to limit the study to hypocalcaemic 
seizures has been explained in section 4.2.2. In previous case series, between 4% to 
27% of children presenting to secondary care with symptomatic vitamin D deficiency 
were reported to have hypocalcaemic seizures (Ahmed et al, 2011; Beck-Nielsen et al, 
2009b; Callaghan et al, 2006; El-Fakhri et al, 2013; Ladhani et al, 2004; Sharma et al, 
2009; Ward et al, 2007; Wheeler et al, 2015). This variation is explained by differences 
in study inclusion criteria, namely age. 
 
Following the completion of this study, the BPSU relaxed their eligibility criteria 
regarding the maximum expected number of cases per year. Subsequently, a separate 
BPSU study of nutritional rickets presenting to secondary care was undertaken 
between March 2015 to March 2017. The final results from the study have not yet been 
published, however preliminary data indicated that 59 confirmed cases were identified 
in the first 13-months of surveillance (Julies & Blair, 2016). 
 
Despite several reminders by post and email, and several attempts to contact 
paediatricians who did not respond by telephone, it was not possible to ascertain case 
status for a minority of reported cases (7%). This proportion is consistent with that of 
previous BPSU studies of between 5% to 14% (Adalat et al, 2014; Khalid et al, 2012; 
Williamson & Greene, 2010). The proportion of reported cases for which case status 
could not be ascertained increased from 3% in the first year of surveillance to 10% in 
the second year of surveillance. One possible explanation for this increase is the 
transition from postal to e-mail reporting during the study period (BPSU, 2013). The 
postal reporting cards contained an attached slip prompting paediatricians to note and 
keep the case identifiers (hospital number or name), which served as a reminder for 
clinicians when completing the questionnaire. However, there was no such reminder 
slip when electronic reporting cards were introduced. Thus paediatricians may have 
been less likely to keep a reminder of the case details when reporting cases, 
increasing the risk of clinicians being unable to recall the patient details when 
completing the questionnaire. 
 
A degree of under-reporting is likely with any voluntary surveillance system, and 
therefore study incidence estimates are likely to be an underestimate of the true 
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incidence. However, the regular monthly intervals at which BPSU reporting cards are 
sent to participating paediatricians, along with reminders for non-response, serve to 
minimise under-reporting. As there was no alternative source available for case 
ascertainment, it is not possible to estimate the potential extent of under-reporting 
using capture-recapture methods (Knowles et al, 2006). Although Hospital Episode 
Statistics (HES) contains national data regarding hospital admissions in England, it 
uses the International Classification of Diseases (ICD) system to code diagnoses. As 
there are no specific codes for hypocalcaemic seizures in the ICD coding system, it 
was not possible to use HES data as a secondary source of case ascertainment for this 
study. 
 
In some cases pathology other than vitamin D deficiency may have contributed to the 
development of hypocalcaemia, such as immaturity of the parathyroid axis in neonates 
as already discussed. Outside of the neonatal period one child had an inappropriately 
low PTH level suggesting hypoparathyroidism (0.3 pmol/L); a 5-month-old Pakistani 
male with radiological signs of rickets, a low 25-OH-D (10 nmol/L) and a raised ALP 
(2,895 iu/L). 
 
 
4.6.4 Conclusions 
 
Hypocalcaemic seizures are a rare complication of vitamin D deficiency in children in 
the UK and Ireland. The national incidence is similar to estimates from other developed 
countries with populations of majority Caucasian ethnicity (Canada and New Zealand). 
Children from high-risk ethnic backgrounds are disproportionately affected; the 
incidence is approximately 1 in every 3,300 infants of South Asian origin under one 
year of age, and 1 in every 3,700 infants of black ethnicity. Although uncommon, 
clinical complications of vitamin D deficiency such as hypocalcaemic seizures are 
preventable through vitamin D supplementation. This study supports the findings of 
previous case series in suggesting that the current implementation of public health 
policy in the UK is not preventing children, particularly those from high-risk 
backgrounds, from developing severe manifestations of vitamin D deficiency. The 
implications of the work described in this chapter, with respect to clinical practice, 
public health policy and future research, are further discussed in the final chapter of the 
thesis.  
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Chapter 5 
 
 
Time Trends and Determinants for the Diagnosis 
of Vitamin D Deficiency in UK Children: A Cohort 
Study Using Primary Care Electronic Health 
Records 
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5.1 Introduction 
 
Vitamin D has attracted considerable clinical and academic interest over the last two 
decades. Anecdotal reports and local case series have suggested an increase in the 
number of children presenting to paediatric services in the UK with symptomatic 
complications of deficiency, and a large body of observational research has stimulated 
debate regarding the postulated role of vitamin D deficiency in the development of 
various non-musculoskeletal diseases. As vitamin D has attracted increasing attention, 
large increases in vitamin D testing and prescribing have been reported in adult 
practice. However, there has not been any empirical investigation of rates of diagnosis 
of vitamin D deficiency in clinical practice, either in the UK or internationally. This 
chapter describes a cohort study undertaken to determine longitudinal trends in the 
diagnosis of vitamin D deficiency in children in the UK. 
 
 
 
 
5.2 Aims and Objectives 
 
 
5.2.1 Study Aims 
 
The overall aims of this study were to explore longitudinal trends in the diagnosis of 
vitamin D deficiency among children in UK clinical practice over the past 15 years, and 
examine differences by socio-demographic characteristics. 
 
 
5.2.2 Study Objectives 
  
i) To determine rates of diagnosis of vitamin D deficiency in children in the UK 
in each year between 2000 to 2014. 
 
ii) To explore differences in rates of diagnosis of vitamin D deficiency in UK 
children by age, sex, ethnicity, socio-economic position, and geographical 
area. 
 
iii) To examine the recording of symptoms, in the primary care health record, 
among children diagnosed with vitamin D deficiency. 
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5.3 Methods 
 
 
5.3.1 Study Design 
 
A cohort study using UK primary care electronic health records, held in The Health 
Improvement Network (THIN) database. 
 
 
5.3.2 Data Sources 
 
 
5.3.2.1 The Health Improvement Network (THIN) Database 
 
THIN is a large longitudinal database containing anonymised patient-level electronic 
medical records from primary care in the UK, and has been widely used for 
epidemiological research (http://www.epic-uk.org/bibliography/bibliography_01.shtml, 
accessed 22/09/2016). Routine consultation data is collected from participating general 
practices that use Vision computer software (In Practice Systems Ltd) to manage 
patient consultations and health records. The anonymised patient data is collected and 
processed for research use by IMS Health Inc., which performs various internal validity 
checks before supplying the THIN data to researchers (http://www.epic-uk.org, 
accessed 22/09/2016).  
 
The database contains information recorded in patients’ electronic medical records as 
part of their routine clinical care, including medical diagnoses, symptoms, medication 
prescriptions, and laboratory test results. Medical diagnoses and symptoms are 
recorded using a hierarchical coding system known as Read codes, which was 
developed for use in UK primary care, includes more than 100,000 codes, and can be 
mapped to the International Classification of Diseases, Tenth Edition (ICD-10) (Booth, 
1994; Davé & Petersen, 2009). Medication prescriptions in primary care are particularly 
well recorded in THIN, as they are issued electronically by general practitioners (GPs) 
and automatically captured in the electronic patient record (Thiru et al, 2003). Further 
consultation details are entered by GPs as free text, which is not routinely available to 
researchers but can be purchased following anonymisation by IMS Health staff. As 
GPs act as gatekeepers in primary care to secondary healthcare services in the UK, 
diagnoses made in secondary care can also be captured, from information contained in 
discharge summaries and outpatient letters. Information in patient-related 
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correspondence from secondary care that is deemed to be important may be coded 
into the primary care electronic health record by GPs or practice administrative staff. 
 
THIN also contains information regarding patients’ demographic characteristics. For 
children below 15 years of age at the time of the data release, year and month of birth 
are available, whilst year of birth is available for older individuals. Sex, date of practice 
registration, date of transfer out of practice, and date of death are recorded. 
Information regarding ethnicity and area-based measures of social deprivation are also 
recorded, albeit with incomplete coverage (Mathur et al, 2014). THIN also contains a 
‘household’ identifier, which is identical for individuals who are registered with the same 
practice and have a matching first line of address at the time of patient registration with 
the practice. In some circumstances, however, the same ‘household’ identifier can 
encompass multiple households and contain a large number of individuals. For 
example, blocks of flats and university halls of residence can be covered under one 
address and share a single ‘household’ identifier in the dataset. Information regarding 
the geographical location of practices is available, at the level of former strategic health 
authorities (SHAs) for practices in England, and at country level for practices in 
Scotland, Wales, and Northern Ireland. SHAs were part of the organisational structure 
of the NHS in England between 2002 and 2013, responsible for management of health 
services at a regional level (Boyle, 2011). Between 2006 and 2013, England was 
divided into 10 SHA regions (Figure 5.1). SHAs were abolished in 2013, and replaced 
by a new NHS organisational structure. 
 
The vast majority of the UK population is registered with a general practice, although 
accurate estimates for this proportion are not available. The total number of registered 
patients in England in 2015 (56.9 million) was greater than the overall population 
estimate (54.8 million) (HSCIC, 2015a; ONS, 2016). There are various reasons for this 
discrepancy including over-counting in GP registers (e.g. double-counting of individuals 
registered with more than one practice, or counting of ‘ghost’ patients who died or 
migrated out of the country without being removed from the GP register), and the 
registration of short-term migrants, who are not included in population estimates, with 
GPs. The THIN cohort has been shown to be broadly representative of the UK 
population as a whole in terms of age and sex distribution (Blak et al, 2011). However, 
it is somewhat over-representative of individuals from more affluent areas, as 
measured by the postcode-based Townsend deprivation index; in analysis of THIN 
patients actively registered in 2009, 23.5% were recorded in the most affluent quintile, 
whilst only 14.6% belonged to the least affluent quintile (20% in each quintile 
nationally) (Blak et al, 2011). Recording of consultations and prescriptions in THIN 
Chapter 5. Trends in Diagnosis of Vitamin D Deficiency 
 123 
South 
Central 
West 
Midlands 
South West 
London 
South East 
Coast 
East of 
England 
East 
Midlands 
Yorkshire and 
The Humber 
North 
West 
North 
East 
practices is comparable to national primary care statistics (Bourke et al, 2004). The 
prevalence of various chronic medical conditions, and mortality rates adjusted for social 
deprivation, in THIN are similar to UK national statistics (Blak et al, 2011).  Well-
established associations between risk factors and a number of common diseases 
(stroke, myocardial infarction, bowel cancer, and peptic ulcer disease) have been 
replicated using THIN data (Lewis et al, 2007). 
 
For the analysis reported in this chapter, the February 2015 release of THIN data was 
used. This contains the medical records of 11.6 million patients in total, registered with 
641 general practices in the UK, from 3rd June 1985 up to 10th February 2015. 3.9 
million patients were actively registered in 2014, representing 5.96% of the UK 
population as a whole. 
 
 
Figure 5.1  Strategic health authorities (SHAs) in England, between 2006 to 2013. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure adapted from: Department of Health (2016) Strategic Health Authority 
Configurations. Available at https://web.archive.org/web/20070130014013/http:// 
www.dh.gov.uk/assetRoot/04/13/37/60/04133760.pdf [Accessed 23rd November 2016]. 
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5.3.2.2 Hospital Episode Statistics (HES) 
 
For a subset of the THIN practices in England, linked patient-level Hospital Episode 
Statistics (HES) data is available. HES is an administrative dataset containing details of 
all care episodes at NHS hospitals in England, including inpatient admissions, 
outpatient appointments and accident and emergency (A&E) attendances 
(http://digital.nhs.uk/hes, accessed 23/09/2016). Each hospital submits data from its 
own Patient Administration System to the centralised HES data warehouse, which is 
then validated and cleaned by NHS Digital (formerly called the Health and Social Care 
Information Centre, HSCIC), according to a pre-specified list of rules. HES data 
includes clinical information regarding diagnoses (recorded using the ICD-10 
classification) and operations, however this is only consistently recorded for inpatient 
admissions data (primary diagnosis was recorded for 100% of admissions in the 2011-
2012 financial year) (HSCIC, 2013b). Recording of clinical diagnoses is very limited in 
the outpatient data (4.1% of attendances in the 2011-2012 financial year) and A&E 
data (49.2% of attendances in the 2011-2012 financial year) (HSCIC, 2012; 2013a). 
Demographic information regarding ethnicity is also recorded in HES. 
 
Linkage of THIN and HES data was performed by Cegedim Strategic Data Medical 
Research UK (which supplied the THIN database at the time of this study, 
subsequently acquired by IMS Health Inc.), in collaboration with Sapior, a third party 
that developed the encryption technology for linkage (CSDMRUK, 2014). This involved 
probabilistic linkage using the NHS number, date of birth and sex (personal 
communication with IMS Health, 2016). The linkage methodology involved encryption 
of patient identifiers (in both the primary care records and HES data) to create 
‘encryption keys’, followed by upload of the encrypted data to a secure website where 
matching keys were linked. This enabled linkage without the need for export of patient 
identifiable data from the data providers (THIN practices and HSCIC). 75.7% of actively 
registered patients from participating THIN practices were linked to one or more event 
in HES (CSDMRUK, 2014). Among the patients who were not matched, it is not known 
what proportion had used hospital services but were failed matches, and what 
proportion had truly never used secondary care services. Thus, the overall 
completeness of the linkage is not known. Among patients who matched to one or 
more HES records, 95% had a one-to-one match on the NHS number without any data 
discrepancies (duplicate matches in either dataset, or conflicting data regarding sex or 
date of birth across the datasets). 
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The coding of clinical information from case notes into diagnostic codes for HES is 
undertaken by administrative staff, rather than clinical staff. Hence, the accuracy of 
HES data has been questioned, particularly with regard to differences in coding 
practices between hospitals (Williams & Mann, 2002). A systematic review of studies 
comparing the agreement of coded discharge diagnoses in HES with either 
independent case note reviews or clinical registry data reported a median agreement of 
80.3% (IQR 63.3% to 88.7%) (Burns et al, 2012). 
 
At the time that the work described in this chapter was undertaken, linked HES 
inpatient and outpatient data was available for 156 THIN practices in England (24% of 
all THIN practices). However, HES A&E data was not provided to researchers. The 
linked HES data covered the time period 1st April 1997 to 31st March 2012, and 
therefore did not overlap entirely with the period for which THIN data was available. 
 
 
5.3.3 Study Population 
 
 
5.3.3.1 Inclusion and Exclusion Criteria 
 
The study population included children aged between 0 to 17 years, who were actively 
registered with a THIN practice between 1st January 2000 and 31st December 2014. 
 
IMS Health runs internal validation checks of the patient records for each individual in 
THIN, and assigns each patient an indicator (Patflag) for the integrity of data in their 
record (CSDMRUK, 2010). Only individuals with an acceptable patient record status 
(Patflag A or C) were included; this excludes individuals with data missing for year of 
birth, sex, or date of registration, patients who are not permanently registered with the 
practice, and patients with out of sequence data records (e.g. year of birth later than 
year of registration, or registration date after date of leaving the practice). 
 
Children with a record meeting the case definition for diagnosis of vitamin D deficiency 
(see section 5.3.4.1) prior to their date of entry to study follow-up (see section 5.3.3.2) 
were excluded, as they represent prevalent rather than incident cases. For the main 
analyses, children with a record of a medical condition that can predispose to vitamin D 
deficiency by interfering with vitamin D absorption or metabolism (chronic renal 
disease, liver disease, or conditions associated with gastrointestinal malabsorption; 
see section 5.3.6.8) were excluded, as routine screening of vitamin D status is 
expected in children with these conditions. 
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5.3.3.2 Entry to Study Observation Period 
 
The study cohort was open (dynamic), meaning that children entered and exited the 
cohort at different time points. Therefore, they were observed over different periods of 
time, and contributed different lengths of follow-up to the study. 
 
The date of entry into the cohort for each individual, i.e. the start of their period of 
observation (follow-up), was set as the latest of the following dates: 
 
i) Start of the study period (1st January 2000). 
 
ii) Date of registration with the GP practice, for children under one year of age at 
the time of registration. 
 
iii) Date of registration with the GP practice plus 3 months, for children ³1 year of 
age at the time of registration (see below for explanation). 
 
iv) The date when the practice met pre-defined criteria for acceptable mortality 
recording (AMR date, see below). 
 
v) The date when the practice met pre-defined criteria for acceptable computer 
usage (ACU date, see below). 
 
 
Diagnoses recorded in primary care databases shortly after the time of patient 
registration with a practice can represent historical information transferred from the 
patient’s medical record, rather than incident events. Lewis and colleagues (2005) 
demonstrated that recorded incidence rates for a variety of conditions were higher than 
baseline during an initial time period after practice registration, and that the length of 
this time period varied depending on the nature of the condition (generally up to 3 
months for acute conditions, and up to 1 year for chronic conditions). Failure to exclude 
this time period from study follow-up can result in the misclassification of prevalent 
cases as incident, and overestimation of incidence rates. Plots of incidence rates of the 
outcome against time since registration (Lewis plots) were used to explore whether 
there was evidence of greater recording of vitamin D deficiency diagnosis in the initial 
period after practice registration (Lewis et al, 2005). These results, described in section 
5.4.1, demonstrated that rates of recorded diagnosis were greatest in the first 3 months 
after registration, and reached baseline after 9 months following registration.  In the 
main analyses, for children aged ³1 year at the time of practice registration, the first 3 
months after registration were excluded from follow-up. A sensitivity analysis was 
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performed to explore the influence of varying this period of exclusion from between 0 to 
9 months after practice registration. The period of exclusion was not necessary for 
infants under one year of age, for whom any recorded diagnoses can be considered 
incident (regardless of proximity to registration) as they will have occurred within the 
preceding year.  
 
The acceptable mortality recording (AMR) and acceptable computer usage (ACU) 
criteria are previously developed data quality indicators for electronic data recording in 
UK primary care databases (Horsfall et al, 2013; Maguire et al, 2009). They were 
developed to identify periods of incomplete use of computerised medical record 
systems by general practices in primary care data, e.g. following the transition from 
paper to electronic patient records, and are widely used for defining periods of follow-
up in studies using THIN data (Horsfall et al, 2014; Sharma et al, 2016; Sheehan et al, 
2015). The AMR date identifies the time from which the observed mortality for each 
practice is similar to expected mortality, based upon national mortality rates applied to 
the age and sex structure of the practice population (Maguire et al, 2009). The ACU 
date identifies the time from which average annual recording rates for consultations, 
health measurements, and prescriptions for each practice meets pre-specified criteria 
(on average at least two therapy records, one medical record, and one additional 
health data record per patient per year) (Horsfall et al, 2013). Use of the AMR and ACU 
criteria have been shown to produce trends over time in disease incidence rates and 
antibiotic prescription rates in THIN that more closely match trends obtained from 
external data sources (Horsfall et al, 2013). The study start date was chosen as 1st 
January 2000, as prior to this year less than half of THIN practices had achieved ACU 
(Horsfall et al, 2013). From 2003 onwards, over 90% of THIN practices meet both AMR 
and ACU criteria.  
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5.3.3.2 Exit from Study Observation Period 
 
The date of exit from the cohort for each individual was set as the earliest of the 
following dates: 
 
i) Mid-point of 18th year after birth. 
 
ii) Date of transfer out of the practice.  
 
iii) Date when the practice stopped contributing data to THIN. 
 
iv) Date of death. 
 
v) End of the study period (31st December 2014). 
 
vi) The date of the earliest entry in the patient’s medical record meeting the case 
definition for diagnosis of vitamin D deficiency (see section 5.3.4.1). 
 
The mid-point of the 18th year after birth was used, as opposed to the 18th birthday, 
because exact dates of birth are not provided in THIN in order to protect patient 
confidentiality. Month of birth is provided for children below 15 years of age at the time 
of the data release, whilst for older individuals only year of birth is available. 
 
 
5.3.4 Outcome 
 
The primary outcome was diagnosis of vitamin D deficiency. 
 
 
5.3.4.1 Case Definition 
 
For the main analyses, diagnosis of vitamin D deficiency was defined as a record of 
any one of the following three criteria in the primary care electronic medical record 
(THIN): 
 
i) A Read code related to vitamin D deficiency or rickets (see section 5.3.6.2). 
 
ii) Prescription of vitamin D (calciferol) at a ‘treatment dose’ (see sections 
5.3.4.2, 5.3.6.4 and 5.3.7.1). 
 
iii) A serum 25-hydroxyvitamin D (25-OH-D) test result with a value of <25 nmol/l 
(see sections 5.3.4.3, 5.3.6.5, and 5.3.7.2). 
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Analysis of UK primary care electronic health data has shown that GPs do not always 
record medical diagnoses using Read codes (Ford et al, 2013). In some cases, 
information regarding diagnosis is only entered as free text. Free text records are not 
routinely available to researchers using THIN data, as manual data cleaning to ensure 
removal of any potentially identifiable information must first be undertaken by IMS 
Health staff. Using diagnosis Read codes alone to identify cases from primary care 
data can therefore result in case under-ascertainment, and underestimation of disease 
incidence or prevalence. For this reason, vitamin D prescriptions and test results were 
also included in the case definition, in order to capture children who had been identified 
with or treated for vitamin D deficiency without the diagnosis having been recorded 
using Read codes. 
 
A sensitivity analysis was performed to explore the influence of using linked HES 
inpatient data as an additional source for case ascertainment. The study population for 
this analysis was limited to individuals registered with THIN practices for which linked 
HES data was available. The time period for which complete years of linked HES data 
were available limited the study period for this analysis to follow-up between 1st 
January 2000 and 31st December 2011. For this analysis, the case definition was a 
record of any one of the following four criteria: 
 
i) A Read code related to vitamin D deficiency or rickets, in the THIN patient 
record. 
 
ii) Prescription of vitamin D (calciferol) at a ‘treatment dose’, in the THIN patient 
record. 
 
iii) A serum 25-hydroxyvitamin D (25-OH-D) test result with a value of <25 nmol/l, 
in the THIN patient record. 
 
iv) An ICD-10 code related to vitamin D deficiency or rickets, in the HES inpatient 
record (see section 5.3.6.3). 
 
 
5.3.4.2 Definition of ‘Treatment Dose’ for Vitamin D Prescriptions 
 
Although there are numerous different treatment regimens for vitamin D deficiency in 
children, doses recommended for the treatment of established deficiency tend to be 
considerably larger than those used for supplementation or prevention of deficiency 
(prophylaxis). The British National Formulary for Children (BNFc) advises that 
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colecalciferol or ergocalciferol are used for the treatment of established deficiency, with 
the following dosage by age (BNFc, 2014): 
 
 1-5 months:   3,000 International Units (IU) per day 
 6 months to 12 years:  6,000 IU per day 
 >12 years:   10,000 IU per day 
 
The BNFc does not specify a dose for neonates under 1 month of age, however 
guidance from the Royal College of Paediatrics and Child Health (RCPCH) 
recommends doses of between 1,000 to 3,000 IU per day in this age group (RCPCH, 
2013). The recommended length of treatment with the above ‘pharmacological’ doses 
of vitamin D is generally between 1 to 3 months, after which it is advised that children 
take low-dose maintenance treatment long-term (Misra et al, 2008; Munns et al, 2016; 
RCPCH, 2013; Shaw & Mughal, 2013a). 
 
As an alternative strategy to daily dosing, vitamin D deficiency can be treated with a 
large dose of calciferol given as either a single dose, or in divided doses over a short 
period of time. This is known as stoss therapy, and typically involves the administration 
of doses between 100,000 to 600,000 IU, either orally or by intramuscular injection 
(Misra et al, 2008; Munns et al, 2016; Pearce & Cheetham, 2010). 
 
Prophylactic doses of vitamin D recommended for the prevention of vitamin D 
deficiency, or maintenance of vitamin D levels after completion of treatment for 
deficiency, are considerably lower than ‘pharmacological’ treatment doses; between 
400 to 1,000 IU per day in children, and 800 to 2,000 IU per day in adults (BNFc, 2014; 
Misra et al, 2008; Munns et al, 2016; Pearce & Cheetham, 2010; RCPCH, 2013). 
 
For the case definition, the intention was to choose dosage criteria that would capture 
prescriptions of vitamin D issued for the treatment of established deficiency, but would 
exclude prescriptions at lower doses compatible with supplementation or maintenance 
therapy. Only prescriptions for pure preparations of calciferol (colecalciferol or 
ergocalciferol) were included in the case definition, as this is the form of vitamin D 
recommended for the treatment of primary vitamin D deficiency (BNFc, 2014; Shaw & 
Mughal, 2013a). Activated analogues of vitamin D, such as alfacalcidol and calcitriol, 
were not included as these are not routinely recommended for the treatment of primary 
vitamin D deficiency, and are generally used in situations where vitamin D metabolism 
is impaired (e.g. chronic renal impairment) or in hypoparathyroidism (see chapter 
2.3.3). Cod liver oil or multivitamin preparations containing vitamin D were not included 
in the case definition, as the calciferol content of these products when taken at 
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recommended doses represents prophylactic doses of vitamin D. The distribution of 
prescribed dosage for records of combined calcium and vitamin D preparations in the 
study cohort was explored. The prescribed dose was <1,000 IU/day in over 99% of 
these records. Therefore, combined calcium and vitamin D preparations were 
considered to represent prophylactic / maintenance therapy, and were excluded from 
the case definition. 
 
The BPSU surveillance study of hypocalcaemic seizures secondary to vitamin D 
deficiency described in chapter 4, and other published case series (El-Fakhri et al, 
2013), have demonstrated considerable variation in the treatment of established 
vitamin D deficiency in clinical practice. Almost a quarter of cases reported to the 
BPSU study were treated with doses of vitamin D lower than those recommended in 
the BNFc (see chapter 4.5.8). Therefore, it was predicted that setting the dosage 
thresholds for the case definition at the BNFc recommended doses could risk missing 
children with established deficiency who were treated with lower doses of vitamin D. 
For the main analyses, the following definition for ‘treatment dose’ of vitamin D was 
used: 
 
 - Daily dose of ³1,500 IU per day if age <6 months 
 - Daily dose of ³3,000 IU per day if age 6 months to 12 years 
 - Daily dose of ³5,000 IU per day if age >12 years 
 - One-off (stoss) dose of ³100,000 IU at any age 
 
These age specific thresholds for daily dosage represent half of the recommended 
doses in the BNFc, and are greater than doses recommended for prophylaxis or 
maintenance. A sensitivity analysis was performed using a range of alternative 
definitions for ‘treatment dose’ vitamin D, to explore the influence of the choice of 
dosage thresholds on the outcome: 
 
 a) Lower alternative definition for ‘treatment dose’ vitamin D: 
 
 - Daily dose of ³1,000 IU per day if age <6 months 
 - Daily dose of ³2,000 IU per day if age 6 months to 12 years 
 - Daily dose of ³3,000 IU per day if age >12 years 
 - One-off (stoss) dose of ³100,000 IU at any age 
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 b) Higher alternative definition for ‘treatment dose’ vitamin D: 
 
 - Daily dose of ³3,000 IU per day if age <6 months 
 - Daily dose of ³6,000 IU per day if age 6 months to 12 years 
 - Daily dose of ³10,000 IU per day if age >12 years 
 - One-off (stoss) dose of ³100,000 IU at any age 
 
 
5.3.4.3 Rationale for the Choice of the 25-OH-D Test Threshold 
 
The evidence base underpinning the level of serum 25-hydroxyvitamin D used to 
define vitamin D deficiency is limited, and various thresholds representing ‘deficiency’ 
and ‘sufficiency’ are used internationally (see chapter 2.4). However, in the UK most 
clinical guidelines are consistent in defining biochemical vitamin D deficiency as a 25-
OH-D level below 25 nmol/l (Arundel et al, 2012; Pearce & Cheetham, 2010; RCPCH, 
2013; Shaw & Mughal, 2013b). It is likely that the majority of clinical biochemistry 
departments will report 25-OH-D results using this cut-off, and therefore that GPs will 
base their interpretation of 25-OH-D test results on this threshold. 
 
 
5.3.5 Covariates 
 
 
The following study covariates were included in analyses exploring associations with 
rates of diagnosis of vitamin D deficiency: sex, age, ethnicity, indices of deprivation, 
geographical area (country, and strategic health authority in England), and calendar 
time. 
 
 
5.3.5.1 Age 
 
For children aged below 15 years at the time of the data release (February 2015), year 
and month of birth were available, and date of birth was taken to be the 15th day of the 
month of birth. For individuals aged 15 years or older at February 2015, only year of 
birth was available, and date of birth was taken to be the 30th of June on the year of 
birth. For analyses exploring associations with the outcome, age was categorised into 
four groups: 0 to 4 years, 5 to 9 years, 10 to 14 years, and 15 to 17 years. 
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5.3.5.2 Ethnicity 
 
Information regarding ethnicity was derived from relevant Read codes in THIN and 
augmented by ethnicity records in linked HES data (see sections 5.3.6.6 and 5.3.7.3). 
In order to further minimise missing data, maternal ethnicity was used as a proxy 
measure for children’s ethnicity for children without an ethnicity record available. 
 
Ethnicity is recorded in HES using the Office for National Statistics (ONS) 2001 Census 
classification (Table 5.1), and relevant Read codes in THIN were also categorised 
using this classification (see appendix G.2) (ONS, 2001). Ethnicity recorded at any 
point in time in the patient record was included, including records outside of the study 
observation period. 
 
Table 5.1  ONS 2001 Census classification of ethnicity. 
Level 1 (5-category) 
classification 
Level 2 (16-category) 
classification 
White 
White British 
Irish 
Other White background 
Mixed 
White and Black Caribbean 
White and Black African 
White and Asian 
Other mixed background 
Asian or Asian British 
Indian 
Pakistani 
Bangladeshi 
Other Asian background 
Black or Black British 
Caribbean 
African 
Other Black background 
Chinese or Other Ethnic Groups 
Chinese 
Other ethnic group 
 
 
Previous work has suggested that ethnicity data in healthcare records is more reliable 
when collapsed into broader (higher-level) categories compared to more detailed 
(lower-level) categories. The level of discordance between recorded ethnicity in HES 
and patients’ self-reported ethnicity was shown to be greater when ethnicity was 
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categorised using a 16-group classification (4.9% overall discordance) compared to a 
6-group classification (1.4% overall discordance) (Saunders et al, 2013). Of note, the 
difference was more marked when considering patients from minority groups. 
Discordance with self-reported ethnicity was 24% among patients with HES ethnicity 
recorded as Indian, Pakistani, Bangladeshi, or other Asian background. However, 
when ethnicity was classified using the broader category of ‘Asian or British Asian’, 
discordance was lower at 11%. Similarly, discordance with self-reported ethnicity was 
32% among patients with HES ethnicity recorded as Caribbean, African, or other black 
background, compared to 15% when ethnicity was classified using the broader 
category of ‘Black or Black British’. Within the study cohort, the consistency of ethnicity 
data within individual patients’ records (THIN and HES) was greater when the higher-
level classification of ethnicity was used. Among children with ethnicity data available, 
the proportion who had multiple ethnicity records belonging to different categories was 
5.5% using the 5-level classification compared to 9.8% using the 16-level classification. 
In view of the above evidence, it was considered that the accuracy of ethnicity data in 
routine healthcare records may not be sufficient to allow reliable analysis at the more 
detailed 16-category level, and therefore the broader 5-category classification was 
used for all subsequent analyses. 
 
 
5.3.5.3 Measures of Socio-Economic Position 
 
Two area-based measures of socio-economic position are available in the THIN 
database; the Townsend Index and the Index of Multiple Deprivation (IMD). Values for 
these measures are linked to individual patient records in THIN using patients’ 
postcodes. The Townsend Index was derived from 2001 Census data at the level of 
the Census output area (average number of households in each area 124, average 
number of people in each area 297), and is available for patients from practices 
throughout the UK (ONS, 2012). The Townsend Index is calculated by summing the 
standardised scores of 4 variables (Townsend et al, 1988): 
 
• The percentage of households without access to a car. 
 
• The percentage of households not in owner occupied accommodation. 
 
• The percentage of households in overcrowded accommodation. 
 
• The percentage of the economically active population aged 16-74 years who 
are unemployed. 
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The resulting scores are grouped into 5 quintiles, from 1 (least deprived) to 5 (most 
deprived). 
 
The Index of Multiple Deprivation is a composite score derived from 37 indicators 
across 7 domains (ODPM, 2004): 
 
• Income deprivation. 
• Employment deprivation. 
• Health deprivation and disability. 
• Education, skills and training deprivation. 
• Barriers to housing and services. 
• Living environment deprivation. 
• Crime. 
 
The majority of the indicators relate to data collected in 2001. The resulting scores are 
again grouped into 5 quintiles. The IMD is measured at the lower layer super output 
area level (average number of households in each area 630, average number of 
people in each area 1,514) (ONS, 2012).  
 
As the IMD is only available for patients from THIN practices in England, this variable 
was only included in analyses limited to THIN practices that have linked HES data 
available (the linked THIN-HES study cohort). The Townsend Index was used both for 
analyses using the full THIN study cohort as well as the linked THIN-HES study cohort. 
 
 
5.3.6 Code List Development 
 
 
5.3.6.1 Strategy for Code List Development 
 
Previously reported guidelines were used to compile Read code lists and drug code 
lists for all outcomes and covariates of interest (Davé & Petersen, 2009). The 
development of Read code lists involved the following steps: 
 
1) Compilation of a list of key words and synonyms for the condition of interest. 
Key words were truncated to produce terms which capture multiple related 
words, e.g. the truncated term *depress* captures the words ‘depression’, 
‘depressed’, and ‘depressive’. 
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2) Searching the Read code dictionary for code descriptions containing these key 
terms, at any location within the code description. 
 
3) Review of the codes identified by the above word search, and identification of 
common code stems among relevant codes. Due to the hierarchical nature of 
the Read coding system, related codes are often grouped together under 
common stems. 
  
4) Searching the Read code dictionary for any additional codes beginning with 
the relevant code stems identified above. 
 
5) Manual review of all identified codes, and exclusion of any irrelevant codes. 
 
Prescribed drugs are recorded in THIN using the Multilex coding system 
(http://www.firstdatabank.co.uk), with the Multilex drug codes encrypted. Each drug 
code is linked to a description of the drug’s generic name, and some codes are linked 
to the British National Formulary (BNF) chapter that the drug appears in. Brand names 
(also called proprietary or trade names) are not made available. The development of 
drug code lists involved the following steps: 
 
1) Manual review of all drug codes listed under the BNF chapter(s) that are felt to 
be relevant to the drug of interest. 
 
2) Compilation of a list of truncated key words and synonyms for the drug of 
interest. 
 
3) Searching the drug code dictionary for code descriptions containing these key 
terms, at any location within the code description. 
 
4) Manual review of all identified codes, and exclusion of any irrelevant codes. 
 
The following steps were used to develop ICD-10 code lists (for the identification of 
medical diagnoses recorded in linked HES data): 
 
1) Compilation of a list of truncated key words and synonyms for the condition of 
interest.  
 
2) Searching the ICD-10 code dictionary for code descriptions containing these 
key terms, at any location within the code description.  
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3) Review of the codes identified by the above word search, and identification of 
common code stems among relevant codes. 
 
4) Searching the ICD-10 code dictionary for any additional codes beginning with 
the relevant code stems identified above. 
 
5) Manual review of all identified codes, and exclusion of any irrelevant codes. 
 
 
5.3.6.2 Identification of Read Codes Related to Vitamin D Deficiency and Rickets 
 
The following truncated search terms were used to identify Read codes related to 
vitamin D deficiency and rickets: ‘ricket’, ‘rachit’, ‘vitamin d’, ‘vit d’, ‘calciferol’, 
‘osteomalacia’, ‘vitaminosis’. Common code stems were used to identify additional 
relevant codes. Codes for rare inherited causes of rickets (e.g. ‘x-linked 
hypophosphataemic rickets’), and rickets related to underlying chronic diseases 
associated with impaired vitamin D absorption or metabolism (e.g. ‘renal rickets’, and 
‘coeliac rickets’), were excluded. The final list of included codes is shown in Table 5.2. 
 
Table 5.2  Read codes related to vitamin D deficiency and rickets. 
Read code Description 
C28..00 Vitamin D deficiency 
C28..12 Rickets 
C280.00 Active rickets 
C28z.00 Avitaminosis D NOS 
C28..11 Osteomalacia 
C282.00 Osteomalacia unspecified 
 
From 2013 onwards, a new code for ‘Vitamin D insufficiency’ (C2B..00) was added to 
the Read code dictionary. A sensitivity analysis was performed to explore the influence 
of additionally including this code on the results. 
 
 
5.3.6.3 Identification of ICD-10 Codes Related to Vitamin D Deficiency and Rickets 
 
The following truncated search terms were used to identify ICD-10 codes related to 
vitamin D deficiency and rickets: ‘ricket’, ‘rachit’, ‘vitamin d’, ‘vit d’, ‘calciferol’, 
‘osteomalacia’, ‘vitaminosis’. Common code stems were used to identify additional 
relevant codes. Codes referring to ‘senile osteomalacia’, ‘adult osteomalacia’, and 
‘puerperal osteomalacia’ were excluded as they refer to conditions in adulthood or 
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related to pregnancy. Codes referring to ‘drug-induced’ osteomalacia were excluded as 
they do not refer to primary vitamin D deficiency. The code E643, ‘sequelae of rickets’, 
was excluded as the code description suggests a historical diagnosis. The final list of 
included codes is shown in Table 5.3. 
 
Table 5.3  ICD-10 codes related to vitamin D deficiency and rickets. 
ICD-10 code Description 
E550 Rickets, active 
E559 Vitamin D deficiency, unspecified 
E55X Vitamin D deficiency 
 
 
5.3.6.4 Identification of Drug Codes Referring to Pure Preparations of Calciferol 
 
All drug codes linked to the BNF chapter for vitamin D (‘09.06.04’: BNF/Nutrition and 
blood/Vitamins/Vitamin D) were manually reviewed, and codes that referred to a pure 
preparation of colecalciferol, ergocalciferol, or calciferol (type not specified) were 
included. Additional relevant codes were identified by searching the drug code 
dictionary for code descriptions containing the following truncated key terms; 
‘calciferol’, ‘colecal’, ‘cholecal’, ‘ergocal’, ‘vitamin d’. Drug codes referring to combined 
calciferol and calcium preparations, multivitamins, cod liver oil, and activated 
analogues of vitamin D were excluded (see section 5.3.4.2). A total of 246 drug codes 
referring to pure preparations of calciferol were identified (see appendix G.1). 
 
 
5.3.6.5 Identification of Read Codes Related to Vitamin D Tests 
 
The following truncated search terms were used to identify Read codes referring to 
vitamin D tests; ‘vitamin d’, ‘vit d’, ‘calciferol’, ‘25-OH-D’, ‘25(OH)D’, ‘25OHD’, ‘250HD’, 
‘25-0H-D’, ‘25(0H)D’. Common code stems were used to identify additional relevant 
codes. Codes referring to levels of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, 
combined total 25-hydroxyvitamin D2 and D3, 25-hydroxyvitamin D (type not specified), 
and unspecified vitamin D were included. Codes referring to 1,25-dihydroxyvitamin D 
tests were excluded, as levels of the biologically active hormone are not used to 
assess an individual’s vitamin D status. The final list of included codes is shown in 
Table 5.4. 
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Table 5.4  Read codes related to vitamin D tests. 
Read code Description 
44LA.00 Serum vitamin D 
44Lg.00 Serum vitamin D2 level 
44LM.00 Plasma 25-Hydroxyvitamin D3 level 
44Ln.00 Serum 25-Hydroxyvitamin D2 level 
44LP.00 Serum 25-Hydroxy vitamin D3 level 
4QB4.00 Vitamin D level 
4QB4000 Vitamin D2 level 
4QB4100 Vitamin D3 level 
4QB4200 25-Hydroxyvitamin D2 level 
4QB4300 25-Hydroxyvitamin D3 level 
4QB4400 Combined total vitamin D2 and D3 level 
4QB4500 25-Hydroxyvitamin D level 
4QB4600 Total 25-hydroxyvitamin D level 
4QB4700 Serum total 25-hydroxy vitamin D level 
5788.00 Radiobioassay - vitamin D 
 
 
5.3.6.6 Identification of Read Codes Related to Ethnicity 
 
The following truncated search terms were used to identify Read codes related to 
ethnicity, nationality, country of birth, or language: ‘ethn’, ‘census’, ‘nationality’, 
‘country’, ‘origin’, ‘race’, ‘born in’, ‘language’, ‘interpreter’, ‘white’, ‘black’, ‘asian’, 
‘british’, ‘irish’, ‘africa’, ‘caribbean’, ‘india’, ‘pakistan’, ‘bangladesh’, ‘chinese’. Common 
code stems were used to identify additional relevant codes. Relevant codes were 
grouped into three categories: 
 
1) Codes referring to ethnicity, nationality, or race.  
2) Codes referring to country of birth.  
3) Codes referring to spoken or read language, or the need for an interpreter. 
 
A total of 954 relevant codes were identified, each of which were manually reviewed 
and coded according to the ONS 2001 Census 5-category and 16-category 
classifications (see appendix G.2). An assumption was made that the code for ‘British 
or mixed British’ represents White British ethnicity. 
 
 
5.3.6.7 Identification of Read Codes Related to Pregnancy or Delivery 
 
The following truncated search terms were used to identify Read codes related to 
pregnancy or delivery: ‘pregnan’, ‘antenatal’, ‘a/n’, ‘ante natal’, ‘matern’, ‘birth’, ‘born’, 
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‘delivery’, ‘caesarean’, ‘c section’, ‘c-section’, ‘baby’, ‘labour’, ‘postnatal’, ‘p/n’, ‘post 
natal’, ‘fetal’. Common code stems were used to identify additional relevant codes. 
Codes referring to stillbirth, miscarriage, or neonatal death were excluded. A total of 
751 relevant codes were identified (see appendix G.3). 
 
 
5.3.6.8 Identification of Read Codes Related to Liver Disease, Chronic Kidney 
Disease, and Conditions Associated with Gastrointestinal Malabsorption 
 
The following truncated search terms were used to identify Read codes related to liver 
disease: ‘liver failure’, ‘liver disease’, ‘liver transplant’, ‘hepatic failure’, ‘hepatic 
disease’, ‘cirrhosis’, ‘biliary atresia’, ‘kasai’, ‘alagille’, ‘antitrypsin’, ‘budd chiari’, 
‘sclerosing cholangitis’, ‘hepatitis’, ‘haemochromatosis’. Common code stems were 
used to identify additional relevant codes. A total of 283 relevant codes were identified 
(see appendix G.4). 
 
The following truncated search terms were used to identify Read codes related to 
chronic kidney disease: ‘renal failure’, ‘kidney failure’, ‘renal impairment’, ‘kidney 
impairment’, ‘renal disease’, ‘kidney disease’, ‘ckd’, ‘dialysis’, ‘kidney transplant’, ‘renal 
transplant’, ‘kidney recipient’, ‘polycystic kidney’, ‘glomeruloneph’, ‘glomerulosclerosis’, 
‘glomerular’, ‘nephritic’, ‘nephrotic’, ‘nephropathy’, ‘dysplasia’, ‘dysplastic’, ‘uropathy’, 
‘tubular’. Common code stems were used to identify additional relevant codes. Codes 
referring specifically to acute conditions were excluded. A total of 544 relevant codes 
were identified (see appendix G.5). 
 
The following truncated search terms were used to identify Read codes related to 
conditions associated with gastrointestinal malabsorption: ‘malabsorption’, ‘cystic 
fibrosis’, ‘crohn’, ‘inflammatory bowel’, ‘ibd’, ‘ulcerative colitis’, ‘coeliac’, ‘celiac’, ‘short 
bowel’, ‘short gut’, ‘parenteral nutrition’, ‘pancreatic insufficiency’, ‘chronic pancreatitis’, 
‘shwachman’. Common code stems were used to identify additional relevant codes. A 
total of 113 relevant codes were identified (see appendix G.6). 
 
 
5.3.6.9 Identification of Read Codes for Symptoms Related to Vitamin D Deficiency 
in Children 
 
A list of symptoms and clinical complications that can be caused by, although are not 
exclusive to, vitamin D deficiency in childhood was developed using information from 
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relevant review articles, guidelines, and case series (Ahmed et al, 2011; Callaghan et 
al, 2006; El-Fakhri et al, 2013; Ladhani et al, 2004; Misra et al, 2008; Munns et al, 
2016; Pearce & Cheetham, 2010; RCPCH, 2013; Shaw & Mughal, 2013a; b; Ward et 
al, 2007; Wheeler et al, 2015). These were then grouped into 12 categories (see Table 
5.5). The search terms used to identify Read codes related to each symptom group, 
and the final list of included codes for each category, are detailed in appendix G.7. 
 
Table 5.5  Grouping of symptoms and clinical complications 
related to vitamin D deficiency in children.  
Symptom Groups 
Musculoskeletal and non-specific pain 
Tiredness and fatigue 
Skeletal deformity 
Bone fracture 
Failure to thrive 
Hypocalcaemia 
Seizure or tetany 
Numbness or paraesthesia 
Abnormal gait 
Muscle weakness 
Delay in motor development 
Cardiomyopathy 
 
 
5.3.7 Data Management 
 
 
5.3.7.1 Calculation of Prescribed Dosage 
 
Records of medication prescriptions in the THIN database contain information 
regarding the generic name and strength of the drug prescribed (through the drug 
code), as well as information regarding the dosage instruction specified by the 
prescriber. The 25,000 most commonly recorded dosage instructions in the database 
have been manually checked for removal of any patient identifiable data by IMS Health 
staff, and are provided in free text form in the dataset. Other dosage instructions are 
not routinely available to researchers, although they can be made available in 
anonymised form by IMS Health on request, for a fee, following manual review of the 
instruction free text and removal of any confidential information by IMS Health staff. 
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The code descriptions for each of the 246 drug codes related to pure preparations of 
calciferol were reviewed, and values for variables referring to the form of the unit of 
dosage (e.g. tablets or millilitres), and the unit strength of the drug in terms of 
international units (IU) of calciferol per dosage unit (i.e. IU per tablet, or IU per ml) were 
derived (see appendix G.1).  
 
A total of 16,998 prescriptions of calciferol were identified in the study population 
during the study observation period. These prescriptions were linked to 5,114 unique 
dosage instructions, of which 874 were already available in the THIN dataset, whilst 
the remaining 4,240 were purchased from IMS Health following anonymisation. The 
free text for each of the 5,114 dosage instructions were manually reviewed, and values 
for the following variables were derived:  
 
i) The form of the unit of dosage (e.g. tablets or millilitres), if specified. 
 
ii) The time interval between the administration of each dose, in hours. 
 
iii) The number of dosage units (e.g. tablets or millilitres) to be taken at the 
administration of each dose. 
 
iv) The number of dosage units to be taken each day. For dosage instructions 
indicating administration at less frequently than daily intervals (e.g. weekly), 
this variable represents the equivalent number of dosage units for each 24-
hour period. 
 
v) The duration of the treatment in days, if specified. 
 
vi) The total number of dosage units to be taken over the duration of the 
treatment, calculated if the duration of treatment was specified as less than 1 
month. 
 
vii) The number of IU of calciferol to be taken each day, if specified in the dosage 
instruction. For dosage instructions indicating administration at less frequently 
than daily intervals (e.g. weekly), this variable represents the equivalent 
number of IU of calciferol for each 24-hour period. 
 
In the case of some dosage instructions, the prescribed dose was not clearly specified 
due to ambiguity in the instruction. In such cases, certain assumptions were made 
when coding the derived dosage variables. If the dosage instruction specified a range 
of possible doses rather than an exact dose, the mid-point of the range was taken. For 
example, for the instruction ‘TAKE 1 OR 2 DAILY’, the derived value for the number of 
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dosage units per day was 1.5. Some dosage instructions specified the frequency of 
administration, but did not indicate the number of dosage units to be taken at each 
administration time-point, e.g. ‘TWICE A DAY’. In such cases, it was assumed that one 
dosage unit was taken at each administration time-point. Thus, the instruction ‘TWICE 
A DAY’ was assumed to represent ‘ONE TWICE A DAY’. This assumption was 
considered more likely to underestimate, rather than overestimate, the true prescribed 
dose. Making these assumptions was considered preferable to treating ambiguous 
dosage instructions as having missing data for the derived dosage variables, which 
would be likely to result in a greater degree of misclassification of cases as non-cases. 
A number of dosage instructions did not contain sufficient information from which to 
derive values for any of the dosage variables, e.g. ‘USE AS DIRECTED’, and in these 
cases the dosage was coded as missing. A selection of example dosage instructions, 
and the derived variables coded from the instruction text, are shown in Table 5.6. 
 
The prescribed daily dose of calciferol in international units was calculated for each 
prescription by multiplying the unit strength of the preparation prescribed (derived from 
the drug code) by the number of dosage units to be taken each day (derived from the 
dosage instruction). Where the dosage instruction text also directly specified the dose 
in terms of IU of calciferol, this was given priority over the calculated daily dose if there 
was discrepancy between the two values. 
 
For the main analyses, dosage instructions that specified a treatment duration of £14 
days were considered to represent stoss (one-off) therapy. In these cases, instead of 
calculating the prescribed daily dose, the total dose of calciferol prescribed over the 
treatment period was calculated. A sensitivity analysis was performed to explore the 
influence of varying the choice of treatment duration considered to represent stoss 
therapy, from £7 days to <28 days. 
 
It was possible to derive the prescribed dosage for 16,591 out of the total of 16,998 
prescriptions of calciferol (97.6%). Dosage information was missing for 407 
prescriptions (2.4%). For 1,303 of the prescriptions where the dosage could be derived 
(7.9%), the dosage instruction was not exact and an assumption was made regarding 
the number of dosage units to be taken at each administration time point.
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Table 5.6  Examples of dosage instructions and derived dosage variables.a 
Dosage instruction Dosage unit Time between doses (hours) 
Dosage units 
per 
administration 
Dosage 
units per 
day 
Treatment 
duration 
(days) 
Total dosage 
units, if duration 
<1 month 
IU of 
calciferol 
per day 
1 TAB DAILY tablet / capsule 24 1 1 - - - 
2MLS TWICE A DAY ml 12 2 4 - - - 
ONE ALTERNATE DAYS - 48 1 0.5 - - - 
1 WEEKLY - 168 1 0.14286 - - - 
ONE MONTHLY - 672 1 0.0357 - - - 
0.5MLS IMMEDIATELY ml - 0.5 - 1 0.5 - 
2 DAILY FOR 4 DAYS - 24 2 2 4 8 - 
2ML (6000 UNITS) ONCE DAILY ml 24 2 2 - - 6,000 
TAKE 1 OR 2 DAILY - 24 1.5 1.5 - - - 
TWICE A DAY - 12 1 2 - - - 
USE AS DIRECTED - - - - - - - 
Abbreviation: IU, international units. 
a Key variables for the calculation of prescribed dose are highlighted in yellow. 
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5.3.7.2 Data Cleaning for Vitamin D Test Results 
 
The majority (90%) of vitamin D test results identified in the study population were 
recorded with the unit of measurement nmol/l, whilst the remaining 10% were recorded 
in ng/ml. As nmol/l is the usual unit of measurement for 25-OH-D in the UK, test results 
recorded in ng/ml were converted to nmol/l by multiplying the result value by a factor of 
2.5 (SACN, 2016). 
 
Read codes related to vitamin D tests (see section 5.3.6.5) were grouped into 4 
categories based on the form of vitamin D specified by the code description (Table 
5.7). 
 
Table 5.7  Categories of vitamin D test codes. 
Test category Read code Code description 
Total 25-hydroxyvitamin D2 
and D3 
4QB4400 Combined total vitamin D2 and D3 level 
4QB4600 Total 25-hydroxyvitamin D level 
4QB4700 Serum total 25-hydroxy vitamin D level 
25-hydroxyvitamin D3 
44LM.00 Plasma 25-Hydroxyvitamin D3 level 
44LP.00 Serum 25-Hydroxy vitamin D3 level 
4QB4100 Vitamin D3 level 
4QB4300 25-Hydroxyvitamin D3 level 
25-hydroxyvitamin D2 
44Lg.00 Serum vitamin D2 level 
44Ln.00 Serum 25-Hydroxyvitamin D2 level 
4QB4000 Vitamin D2 level 
4QB4200 25-Hydroxyvitamin D2 level 
Unspecified vitamin D test 
44LA.00 Serum vitamin D 
4QB4.00 Vitamin D level 
4QB4500 25-Hydroxyvitamin D level 
5788.00 Radiobioassay - vitamin Da 
a There were no records for this code in the study cohort. 
 
 
The distribution of test values for vitamin D tests identified in the study population were 
compared across each of the test categories (Table 5.8). The distribution of test values 
for the unspecified vitamin D tests was similar to that for vitamin D3 tests and total 
vitamin D2 & D3 tests. Therefore, unspecified vitamin D tests were considered to 
represent measurement of either 25-hydroxyvitamin D3 or total 25-hydroxyvitamin D2 
& D3. 
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Table 5.8  Distribution of test values across the vitamin D test categories. 
Test category No. of tests 
Distribution of test values in nmol/l 
Median  (IQR)  [1st–99th centiles] 
Total vitamin D2 & D3 8,503 38  (22–59)  [6.0–139] 
Vitamin D3 20,178 35  (20–57)  [5.0–144] 
Vitamin D2 12,421 2.8  (1.0–5.0)  [0.0–54] 
Unspecified vitamin D 43,698 37  (22–59)  [7.0–147] 
Abbreviation: IQR, interquartile range. 
 
Where a separate vitamin D2 and vitamin D3 test were recorded on the same date, the 
sum of the test results was calculated to give the total vitamin D2 & D3. Vitamin D test 
records were considered to represent vitamin D deficiency, and meet the case 
definition for the outcome, if there was a record of either a total vitamin D2 & D3, a 
vitamin D3, or an unspecified vitamin D test result with a value of <25 nmol/L. 
 
 
5.3.7.3 Data Cleaning for Ethnicity Records 
 
The consistency of ethnicity data within patient records has been shown to be higher in 
primary care electronic health data than in HES (Mathur et al, 2014). Therefore, for 
children with data available from both THIN and HES, ethnicity was assigned using 
THIN data. THIN Read codes referring directly to ethnicity, nationality or race were 
given precedence over codes referring to country of birth or language. Among children 
in the study cohort with ethnicity data available, final ethnicity was derived from codes 
referring directly to ethnicity, nationality or race for 99.5%, and from codes referring to 
country of birth or language in the remaining 0.5%.  
 
In order to minimise conflicting ethnicity data within individual patients’ records, a group 
of Read codes were identified which are less specific than others in their description of 
ethnicity, and which commonly caused conflict with other ethnicity records in the study 
population (Table 5.9). 
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Table 5.9  Read codes that have a non-specific description of ethnicity. 
Read code Description 
9SA..00 Other ethnic non-mixed (NMO) 
9SAD.00 Other ethnic NEC (NMO) 
9SJ..00 Other ethnic group 
9iF..00 Other - ethnic category 2001 census 
9iFK.00 Any other group - ethnic category 2001 census 
9i0..00 British or mixed British - ethnic category 2001 census 
 
All other ethnicity related Read codes were given precedence over these codes. For 
example, for a child with two ethnicity records, one for ‘Other ethnic group’ and the 
other for ‘Indian’, final ethnicity was coded as Indian. Similarly, for a child with an 
ethnicity record for ‘British or mixed British - ethnic category 2001 census’ as well as a 
record for ‘Black British - ethnic category 2001 census’, final ethnicity was coded as 
Black British. 
 
Another common cause of conflict within individuals’ ethnicity records was the 
combination of a code referring to ‘other Asian’ background (coded as ‘Asian or Asian 
British’ using the ONS 2001 Census 5-level classification), and a code referring to a 
Far Eastern, Middle Eastern or Arab background (which are all coded as ‘Chinese or 
Other Ethnic Groups’ using the ONS 2001 Census 5-level classification). Read codes 
referring to a non-specific Asian background are shown in Table 5.10. 
 
Table 5.10  Read codes referring to a non-specific Asian background. 
Read code Description 
1343.00 Asian origin 
2263.11 O/E - Asian origin 
9SA8.00 Other Asian (NMO) 
9SH.00 Other Asian ethnic group 
9T1E.00 Other Asian 
9iA.00 Other Asian background - ethnic category 2001 census 
9iAA.00 Other Asian or Asian unspecified ethnic category 2001 
 
All codes assigned a 5-category ethnic group of ‘Chinese or Other Ethnic Groups’ were 
given precedence over the codes referring to a non-specific Asian background shown 
in Table 5.10. For example, for a child with an ethnicity record for ‘Other Asian ethnic 
group’ as well as a record for ‘RACE: Korean’, final ethnicity was coded as ‘Chinese or 
Other Ethnic Groups’. 
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Following all of the above data management steps, among children with ethnicity data 
available, the proportion who had multiple ethnicity records belonging to different 5-
level categories across THIN and HES was reduced from 5.5% to 0.5%. Among 
remaining children with ethnicity records belonging to more than one 5-level category, 
the most frequently recorded category was used. Where clashing ethnicity codes were 
recorded with the same frequency, ethnicity was coded as missing. 
 
For children with no ethnicity data available, maternal ethnicity was used as a proxy 
measure for the child’s ethnicity where it was available. The procedure for linking 
children to mothers in the THIN dataset is explained in section 5.3.7.4. Among children 
who had an ethnicity record available both for themselves as well as their linked 
mother, the two records matched at the 5-level ethnicity classification in 94% of cases. 
 
 
5.3.7.4 Linkage of Children to Mothers 
 
Children in the study cohort were linked to their mothers’ in order to obtain information 
regarding maternal ethnicity, which was used as a proxy measure for children’s 
ethnicity where this was missing (see section 5.3.5.2). A procedure for child-to-mother 
linkage was developed which was closely related to methods that have previously been 
used to link a cohort of pregnant women in THIN to their children (Petersen et al, 
2016a). In summary, children in the study cohort were linked to women registered with 
the same general practice and sharing an identical ‘household’ identifier (see section 
5.3.2.1), whose year of birth was between 14 to 50 years before the child’s year of 
birth, and who had a record of pregnancy or delivery in their medical record where the 
expected, recorded, or predicted date of delivery was in proximity to the child’s month 
of birth (or year of birth for older children age ³15 years at February 2015). 
 
Pregnancy or delivery related data is often recorded in the THIN database in the 
additional health data (AHD) file, using a separate group of codes called AHD codes. 
This allows additional data fields to be recorded, specific to each AHD code, such as 
the estimated date of delivery (EDD) or date of the last menstrual period (LMP). All 
AHD codes were manually reviewed (n=544), and those that are related to pregnancy 
or delivery were identified (Table 5.11). In addition to the AHD records, pregnancy and 
delivery records were also identified using relevant Read codes in patients’ medical 
records (see section 5.3.6.7). Relevant Read codes were grouped into 19 categories, 
each referring to a common theme (Table 5.12) (see appendix G.3). 
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Table 5.11  AHD codes related to pregnancy or delivery. 
AHD code Description 
1001400092 Pregnancy test a 
1001400161 Maternity ultra sound scan 
1001400306 Ante natal blood tests 
1009800000 CHS – APGAR Score At 1 Minute 
1009810000 CHS – APGAR Score At 5 Minutes 
1015000000 Maternity outcome b 
1040000000 Ante natal booking 
1041000000 Ante natal consultation 
1044000000 Postnatal examination 
1044100000 Postnatal visit 
1046100000 Ante natal fetal examination 
1047000000 Maternity outcome gestational age of baby 
1048000000 Maternity pregnancy dates – event date = LMP date 
1048100000 Maternity delivery details baby b 
1048200000 Maternity placenta 
1049000000 CHS – gestation 
1050300000 Maternity feeding 
1052500000 Maternity infant details b 
1055400000 Maternity perineum 
1055405000 Maternity care plan 
1055500000 CHS – delivery details b 
1055520000 Maternity stages of labour 
a Only included in linkage if the test was specified as being positive. 
b Not included in linkage if the outcome was specified as being a  
  stillbirth, miscarriage, or neonatal death. 
 
 
Table 5.12  Categories of Read codes related to pregnancy or delivery. 
Category 
Pregnant 
Pregnancy Test 
Antenatal ultrasound scan 
Antenatal examination 
Antenatal care 
Antenatal screening or test 
Delivery booking 
Estimated delivery date 
Amniocentesis 
Birth or delivery 
Length of labour 
Mode of birth 
Sex of baby 
Gestational age 
Postnatal visit 
Postnatal care 
Postnatal examination 
Hearing screen 
Newborn registration 
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Proximity rules for considering there to be a match between children’s birth records and 
maternal pregnancy or delivery records were derived separately for each AHD code 
and each Read code group. Children in the study cohort were first linked to all women 
meeting each of the following criteria: 
 
• Registered with the same general practice as the child. 
 
• Recorded as having an acceptable patient record status (Patflag A or C). 
 
• Period of active registration with the practice overlapping that of the child. 
 
• Sharing an identical ‘household’ identifier with the child. 
 
• Year of birth between 14 to 50 years before the child’s year of birth. 
 
• Recorded to have any pregnancy or delivery related AHD code or Read code 
in their patient record. 
 
For each linked pair, the difference in time (in months) between the child’s month of 
birth and the date of each maternal pregnancy or delivery record was calculated. The 
distribution of time differences between the children’s birth records and maternal 
pregnancy / delivery records was explored, for each AHD code and each Read code 
group separately, to identify the period of proximity in which there was an increase or 
spike in frequency of records. This period was then used to derive proximity rules for 
considering the children’s and maternal records to be a match, specific to each AHD 
code and Read code group. For example, for the AHD code for ‘Maternity care plan’ 
(1055405000), the frequency of records was above baseline in the period between 0 to 
9 months before the children’s month of birth (Figure 5.2). Therefore, where this code 
was recorded between 0 to 9 months before a child’s month of birth, it was considered 
to represent a match between mother and child. 
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Figure 5.2  Distribution of the timing of maternal records for the ‘Maternity care plan’ 
AHD code in relation to children’s month of birth.a 
 
a Graph limited to the period 15 months either side of children’s month of birth, for purposes 
of clarity. This analysis includes all records for the AHD code 1055405000 (‘Maternity care 
plan’) in women in THIN, where women are registered with the same practice and share an 
identical ‘household’ identifier with a child in the study cohort, and where the woman’s year 
of birth is between 14 to 50 years before the child’s year of birth (n=655,540). 
 
 
For AHD records providing information regarding the EDD or actual date of delivery, or 
other data from which the EDD could be calculated (such as the date of the LMP), the 
difference between the child’s month of birth and the EDD or actual delivery date was 
calculated. Where the date of the LMP was given, the EDD was calculated as 280 days 
after the date of the LMP (ACOG, 2014). The distribution of time differences between 
the children’s month of birth and the EDD or actual delivery dates was explored, and 
the period of proximity in which there was an increase in frequency of records was 
identified. For example, for the AHD code for ‘Maternity pregnancy dates – event date 
= LMP date’ (1048000000), the frequency of records demonstrated a spike where the 
EDD was between 1 month before to 1 month after the children’s month of birth (Figure 
5.3). Therefore, where this code was recorded with an EDD 1 month either side of a 
child’s month of birth, it was considered to represent a match between mother and 
child. 
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Figure 5.3  Distribution of the timing of estimated delivery dates (EDD) in relation to 
children’s month of birth, for records of the AHD code ‘Maternity pregnancy dates – 
event date = LMP date’.a 
 
a Graph limited to the period 15 months either side of children’s month of birth, for purposes 
of clarity. This analysis includes all records for the AHD code 1048000000 (‘Maternity 
pregnancy dates – event date = LMP date’) in women in THIN, where women are 
registered with the same practice and share an identical ‘household’ identifier with a child in 
the study cohort, and where the woman’s year of birth is between 14 to 50 years before the 
child’s year of birth (n=968,006). 
 
 
For children age ³15 years at February 2015, for whom only year of birth was 
available, maternity records where the EDD or actual date of delivery were in the same 
year as the child’s year of birth were considered to represent a match between mother 
and child. For maternity records where the EDD or actual date of delivery were not 
given, the month of the maternity record was used to determine whether children born 
in the same year, previous year, or subsequent year were considered to represent a 
match. This decision was based upon the most common time at which each maternity 
related AHD code and Read code group was recorded in relation to the children’s 
month of birth, determined using data from younger children for whom month of birth 
was available. For example, for the AHD code for ‘Maternity care plan’ (1055405000), 
there was a peak in frequency of records between 7 to 8 months before children’s birth 
(Figure 5.2). Therefore, for older children for whom only year of birth was available, 
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where a maternity care plan was recorded between January to June, a child born in the 
same year was considered a match. However, for maternity care plans recorded 
between July to December, children born in the subsequent year were considered a 
match. 
 
Proximity rules derived for child to mother linkage for each pregnancy or delivery 
related AHD code and Read code group are shown in appendix F. 
 
Child to mother linkage was not performed for children with a ‘household’ identifier 
which was shared by a large number of people (³20) during the period of the child’s 
registration with the practice (1.1% of children in the study cohort). In such cases, the 
‘household’ identifier was considered likely to represent a block of flats, and the risk of 
erroneous linkage was considered to be high. Linked mothers were excluded if children 
were matched to more than one potential mother (0.2% of children in the study cohort). 
Overall, 59.2% of children in the study cohort were successfully matched to a single 
mother. 
 
 
5.3.8 Statistical Analysis 
 
All statistical and graphical analyses were performed using Stata MP version 14.2 
(StataCorp, USA). 
 
 
5.3.8.1 Descriptive Analysis 
 
Descriptive characteristics of the study cohort were summarised using the numbers 
and percentages of individuals in each category for categorical variables, and using 
medians and interquartile ranges (IQR) for non-normally distributed continuous 
variables. Among children diagnosed with vitamin D deficiency, the frequency of 
recording of relevant symptom codes in the 6 months either side of the date of the first 
record meeting the case definition for the diagnosis of vitamin D deficiency was 
analysed. In addition, free text entries in the primary care medical record were 
purchased for a convenience sample of 55 children in the cohort with a diagnosis of 
vitamin D deficiency, in order to explore the extent to which free text could be used to 
obtain additional information regarding the presence of relevant symptoms. The 
convenience sample was chosen on the basis that free text dosage instructions were 
also being purchased for these children. All free text entries in the primary care medical 
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record in the 6 months either side of the date of the first record meeting the case 
definition for the diagnosis of vitamin D deficiency were examined. The free text 
provided additional information regarding symptoms related to vitamin D deficiency 
(Table 5.5), not already available from Read codes, in only 4 out of the 55 children 
(7.3%). Therefore, the purchase of further free text records for identification of 
symptoms among cases was not felt to be cost-efficient. 
 
 
5.3.8.2 Analysis of Time Trends in the Diagnosis of Vitamin D Deficiency 
 
Crude incidence rates for the diagnosis of vitamin D deficiency were calculated per 
100,000 person-years at risk (PYAR), using the stset and strate functions in Stata. In 
order to explore incidence rates stratified by time-changing variables (age and calendar 
time), Lexis expansions were used to divide individuals’ follow-up into distinct 
categories of the time-changing variables, using the stsplit function in Stata (Kirkwood 
& Sterne, 2003). Calendar time was split into individual years, between 2000 to 2014. 
 
Plots of incidence rates for the diagnosis of vitamin D deficiency against time since 
registration with the general practice (Lewis plots) were used to explore whether there 
was evidence of greater recording of vitamin D deficiency diagnosis in the initial period 
after practice registration (Lewis et al, 2005). 
 
 
5.3.8.3 Crude Associations Between Study Covariates and Rates of Diagnosis of 
Vitamin D Deficiency 
 
Differences in rates of diagnosis of vitamin D deficiency by various socio-demographic 
factors were initially explored using rate ratios (RRs) to examine crude associations 
between incidence rates and each study covariate separately, using the stmh function 
in Stata. Significance tests were used to examine the null hypothesis that rate ratios 
were equal to 1.  
 
 
5.3.8.4 Multivariable Analyses 
 
Multivariable analyses were subsequently performed to examine adjusted associations 
between socio-demographic factors and incidence rates, taking into account the effect 
of all covariates simultaneously. For the multivariable analyses, the study cohort was 
limited to children registered with THIN practices that have linked HES data available 
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(the linked THIN-HES study cohort), in order to minimise missing data for ethnicity. 
Whilst ethnicity was available for only 48.1% of the full THIN study cohort, the addition 
of HES data substantially increased the availability of ethnicity data to 81.5% in the 
linked THIN-HES cohort (see section 5.4.2). The study period for the multivariable 
analyses was restricted to follow-up between 1st January 2008 and 31st December 
2014, in view of the small numbers of cases (<30) of the outcome (diagnosis of vitamin 
D deficiency) in each year prior to 2008 (see section 5.4.3.9). 
 
In the main multivariable analyses, Poisson regression was used to model rates of 
incident diagnosis of vitamin D deficiency whilst adjusting for sex, age group, ethnicity, 
Index of Multiple Deprivation (IMD), and calendar year (included as a categorical 
variable), using the poisson command in Stata. A sensitivity analysis was performed 
using the Townsend Index instead of the IMD, to explore the influence of the choice of 
measure of socio-economic position on the results. The IMD was used in subsequent 
analyses, on the basis that it is derived from a considerably broader range of indicator 
variables than the Townsend Index (see section 5.3.5.3). 
 
Likelihood ratio tests (LRTs) were used to compare nested models with and without the 
inclusion of each covariate, to examine the null hypothesis of no overall association 
between each covariate and the rate of diagnosis of vitamin D deficiency. Evidence for 
interaction (effect modification) between explanatory variables in the model was 
investigated by examining the heterogeneity of stratum-specific rate ratios, and 
performing LRTs comparing the fit of models with and without the corresponding 
interaction terms. Evidence for interaction between covariates is presented graphically 
using plots of predicted margins (adjusted incidence rates predicted from Poisson 
regression models containing interaction terms) across the different categories of the 
relevant covariates (Williams, 2012). Interaction terms were retained in the final model 
if their inclusion resulted in both a qualitative change in parameter rate ratios and a 
significant LRT result (p<0.05).  
 
 
5.3.8.5 Multilevel Models 
 
The multivariable analysis was conducted with and without taking into account the 
clustered structure of the data. Initial model development and investigation of 
interaction was performed using single-level Poisson regression models, which did not 
account for data clustering. Multilevel Poisson regression models were developed to 
take into account the nested structure of the data. A two-level mixed-effects model was 
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developed with inclusion of the general practice as a random effect, using the 
xtpoisson command in Stata. A three-level mixed-effects model was also developed, 
additionally accounting for the nesting of practices within strategic health authority 
regions, using the meqrpoisson command in Stata. 
 
 
5.3.8.6 Methods for Handling Missing Data 
 
In the main multivariable analyses, missing data for model covariates was handled 
using complete cases analysis (listwise deletion). A sensitivity analysis was performed 
using multiple imputation of missing data, to explore the influence of the choice of 
method for handling missing data on the results. Data was incomplete for ethnicity and 
IMD, whilst complete data was available for the other model covariates (see section 
5.4.2.2). Multivariable multiple imputation using chained equations was performed 
using the mi impute chained command in Stata (White et al, 2011). The imputation 
model included all variables in the substantive model, in addition to the following 
auxiliary variables which were shown to be associated with either ethnicity or IMD in 
the cohort: 
 
• Year of birth, included as a continuous variable. 
• Strategic health authority region. 
• Townsend Index of deprivation. 
• Ethnicity distribution of individuals sharing the same ‘household’ identifier. 
Separate categorical variables were created for each of the 5 ethnic groups, 
representing the proportion of individuals in the ‘household’ with the 
corresponding ethnicity (excluding individuals with missing data). Coded into 4 
categories: 0, 0<x<0.5, 0.5≤x<1, 1. 
• Ethnicity distribution of individuals registered with the same general practice. 
Separate continuous variables were created for each of the 4 non-white ethnic 
groups, representing the proportion of the practice population with the 
corresponding ethnicity (excluding individuals with missing data). A variable 
for white ethnicity was not included, as inclusion of variables for all 5 ethnic 
groups resulted in collinearity (as their values always sum to 1). 
• The mode (most common) IMD value among individuals sharing the same 
‘household’ identifier. 
Chapter 5. Trends in Diagnosis of Vitamin D Deficiency 
 157 
• The IMD distribution among individuals registered with the same general 
practice. Four separate continuous variables were created for the IMD 
categories between 2 to 5, representing the proportion of the practice 
population with the corresponding IMD (excluding individuals with missing 
data). A variable for the IMD value of 1 was not included, as inclusion of 
variables for all 5 IMD categories resulted in collinearity (as their values 
always sum to 1). 
 
The imputation model included any interaction terms present in the substantive model. 
Multinomial logistic regression was used for the conditional imputation model of 
ethnicity, whilst ordinal logistic regression was used for the conditional imputation 
model of IMD. Twenty imputed datasets were created. 
 
 
5.3.9 Ethical Approval 
 
The THIN data collection was approved by the NHS South-East Multicentre Research 
Ethics Committee in 2003 (http://www.epic-uk.org/our-data/ethics.shtml, accessed 
22/10/2016). Under the terms of this approval, pre-collected, pseudo-anonymised 
patient data can be provided to researchers following independent scientific review, 
without the necessity for further approval from a Research Ethics Committee. Scientific 
approval for use of THIN data for this study was obtained from Cegedim Strategic Data 
Medical Research UK’s Scientific Review Committee (reference 14–013, see appendix 
B.4). 
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5.4 Results 
 
 
5.4.1 Relationship Between Time After Practice Registration and Rates of 
Diagnosis of Vitamin D Deficiency 
 
Plots of incidence rates for the diagnosis of vitamin D deficiency against time since 
registration with the general practice (Lewis plots) demonstrated that rates of recorded 
diagnosis were greatest in the first 3 months after registration, and reached baseline 
after 9 months following registration (Figures 5.4 and 5.5). In the main analyses, for 
children aged ³1 year at the time of practice registration, the first 3 months after 
registration were excluded from follow-up. A sensitivity analysis was performed to 
explore the influence of varying this period of exclusion from between 0 to 9 months 
after practice registration. The period of exclusion was not necessary for infants under 
one year of age, for whom any recorded diagnoses can be considered incident 
(regardless of proximity to registration) as they will have occurred within the preceding 
year.  
 
 
Figure 5.4  Rates of diagnosis of vitamin D deficiency by time after registration with the 
general practice, in single month intervals.a 
 
a Crude incidence rates are shown, with 95% confidence intervals represented by vertical lines. 
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Figure 5.5  Rates of diagnosis of vitamin D deficiency by time after registration with the 
general practice, in 3 month intervals.a 
 
a Crude incidence rates are shown, with 95% confidence intervals represented by vertical lines. 
 
 
 
5.4.2 Descriptive Characteristics of the Study Cohort 
 
 
5.4.2.1 Full THIN Study Cohort 
 
The full study cohort consisted of 2,338,529 children, from 639 general practices, with 
a total period of follow-up of 11.5 million person-years. Median duration of study follow-
up was 3.7 years per individual (IQR 1.5 to 7.7). 11,913 children with a record of either 
chronic renal disease, liver disease, or conditions associated with gastrointestinal 
malabsorption, were excluded from the study cohort. Descriptive characteristics of the 
study population are shown in Table 5.13. 7,297 children in the study cohort met the 
case definition for diagnosis of vitamin D deficiency during their period of follow-up. 
 
In the full study cohort, information regarding ethnicity was derived from THIN primary 
care records only. Ethnicity was directly available for 40.1% of children in the cohort, 
and maternal ethnicity was available as a proxy measure of children’s ethnicity for a 
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further 8.0% of the cohort. Ethnicity was missing for 51.9% of the study cohort. 
Townsend deprivation index was available for 93.8% of the cohort (missing for 6.2%). 
 
 
Table 5.13  Descriptive characteristics of the full study cohort (n=2,338,529). 
Age at entry to follow-up (years) Median  (IQR) 
  4.5  (0.42–10.7) 
Sex n  (%) 
 Male 1,205,379  (51.5%) 
 Female 1,133,150  (48.5%) 
Ethnicity a n  (%) 
 White 939,886  (40.2%) 
 Asian or Asian British 75,356  (3.2%) 
 Black or black British 50,480  (2.2%) 
 Mixed 30,795  (1.3%) 
 Chinese or other ethnic group 29,141  (1.3%) 
 Missing 1,212,871  (51.9%) 
Townsend deprivation index quintile n  (%) 
 1 (least deprived) 497,087  (21.3%) 
 2 430,223  (18.4%) 
 3 466,594  (20.0%) 
 4 455,296  (19.5%) 
 5 (most deprived) 344,941  (14.8%) 
 Missing 144,388  (6.2%) 
Country, and strategic health authority in England n  (%) 
 England 1,828,119  (78.2%) 
 South Central 269,240  (11.5%) 
 London 254,965  (10.9%) 
 South East Coast 211,205  (9.0%) 
 South West 208,298  (8.9%) 
 North West 199,913  (8.6%) 
 West Midlands 194,860  (8.3%) 
 East of England 153,355  (6.6%) 
 East Midlands 74,825  (3.2%) 
 Yorkshire & Humber 69,886  (3.0%) 
 North East 52,371  (2.2%) 
 Missing 139,201  (6.0%) 
 Scotland 269,606  (11.5%) 
 Wales 164,380  (7.0%) 
 Northern Ireland 76,424  (3.3%) 
Abbreviations: IQR, interquartile range. 
a Ethnicity data was available from the child’s THIN record for 40.1% of the cohort, 
and maternal ethnicity was available as a proxy measure for a further 8.0%. 
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5.4.2.2 Study Cohort with Linked HES Data Available 
 
When the analysis was limited to children registered with one of the 156 THIN practices 
in England for which linked HES data was available, the study cohort consisted of 
711,788 children, with a total period of follow-up of 3.6 million person-years. Median 
duration of study follow-up was 3.9 years per individual (IQR 1.5 to 8.0). 3,916 children 
with a record of either chronic renal disease, liver disease, or conditions associated 
with gastrointestinal malabsorption, were excluded from the study cohort. Descriptive 
characteristics of the linked THIN-HES study population are shown in Table 5.14. 2,918 
children in the cohort met the case definition for diagnosis of vitamin D deficiency 
during their period of follow-up. 
 
In the linked THIN-HES study cohort, information regarding ethnicity was derived from 
both THIN and HES records. Ethnicity was directly available for 67.7% of children in 
the cohort, and maternal ethnicity was available as a proxy measure of children’s 
ethnicity for a further 13.8% of the cohort. Ethnicity was missing for 18.5% of the study 
cohort. Townsend deprivation index was available for 95.7% of the cohort (missing for 
4.3%), and Index of Multiple Deprivation was available for 93.3% of the cohort (missing 
for 6.7%). 
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Table 5.14  Descriptive characteristics of the THIN-HES linked study cohort 
(n=711,788). 
Age at entry to follow-up (years) Median  (IQR) 
  4.1  (0.40–10.5) 
Sex n  (%) 
 Male 366,378  (51.5%) 
 Female 345,410  (48.5%) 
Ethnicity a n  (%) 
 White 491,962  (69.1%) 
 Asian or Asian British 34,521  (4.9%) 
 Black or black British 24,797  (3.5%) 
 Mixed 15,558  (2.2%) 
 Chinese or other ethnic group 13,443  (1.9%) 
 Missing 131,507  (18.5%) 
Townsend deprivation index quintile n  (%) 
 1 (least deprived) 171,842  (24.1%) 
 2 129,172  (18.2%) 
 3 148,404  (20.9%) 
 4 141,244  (19.8%) 
 5 (most deprived) 90,595  (12.7%) 
 Missing 30,531  (4.3%) 
Index of Multiple Deprivation quintile n  (%) 
 1 (least deprived) 158,866  (22.3%) 
 2 134,765  (18.9%) 
 3 138,264  (19.4%) 
 4 136,498  (19.2%) 
 5 (most deprived) 95,656  (13.4%) 
 Missing 47,739  (6.7%) 
Strategic health authority n  (%) 
 South Central 158,547  (22.3%) 
 South West 111,817  (15.7%) 
 London 100,718  (14.2%) 
 South East Coast 91,619  (12.9%) 
 West Midlands 89,796  (12.6%) 
 North West 64,152  (9.0%) 
 East of England 57,961  (8.1%) 
 North East 18,532  (2.6%) 
 Yorkshire & Humber 14,209  (2.0%) 
 East Midlands 4,437  (0.6%) 
Abbreviations: IQR, interquartile range. 
a Ethnicity data was available from the child’s THIN or HES record for 67.7% of the 
cohort, and maternal ethnicity was available as a proxy measure for a further 
13.8%. 
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5.4.3 Time Trends in the Diagnosis of Vitamin D Deficiency in Children 
 
 
5.4.3.1 Main Results Using the Full Study Cohort 
 
Overall incidence rates for the diagnosis of vitamin D deficiency in the full THIN study 
cohort over time are shown in Figure 5.6 and Table 5.15. There was a marked increase 
in crude rates of diagnosis between 2008 to 2013, after which rates plateaued between 
2013 to 2014. 
 
Figure 5.6  Time trends in the diagnosis of vitamin D deficiency in the full study cohort, 
between 2000 and 2014.a 
 
a Crude incidence rates are shown, with 95% confidence limits represented by the dashed lines. 
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Table 5.15  Crude incidence rates for the diagnosis of vitamin D deficiency in the full 
study cohort, by year between 2000 and 2014. 
Year Number of cases Person-years at risk (PYAR) 
Incidence rate per 100,000 PYAR 
(95% CI) 
2000 11 430,721 2.55  (1.41–4.61) 
2001 14 515,596 2.72  (1.61–4.58) 
2002 14 614,946 2.28  (1.35–3.84) 
2003 19 688,371 2.76  (1.76–4.33) 
2004 27 766,064 3.52  (2.42–5.14) 
2005 39 805,582 4.84  (3.54–6.63) 
2006 59 831,792 7.09  (5.50–9.15) 
2007 67 860,350 7.79  (6.13–9.89) 
2008 143 875,935 16.3  (13.9–19.2) 
2009 312 883,603 35.3  (31.6–39.5) 
2010 496 865,219 57.3  (52.5–62.6) 
2011 901 872,353 103  (96.8–110) 
2012 1,652 877,054 188  (179–198) 
2013 1,839 841,381 219  (209–229) 
2014 1,704 761,971 224  (213–235) 
Abbreviations: CI, confidence interval; PYAR, person-years at risk. 
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5.4.3.2 Sources of Case Identification 
 
Figure 5.7 shows the overlap between cases identified from diagnosis codes, 
prescription records, and 25-OH-D test records.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Considerably lower incidence rates were obtained when the three components of the 
case definition were examined independently rather than being used together (Figure 
5.8 and Table 5.16). Similar trends over time were seen with each source of case 
identification. 
 
1,520 
(20.8%) 
1,186 
(16.3%) 
579 
(7.9%) 
821 
(11.3%) 
Prescriptions 
(46.3%) 
796 
(10.9%) 
25-OH-D tests 
(55.0%) 
1,496 
(20.5%) 899 
(12.3%) 
Diagnosis codes 
(52.0%) 
Figure 5.7  Venn diagram showing the overlap between the sources of case 
identification.a 
a The figures represent numbers of cases (percentages). N=7,297.  
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Figure 5.8  Time trends in incidence rates for the diagnosis of vitamin D deficiency, 
using all components of the case definition together and each source of case 
identification independently.a 
 
a Crude incidence rates are shown between 2000 and 2014 in the full study cohort. 
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Table 5.16  Crude incidence rates obtained using each component of the case 
definition for diagnosis of vitamin D deficiency separately, in each year between 2000 
and 2014.a 
Year 
Diagnosis Read codes Vitamin D prescription records 25-OH-D test records 
No. of 
cases 
Incidence rate per 
100,000 PYAR  
(95% CI) 
No. of 
cases 
Incidence rate per 
100,000 PYAR 
(95% CI) 
No. of 
cases 
Incidence rate per 
100,000 PYAR 
(95% CI) 
2000 11 2.55  (1.41–4.61) 0 0 0 0 
2001 13 2.52  (1.46–4.34) 0 0 2 0.39  (0.10–1.55) 
2002 13 2.11  (1.23–3.64) 2 0.33  (0.08–1.30) 0 0 
2003 14 2.03  (1.20–3.43) 2 0.29  (0.07–1.16) 5 0.73  (0.30–1.74) 
2004 17 2.22  (1.38–3.57) 4 0.52  (0.20–1.39) 11 1.44  (0.80–2.59) 
2005 31 3.85  (2.71–5.47) 6 0.74  (0.33–1.66) 6 0.74  (0.33–1.66) 
2006 47 5.65  (4.25–7.52) 8 0.96  (0.48–1.92) 18 2.16  (1.36–3.43) 
2007 46 5.35  (4.00–7.14) 12 1.39  (0.79–2.46) 27 3.14  (2.15–4.57) 
2008 91 10.4  (8.46–12.8) 23 2.62  (1.74–3.95) 63 7.19  (5.62–9.20) 
2009 170 19.2  (16.6–22.4) 79 8.94  (7.17–11.1) 181 20.5  (17.7–23.7) 
2010 272 31.4  (27.9–35.4) 146 16.9  (14.3–19.8) 309 35.7  (31.9–39.9) 
2011 489 56.0  (51.3–61.2) 254 29.1  (25.7–32.9) 570 65.3  (60.1–70.9) 
2012 895 102  (95.5–109) 667 75.9  (70.4–81.9) 956 109  (102–116) 
2013 943 112  (105–119) 1,085 129  (121–136) 986 117  (110–124) 
2014 707 92.6  (86.0–99.6) 1,142 149  (141–158) 890 116  (109–124) 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; CI, confidence interval; PYAR, person-years at 
risk. 
a The analysis used the full study cohort. 
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5.4.3.3 Sensitivity Analysis Exploring the Impact of Varying the Period of Exclusion 
from Follow-up after Practice Registration 
 
Observed rates of diagnosis of vitamin D deficiency did not differ substantially when the 
period of exclusion from follow-up following practice registration was varied between 0 
to 9 months, for children aged ³1 year at the time of practice registration (Figure 5.9 
and Table 5.17). 
 
 
 
Figure 5.9  Time trends in the diagnosis of vitamin D deficiency, using varying periods 
of exclusion from follow-up after practice registration.a 
 
a Crude incidence rates are shown between 2000 and 2014 in the full study cohort. For children 
aged ³1 year at the time of practice registration, varying periods of time following practice 
registration were excluded from follow-up; no period of exclusion (dashed blue line), 3-month 
period of exclusion (solid red line), and 9-month period of exclusion (dashed green line). No 
period of exclusion was employed for infants under the age of one year at the time of practice 
registration. 
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Table 5.17  Crude incidence rates for the diagnosis of vitamin D deficiency between 
2000 and 2014, using varying periods of exclusion from follow-up after practice 
registration.a 
Year 
No period of exclusion 
after registration 
3-month period of 
exclusion after registration 
9-month period of  
exclusion after registration 
No. of 
cases 
Incidence rate per 
100,000 PYAR  
(95% CI) 
No. of 
cases 
Incidence rate per 
100,000 PYAR 
(95% CI) 
No. of 
cases 
Incidence rate per 
100,000 PYAR 
(95% CI) 
2000 11 2.52  (1.39–4.54) 11 2.55  (1.41–4.61) 10 2.39  (1.29–4.45) 
2001 16 3.06  (1.87–4.99) 14 2.72  (1.61–4.58) 13 2.60  (1.51–4.47) 
2002 16 2.56  (1.57–4.19) 14 2.28  (1.35–3.84) 12 2.01  (1.14–3.54) 
2003 21 3.01  (1.96–4.61) 19 2.76  (1.76–4.33) 15 2.24  (1.35–3.72) 
2004 27 3.47  (2.38–5.06) 27 3.52  (2.42–5.14) 27 3.63  (2.49–5.30) 
2005 41 5.01  (3.69–6.81) 39 4.84  (3.54–6.63) 35 4.48  (3.22–6.24) 
2006 61 7.22  (5.62–9.28) 59 7.09  (5.50–9.15) 54 6.69  (5.13–8.74) 
2007 69 7.89  (6.24–10.0) 67 7.79  (6.13–9.89) 65 7.79  (6.11–9.94) 
2008 144 16.2  (13.7–19.0) 143 16.3  (13.9–19.2) 140 16.5  (14.0–19.5) 
2009 323 36.0  (32.3–40.1) 312 35.3  (31.6–39.5) 308 36.0  (32.2–40.2) 
2010 498 56.6  (51.9–61.8) 496 57.3  (52.5–62.6) 486 58.0  (53.1–63.4) 
2011 906 102.2  (95.8–109) 901 103  (96.8–110) 886 105  (98.2–112) 
2012 1,672 188  (179–197) 1,652 188  (179–198) 1,640 193  (184–203) 
2013 1,854 217  (207–227) 1,839 219  (209–229) 1,823 224  (213–234) 
2014 1,716 222  (212–233) 1,704 224  (213–235) 1,692 229  (218–240) 
Abbreviations: CI, confidence interval; PYAR, person-years at risk. 
a The analysis used the full study cohort. For children aged ³1 year at the time of practice 
registration, varying periods of time following practice registration were excluded from follow-
up; no period of exclusion, 3-month period of exclusion, and 9-month period of exclusion. No 
period of exclusion was employed for infants under the age of one year at the time of practice 
registration. 
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5.4.3.4 Sensitivity Analysis Exploring the Impact of Inclusion of the Read Code for 
‘Vitamin D insufficiency’ in the Case Definition 
 
Observed rates of diagnosis of vitamin D deficiency did not differ substantially when the 
Read code for ‘Vitamin D insufficiency’ (C2B..00), which was added to the Read code 
dictionary in 2013, was included in the case definition (Figure 5.10 and Table 5.18). 
 
 
Figure 5.10  Time trends in the diagnosis of vitamin D deficiency, with and without 
inclusion of the Read code for ‘Vitamin D insufficiency’ in the case definition.a 
 
a Crude incidence rates are shown between 2000 and 2014 in the full study cohort. 
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Table 5.18  Crude incidence rates for the diagnosis of vitamin D deficiency between 
2000 and 2014, with and without inclusion of the Read code for ‘Vitamin D 
insufficiency’ in the case definition.a 
Year 
Not including Read code for ‘Vitamin D 
Insufficiency’ 
Including Read code for ‘Vitamin D 
Insufficiency’ 
No. of 
cases 
Incidence rate per 100,000 
PYAR  (95% CI) 
No. of 
cases 
Incidence rate per 100,000 
PYAR  (95% CI) 
2000 11 2.55  (1.41–4.61) 11 2.55  (1.41–4.61) 
2001 14 2.72  (1.61–4.58) 14 2.72  (1.61–4.58) 
2002 14 2.28  (1.35–3.84) 14 2.28  (1.35–3.84) 
2003 19 2.76  (1.76–4.33) 19 2.76  (1.76–4.33) 
2004 27 3.52  (2.42–5.14) 27 3.52  (2.42–5.14) 
2005 39 4.84  (3.54–6.63) 39 4.84  (3.54–6.63) 
2006 59 7.09  (5.50–9.15) 59 7.09  (5.50–9.15) 
2007 67 7.79  (6.13–9.89) 67 7.79  (6.13–9.89) 
2008 143 16.3  (13.9–19.2) 143 16.3  (13.9–19.2) 
2009 312 35.3  (31.6–39.5) 312 35.3  (31.6–39.5) 
2010 496 57.3  (52.5–62.6) 496 57.3  (52.5–62.6) 
2011 901 103  (96.8–110) 901 103  (96.8–110) 
2012 1,652 188  (179–198) 1,652 188  (179–198) 
2013 1,839 219  (209–229) 1,875 223  (213–233) 
2014 1,704 224  (213–235) 1,745 229  (219–240) 
Abbreviations: CI, confidence interval; PYAR, person-years at risk. 
a The analysis used the full study cohort. 
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5.4.3.5 Sensitivity Analysis Exploring the Impact of Using Different Dosage 
Thresholds for Calciferol Prescriptions in the Case Definition 
 
Observed rates of diagnosis of vitamin D deficiency prior to 2013 were very similar 
when a range of alternative dosage thresholds representing ‘treatment dose’ 
prescriptions of calciferol were used in the case definition (Figure 5.11 and Table 5.19). 
In 2013 and 2014, rates were somewhat lower when the higher alternative dosage 
thresholds (representing recommended treatment doses in the BNFc) were used. The 
maximal relative difference between rates obtained using the dosage thresholds used 
in the main analysis and the higher BNFc thresholds was 10.3%, in 2014.  
 
 
Figure 5.11  Time trends in the diagnosis of vitamin D deficiency, using alternative 
dosage thresholds to represent ‘treatment dose’ prescriptions of calciferol in the case 
definition.a 
 
a Crude incidence rates are shown between 2000 and 2014 in the full study cohort. In the main 
analyses, ‘treatment dose’ of calciferol was defined as: ≥1,500 units/day if age <6 months, 
≥3,000 units/day if age 6 months to 12 years, ≥5,000 units/day if age >12 years, or a one-off 
(stoss) dose of ≥100,000 units at any age (solid blue line). Using the lower alternative dosage 
thresholds, ‘treatment dose’ of calciferol was defined as: ≥1,000 units/day if age <6 months, 
≥2,000 units/day if age 6 months to 12 years, ≥3,000 units/day if age >12 years, or a one-off 
dose of ≥100,000 units at any age (dashed red line). Using the higher alternative dosage 
thresholds, ‘treatment dose’ of calciferol was defined as: ≥3,000 units/day if age <6 months, 
≥6,000 units/day if age 6 months to 12 years, ≥10,000 units/day if age >12 years, or a one-off 
dose of ≥100,000 units at any age (dashed green line). 
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Table 5.19  Crude incidence rates for the diagnosis of vitamin D deficiency between 
2000 and 2014, using alternative dosage thresholds to represent ‘treatment dose’ 
prescriptions of calciferol in the case definition.a 
Year 
Dosage thresholds used in 
the main analyses b 
Lower alternative dosage 
thresholds c 
Higher alternative dosage 
thresholds d 
No. of 
cases 
Incidence rate per 
100,000 PYAR  
(95% CI) 
No. of 
cases 
Incidence rate per 
100,000 PYAR 
(95% CI) 
No. of 
cases 
Incidence rate per 
100,000 PYAR 
(95% CI) 
2000 11 2.55  (1.41–4.61) 11 2.55  (1.41–4.61) 11 2.55  (1.41–4.61) 
2001 14 2.72  (1.61–4.58) 14 2.72  (1.61–4.58) 14 2.72  (1.61–4.58) 
2002 14 2.28  (1.35–3.84) 14 2.28  (1.35–3.84) 13 2.11  (1.23–3.64) 
2003 19 2.76  (1.76–4.33) 19 2.76  (1.76–4.33) 19 2.76  (1.76–4.33) 
2004 27 3.52  (2.42–5.14) 27 3.52  (2.42–5.14) 25 3.26  (2.21–4.83) 
2005 39 4.84  (3.54–6.63) 39 4.84  (3.54–6.63) 38 4.72  (3.43–6.48) 
2006 59 7.09  (5.50–9.15) 59 7.09  (5.50–9.15) 59 7.09  (5.50–9.15) 
2007 67 7.79  (6.13–9.89) 67 7.79  (6.13–9.89) 66 7.67  (6.03–9.76) 
2008 143 16.3  (13.9–19.2) 144 16.4  (14.0–19.4) 140 16.0  (13.5–18.9) 
2009 312 35.3  (31.6–39.5) 313 35.4  (31.7–39.6) 305 34.5  (30.9–38.6) 
2010 496 57.3  (52.5–62.6) 499 57.7  (52.8–63.0) 487 56.3  (51.5–61.5) 
2011 901 103  (96.8–110) 909 104  (97.6–111) 876 100  (94.0–107) 
2012 1,652 188  (179–198) 1,663 190  (181–199) 1,593 182  (173–191) 
2013 1,839 219  (209–229) 1,899 226  (216–236) 1,721 205  (195–214) 
2014 1,704 224  (213–235) 1,784 234  (224–245) 1,529 201  (191–211) 
Abbreviations: CI, confidence interval; PYAR, person-years at risk. 
a The analysis used the full study cohort. 
b In the main analyses, ‘treatment dose’ of calciferol was defined as: ≥1,500 units/day if age <6 
months, ≥3,000 units/day if age 6 months to 12 years, ≥5,000 units/day if age >12 years, or a 
one-off (stoss) dose of ≥100,000 units at any age. 
c Using the lower alternative dosage thresholds, ‘treatment dose’ of calciferol was defined as: 
≥1,000 units/day if age <6 months, ≥2,000 units/day if age 6 months to 12 years, ≥3,000 
units/day if age >12 years, or a one-off dose of ≥100,000 units at any age. 
d Using the higher alternative dosage thresholds, ‘treatment dose’ of calciferol was defined as: 
≥3,000 units/day if age <6 months, ≥6,000 units/day if age 6 months to 12 years, ≥10,000 
units/day if age >12 years, or a one-off dose of ≥100,000 units at any age. 
 
 
5.4.3.6 Sensitivity Analysis Exploring the Impact of Varying the Duration of 
Treatment with Calciferol Considered to Represent One-Off (Stoss) Therapy 
 
Observed rates of diagnosis of vitamin D deficiency remained identical when the 
duration of treatment with calciferol considered to represent one-off (stoss) therapy was 
varied between £7 days to <28 days. 
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5.4.3.7 Sensitivity Analysis Exploring the Impact of Inclusion ICD-10 Codes from 
HES Inpatient Records in the Case Definition 
 
Observed rates of diagnosis of vitamin D deficiency did not differ substantially when 
ICD-10 codes related to vitamin D deficiency or rickets, from HES inpatient records, 
were included in the case definition (Figure 5.12 and Table 5.20). The study population 
for this analysis was limited to individuals registered with THIN practices for which 
linked HES data was available. The time period for which linked HES data was 
available limited the study period for this analysis to follow-up between 1st January 
2000 and 31st December 2011. 
 
 
Figure 5.12  Time trends in the diagnosis of vitamin D deficiency, with and without 
inclusion of ICD-10 codes related to vitamin D deficiency and rickets from HES 
inpatient records in the case definition.a 
 
a Crude incidence rates are shown between 2000 and 2011 in the linked THIN-HES study 
cohort. 
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Table 5.20  Crude incidence rates for the diagnosis of vitamin D deficiency between 
2000 and 2011, with and without inclusion of ICD-10 codes related to vitamin D 
deficiency and rickets from HES inpatient records in the case definition.a 
Year 
THIN data only used for case 
identification 
HES inpatient records used as an 
additional source of case identification 
No. of 
cases PYAR 
Incidence rate per 
100,000 PYAR  
(95% CI) 
No. of 
cases PYAR 
Incidence rate per 
100,000 PYAR 
 (95% CI) 
2000 5 159,318 3.14  (1.31–7.54) 5 159,318 3.14  (1.31–7.54) 
2001 5 177,945 2.81  (1.17–6.75) 5 177,945 2.81  (1.17–6.75) 
2002 9 208,386 4.32  (2.25–8.30) 9 208,386 4.32  (2.25–8.30) 
2003 8 219,036 3.65  (1.83–7.30) 8 219,035 3.65  (1.83–7.30) 
2004 18 231,690 7.77  (4.89–12.3) 19 231,687 8.20  (5.23–12.9) 
2005 12 240,543 4.99  (2.83–8.78) 12 240,540 4.99  (2.83–8.78) 
2006 28 247,374 11.3  (7.82–16.4) 28 247,367 11.3  (7.82–16.4) 
2007 27 253,053 10.7  (7.32–15.6) 30 253,043 11.9  (8.29–17.0) 
2008 54 260,812 20.7  (15.9–27.0) 54 260,798 20.7  (15.9–27.0) 
2009 110 266,102 41.3  (34.3–49.8) 111 266,086 41.7  (34.6–50.2) 
2010 212 273,216 77.6  (67.8–88.8) 216 273,190 79.1  (69.2–90.3) 
2011 351 279,387 126  (113–139) 354 279,348 127  (114–141) 
Abbreviations: CI, confidence interval; HES, Hospital Episode Statistics; ICD-10, International 
Classification of Diseases 10th edition; PYAR, person-years at risk; THIN, The Health 
Improvement Network. 
a The analysis used the linked THIN-HES study cohort. 
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5.4.3.8 Diagnosis of Vitamin D Deficiency Among Children with Medical Conditions 
that Interfere with Vitamin D Absorption or Metabolism 
 
In analysis including children with a record of a medical condition that can predispose 
to vitamin D deficiency by interfering with vitamin D absorption or metabolism (chronic 
renal disease, liver disease, or conditions associated with gastrointestinal 
malabsorption), incidence rates for the diagnosis of vitamin D deficiency were 
considerably higher among children with a predisposing condition (Figure 5.13 and 
Table 5.21). Among children with predisposing conditions (n=11,913), observed 
diagnosis rates in the earlier years of the study period should be treated with caution in 
view of the small numbers of cases in each year (<10 per year prior to 2008). 
 
 
Figure 5.13  Time trends in the diagnosis of vitamin D deficiency, among children with 
and without predisposing medical conditions that can interfere with vitamin D 
absorption or metabolism.a 
 
a Crude incidence rates are shown between 2000 and 2014 in the full study cohort, including 
children with a record of a medical condition that can predispose to vitamin D deficiency by 
interfering with vitamin D absorption or metabolism (chronic renal disease, liver disease, or 
conditions associated with gastrointestinal malabsorption). The dashed lines represent 95% 
confidence limits. 
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Table 5.21  Crude incidence rates for the diagnosis of vitamin D deficiency between 
2000 and 2011, among children with and without predisposing medical conditions that 
can interfere with vitamin D absorption or metabolism.a 
Year 
Children without chronic renal disease, 
liver disease, or conditions associated 
with gastrointestinal malabsorption 
(n= 2,338,529) 
Children with chronic renal disease, liver 
disease, or conditions associated with 
gastrointestinal malabsorption  
(n=11,913) 
No. of 
cases PYAR 
Incidence rate per 
100,000 PYAR  
(95% CI) 
No. of 
cases PYAR 
Incidence rate per 
100,000 PYAR   
(95% CI) 
2000 11 430,721 2.55  (1.41–4.61) 1 3,843 26.0  (3.67–185) 
2001 14 515,596 2.72  (1.61–4.58) 0 4,392 0 
2002 14 614,946 2.28  (1.35–3.84) 2 4,968 40.3  (10.1–161) 
2003 19 688,371 2.76  (1.76–4.33) 0 5,324 0 
2004 27 766,064 3.52  (2.42–5.14) 2 5,616 35.6  (8.91–142) 
2005 39 805,582 4.84  (3.54–6.63) 1 5,605 17.8  (2.51–127) 
2006 59 831,792 7.09  (5.50–9.15) 2 5,453 36.7  (9.17–147) 
2007 67 860,350 7.79  (6.13–9.89) 8 5,435 147  (73.6–294) 
2008 143 875,935 16.3  (13.9–19.2) 10 5,208 192  (103–357) 
2009 312 883,603 35.3  (31.6–39.5) 16 4,922 325  (199–531) 
2010 496 865,219 57.3  (52.5–62.6) 19 4,512 421  (269–660) 
2011 901 872,353 103  (96.8–110) 47 4,170 1,127  (847–1,500) 
2012 1,652 877,054 188  (179–198) 70 3,825 1,830  (1,448–2,313) 
2013 1,839 841,381 219  (209–229) 59 3,342 1,766  (1,368–2,279) 
2014 1,704 761,971 224  (213–235) 44 2,656 1,657  (1,233–2,226) 
Abbreviations: CI, confidence interval; PYAR, person-years at risk. 
a The analysis used the full study cohort, including children with a record of a medical condition 
that can predispose to vitamin D deficiency by interfering with vitamin D absorption or 
metabolism (chronic renal disease, liver disease, or conditions associated with gastrointestinal 
malabsorption). 
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5.4.3.9 Time Trends in Diagnosis Using the Linked THIN-HES Study Cohort 
 
Time trends in the diagnosis of vitamin D deficiency observed in the linked THIN-HES 
study cohort were similar to those seen in the full THIN study cohort, although overall 
rates of diagnosis were somewhat higher in the linked THIN-HES cohort compared to 
the full THIN cohort (Figure 5.14 and Table 5.22). 
 
 
Figure 5.14  Time trends in the diagnosis of vitamin D deficiency in the full THIN study 
cohort and in the linked THIN-HES study cohort, between 2000 and 2014.a 
 
a Crude incidence rates are shown, with 95% confidence intervals represented by the shaded 
areas. 
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Table 5.22  Crude incidence rates for the diagnosis of vitamin D deficiency in the full 
THIN study cohort and in the linked THIN-HES study cohort, by year between 2000 
and 2014. 
Year 
Full THIN study cohort 
(n= 2,338,529) 
Linked THIN-HES study cohort  
(n=711,788) 
No. of 
cases PYAR 
Incidence rate per 
100,000 PYAR  
(95% CI) 
No. of 
cases PYAR 
Incidence rate per 
100,000 PYAR   
(95% CI) 
2000 11 430,721 2.55  (1.41–4.61) 5 159,318 3.14  (1.31–7.54) 
2001 14 515,596 2.72  (1.61–4.58) 5 177,945 2.81  (1.17–6.75) 
2002 14 614,946 2.28  (1.35–3.84) 9 208,386 4.32  (2.25–8.30) 
2003 19 688,371 2.76  (1.76–4.33) 8 219,036 3.65  (1.83–7.30) 
2004 27 766,064 3.52  (2.42–5.14) 18 231,690 7.77  (4.89–12.3) 
2005 39 805,582 4.84  (3.54–6.63) 12 240,543 4.99  (2.83–8.78) 
2006 59 831,792 7.09  (5.50–9.15) 28 247,374 11.3  (7.82–16.4) 
2007 67 860,350 7.79  (6.13–9.89) 27 253,053 10.7  (7.32–15.6) 
2008 143 875,935 16.3  (13.9–19.2) 54 260,812 20.7  (15.9–27.0) 
2009 312 883,603 35.3  (31.6–39.5) 110 266,102 41.3  (34.3–49.8) 
2010 496 865,219 57.3  (52.5–62.6) 212 273,216 77.6  (67.8–88.8) 
2011 901 872,353 103  (96.8–110) 351 279,387 126  (113–139) 
2012 1,652 877,054 188  (179–198) 673 283,111 238  (220–256) 
2013 1,839 841,381 219  (209–229) 761 277,985 274  (255–294) 
2014 1,704 761,971 224  (213–235) 645 247,604 261  (241–281) 
Abbreviations: CI, confidence interval; PYAR, person-years at risk. 
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5.4.4 Differences in Rates of Diagnosis of Vitamin D Deficiency by Socio-
Demographic Factors: Crude Associations 
 
 
5.4.4.1 Analysis Using the Full Study Cohort 
 
In unadjusted analyses, vitamin D deficiency was diagnosed more frequently in girls 
compared to boys, in older children compared to younger children, and in children from 
more deprived backgrounds (Table 5.23). Children from minority ethnic groups were 
considerably more likely to be diagnosed with vitamin D deficiency than children from 
white ethnic backgrounds, although it should be noted that there was a large proportion 
of missing data for ethnicity (51.9%). Vitamin D deficiency was diagnosed more 
commonly in children residing in England compared to the other countries in the UK, 
and within England diagnosis rates were highest in children in London and the West 
Midlands. Rates of diagnosis increased markedly over time during the study period. 
 
In separate analysis including children with medical conditions that can predispose to 
deficiency by interfering with vitamin D absorption or metabolism, vitamin D deficiency 
was diagnosed more frequently in children with liver disease (RR 8.78, 95% CI: 6.26 to 
11.7, p<0.001), children with chronic renal disease (RR 4.82, 95% CI: 3.80 to 6.11, 
p<0.001), and children with conditions associated with gastrointestinal malabsorption 
(RR 6.41, 95% CI: 5.47 to 7.51, p<0.001) compared to children without any of these 
co-morbidities. 
 
 
5.4.4.2 Analysis Using the Linked THIN-HES Study Cohort 
 
Crude associations between the study covariates and rates of diagnosis of vitamin D 
deficiency in the linked THIN-HES cohort were similar to the results of analyses using 
the full study cohort (Table 5.24). 
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Table 5.23  Crude associations between each study covariate and the rate of 
diagnosis of vitamin D deficiency, in the full study cohort (n=2,338,529). 
Covariate PYAR (100,000s) 
No. of 
cases 
Rate ratio 
(95% CI) p-value 
a 
Sex b     
 Male 59.6 2,896 Baseline - 
 Female 55.3 4,401 1.64  (1.54–1.72) <0.001 
Age group b     
 0 – 4 years 31.1 1,152 Baseline - 
 5 – 9 years 32.9 1,377 1.13  (1.04–1.22) 0.002 
 10 – 14 years 32.3 2,652 2.22  (2.07–2.37) <0.001 
 15 – 17 years 18.7 2,116 3.05  (2.84–3.28) <0.001 
Ethnicity c     
 White 44.8 1,348 Baseline - 
 Asian or Asian British 3.17 2,401 25.2  (23.6–26.9) <0.001 
 Black or black British 1.86 1,091 19.5  (18.0–21.1) <0.001 
 Mixed 1.10 227 6.83  (5.93–7.86) <0.001 
 Chinese or other ethnic group 0.95 346 12.1  (10.7–13.6) <0.001 
Townsend deprivation index 
quintile d     
 1 (least deprived) 28.1 681 Baseline - 
 2 22.6 664 1.21  (1.09–1.35) <0.001 
 3 22.8 1,295 2.34  (2.13–2.57) <0.001 
 4 21.1 1,761 3.44  (3.15–3.76) <0.001 
 5 (most deprived) 15.4 1,964 5.26  (4.82–5.74) <0.001 
Country b     
 England 89.3 6,794 Baseline - 
 Scotland 12.8 219 0.23  (0.20–0.26) <0.001 
 Wales 8.32 234 0.37  (0.32–0.42) <0.001 
 Northern Ireland 4.42 50 0.15  (0.11–0.20) <0.001 
Strategic Health Authority e     
 South Central 13.6 343 Baseline - 
 North West 10.9 541 1.98  (1.73–2.27) <0.001 
 London 10.7 2,924 10.8  (9.67–12.1) <0.001 
 South West 10.3 100 0.39  (0.31–0.48) <0.001 
 South East Coast 10.3 273 1.06  (0.90–1.24) 0.485 
 West Midlands 9.88 1,592 6.40  (5.70–7.20) <0.001 
 East of England 7.27 207 1.13  (0.95–1.35) 0.158 
 East Midlands 3.75 111 1.18  (0.95–1.46) 0.133 
 Yorkshire & Humber 3.34 46 0.55  (0.40–0.74) <0.001 
 North East 2.69 113 1.67  (1.35–2.07) <0.001 
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Table 5.23  continued. 
Covariate PYAR (100,000s) 
No. of 
cases 
Rate ratio 
(95% CI) p-value 
Calendar year b     
 2000 4.31 11 Baseline - 
 2001 5.16 14 1.06  (0.48–2.34) 0.879 
 2002 6.15 14 0.89  (0.41–1.96) 0.775 
 2003 6.88 19 1.08  (0.51–2.27) 0.838 
 2004 7.66 27 1.38  (0.69–2.78) 0.366 
 2005 8.06 39 1.90  (0.97–3.70) 0.057 
 2006 8.32 59 2.78  (1.46–5.29) 0.001 
 2007 8.60 67 3.05  (1.61–5.77) <0.001 
 2008 8.76 143 6.39  (3.46–11.8) <0.001 
 2009 8.84 312 13.8  (7.58–25.2) <0.001 
 2010 8.65 496 22.4  (12.4–40.8) <0.001 
 2011 8.72 901 40.4  (22.3–73.3) <0.001 
 2012 8.77 1,652 73.8  (40.8–133) <0.001 
 2013 8.41 1,839 85.6  (47.3–155) <0.001 
 2014 7.62 1,704 87.6  (48.4–158) <0.001 
Abbreviations: CI, confidence interval; PYAR, person-years at risk. 
a P-value for the null hypothesis that the true rate ratio is equal to 1. 
b Complete data is available for these variables. 
c Data missing for 51.9% of the cohort. 
d Data missing for 6.2% of the cohort. 
e Data missing for 6.0% of the cohort. 
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Table 5.24  Crude associations between each study covariate and the rate of 
diagnosis of vitamin D deficiency, in the linked THIN-HES study cohort (n=711,788). 
Covariate PYAR (100,000s) 
No. of 
cases 
Rate ratio 
(95% CI) p-value 
a 
Sex b     
 Male 18.8 1,133 Baseline - 
 Female 17.4 1,785 1.70  (1.58–1.83) <0.001 
Age group b     
 0 – 4 years 9.97 400 Baseline - 
 5 – 9 years 10.4 558 1.33  (1.17–1.51) <0.001 
 10 – 14 years 10.1 1,161 2.86  (2.56–3.21) <0.001 
 15 – 17 years 5.74 799 3.47  (3.08–3.91) <0.001 
Ethnicity c     
 White 26.8 635 Baseline - 
 Asian or Asian British 0.63 1,203 33.1  (30.0–36.4) <0.001 
 Black or black British 1.53 585 25.3  (22.6–28.3) <0.001 
 Mixed 0.98 117 7.83  (6.43–9.54) <0.001 
 Chinese or other ethnic group 0.53 156 12.5  (10.5–14.8) <0.001 
Townsend deprivation index 
quintile d     
 1 (least deprived) 9.98 171 Baseline - 
 2 7.00 205 1.71  (1.39–2.09) <0.001 
 3 7.50 561 4.36  (3.68–5.18) <0.001 
 4 6.68 741 6.48  (5.48–7.65) <0.001 
 5 (most deprived) 4.04 697 10.1  (8.51–11.9) <0.001 
Index of Multiple Deprivation 
quintile e     
 1 (least deprived) 9.25 172 Baseline - 
 2 7.31 333 2.45  (2.04–2.94) <0.001 
 3 7.16 520 3.90  (3.29–4.64) <0.001 
 4 6.88 635 4.97  (4.20–5.88) <0.001 
 5 (most deprived) 4.68 648 7.44  (6.29–8.80) <0.001 
Strategic Health Authority b     
 South Central 8.25 165 Baseline - 
 North West 3.54 100 1.41  (1.10–1.81) 0.006 
 London 4.28 1,295 15.1  (12.9–17.8) <0.001 
 South West 5.79 51 0.44  (0.32–0.60) <0.001 
 South East Coast 4.67 123 1.32  (1.04–1.66) 0.020 
 West Midlands 4.63 971 10.5  (8.90–12.4) <0.001 
 East of England 3.06 102 1.67  (1.30–2.13) <0.001 
 East Midlands 0.24 0 - - 
 Yorkshire & Humber 0.80 12 0.75  (0.42–1.35) 0.334 
 North East 1.00 99 4.97  (3.88–6.38) <0.001 
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Table 5.24  continued. 
Covariate PYAR (100,000s) 
No. of 
cases 
Rate ratio 
(95% CI) p-value 
Calendar year b     
 2000 1.59 5 Baseline - 
 2001 1.78 5 0.90  (0.26–3.09) 0.861 
 2002 2.08 9 1.38  (0.46–4.11) 0.565 
 2003 2.19 8 1.16  (0.38–3.56) 0.790 
 2004 2.32 18 2.48  (0.92–6.67) 0.064 
 2005 2.41 12 1.59  (0.56–4.51) 0.380 
 2006 2.47 28 3.61  (1.39–9.34) 0.005 
 2007 2.53 27 3.40  (1.31–8.83) 0.008 
 2008 2.61 54 6.60  (2.64–16.5) <0.001 
 2009 2.66 110 13.2  (5.38–32.3) <0.001 
 2010 2.73 212 24.7  (10.2–60.0) <0.001 
 2011 2.79 351 40.0  (16.6–96.8) <0.001 
 2012 2.83 673 75.7  (31.4–183) <0.001 
 2013 2.78 761 87.2  (36.2–210) <0.001 
 2014 2.48 645 83.0  (34.4–200) <0.001 
Abbreviations: CI, confidence interval; PYAR, person-years at risk. 
a P-value for the null hypothesis that the true rate ratio is equal to 1. 
b Complete data is available for these variables. 
c Data missing for 18.5% of the cohort. 
d Data missing for 4.3% of the cohort. 
e Data missing for 6.7% of the cohort. 
 
 
 
5.4.5 Differences in Rates of Diagnosis of Vitamin D Deficiency by Socio-
Demographic Factors: Multivariable Analyses 
 
 
5.4.5.1 Single Level Poisson Regression Models, Without Interactions Between 
Covariates 
 
In multivariable analysis, female sex, older age, non-white ethnicity, and greater socio-
economic deprivation (measured using the Index of Multiple Deprivation) remained 
strongly associated with higher rates of vitamin D deficiency diagnosis (Table 5.25). 
After accounting for temporal changes in socio-demographic factors, a 15-fold increase 
in diagnosis (95% CI: 10 to 21) was seen between 2008 to 2014. The magnitude of the 
effects of IMD and ethnicity were somewhat reduced after adjustment for the other 
study covariates. The magnitude of the effects of the other study covariates were 
similar in the crude and adjusted analyses. 
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Table 5.25  Adjusted associations between the study covariates and the rate of 
diagnosis of vitamin D deficiency, using single-level Poisson regression with socio-
economic position measured using the IMD (n=414,182). 
Covariate Unadjusted RR (95% CI) a 
Adjusted RR 
(95% CI) b 
LRT 
p-value c 
Sex   <0.001 
 Male Baseline Baseline  
 Female 1.69  (1.57–1.83) 1.63  (1.49–1.78)  
Age group   <0.001 
 0 – 4 years Baseline Baseline  
 5 – 9 years 1.51  (1.32–1.73) 1.45  (1.25–1.69)  
 10 – 14 years 3.18  (2.82–3.58) 3.79  (3.31–4.34)  
 15 – 17 years 3.71  (3.27–4.20) 4.91  (4.25–5.67)  
Ethnicity d   <0.001 
 White Baseline Baseline  
 Asian or Asian British 25.5  (24.0–29.2) 22.4  (20.1–24.9)  
 Black or black British 20.6  (18.4–23.1) 14.2  (12.5–16.2)  
 Mixed 6.07  (4.97–7.41) 5.64  (4.52–7.03)  
 Chinese or other ethnic group 10.5  (8.79–12.5) 8.91  (7.38–10.8)  
IMD quintile   <0.001 
 1 (least deprived) Baseline Baseline  
 2 2.40  (1.99–2.89) 1.98  (1.63–2.41)  
 3 3.89  (3.27–4.63) 2.40  (2.00–2.88)  
 4 4.82  (4.07–5.72) 2.67  (2.23–3.20)  
 5 (most deprived) 7.38  (6.23–8.75) 3.54  (2.96–4.24)  
Calendar year    
 2008 Baseline Baseline <0.001 
 2009 2.00  (1.44–2.77) 2.20  (1.45–3.35)  
 2010 3.75  (2.78–5.05) 3.87  (2.62–5.71)  
 2011 6.07  (4.56–8.08) 6.61  (4.55–9.60)  
 2012 11.5  (8.70–15.1) 12.7  (8.83–18.2)  
 2013 13.2  (10.0–17.4) 14.7  (10.2–21.1)  
 2014 12.6  (9.53–16.6) 14.7  (10.2–21.2)  
Abbreviations: CI, confidence interval; IMD, Index of Multiple Deprivation; LRT, likelihood ratio 
test; RR, rate ratio. 
a Crude associations between incidence rates and each study covariate separately. 
b Results from a single-level multivariable Poisson regression model, adjusted for all variables 
listed in the table. Missing data was handled using complete cases analysis. n=414,182. 
c P values from LRTs comparing nested models with and without the variable of interest. 
d Ethnicity data was available from the child’s THIN or HES record for 84.6% of included 
children. Maternal ethnicity was used as a proxy measure for the remaining 15.4%. 
  
 
Similar results were obtained when socio-economic position was measured using the 
Townsend Index as opposed to the IMD (Table 5.26). The IMD was used in 
subsequent analyses, on the basis that it is derived from a considerably broader range 
of indicator variables than the Townsend Index (see section 5.3.5.3). 
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Table 5.26  Adjusted associations between the study covariates and the rate of 
diagnosis of vitamin D deficiency, using single-level Poisson regression with socio-
economic position measured using the Townsend Index (n=423,817). 
Covariate Unadjusted RR (95% CI) a 
Adjusted RR 
(95% CI) b 
LRT 
p-value c 
Sex   <0.001 
 Male Baseline Baseline  
 Female 1.69  (1.57–1.83) 1.62  (1.48–1.77)  
Age group   <0.001 
 0 – 4 years Baseline Baseline  
 5 – 9 years 1.51  (1.32–1.73) 1.50  (1.29–1.75)  
 10 – 14 years 3.18  (2.82–3.58) 3.88  (3.39–4.44)  
 15 – 17 years 3.71  (3.27–4.20) 4.98  (4.32–5.74)  
Ethnicity d   <0.001 
 White Baseline Baseline  
 Asian or Asian British 25.5  (24.0–29.2) 20.5  (18.4–22.8)  
 Black or black British 20.6  (18.4–23.1) 12.5  (11.0–14.3)  
 Mixed 6.07  (4.97–7.41) 5.14  (4.12–6.42)  
 Chinese or other ethnic group 10.5  (8.79–12.5) 8.24  (6.83–9.93)  
Townsend Index quintile   <0.001 
 1 (least deprived) Baseline Baseline  
 2 1.68  (1.37–2.06) 1.48  (1.19–1.84)  
 3 4.24  (3.56–5.05) 2.66  (2.21–3.19)  
 4 6.11  (5.16–7.24) 3.12  (2.61–3.73)  
 5 (most deprived) 9.62  (8.12–11.4) 4.11  (3.43–4.93)  
Calendar year    
 2008 Baseline Baseline <0.001 
 2009 2.00  (1.44–2.77) 2.17  (1.46–3.22)  
 2010 3.75  (2.78–5.05) 3.36  (2.32–4.87)  
 2011 6.07  (4.56–8.08) 5.85  (4.11–8.33)  
 2012 11.5  (8.70–15.1) 11.3  (8.01–15.9)  
 2013 13.2  (10.0–17.4) 13.1  (9.30–18.4)  
 2014 12.6  (9.53–16.6) 13.4  (9.49–18.8)  
Abbreviations: CI, confidence interval; LRT, likelihood ratio test; RR, rate ratio. 
a Crude associations between incidence rates and each study covariate separately. 
b Results from a single-level multivariable Poisson regression model, adjusted for all variables 
listed in the table. Missing data was handled using complete cases analysis. n=423,817. 
c P values from LRTs comparing nested models with and without the variable of interest. 
d Ethnicity data was available from the child’s THIN or HES record for 83.8% of included 
children. Maternal ethnicity was used as a proxy measure for the remaining 16.2%. 
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5.4.5.2 Examination of Interactions Between Model Covariates 
 
A significant interaction between sex and age group was seen (LRT p-value <0.001); 
among children aged ≥10 years girls exhibited higher rates of vitamin D deficiency 
diagnosis than boys, whilst among children aged <5 years boys exhibited higher rates 
than girls (Figure 5.15 and Table 5.27). There was no difference in rates of diagnosis 
between boys and girls aged between 5 to 9 years. 
 
 
Figure 5.15  Adjusted predicted incidence rates for the diagnosis of vitamin D 
deficiency in children across categories of age, showing an interaction with sex.a 
 
Abbreviations: PYAR, person-years at risk. 
a Predicted margins were derived from a single-level multivariable Poisson regression model, at 
average values for the remaining covariates (ethnicity, Index of Multiple Deprivation, and 
calendar year). The vertical bars represent 95% confidence intervals. Missing data was handled 
using complete cases analysis. n=414,182. 
 
 
There was no evidence of any important interactions between the other study 
covariates, as inclusion of interaction terms did not result in qualitative changes in 
parameter rate ratios (see appendix E). The interaction between sex and age group 
was retained in the multivariable regression model (Table 5.27). 
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Table 5.27  Adjusted associations between the study covariates and the rate of 
diagnosis of vitamin D deficiency, using single-level Poisson regression with an 
interaction between sex and age group (n=414,182). 
Covariate Adjusted RR (95% CI) a p-value b 
Sex, stratified by age group  <0.001 
 0 – 4 years: Male Baseline 
  Female 0.73  (0.57–0.93) 
 5 – 9 years: Male Baseline 
  Female 1.06  (0.87–1.29) 
 10 – 14 years: Male Baseline 
  Female 1.97  (1.71–2.27) 
 15 – 17 years: Male Baseline 
  Female 2.60  (2.18–3.11) 
Age group, stratified by sex  <0.001 
 Males: 0 – 4 years Baseline  
  5 – 9 years 1.22  (0.99–1.50)  
  10 – 14 years 2.22  (1.83–2.70)  
  15 – 17 years 2.39  (1.93–2.96)  
 Females: 0 – 4 years Baseline  
  5 – 9 years 1.77  (1.41–2.23)  
  10 – 14 years 6.00  (4.91–7.34)  
  15 – 17 years 8.52  (6.93–10.5)  
Ethnicity  <0.001 
 White Baseline  
 Asian or Asian British 22.4  (20.1–24.9)  
 Black or black British 14.2  (12.5–16.2)  
 Mixed 5.64  (4.52–7.03)  
 Chinese or other ethnic group 8.91  (7.38–10.8)  
IMD quintile  <0.001 
 1 (least deprived) Baseline  
 2 1.98  (1.63–2.41)  
 3 2.40  (2.00–2.88)  
 4 2.67  (2.23–3.20)  
 5 (most deprived) 3.54  (2.96–4.24)  
Calendar year  <0.001 
 2008 Baseline  
 2009 2.20  (1.45–3.35)  
 2010 3.87  (2.62–5.71)  
 2011 6.61  (4.55–9.60)  
 2012 12.7  (8.83–18.2)  
 2013 14.7  (10.2–21.1)  
 2014 14.7  (10.2–21.2)  
Abbreviations: CI, confidence interval; IMD, Index of Multiple Deprivation; RR, rate ratio. 
a Results from a single-level multivariable Poisson regression model, adjusted for all variables 
listed in the table, including an interaction between sex and age group. Likelihood ratio test 
(LRT) for interaction p-value <0.001. Missing data was handled using complete cases analysis. 
b p-values from LRTs comparing nested models with & without variables of interest. 
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5.4.5.3 Multilevel Models Accounting for the Clustered Structure of the Data 
 
Table 5.28 shows the results of multivariable analyses using both the single-level 
Poisson regression model, as well as a two-level mixed-effects model that accounts for 
the clustering of children within general practices. The magnitude of the effects of 
ethnicity and socio-economic deprivation were attenuated after accounting for 
clustering by practice, however they both remained strongly associated with rates of 
diagnosis of vitamin D deficiency. Associations between the other covariates (sex, age 
group, and calendar year) and the outcome were very similar in the single-level and 
multilevel analyses. 
 
Results obtained from a three-level mixed-effects Poisson regression model, which 
additionally accounted for the nesting of practices within strategic health authority 
regions, were essentially the same as those obtained from the two-level model (Table 
5.29).  
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Table 5.28  Adjusted associations between study covariates and diagnosis of vitamin 
D deficiency, with and without accounting for clustering by practice (n=414,182).a 
Covariate 
Single-level Model  Multilevel Model 
Adjusted RR 
(95% CI) p-value 
b Adjusted RR (95% CI) p-value 
b 
Sex, stratified by age group  <0.001   <0.001 
 0 – 4 years: Male Baseline 
 
 Baseline 
 
  Female 0.73  (0.57–0.93)  0.72  (0.57–0.92) 
 5 – 9 years: Male Baseline  Baseline 
  Female 1.06  (0.87–1.29)  1.04  (0.86–1.27) 
 10 – 14 years: Male Baseline  Baseline 
  Female 1.97  (1.71–2.27)  1.97  (1.71– 2.27) 
 15 – 17 years: Male Baseline  Baseline 
  Female 2.60  (2.18–3.11)  2.65  (2.21–3.16) 
Age group, stratified by sex  <0.001   <0.001 
 Males 0 – 4 years Baseline   Baseline  
  5 – 9 years 1.22  (0.99–1.50)   1.20  (0.98–1.48)  
  10 – 14 years 2.22  (1.83–2.70)   2.19  (1.80–2.65)  
  15 – 17 years 2.39  (1.93–2.96)   2.36  (1.90–2.93)  
 Females: 0 – 4 years Baseline   Baseline  
  5 – 9 years 1.77  (1.41–2.23)   1.73  (1.37–2.18)  
  10 – 14 years 6.00  (4.91–7.34)   5.95  (4.86–7.27)  
  15 – 17 years 8.52  (6.93–10.5)   8.61  (7.00–10.6)  
Ethnicity  <0.001   <0.001 
 White Baseline   Baseline  
 Asian or Asian British 22.4  (20.1–24.9)   7.98  (6.98–9.13)  
 Black or black British 14.2  (12.5–16.2)   5.47  (4.70–6.37)  
 Mixed 5.64  (4.52–7.03)   2.99  (2.38–3.76)  
 Chinese or other ethnic group 8.91  (7.38–10.8)   3.63  (2.96–4.45)  
IMD quintile  <0.001   <0.001 
 1 (least deprived) Baseline   Baseline  
 2 1.98  (1.63–2.41)   1.34  (1.07–1.67)  
 3 2.40  (2.00–2.88)   1.41  (1.12–1.77)  
 4 2.67  (2.23–3.20)   1.63  (1.29–2.05)  
 5 (most deprived) 3.54  (2.96–4.24)   1.96  (1.52–2.53)  
Calendar year  <0.001   <0.001 
 2008 Baseline   Baseline  
 2009 2.20  (1.45–3.35)   2.19  (1.44–3.34)  
 2010 3.87  (2.62–5.71)   3.66  (2.48–5.40)  
 2011 6.61  (4.55–9.60)   6.28  (4.32–9.12)  
 2012 12.7  (8.83–18.2)   12.1  (8.43–17.4)  
 2013 14.7  (10.2–21.1)   14.1  (9.85–20.3)  
 2014 14.7  (10.2–21.2)   15.7  (10.9–22.6)  
Abbreviations: CI, confidence interval; IMD, Index of Multiple Deprivation; RR, rate ratio. 
a Results of multivariable Poisson regression models of rates of incident diagnosis of vitamin D 
deficiency, adjusted for all listed variables and including an interaction term between age group 
and sex. Missing data is handled using complete cases analysis. The multilevel model 
additionally includes the general practice as a random effect. 
b p-values from likelihood ratio tests comparing nested models with & without each variable. 
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Table 5.29  Associations between study covariates and diagnosis of vitamin D 
deficiency, with and without accounting for nesting of practices within SHA regions.a 
Covariate 
Two-level Model 
 
Three-level Model 
Adjusted RR 
(95% CI) p-value 
b Adjusted RR (95% CI) p-value 
b 
Sex, stratified by age group  <0.001   <0.001 
 0 – 4 years: Male Baseline 
 
 Baseline 
 
  Female 0.72  (0.57–0.92)  0.72  (0.57–0.92) 
 5 – 9 years: Male Baseline  Baseline 
  Female 1.04  (0.86–1.27)  1.04  (0.86–1.27) 
 10 – 14 years: Male Baseline  Baseline 
  Female 1.97  (1.71– 2.27)  1.97  (1.71– 2.27) 
 15 – 17 years: Male Baseline  Baseline 
  Female 2.65  (2.21–3.16)  2.65  (2.21–3.16) 
Age group, stratified by sex  <0.001   <0.001 
 Males 0 – 4 years Baseline   Baseline  
  5 – 9 years 1.20  (0.98–1.48)   1.20  (0.98–1.48)  
  10 – 14 years 2.19  (1.80–2.65)   2.19  (1.81–2.66)  
  15 – 17 years 2.36  (1.90–2.93)   2.36  (1.90–2.93)  
 Females: 0 – 4 years Baseline   Baseline  
  5 – 9 years 1.73  (1.37–2.18)   1.73  (1.37–2.17)  
  10 – 14 years 5.95  (4.86–7.27)   5.95  (4.86–7.27)  
  15 – 17 years 8.61  (7.00–10.6)   8.62  (7.01–10.6)  
Ethnicity  <0.001   <0.001 
 White Baseline   Baseline  
 Asian or Asian British 7.98  (6.98–9.13)   7.64  (6.69–8.73)  
 Black or black British 5.47  (4.70–6.37)   5.20  (4.47–6.05)  
 Mixed 2.99  (2.38–3.76)   2.87  (2.28–3.61)  
 Chinese or other ethnic group 3.63  (2.96–4.45)   3.45  (2.82–4.23)  
IMD quintile  <0.001   <0.001 
 1 (least deprived) Baseline   Baseline  
 2 1.34  (1.07–1.67)   1.27  (1.02–1.58)  
 3 1.41  (1.12–1.77)   1.32  (1.06–1.65)  
 4 1.63  (1.29–2.05)   1.53  (1.22–1.92)  
 5 (most deprived) 1.96  (1.52–2.53)   1.85  (1.44–2.38)  
Calendar year  <0.001   <0.001 
 2008 Baseline   Baseline  
 2009 2.19  (1.44–3.34)   2.19  (1.44–3.34)  
 2010 3.66  (2.48–5.40)   3.66  (2.48–5.40)  
 2011 6.28  (4.32–9.12)   6.29  (4.33–9.14)  
 2012 12.1  (8.43–17.4)   12.1  (8.44–17.5)  
 2013 14.1  (9.85–20.3)   14.1  (9.83–20.3)  
 2014 15.7  (10.9–22.6)   15.8  (11.0–22.7)  
Abbreviations: CI, confidence interval; IMD, Index of Multiple Deprivation; LRT, likelihood ratio test; 
RR, rate ratio; SHA, strategic health authority. 
a Results of multivariable Poisson regression models of rates of incident diagnosis of vitamin D 
deficiency, adjusted for all listed variables and including an interaction term between age group and 
sex. Missing data is handled using complete cases analysis. Both models include the general 
practice as a random effect. The 3-level model additionally accounts for nesting of practices within 
SHAs. p-values are from LRTs comparing nested models with & without each variable. n=414,182. 
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5.4.5.4 Sensitivity Analysis Using Multiply Imputed Data 
 
Table 5.31 shows the results of the multivariable Poisson regression models when 
missing data was handled using multiple imputation. These are very similar to the 
results of the main analyses using complete cases (Table 5.28). 
 
 
 
5.4.6 Investigation of Recorded Symptoms Among Children Diagnosed with 
Vitamin D Deficiency 
 
Among the 7,297 children in the full THIN study cohort with a diagnosis of vitamin D 
deficiency, 3,061 (42%) had a relevant symptom code recorded in their primary care 
electronic health record in the 6 months either side of the initial diagnosis. 312 children 
(4.3%) had a symptom from more than one symptom group recorded. Among those 
with a relevant symptom code recorded, the proportion of children with a code from 
each symptom category is shown in Table 5.30. The most commonly recorded 
symptoms were those related to musculoskeletal or non-specific pain, and tiredness or 
fatigue. 
 
Table 5.30  Frequency of each symptom category, among children 
with a relevant symptom code recorded in proximity to the date of 
initial diagnosis of vitamin D deficiency (n=3,061). 
Symptom Category n (%) a 
Musculoskeletal and non-specific pain 1,916  (62.6%) 
Tiredness and fatigue 919  (30.0%) 
Skeletal deformity 136  (4.44%) 
Bone fracture 115  (3.76%) 
Failure to thrive 112  (3.66%) 
Hypocalcaemia 43  (1.40%) 
Seizure or tetany 41  (1.34%) 
Numbness or paraesthesia 33  (1.08%) 
Abnormal gait 31  (1.01%) 
Muscle weakness 26  (0.85%) 
Delay in motor development 6  (0.20%) 
Cardiomyopathy 5  (0.16%) 
a The sum of the percentages is greater than 100, because 10% of 
the children had symptoms recorded from more than one category. 
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Table 5.31  Associations between study covariates and diagnosis of vitamin D 
deficiency, with missing data handled using multiple imputation (n=511,868).a 
Covariate 
Single-level Model  Multilevel Model 
Adjusted IRR b 
(95% CI) 
p-value 
c 
Adjusted IRR b 
(95% CI) 
p-value 
c 
Sex, stratified by age group  <0.001   <0.001 
 0 – 4 years: Male Baseline 
 
 Baseline 
 
  Female 0.78  (0.64–0.97)  0.78  (0.63–0.96) 
 5 – 9 years: Male Baseline  Baseline 
  Female 1.18  (1.00–1.41)  1.18  (1.00–1.40) 
 10 – 14 years: Male Baseline  Baseline 
  Female 1.98  (1.75–2.24)  1.99  (1.76–2.25) 
 15 – 17 years: Male Baseline  Baseline 
  Female 2.57  (2.20–3.00)  2.63  (2.25–3.06) 
Age group, stratified by sex  <0.001   <0.001 
 Males 0 – 4 years Baseline   Baseline  
  5 – 9 years 1.28  (1.07–1.54)   1.26  (1.05–1.52)  
  10 – 14 years 2.30  (1.94–2.72)   2.26  (1.90–2.67)  
  15 – 17 years 2.39  (1.98–2.89)   2.37  (1.96–2.87)  
 Females: 0 – 4 years Baseline   Baseline  
  5 – 9 years 1.94  (1.60–2.26)   1.92  (1.58–2.33)  
  10 – 14 years 5.81  (4.89–6.91)   5.77  (4.85–6.86)  
  15 – 17 years 7.82  (6.54–9.36)   8.00  (6.68–9.56)  
Ethnicity d  <0.001   <0.001 
 White Baseline   Baseline  
 Asian or Asian British 21.8  (19.8–24.0)   7.14  (6.31–8.07)  
 Black or black British 15.3  (13.6–17.1)   5.42  (4.74–6.20)  
 Mixed 5.85  (4.80–7.14)   2.97  (2.42–3.65)  
 Chinese or other ethnic group 8.56  (7.18–10.2)   3.41  (2.82–4.13)  
IMD quintile e  <0.001   <0.001 
 1 (least deprived) 1   1  
 2 2.01  (1.67–2.42)   1.33  (1.08–1.65)  
 3 2.48  (2.08–2.95)   1.47  (1.18–1.83)  
 4 2.94  (2.48–3.49)   1.70  (1.36–2.13)  
 5 (most deprived) 4.51  (3.82–5.32)   1.94  (1.52–2.48)  
Calendar year  <0.001   <0.001 
 2008 Baseline   Baseline  
 2009 1.95  (1.41–2.71)   1.95  (1.40–2.70)  
 2010 3.54  (2.62–4.78)   3.34  (2.47–4.51)  
 2011 5.63  (4.21–7.51)   5.34  (4.00–7.13)  
 2012 10.4  (7.87–13.8)   9.95  (7.52–13.2)  
 2013 11.8  (8.93–15.6)   11.4  (8.63–15.1)  
 2014 12.2  (9.21–16.1)   12.9  (9.70–17.0)  
Abbreviations: CI, confidence interval; IMD, Index of Multiple Deprivation; RR, rate ratio. 
a Results of multivariable Poisson regression models of rates of incident diagnosis of vitamin D 
deficiency. Missing data is handled using multivariable multiple imputation. 
b Adjusted for all variables listed in the table, including an interaction term between age and sex 
(likelihood ratio test for interaction p value<0.001). The multilevel model additionally includes 
the general practice as a random effect. 
c p-values from likelihood ratio tests comparing nested models with & without each variable. 
d Ethnicity data was available from the child’s THIN or HES record for 73.4% of children, 
maternal ethnicity was used as a proxy measure for 13.9%, and it was imputed for the 
remaining 12.7%. 
e IMD was available from the THIN record for 91.7% of children, and was imputed for 8.3%.  
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5.5 Discussion 
 
 
5.5.1 Summary of Results and Comparison with Existing Studies 
 
 
5.5.1.1 Time Trends in the Diagnosis of Vitamin D Deficiency 
 
A marked increase in the diagnosis of vitamin D deficiency in clinical practice was 
observed among children in the UK over the past decade. Prior to 2008, overall rates 
of diagnosis of vitamin D deficiency were below 10 per 100,000 person-years. Between 
2008 and 2013 this increased to over 200 per 100,000 person-years, after which rates 
plateaued between 2013 to 2014. After accounting for temporal changes in socio-
demographic factors within the cohort (age, sex, ethnicity, and Index of Multiple 
Deprivation), an increase in diagnosis of approximately 15-fold (95% CI: 10 to 21) was 
seen between 2008 to 2014. 
 
This is the first study to report estimates for overall rates of diagnosis of vitamin D 
deficiency in clinical practice, either among children or adults, in the UK or 
internationally. Therefore, the observed rates of diagnosis cannot be directly compared 
with existing research. A number of previous studies have investigated the incidence of 
symptomatic vitamin D deficiency in children presenting to secondary care services 
(see chapter 3). In contrast to these reports, the current study includes all children 
diagnosed with or treated for vitamin D deficiency irrespective of the presence of 
clinical symptoms, and captures children in primary as well as secondary care. Studies 
from the UK, Denmark, Canada, and New Zealand have provided annual incidence 
estimates for symptomatic vitamin D deficiency in secondary care of between 2.2 to 7.5 
per 100,000 children (Beck-Nielsen et al, 2009a; Callaghan et al, 2006; El-Fakhri et al, 
2013; Ward et al, 2007; Wheeler et al, 2015). Whilst the rates of diagnosis of vitamin D 
deficiency observed in the earlier years of this study (prior to 2008) are comparable 
with these figures, it is clear that the rates of diagnosis observed in more recent years 
are considerably higher. 
 
Although time trends in rates of diagnosis of vitamin D deficiency have not been 
previously reported, trends in vitamin D testing among the general population in 
Australia (including adults and children) have shown a similar large increase over time 
(Bilinski & Boyages, 2013). National rates of 25-OH-D testing in Australia increased 
over 50-fold from 59 tests per 100,000 people in 2001 to 3,648 tests per 100,000 
people in 2011. 
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5.5.1.2 Associations Between Socio-Demographic Factors and the Diagnosis of 
Vitamin D Deficiency 
 
Vitamin D deficiency was diagnosed considerably more frequently in children from 
minority ethnic groups compared to children from white ethnic backgrounds. In the 
single-level model, diagnosis rates were 22-fold higher in Asian children (95% CI: 20 to 
25), and 14-fold higher in black children (95% CI: 13 to 16), when compared to white 
children. It is not surprising that vitamin D deficiency was diagnosed more frequently in 
these groups, as pigmented skin is well known to be an important risk factor for vitamin 
D deficiency; children from non-white backgrounds have lower vitamin D levels than 
white children (Absoud et al, 2011; Gordon et al, 2004; Mansbach et al, 2009; Petersen 
et al, 2016b; Tolppanen et al, 2012), and children from South Asian and black 
backgrounds are at highest risk of symptomatic vitamin D deficiency (Ahmed et al, 
2011; Callaghan et al, 2006; El-Fakhri et al, 2013; Ladhani et al, 2004; Sharma et al, 
2009). 
 
Vitamin D deficiency was also diagnosed more frequently in children from more 
deprived backgrounds, independent of ethnicity. This association was consistent when 
two different area-based measures of socio-economic position (SEP) were used (the 
Townsend Index and the Index of Multiple Deprivation). In the single-level model, the 
rate ratio for diagnosis in children from the most deprived compared to the least 
deprived IMD quintile was 3.5 (95% CI: 3.0 to 4.2). Lower socio-economic position, 
measured using a variety of indicators in different studies, has been associated with 
lower vitamin D levels in children independent of ethnicity (Absoud et al, 2011; 
Tolppanen et al, 2012; Turer et al, 2013), and with reduced use of vitamin D 
supplements among infants and school aged children (Millette et al, 2014; Munasinghe 
et al, 2015). Another factor that may explain the association, between SEP and rates of 
diagnosis of vitamin D deficiency, is higher overall primary care consultation rates 
among children from more deprived backgrounds (Saxena et al, 1999). 
 
The magnitude of the effects of ethnicity and SEP were reduced after accounting for 
clustering by practice. In the multilevel model, rate ratios for the diagnosis of vitamin D 
deficiency were 8.0 in Asian children (95% CI: 7.0 to 9.1) and 5.5 in black children 
(95% CI: 4.7 to 6.4), when compared to children from white ethnic backgrounds. The 
rate ratio in children from the most deprived compared to the least deprived IMD 
quintile was 2.0 (95% CI: 1.5 to 2.3). One possible explanation for this observation is 
that the socio-demographic characteristics of a practice population may have 
contextual effects on clinicians’ diagnostic behaviour, separate from the influence of 
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individual patients’ characteristics. GPs working in practices with more deprived and 
ethnically diverse patient populations may be more likely to test for vitamin D deficiency 
even in low-risk patients (i.e. independently of the characteristics of individual patients).  
This could be due to increased awareness and consideration of vitamin D deficiency 
among GPs working in such areas. 
 
Vitamin D deficiency was diagnosed more frequently in older compared to younger 
children, and the influence of age was more pronounced in girls compared to boys. The 
rate ratio for diagnosis in girls aged 15 to 17 years compared to girls aged 0 to 4 years 
was 8.5 (95% CI: 6.9 to 10.5). In boys, the rate ratio for children aged 15 to 17 
compared to those aged 0 to 4 years was 2.4 (95% CI: 1.9 to 3.0). In children aged <5 
years, vitamin D deficiency was diagnosed less frequently in girls compared to boys 
(RR 0.78, 95% CI: 0.64 to 0.97). In older children, diagnosis rates were higher in girls; 
among children aged 15 to 17 years the rate ratio for diagnosis in girls compared to 
boys was 2.6 (95% CI: 2.2 to 3.0). One possible explanation for these findings may be 
that chronic pain and other non-specific or medically unexplained symptoms, which 
may prompt investigation of vitamin D status, are more frequent among older 
compared to younger children, and in girls compared to boys (Berntsson & Kohler, 
2001; Campo et al, 1999; Eminson et al, 1996; King et al, 2011; Lieb et al, 2000; Vila et 
al, 2009). Other contributing factors for the sex difference observed in older children 
may include higher overall primary care consultation rates among girls compared to 
boys during adolescence (Wang et al, 2013), and the influence of cultural or religious 
dress in females from certain ethnic or religious groups. The difference in diagnosis 
rates by age may also be related to higher thresholds for undertaking blood tests in 
younger children; clinicians may be less likely to request vitamin D tests in younger 
children with vague or non-specific symptoms, compared to older children. 
 
 
5.5.1.3 Presenting Symptoms Among Children Diagnosed with Vitamin D Deficiency 
 
Symptoms and clinical complications that can be caused by vitamin D deficiency were 
coded in the primary care medical record in a minority (42%) of the children who met 
the case criteria for diagnosis of vitamin D deficiency. In >90% of these children, a non-
specific symptom was recorded (musculoskeletal or non-specific pain, or tiredness / 
fatigue). There are no previous studies that have investigated the clinical presentation 
of children diagnosed with vitamin D deficiency in primary care, with which these 
results can be compared. 
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5.5.2 Study Strengths 
 
THIN is a prospectively collected database of electronic healthcare records from UK 
primary care. As it contains routine consultation data, it is representative of real life, 
contemporary clinical practice. The large sample size of the THIN database is a major 
strength and was necessary for the investigation of the diagnosis of vitamin D 
deficiency in children, which is a relatively uncommon outcome, and the exploration of 
associations with socio-demographic characteristics. The longitudinal nature of the 
data allowed investigation of trends in the diagnosis of vitamin D deficiency in children 
over time. 
 
The vast majority of the UK population is registered with a general practice, and the 
THIN cohort has been shown to be broadly representative of the UK population as a 
whole in terms of age and sex distribution, mortality rates, and the prevalence of 
various chronic medical conditions (Blak et al, 2011). Furthermore, the recording of 
consultations and prescriptions in THIN practices is comparable to national primary 
care statistics (Bourke et al, 2004). Therefore, the results of the study should be 
broadly generalisable to children in the UK as a whole. 
 
The inclusion of vitamin D prescriptions and tests in the case definition allowed 
identification of children where the diagnosis of vitamin D deficiency was not recorded 
using Read codes, for example where the diagnosis may have been entered in free 
text. Analysis of UK primary care electronic health data has shown that GPs do not 
always record medical diagnoses using Read codes (Ford et al, 2013). In the present 
study, the rates of diagnosis of vitamin D deficiency obtained when only diagnosis 
Read codes were used for case identification were approximately half that observed 
when all three components of the case definition were used together (see section 
5.4.3.2), highlighting the degree of case under-ascertainment that can occur if 
diagnosis Read codes alone are used to identify cases from primary care data.  
 
Medication prescriptions in primary care are particularly well recorded in THIN, as they 
are issued electronically by general practitioners (GPs) and automatically captured in 
the electronic patient record (Thiru et al, 2003). Most THIN practices are electronically 
linked to pathology laboratories, and the results of tests requested in primary care are 
sent electronically to the practice and automatically stored in patients’ health records 
(CSDMRUK, 2010). As GPs act as gatekeepers in primary care to secondary 
healthcare services in the UK, diagnoses made in secondary care can also be 
captured in THIN, from information contained in discharge summaries and outpatient 
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letters. Information in patient-related correspondence from secondary care that is 
deemed to be important may be coded into the primary care electronic health record by 
GPs themselves or by practice administrative staff. Furthermore, the continuation of 
medication commenced in secondary care usually requires further prescriptions to be 
issued in primary care. Therefore, children diagnosed with vitamin D deficiency and 
started on treatment with calciferol in secondary care may be captured in THIN, if 
repeat prescriptions required to complete the course of treatment are issued by the GP. 
 
Missing data for ethnicity was substantially reduced by utilising linked HES data, and 
by linking children to their mothers in the THIN database and taking maternal ethnicity 
as a proxy measure where the child’s ethnicity was not available. Using these methods 
considerably reduced the proportion of children with missing data for ethnicity in the 
linked THIN-HES cohort from 57.8% to 18.5%. 
 
 
5.5.3 Study Limitations 
 
Although the THIN cohort has been shown to be broadly comparable to the UK 
population as a whole, information regarding the representativeness of the subgroup of 
the cohort linked to HES data is not available. However, in this study, the full THIN 
cohort and the linked THIN-HES cohort were similar in terms of distribution of age, sex, 
ethnicity, and Townsend Index of deprivation. 
 
THIN has been shown to be somewhat under-representative of individuals from the 
most deprived areas in the country, as measured by the Townsend deprivation index 
(Blak et al, 2011). This pattern was also observed among children in the study cohort. 
Given that socio-economic deprivation was positively associated with the diagnosis of 
vitamin D deficiency, the diagnosis rates observed in the study cohort may 
underestimate true national rates to an extent. 
 
Although vitamin D prescriptions and tests were included in the case definition to 
minimise case under-ascertainment, it is possible that some cases may still have been 
missed. For example, children who were diagnosed and received their full course of 
treatment in secondary care would have been missed if the diagnosis was not 
subsequently entered into the primary care record from hospital correspondence. The 
use of HES data as an additional source of case identification had negligible influence 
on observed rates of diagnosis. This is likely to be due to the limitation that information 
regarding clinical diagnoses was only available in HES inpatient data, whilst the 
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majority of children diagnosed with vitamin D deficiency in secondary care are likely to 
be identified in the outpatient setting. 
 
Prior to 2013, a Read code for ‘Vitamin D insufficiency’ was not available, and it is 
possible that some children in whom a Read code for vitamin D deficiency was 
recorded may have had serum 25-OH-D levels in the range that is commonly defined 
as representing insufficiency (25 to 50 nmol/L). However, sensitivity analysis 
demonstrated that the inclusion of the ‘Vitamin D insufficiency’ Read code in the case 
definition had little overall impact (<3% difference) on observed rates of diagnosis of 
vitamin D deficiency between 2013 to 2014 (see section 5.4.3.4). Some 
misclassification of case status may also have arisen from assumptions made when 
coding prescription dosage instructions, and from the choice of dosage thresholds 
representing ‘treatment dose’ calciferol in the case definition. However, this is not 
expected to have had a major overall effect on the results, as dosage assumptions 
were made in a minority of prescription records (7.9%), and overall time trends in the 
diagnosis of vitamin D deficiency were similar when a range of alternative dosage 
thresholds representing ‘treatment dose’ calciferol were used (the maximal difference 
in rates across the range of alternatives was <15%, in 2014) (see section 5.4.3.5). 
 
Whilst the accuracy of recorded ethnicity in HES has been shown to be high for 
patients from white backgrounds, it is less reliable for individuals from ethnic minority 
groups. Among adults with cancer, concordance between ethnicity recorded in HES 
with self-reported ethnicity, collected for the English Cancer Patient Experience Survey, 
has been shown to be very high for patients with ethnicity recorded as ‘white’ in HES 
(99.4%), and reasonable for patients with ethnicity recorded as ‘Asian or Asian British’ 
(88.9%) or ‘black or black British’ (84.6%) in HES (Saunders et al, 2013). However, 
concordance was low for patients with ethnicity recorded as ‘Chinese or other ethnic 
group’ (67.0%) or ‘mixed’ (25.1%) in HES. To date, validation studies have not been 
conducted to investigate the accuracy of ethnicity data in UK primary care health 
records. Therefore, particular caution should be used in the interpretation of observed 
rate ratios for the diagnosis of vitamin D deficiency in the ‘mixed’ and ‘Chinese or other’ 
ethnic groups, among whom the risk of misclassification of ethnicity is likely to be 
greatest. Whilst the use of maternal ethnicity as a proxy measure for children’s ethnicity 
helped to reduce the extent of missing data for this variable, the risk of misclassification 
will be greater where maternal ethnicity was used instead of a direct record of ethnicity 
for the child. However, this is not expected to have had a major impact on the results 
as, where data was available for both children’s and maternal ethnicity, overall 
agreement between the variables was found to be high (94%). 
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There was a moderate proportion of missing data for ethnicity (12.7%) and Index of 
Multiple Deprivation (8.3%) in the multivariable analyses. However, the results were 
very similar when missing data was handled using complete cases analysis and 
multiple imputation, suggesting that missing data did not substantially influence the 
findings under the missing at random assumption (Sterne et al, 2009). 
 
Exploration of presenting symptoms among children diagnosed with vitamin D 
deficiency was limited by the data available in the primary care electronic record. Only 
42% of children meeting the case criteria for diagnosis of vitamin D deficiency had a 
relevant symptom code recorded in the 6 months either side of their initial diagnosis. 
One reason for this may be that GPs enter some clinical information as free text rather 
than using Read codes (Ford et al, 2013). However, exploration of free text entries in 
the primary care record, for a convenience sample of 55 children diagnosed with 
vitamin D deficiency, provided additional information regarding presenting symptoms, 
not already available from Read codes, in only 4 of the children (7.3%). Given the time 
constraints of consultations in primary care, it is likely that GPs are not able to enter 
detailed records during consultations, and it is possible that information regarding 
symptoms that prompted investigation of vitamin D status were not recorded. 
Furthermore, for children who were diagnosed with vitamin D deficiency in secondary 
care, it is unlikely that information regarding their clinical presentation will have been 
recorded in the primary care record. Another explanation for the limited recording of 
symptoms among cases is likely to be that a proportion of children diagnosed with 
vitamin D deficiency will have been asymptomatic, with screening of vitamin D status 
prompted by the presence of risk factors or non-musculoskeletal diseases that have 
been linked to vitamin D deficiency in observational studies. 
 
 
5.5.4 Conclusions 
 
There has been a marked increase in the diagnosis of vitamin D deficiency in UK 
children in clinical practice over the last decade. Given the magnitude of the increase in 
diagnosis over a relatively short period of time, it is highly unlikely to be explained by 
changes in population vitamin D levels, incidence of clinical complications of vitamin D 
deficiency, or population demographics. It is likely that the rise in testing and treatment 
has been driven by increased awareness and consideration of vitamin D deficiency 
among clinicians. The data available did not permit meaningful exploration of the 
clinical indications prompting investigation of vitamin D status. Therefore, it is not clear 
how much the increase in diagnosis is being driven by improved recognition of children 
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with clinical features consistent with symptomatic vitamin D deficiency, or by testing in 
other clinical situations (for example screening of asymptomatic children, testing in 
children with non-specific symptoms, or testing prompted by the presence of non-
musculoskeletal diseases that have been linked to vitamin D deficiency). The 
implications of the work described in this chapter, with respect to clinical practice, 
public health policy and future research, are further discussed in the final chapter of the 
thesis.  
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Chapter 6 
 
 
Costs of Vitamin D Testing and Prescribing 
Among Children in Primary Care in the UK: A 
Cohort Study Using Primary Care Electronic 
Health Records 
  
Chapter 6. Costs of Vitamin D Testing & Prescribing 
 
 204 
6.1 Introduction 
 
Large increases in healthcare expenditure on vitamin D tests and prescriptions have 
been reported in adult practice in the UK, Australia, and Canada over the last decade. 
In the previous chapter, data was presented demonstrating a marked increase in the 
diagnosis of vitamin D deficiency in clinical practice among children in the UK between 
2008 to 2014. This chapter describes a cohort study undertaken to explore the 
economic implications of this change in diagnostic behaviour, by investigating 
longitudinal trends in healthcare expenditure arising from vitamin D testing and 
prescribing among children in primary care in the UK. 
 
 
 
6.2 Aims and Objectives 
 
 
6.2.1 Study Aims 
 
The overall aim of this study was to explore longitudinal trends in healthcare 
expenditure arising from vitamin D testing and prescribing among children in primary 
care in the UK over the past 15 years. 
 
 
6.2.2 Study Objectives 
  
i) To determine healthcare costs in primary care in the UK arising from 
calciferol prescriptions and 25-hydroxyvitamin D (25-OH-D) tests for children, 
in each year between 2000 and 2014. 
 
ii) To estimate overall costs of calciferol prescriptions and 25-OH-D tests for 
children in primary care at the national level in England. 
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6.3 Methods 
 
 
6.3.1 Study Design 
 
A cohort study using UK primary care electronic health records, held in The Health 
Improvement Network (THIN) database. 
 
 
6.3.2 Data Sources 
 
The Health Improvement Network database has been described in chapter 5.3.2.1. 
The February 2015 release of THIN data was used for the analysis reported in this 
chapter, containing primary care medical records for 11.6 million patients in total, 
registered with 641 general practices in the UK, from 3rd June 1985 up to 10th February 
2015. Linked Hospital Episode Statistics (HES) data was used to augment information 
regarding ethnicity. This was available for a subset of THIN practices in England 
(n=156), covering the time period 1st April 1997 to 31st March 2012, and has been 
described in chapter 5.3.2.2. 
 
 
6.3.3 Study Population 
 
6.3.3.1 Inclusion and Exclusion Criteria 
 
The study population included children aged between 0 to 17 years, who were actively 
registered with a THIN practice between 1st January 2000 and 31st December 2014. 
Only individuals with an acceptable patient record status (Patflag A or C) were included 
(see chapter 5.3.3.1). Children with a record of a medical condition that can predispose 
to vitamin D deficiency by interfering with vitamin D absorption or metabolism (chronic 
renal disease, liver disease, or conditions associated with gastrointestinal 
malabsorption; see chapter 5.3.6.8) were excluded, as routine screening of vitamin D 
status is expected in children with these conditions. 
 
The full THIN study cohort was used for the main analysis of time-trends in healthcare 
costs arising from calciferol prescriptions and 25-OH-D tests among children in primary 
care. For the extrapolation of national cost estimates from costs observed in the cohort, 
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the analysis was limited to THIN practices for which linked HES data was available (the 
linked THIN-HES study cohort), in order to minimise missing data for ethnicity (see 
chapter 5.4.2, and section 6.3.6.2). 
 
 
6.3.3.2 Entry to Study Observation Period 
 
The study cohort was open (dynamic), meaning that children entered and exited the 
cohort at different time points. Therefore, they were observed over different periods of 
time, and contributed different lengths of follow-up to the study. 
 
The date of entry into the cohort for each individual, i.e. the start of their period of 
observation (follow-up), was set as the latest of the following dates: 
 
i) Start of the study period (1st January 2000). 
 
ii) Date of registration with the GP practice. 
 
iii) The date when the practice met pre-defined criteria for acceptable mortality 
recording (AMR date, see chapter 5.3.3.2). 
 
iv) The date when the practice met pre-defined criteria for acceptable computer 
usage (ACU date, see chapter 5.3.3.2). 
 
 
6.3.3.2 Exit from Study Observation Period 
 
The date of exit from the cohort for each individual was set as the earliest of the 
following dates: 
 
i) Mid-point of 18th year after birth. 
 
ii) Date of transfer out of the practice.  
 
iii) Date when the practice stopped contributing data to THIN. 
 
iv) Date of death. 
 
v) End of the study period (31st December 2014). 
 
The mid-point of the 18th year after birth was used, as opposed to the 18th birthday, 
because exact dates of birth are not provided in THIN in order to protect patient 
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confidentiality. Month of birth is provided for children below 15 years of age at the time 
of the data release, whilst for older individuals only year of birth is available. 
 
 
6.3.4 Outcome 
 
The primary outcome was the cost arising from calciferol prescriptions and 25-OH-D 
tests in primary care among children in the study cohort. 
 
6.3.4.1 Identification of Calciferol Prescriptions and 25-OH-D Tests 
 
All prescriptions for pure preparations of calciferol (colecalciferol or ergocalciferol) were 
included. Activated analogues of vitamin D, such as alfacalcidol and calcitriol, were not 
included as these are not routinely recommended for the treatment of primary vitamin 
D deficiency, and are generally used in situations where vitamin D metabolism is 
impaired (e.g. chronic renal impairment) or in hypoparathyroidism (see chapter 2.3.3). 
The strategy used for identification of drug codes referring to pure preparations of 
calciferol is described in chapter 5.3.6.4, and the final list of included codes is shown in 
Appendix G.1. 
 
The strategy used for identification of Read codes referring to vitamin D tests, along 
with the final list of included codes, is described in chapter 5.3.6.5. Codes referring to 
levels of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, combined total 25-
hydroxyvitamin D2 and D3, 25-hydroxyvitamin D (type not specified), and unspecified 
vitamin D were included. The distribution of test values for the unspecified vitamin D 
tests was similar to that for vitamin D3 tests and total vitamin D2 & D3 tests (see 
chapter 5.3.7.2). Therefore, unspecified vitamin D tests were considered to represent 
measurement of either 25-hydroxyvitamin D3 or total 25-hydroxyvitamin D2 & D3. 
Codes referring to 1,25-dihydroxyvitamin D tests were excluded, as levels of the 
biologically active hormone are not used to assess an individual’s vitamin D status. 
 
For the purpose of this study, the outcome of interest was total healthcare expenditure 
on vitamin D testing and prescribing for children in primary care. Therefore, distinction 
was not made between ‘prophylactic’ and ‘treatment’ dosage, and all prescriptions of 
calciferol were included irrespective of dosage. Similarly, all records representing 25-
OH-D tests were included, irrespective of the value of the test result. 
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Where individuals had more than one vitamin D test code recorded on the same date 
(for example separate codes for levels of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, 
and combined total 25-hydroxyvitamin D2 and D3), this was taken to represent a single 
25-OH-D test. 
 
 
6.3.4.2 Unit Cost of 25-OH-D Tests 
 
In an economic evaluation commissioned by the National Institute for Health and Care 
Excellence (NICE), a unit cost for vitamin D tests was derived from information 
contained in local clinical guidelines published by two NHS trusts (Filby et al, 2014); 
The Royal National Orthopaedic Hospital gave a unit cost of £20 (Jacobs, 2013), and a 
statement from NHS Derby City and NHS Derbyshire County reported a cost of £13 
(Filby et al, 2014).  
 
A search was conducted on 2nd February 2016 to identify any further data published by 
NHS trusts regarding the unit cost of vitamin D tests. Three additional clinical 
guidelines, and one service tariff, were identified. Clinical guidelines published by the 
Nottinghamshire Area Prescribing Committee (Prinsloo et al, 2015), and NHS Forth 
Valley (Allan et al, 2015), reported the unit cost of a 25-OH-D test to be £15. A provider 
to provider services tariff from University College London Hospitals NHS Foundation 
Trust also reported a unit cost for 25-OH-D tests of £15 (UCLH, 2012). A clinical 
guideline published by the NHS Wandsworth Clinical Effectiveness and Medicines 
Management Group reported the unit cost of a 25-OH-D test to be £15.61 (Wouda, 
2010). 
 
The unit cost of a 25-OH-D test was taken as £15 for the main analyses, as this was 
the most frequently reported value in the sources of information identified above. A 
sensitivity analysis was performed to explore the influence on the results of varying the 
25-OH-D test unit cost between £13 to £20. 
 
 
6.3.4.3 Unit Costs of Calciferol Preparations 
 
Unit costs for the different preparations of pure calciferol, identified in the THIN drug 
code dictionary (see appendix G.1), were derived from Prescription Cost Analysis 
(PCA) for England 2014 data (HSCIC, 2015b). PCA data is published by NHS Digital 
(formerly known as the Health and Social Care Information Centre [HSCIC]), and 
contains details of all NHS prescriptions dispensed in the community (by community 
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pharmacies or dispensing doctors) in England in each year. For every drug, PCA data 
includes information regarding the number of items (prescriptions) dispensed, quantity 
of drug dispensed (measured in units depending on the form of the drug, e.g. tablets, 
capsules, millilitres), and the total net ingredient cost (NIC) for all prescriptions of the 
drug. The NIC refers to the cost of the drug before discounts, and does not include any 
dispensing costs or fees. The NIC is generally equivalent to the NHS indicative price 
listed in the British National Formulary (BNF). The average NIC per item (prescription), 
and the average NIC per quantity of drug (NIC/Qty) have been derived and are 
available in the PCA data. 
 
For each drug or chemical entity, the PCA lists all forms (e.g. tablets, capsules, liquid) 
and strengths of the drug. For each form and strength of a drug, all proprietary 
(branded) and generic names under which the drug is sold are listed. In contrast, 
proprietary names of prescribed drugs are not made available in THIN. THIN drug 
codes are linked to a description of the drug’s generic name only, as well its form and 
strength. Therefore, there can be multiple drugs listed in the PCA corresponding to 
each THIN drug code. An example is shown in Table 6.1. 
 
For each THIN drug code, a unit cost was calculated representing the cost (in £) per 
quantity of the drug (i.e. per tablet, capsule, or millilitre). For THIN drug codes 
corresponding to a single drug entry in the PCA, the NIC/Qty in the PCA was taken to 
represent the unit cost of the drug. In the case of THIN drug codes corresponding to 
multiple different drugs (with identical form and strength) listed in the PCA, a weighted 
mean unit cost was calculated using the NIC/Qty, with weighting by the relative 
frequency with which each drug was dispensed in 2014, as shown below: 
 
!"#$ℎ&"'	)*#&	+,-&	 = 		∑ (123_5&67 		×		17)7 ∑ 177  
   Key:	 i	:		each	drug	listed	in	the	PCA	corresponding	to	the	same	THIN	drug	code		 NIC_Qty	:		the	net	ingredient	cost	per	quantity	(e.g.	tablet	or	ml)	of	the	drug		 N	:		the	total	number	of	items	(prescriptions)	of	each	drug	dispensed	in	2014	
 
An example of the calculation of weighted unit cost for a THIN drug code is shown in 
Table 6.1.  
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Table 6.1  An example of the calculation of the weighted unit cost for a THIN drug code 
that has more than one corresponding drug listed in the PCA. 
THIN drug code 
description 
Variables from Prescription Cost Analysis Derived variables 
Drug Name 
(i) 
NIC_Qty 
(£ / ml) 
Items 
dispensed 
(N) (1,000s) 
Total items 
(∑N) 
(1,000s) 
Weight 
(N / ∑N) 
Weighted 
unit cost 
(£ / ml) a 
 
Colecalciferol 
2,000units/ml oral 
drops sugar free 
 
Colecal_Oral 
Dps 2,000u/ml 
S/F 
2.64 0.638 11.945 0.0534 0.65 
E-D3_Oral 
Dps 2,000u/ml 4.99 0.118 11.945 0.0099 0.65 
Pro D3_Oral 
Dps 2,000u/ml 0.49 11.189 11.945 0.9367 0.65 
Abbreviations: NIC_Qty, net ingredient cost per quantity of drug. 
a The weighted unit cost is calculated as follows: ∑i (NIC_Qty x weight). 
 
 
Unit costs were kept constant over time, so that analysis of time-trends in expenditure 
represented changes in levels of healthcare activity over time rather than changes in 
the monetary value of drugs. 2014 was chosen as the index (base) year for costs, as 
this was the most recent year for which follow-up data was available for the study. 
 
 
6.3.4.4 Calculation of Costs of Individual Prescriptions 
 
The cost of each prescription of pure calciferol recorded in the study cohort was 
calculated by multiplying the weighted unit cost of the drug by the quantity prescribed. 
For most records, the variable for ‘quantity prescribed’ in the THIN prescription record 
represents the amount of the drug prescribed in terms of units of measurement of the 
form of the drug (e.g. tablets, capsules, millilitres). However, in a minority of 
prescription records the variable ‘quantity prescribed’ represents the number of ‘packs’ 
of the drug prescribed. A ‘pack’ can represent, for example, a packet of tablets, or a 
bottle of liquid medication. Therefore, for each THIN drug code separately, the 
distribution of the variable ‘quantity prescribed’ was examined for all prescriptions of 
the drug in the study cohort, in order to identify low value outliers likely to represent the 
number of packs prescribed as opposed to the quantity of drug prescribed. An example 
is shown in Table 6.2. 
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Table 6.2  Distribution of the variable ‘quantity prescribed’ for 
prescriptions of the THIN drug code for ‘Colecalciferol 
3,000units/ml oral solution sugar free’. 
Quantity prescribed Frequency (N = 240) Percentage 
1 1 0.42 
20 1 0.42 
28 2 0.83 
30 41 17.1 
50 122 50.8 
60 20 8.3 
100 31 12.9 
120 1 0.42 
150 4 1.7 
180 1 0.42 
200 15 6.3 
300 1 0.42 
 
 
In the example shown in Table 6.2, the prescription record for ‘Colecalciferol 
3,000units/ml oral solution sugar free’ with a ‘quantity prescribed’ of 1 was considered 
to represent a low value outlier, where the ‘quantity prescribed’ was likely to represent 
the number of packs prescribed. For such prescription records, where the ‘quantity 
prescribed’ was considered to be a low value outlier, the value of the variable was 
replaced using the mode value from the distribution of the variable for all prescriptions 
of the same drug code (i.e. the most frequently recorded ‘quantity prescribed’ for 
prescriptions of the identical drug). In the case of the example shown in Table 6.2, for 
the prescription record for ‘Colecalciferol 3,000units/ml oral solution sugar free’ with the 
‘quantity prescribed’ recorded as 1, the value of this variable was replaced with 50. 
 
For high strength preparations of calciferol, defined as ≥10,000 units per dosage unit 
(i.e. tablet or ml), exploration of dosage instructions linked to prescriptions with low 
values (<5) for the ‘quantity prescribed’ revealed that many such prescriptions were 
linked to dosage instructions specifying infrequent administration (e.g. once monthly, or 
once weekly). In such cases, the ‘quantity prescribed’ was considered likely to 
represent the amount of the drug prescribed in terms of units of measurement of the 
form of the drug (e.g. tablets, capsules, millilitres), rather than number of packs. 
Therefore, for preparations of calciferol with a strength ≥10,000 units per dosage unit, 
low values for ‘quantity prescribed’ were not considered to represent outliers, and the 
original values were retained when calculating costs of prescriptions. 
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In cases where individuals had more than one prescription for calciferol issued on the 
same day, the cost of all prescriptions issued on that date were summed and 
considered to represent a single prescription, for the purpose of calculation of mean 
prescription costs (see section 6.3.6.1). 
 
 
6.3.5 Covariates 
 
The following study covariates were used to stratify observed costs in the study cohort: 
sex, age, and ethnicity. The methods for handling and coding data for the study 
covariates is described in chapter 5.3.5. 
 
 
6.3.6 Statistical Analysis 
 
All statistical and graphical analyses were performed using Stata MP version 14.2 
(StataCorp, USA). 
 
 
6.3.6.1 Analysis of Time Trends in Costs of Vitamin D Testing and Prescribing in the 
Study Cohort 
 
Crude rates for 25-OH-D tests and calciferol prescriptions in the cohort were calculated 
separately, per 100,000 person-years at risk (PYAR), using the stset and strate 
functions in Stata. All test and prescription records for each individual were included in 
the analysis. Multiple test, or prescription, records on the same date for an individual 
were considered to represent a single event. In order to explore incidence rates 
stratified by time-changing variables (age and calendar time), Lexis expansions were 
used to divide individuals’ follow-up into distinct categories of the time-changing 
variables, using the stsplit function in Stata (Kirkwood & Sterne, 2003). Calendar time 
was split into individual years, between 2000 to 2014. 
 
Mean costs of calciferol prescriptions in each year between 2000 and 2014 were 
calculated, using bootstrapping to derive confidence intervals as the distribution of 
prescription costs was severely positively skewed (Figure 6.1). The bootstrap approach 
is a non-parametric method that makes very limited distributional assumptions 
concerning the statistic in question, and is recommended as an appropriate method for 
handling sampling uncertainty in healthcare cost data which often follows a skewed 
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distribution (Briggs & Gray, 1999; Desgagne et al, 1998; Thompson & Barber, 2000). 
The bootstrap function in Stata was used to re-sample observations (with replacement) 
from the original sample of prescription costs in each year, to generate 10,000 re-
sampled datasets. The percentile method was used to calculate confidence intervals 
from the resampled datasets (Kirkwood & Sterne, 2003). Using this method, the 95% 
confidence interval for the mean prescription cost in each year was derived from the 
2.5th and 97.5th percentile values from the distribution of mean prescription costs from 
the re-sampled datasets. A sensitivity analysis was performed to explore the influence 
of using the alternative bias-corrected and accelerated (BCa) method for deriving 
bootstrap confidence intervals (Kirkwood & Sterne, 2003). 
 
Figure 6.1  Distribution of the cost of calciferol prescriptions in the study cohort. 
 
 
Total costs of 25-OH-D tests in each year were calculated per 100,000 PYAR, by 
multiplying rates of testing in each year by the unit cost of a 25-OH-D test (£15 for the 
main analysis). 95% confidence intervals around these cost estimates were calculated 
by multiplying the 95% confidence limits for the rates of testing in each year by the unit 
cost of a 25-OH-D test. 
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Total costs of calciferol prescriptions in each year were calculated per 100,000 PYAR, 
by multiplying rates of prescribing in each year by the mean prescription cost in the 
corresponding year. 95% confidence intervals around these cost estimates were 
calculated by multiplying the lower (and upper) 95% confidence limit for the rate of 
prescribing in each year by the lower (and upper) 95% confidence limit for the mean 
prescription cost in the corresponding year. 
 
 
6.3.6.2 Extrapolation of National Cost Estimates 
 
Overall costs of calciferol prescriptions and 25-OH-D tests for children in primary care 
were estimated at the national level for England in 2014. Stratified rates of expenditure 
observed in the linked THIN-HES study cohort were applied to 2014 population 
estimates for England. This analysis involved the following steps: 
 
i) Observed rates of calciferol prescription and 25-OH-D testing in the linked 
THIN-HES study cohort in 2014 were stratified by age group, sex, and ethnicity, 
using the stsplit and strate functions in Stata. 
 
ii) Variation in the cost of vitamin D prescriptions, issued in the linked THIN-HES 
study cohort in 2014, was explored by age group, sex, and ethnicity. 
Multivariable generalised linear models were used in view of the highly-skewed 
distribution of the data (Barber & Thompson, 2004), using the glm function in 
Stata. Models with a gamma distribution function were found to provide a better 
fit for the data compared to models specifying an inverse Gaussian or Gaussian 
distribution (as assessed using residual plots and the Akaike information 
criterion). However, even with the gamma distribution function, the histogram of 
residuals was not normally distributed and the normal probability plot of the 
residuals was not straight (Barber & Thompson, 2004). Therefore, the 
distributional assumptions of the model were relaxed using robust standard 
errors. 
 
Significant variation in prescription costs was observed by age group, however 
there were no significant differences observed by sex or ethnicity (Table 6.3). 
Therefore, age group specific mean calciferol prescription costs were derived 
using a generalised linear model (with gamma distribution function, log link 
function, and robust standard errors) which included only age group as an 
explanatory variable (Table 6.4). 
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Table 6.3  Associations between selected demographic factors and 
calciferol prescription costs.a 
Covariate Regression coefficient (95% CI) b p-value 
c 
Sex  0.366 
 Male Baseline  
 Female 0.92  (0.77–1.10)  
Age group  <0.001 
 0 – 4 years Baseline  
 5 – 9 years 0.84  (0.68–1.03)  
 10 – 14 years 0.39  (0.31–0.49)  
 15 – 17 years 0.29  (0.23–0.37)  
Ethnicity  0.708 
 White Baseline  
 Asian or Asian British 0.88  (0.72–1.07)  
 Black or black British 0.95  (0.74–1.21)  
 Mixed 0.93  (0.71–1.21)  
 Chinese or other ethnic group 0.88  (0.68–1.13)  
Constant (£) 63.7  (51.8–78.4) - 
Abbreviations: CI, confidence interval 
a The analysis included all prescriptions of calciferol issued in 2014 in the 
linked THIN-HES study cohort. Missing data for ethnicity was handled using 
complete cases analysis. N=1,428. 
b Exponentiated regression coefficients from a multivariable generalised linear 
model with gamma distribution function, log link function, and robust standard 
errors. The model adjusted for all variables listed in the table. In this model 
covariates act multiplicatively on the mean, and the exponentiated regression 
coefficients therefore represent the relative difference in mean prescription 
costs between categories of the covariates. 
c p-values from Wald tests of the overall association between each variable 
and prescription costs. 
 
Table 6.4  Predicted mean calciferol prescription costs for each age 
group category.a 
Age group Mean Prescription Cost (£) b 95% CI (£) 
0 – 4 years 57.3 48.3–66.3 
5 – 9 years 47.9 41.8–54.0 
10 – 14 years 22.6 19.4–25.8 
15 – 17 years 16.3 13.9–18.6 
Abbreviations: CI, confidence interval 
a The analysis included all prescriptions of calciferol issued in 2014 in the 
linked THIN-HES study cohort. N=1,542. 
b Predicted margins from a generalised linear model with gamma distribution 
function, log link function, and robust standard errors. The model included age 
group as the only independent variable. 
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iii) Rates of vitamin D testing in each of the cohort strata (defined by age group, 
sex, and ethnicity) were multiplied by the unit cost of a 25-OH-D test (£15), to 
derive stratum-specific costs of vitamin D testing per 100,000 PYAR. 95% 
confidence intervals around the stratum specific cost estimates were calculated 
by multiplying the 95% confidence limits for the rates of testing in each stratum 
by the unit cost of a 25-OH-D test. 
 
iv) Rates of vitamin D prescribing in each of the cohort strata were multiplied by 
age-specific unit costs of calciferol prescriptions (Table 6.4), to derive stratum 
specific costs of vitamin D prescribing per 100,000 PYAR. 95% confidence 
intervals around the stratum specific cost estimates were calculated by 
multiplying the lower (and upper) 95% confidence limits for the rate of 
prescribing in each stratum by the lower (and upper) 95% confidence limits for 
the mean prescription cost for the corresponding age group. 
 
v) 2014 population estimates for children in England, stratified by age group and 
sex, were available from the Office for National Statistics (ONS) (ONS, 2015). 
However, population estimates stratified by ethnicity were not available for 
2014. The ethnicity distribution of children in the 2011 census was calculated 
(ONS, 2013a), separately for strata defined by age group and sex. The strata-
specific ethnicity distributions from 2011 were then applied to 2014 population 
estimates stratified by age group and sex, to derive population estimates for 
2014 stratified by age group, sex, and ethnicity. 
 
vi) Stratum-specific rates of expenditure for vitamin D testing and prescribing 
observed in the study cohort (derived in steps iii and iv) were applied to 2014 
population estimates stratified by age group, sex, and ethnicity (derived in step 
v), in order to derive estimated costs in each population stratum in England in 
2014. Stratum specific costs were summed to derive total estimated costs of 
vitamin D testing and prescribing in England in 2014. 
 
 
6.3.7 Ethical Approval 
 
The ethical approval for this study is described in chapter 5.3.9. 
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6.4 Results 
 
 
6.4.1 Descriptive Characteristics of the Study Cohort 
 
 
6.4.1.1 Full THIN Study Cohort 
 
The full study cohort consisted of 2,372,913 children, from 639 general practices, with 
a total period of follow-up of 11.7 million person-years. Median duration of study follow-
up was 3.7 years per individual (IQR 1.5 to 7.7). 11,974 children with a record of either 
chronic renal disease, liver disease, or conditions associated with gastrointestinal 
malabsorption, were excluded from the study cohort. Descriptive characteristics of the 
study population are shown in Table 6.5.  
 
There were a total of 17,719 vitamin D test records, among 13,498 children in the full 
study cohort, during the period of follow-up. There were a total of 13,664 calciferol 
prescription records, among 6,168 children in the cohort, during the period of follow-up. 
It was possible to derive the prescription cost for 13,661 of the prescriptions (>99.9%).  
 
 
6.4.1.2 Study Cohort with Linked HES Data Available 
 
When the analysis was limited to children registered with one of the 156 THIN practices 
in England for which linked HES data was available, the study cohort consisted of 
722,525 children, with a total period of follow-up of 3.7 million person-years. Median 
duration of study follow-up was 3.9 years per individual (IQR 1.5 to 8.1). 3,918 children 
with a record of either chronic renal disease, liver disease, or conditions associated 
with gastrointestinal malabsorption, were excluded from the study cohort. Descriptive 
characteristics of the linked THIN-HES study population are shown in Table 6.6. 
Ethnicity was directly available for 67.6% of children in the cohort, and maternal 
ethnicity was available as a proxy measure of children’s ethnicity for a further 14.0% of 
the cohort. Ethnicity was missing for 18.4% of the study cohort. 
 
There were a total of 7,029 vitamin D test records, among 5,338 children in the linked 
THIN-HES study cohort, during the period of follow-up. There were a total of 4,586 
calciferol prescription records, among 2,272 children in the cohort, during the period of 
follow-up. It was possible to derive the prescription cost for all of these prescriptions. 
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Table 6.5  Descriptive characteristics of the full study cohort (n=2,372,913). 
Age at entry to follow-up (years) Median  (IQR) 
  4.5  (0.16–10.6) 
Sex n  (%) 
 Male 1,223,081  (51.5%) 
 Female 1,149,832  (48.5%) 
Ethnicity a n  (%) 
 White 956,325  (40.3%) 
 Asian or Asian British 77,139  (3.3%) 
 Black or black British 51,651  (2.2%) 
 Mixed 31,512  (1.3%) 
 Chinese or other ethnic group 29,711  (1.3%) 
 Missing 1,226,575  (51.7%) 
Townsend deprivation index quintile n  (%) 
 1 (least deprived) 501,883  (21.2%) 
 2 435,299  (18.3%) 
 3 473,402  (20.0%) 
 4 462,823  (19.5%) 
 5 (most deprived) 351,383  (14.8%) 
 Missing 148,123  (6.2%) 
Country, and strategic health authority in England n  (%) 
 England 1,855,456  (78.2%) 
 South Central 273,327  (11.5%) 
 London 259,487  (10.9%) 
 South East Coast 214,224  (9.0%) 
 South West 211,115  (8.9%) 
 North West 202,768  (8.6%) 
 West Midlands 197,903  (8.3%) 
 East of England 155,625  (6.6%) 
 East Midlands 75,823  (3.2%) 
 Yorkshire & Humber 70,725  (3.0%) 
 North East 53,031  (2.2%) 
 Missing 141,428  (6.0%) 
 Scotland 273,400  (11.5%) 
 Wales 166,746  (7.0%) 
 Northern Ireland 77,311  (3.3%) 
Abbreviations: IQR, interquartile range. 
a Ethnicity data was available from the child’s THIN record for 40.1% of the cohort, 
and maternal ethnicity was available as a proxy measure for a further 8.2%. 
 
  
Chapter 6. Costs of Vitamin D Testing & Prescribing 
 
 219 
Table 6.6  Descriptive characteristics of the THIN-HES linked study cohort 
(n=722,525). 
Age at entry to follow-up (years) Median  (IQR) 
  3.9  (0.15–10.5) 
Sex n  (%) 
 Male 371,835  (51.5%) 
 Female 350,690  (48.5%) 
Ethnicity a n  (%) 
 White 499,132  (69.1%) 
 Asian or Asian British 35,322  (4.9%) 
 Black or black British 25,315  (3.5%) 
 Mixed 15,886  (2.2%) 
 Chinese or other ethnic group 13,712  (1.9%) 
 Missing 133,158  (18.4%) 
Townsend deprivation index quintile n  (%) 
 1 (least deprived) 173,445  (24.0%) 
 2 130,713  (18.1%) 
 3 150,717  (20.9%) 
 4 143,669  (19.9%) 
 5 (most deprived) 92,500  (12.8%) 
 Missing 31,481  (4.4%) 
Strategic health authority n  (%) 
 South Central 160,925  (22.3%) 
 South West 113,327  (15.7%) 
 London 102,482  (14.2%) 
 South East Coast 92,871  (12.9%) 
 West Midlands 91,336  (12.6%) 
 North West 65,080  (9.0%) 
 East of England 58,829  (8.1%) 
 North East 18,805  (2.6%) 
 Yorkshire & Humber 14,406  (2.0%) 
 East Midlands 4,464  (0.6%) 
Abbreviations: IQR, interquartile range. 
a Ethnicity data was available from the child’s THIN or HES record for 67.6% of the 
cohort, and maternal ethnicity was available as a proxy measure for a further 
14.0%. 
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6.4.2 Variation in Calciferol Prescription Costs Over Time 
 
Mean costs of calciferol prescriptions in the full THIN study cohort, in each year 
between 2000 and 2014, are shown in Figure 6.2 and Table 6.7. Mean prescription 
costs peaked in 2005, then decreased considerably between 2005 to 2014. 95% 
confidence intervals around mean prescription costs were similar whether the 
percentile method or the bias-corrected and accelerated (BCa) method for deriving 
bootstrap confidence intervals were used. Bootstrap confidence intervals derived using 
the percentile method were used for all further analyses. 
 
 
Figure 6.2  Mean calciferol prescription costs in each year between 2000 and 2014, 
using two alternative methods for deriving bootstrap 95% confidence intervals.a 
 
Abbreviations: BCa, bias-corrected and accelerated; CIs, confidence intervals. 
a 95% confidence intervals calculated using the percentile method for deriving bootstrap CIs are 
represented by red vertical lines. 95% confidence intervals calculated using the bias-corrected 
and accelerated method for deriving bootstrap CIs are represented by green vertical lines. 
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Table 6.7  Mean calciferol prescription costs in each year between 2000 and 2014, 
using two alternative methods for deriving bootstrap 95% confidence intervals. 
Year 
Number of 
calciferol 
prescriptions 
Mean 
prescription 
cost (£) 
95% CI derived using the 
percentile method (£) 
95% CI derived using 
the BCa method (£) 
2000 6 43.1 43.1 – 43.1 - 
2001 10 47.2 35.9 – 60.8 37.0 – 64.2 
2002 10 80.5 45.1 – 128.5 47.1 – 130.5 
2003 33 175.1 136.1 – 216.4 138.2 – 217.5 
2004 26 150.0 108.7 – 197.9 110.9 – 204.2 
2005 52 319.5 244.0 – 406.0 251.7 – 415.9 
2006 56 208.4 169.2 – 259.3 177.2 – 279.6 
2007 82 188.3 158.5 – 223.6 161.6 – 228.6 
2008 98 151.6 130.3 – 174.4 129.8 – 175.2 
2009 283 168.3 148.8 – 191.4 151.4 – 196.9 
2010 452 127.8 116.9 – 139.0 117.4 – 139.6 
2011 865 99.1 89.6 – 109.0 90.2 – 110.3 
2012 2,295 53.6 49.7 – 57.8 49.9 – 58.2 
2013 4,379 35.2 33.5 – 37.0 33.6 – 37.1 
2014 5,014 27.7 26.5 – 29.0 26.5 – 29.0 
Abbreviations: BCa, bias-corrected and accelerated; CI, confidence interval. 
 
 
 
6.4.3 Time Trends in Healthcare Expenditure on Vitamin D Testing and 
Prescribing among Children in Primary Care 
 
6.4.3.1 Main Results Using the Full THIN Study Cohort 
 
Analysis of time trends showed a marked increase in healthcare costs arising from both 
vitamin D prescriptions and tests among children in the full study cohort after 2008 
(Table 6.8 and Figure 6.3). The combined cost of calciferol prescriptions and 25-OH-D 
tests increased from £2,101 per 100,000 person-years in 2008 (95% CI: £1,559 to 
£2,828) to £28,004 per 100,000 person-years in 2014 (95% CI: £26,465 to £29,640). 
 
Liquid formulations of calciferol accounted for 35% of prescriptions, and 76% of 
prescription costs. The majority of calciferol prescriptions (70%, accounting for 75% of 
prescription costs) were for doses higher than those recommended for prophylactic 
supplementation or maintenance therapy (>1,000 international units per day).  
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Table 6.8  Costs of vitamin D prescriptions and tests among children in the full study cohort, in each year between 2000 to 2014. 
Year PY of follow-up 
Calciferol Prescriptions  
 
25-OH-D Tests Combined cost of 
prescriptions & tests 
per 100,000 PY,  
£ (95% CI) 
n Rate per 100,000 PY (95% CI) 
Mean prescription 
cost, £ (95% CI)a 
Cost per 100,000 PY,  
£ (95% CI) n 
Rate per 100,000 
PY (95% CI) 
Cost per 100,000 PY, 
£ (95% CI) b 
2000 437,455 6 1.37  (0.62–3.05) 43.1  (43.1–43.1) 59.1  (26.6–132)  2 0.46  (0.11–1.83) 6.86  (1.72–27.4) 66.0  (28.3–159) 
2001 523,589 10 1.91  (1.03–3.55) 47.2  (35.9–60.8) 90.1  (36.9–216)  4 0.76  (0.29–2.04) 11.5  (4.30–30.5) 102  (41.2–246) 
2002 624,080 10 1.60  (0.86–2.98) 80.5  (45.1–129) 129  (38.9–383)  5 0.80  (0.33–1.92) 12.0  (5.00–28.9) 141  (43.9–412) 
2003 699,008 33 4.72  (3.36–6.64) 175  (136–216) 827  (457–1,437)  12 1.72  (0.97–3.02) 25.8  (14.6–45.3) 852  (472–1,482) 
2004 778,142 29 3.73  (2.59–5.36) 150  (109–198) 559  (282–1,061)  34 4.37  (3.12–6.12) 65.5  (46.8–91.7) 624  (328–1,153) 
2005 818,284 52 6.35  (4.84–8.34) 319  (244–406) 2,030  (1,182–3,386)  44 5.38  (4.00–7.23) 80.7  (60.0–108) 2,111  (1,242–3,494) 
2006 845,216 56 6.63  (5.10–8.61) 208  (169–259) 1,381  (862–2,233)  68 8.05  (6.34–10.2) 121  (95.2–153) 1,502  (958–2,386) 
2007 874,533 82 9.38  (7.55–11.6) 188  (159–224) 1,765  (1,197–2,603)  105 12.0  (9.92–14.5) 180  (149–218) 1,945  (1,346–2,821) 
2008 890,603 98 11.0  (9.03–13.4) 152  (130–174) 1,669  (1,176–2,339)  257 28.9  (25.5–32.6) 433  (383–489) 2,101  (1,559–2,828) 
2009 898,407 283 31.5  (28.0–35.4) 168  (149–191) 5,303  (4,172–6,774)  601 66.9  (61.8–72.5) 1,003  (926–1,087) 6,306  (5,099–7,860) 
2010 880,419 452 51.3  (46.8–56.3) 128  (117–139) 6,561  (5,473–7,826)  983 112  (105–119) 1,675  (1,573–1,783) 8,235  (7,047–9,609) 
2011 888,296 865 97.4  (91.1–104) 99.1  (89.6–109) 9,649  (8,167–11,349)  1,805 203  (194–213) 3,048  (2,911–3,192) 12,697  (11,077–14,541) 
2012 894,047 2,295 257  (246–267) 53.6  (49.7–57.8) 13,768  (12,239–15,454)  3,543 396  (383–410) 5,944  (5,752–6,143) 19,713  (17,990–21,597) 
2013 858,557 4,379 510  (495–525) 35.2  (33.5–37.0) 17,962  (16,585–19,450)  4,994 582  (566–598) 8,725  (8,486–8,970) 26,687  (25,071–28,421) 
2014 778,118 5,014 644  (627–662) 27.7  (26.5–29.0) 17,860  (16,591–19,219)  5,262 676  (658–695) 10,144  (9,873–10,422) 28,004  (26,465–29,640) 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; CI, confidence interval; PY, person-years. 
a Confidence intervals around mean prescription costs were calculated using bootstrapping with the percentile method. 
b The unit cost of a 25-OH-D test was priced at £15. 
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Figure 6.3  Time trends in costs arising from vitamin D prescriptions and tests among 
children in the full study cohort, between 2000 to 2014.a 
 
a Costs of calciferol prescriptions and 25-OH-D tests are shown separately (red and green lines 
respectively), as well as combined (blue line). The dashed lines indicate 95% confidence limits. 
 
 
 
 
6.4.3.2 Sensitivity Analysis Exploring the Impact of Varying the Unit Cost of 25-OH-
D Tests 
 
Table 6.9 and Figure 6.4 show the combined costs of vitamin D prescriptions and tests 
in the full study cohort between 2000 and 2014, using alternative values for the unit 
cost of a 25-OH-D test. The maximal relative difference in combined costs of vitamin D 
prescriptions and tests derived using the minimum (£13) and maximum (£20) values for 
a 25-OH-D test unit cost was 15.1% in 2014. 
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Table 6.9  Costs of vitamin D tests, shown separately and combined with the cost of vitamin D prescriptions, in each year between 2000 to 2014, 
using alternative values for the unit cost of a 25-OH-D test.a 
Year 
Cost of 25-OH-D tests per 100,000 PY, £ (95% CI) Combined cost of 25-OH-D tests and calciferol prescriptions per 100,000 PY, £ (95% CI) 
25-OH-D test unit cost: 
£13 
25-OH-D test unit cost: 
£15 
25-OH-D test unit cost: 
£20 
25-OH-D test unit cost: 
£13 
25-OH-D test unit cost: 
£15 
25-OH-D test unit cost: 
£20 
2000 5.94  (1.49–23.8) 6.86  (1.72–27.4) 9.14  (2.29–36.6) 65.1  (28.1–155) 66.0  (28.3–159) 68.3  (28.9–168) 
2001 9.93  (3.73–26.5) 11.5  (4.30–30.5) 15.3  (5.73–40.7) 100  (40.6–242) 102  (41.2–246) 105  (42.6–257) 
2002 10.4  (4.34–25.0) 12.0  (5.00–28.9) 16.0  (6.67–38.5) 139  (43.2–408) 141  (43.9–412) 145  (45.6–421) 
2003 22.3  (12.7–39.3) 25.8  (14.6–45.3) 34.3  (19.5–60.5) 849  (470–1,476) 852  (472–1,482) 861  (476–1,497) 
2004 56.8  (40.6–79.5) 65.5  (46.8–91.7) 87.4  (62.4–122) 616  (322–1,141) 624  (328–1,153) 646  (344–1,184) 
2005 69.9  (52.0–93.9) 80.7  (60.0–108) 108  (80.0–145) 2,100  (1,234–3,479) 2,111  (1,242–3,494) 2,138  (1,262–3,530) 
2006 105  (82.5–133) 121  (95.2–153) 161  (127–204) 1,486  (945–2,365) 1,502  (958–2,386) 1,542  (989–2,437) 
2007 156  (129–189) 180  (149–218) 240  (198–291) 1,921  (1,326–2,792) 1,945  (1,346–2,821) 2,005  (1,395–2,894) 
2008 375  (332–424) 433  (383–489) 577  (511–652) 2,044  (1,508–2,763) 2,101  (1,559–2,828) 2,246  (1,687–2,992) 
2009 870  (803–942) 1,003  (926–1,087) 1,338  (1,235–1,449) 6,173  (4,975–7,716) 6,306  (5,099–7,860) 6,641  (5,408–8,223) 
2010 1,451  (1,364–1,545) 1,675  (1,573–1,783) 2,233  (2,098–2,377) 8,012  (6,837–9,371) 8,235  (7,047–9,609) 8,794  (7,571–10,203) 
2011 2,642  (2,522–2,766) 3,048  (2,911–3,192) 4,064  (3,881–4,256) 12,290  (10,689–14,116) 12,697  (11,077–14,541) 13,713  (12,047–15,605) 
2012 5,152  (4,985–5,324) 5,944  (5,752–6,143) 7,926  (7,669–8,191) 18,920  (17,223–20,778) 19,713  (17,990–21,597) 21,694  (19,908–23,645) 
2013 7,562  (7,355–7,774) 8,725  (8,486–8,970) 11,633  (11,315–11,961) 25,524  (23,940–27,225) 26,687  (25,071–28,421) 29,596  (27,900–31,411) 
2014 8,791  (8,557–9,032) 10,144  (9,873–10,422) 13,525  (13,164–13,895) 26,651  (25,148–28,251) 28,004  (26,465–29,640) 31,385  (29,756–33,114) 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; CI, confidence interval; PY, person-years. 
a The analysis used the full study cohort. 
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Figure 6.4  Time trends in healthcare costs arising from vitamin D prescriptions and 
tests, using alternative unit costs for 25-OH-D tests.a 
 
a Combined costs of calciferol prescriptions and 25-OH-D tests in the full study cohort between 
2000 and 2014 are shown. 
  
 
 
 
6.4.3.3 Results Using the Linked THIN-HES Study Cohort 
 
Costs of vitamin D prescriptions and tests in the linked THIN-HES study cohort, 
between 2000 and 2014, are shown in Table 6.10. Time trends in the combined cost of 
vitamin D prescriptions and tests observed in the linked THIN-HES study cohort were 
similar to those seen in the full THIN study cohort (Figure 6.5).  
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Table 6.10  Costs of vitamin D prescriptions and tests among children in the linked THIN-HES study cohort, in each year between 2000 to 2014. 
Year PY of follow-up 
Calciferol Prescriptions  
 
25-OH-D Tests Combined cost of 
prescriptions & tests 
per 100,000 PY,  
£ (95% CI) 
n Rate per 100,000 PY (95% CI) 
Mean prescription 
cost, £ (95% CI)a 
Cost per 100,000 PY,  
£ (95% CI) n 
Rate per 100,000 
PY (95% CI) 
Cost per 100,000 PY, £ 
(95% CI) b 
2000 161,897 0 0 - -  1 0.62  (0.09–4.38) 9.27  (1.31–65.8) 9.27  (1.31–65.8) 
2001 180,797 2 1.11  (0.28–4.42) 37.7  (12.3–63.0) 41.7  (3.41–279)  2 1.11  (0.28–4.42) 16.6  (4.15–66.3) 58.3  (7.56–345) 
2002 211,593 0 0 - -  2 0.95  (0.24–3.78) 14.2  (3.55–56.7) 14.2  (3.55–56.7) 
2003 222,486 1 0.45  (0.06–3.19) 9.10  (9.10–9.10) 4.09  (0.58–29.0)  7 3.15  (1.50–6.60) 47.2  (22.5–99.0) 51.3  (23.1–128) 
2004 235,500 4 1.70  (0.64–4.53) 175  (105–210) 297  (66.6–950)  19 8.07  (5.15–12.7) 121  (77.2–190) 418  (144–1,140) 
2005 244,548 17 6.95  (4.32–11.2) 455  (277–653) 3,164  (1,197–7,299)  20 8.18  (5.28–12.7) 123  (79.1–190) 3,286  (1,276–7,489) 
2006 251,499 18 7.16  (4.51–11.4) 188  (156–210) 1,349  (703–2,386)  23 9.15  (6.08–13.8) 137  (91.2–206) 1,486  (794–2,592) 
2007 257,336 17 6.61  (4.11–10.6) 156  (114–196) 1,033  (471–2,085)  44 17.1  (12.7–23.0) 256  (191–345) 1,290  (662–2,430) 
2008 265,314 22 8.29  (5.46–12.6) 120  (71.8–177) 997  (392–2,227)  115 43.3  (36.1–52.0) 650  (542–781) 1,647  (934–3,007) 
2009 270,643 65 24.0  (18.8–30.6) 201  (136–285) 4,818  (2,563–8,717)  240 88.7  (78.1–101) 1,330  (1,172–1,510) 6,148  (3,735–10,226) 
2010 278,167 106 38.1  (31.5–46.1) 123  (97.4–151) 4,696  (3,067–6,983)  431 155  (141–170) 2,324  (2,115–2,554) 7,020  (5,182–9,537) 
2011 284,678 266 93.4  (82.9–105) 75.9  (59.0–97.7) 7,092  (4,887–10,298)  733 257  (240–277) 3,862  (3,593–4,152) 10,954  (8,480–14,450) 
2012 288,818 913 316  (296–337) 47.6  (42.1–53.5) 15,034  (12,448–18,015)  1,385 480  (455–505) 7,193  (6,824–7,582) 22,227  (19,272–25,597) 
2013 283,990 1,604 565  (538–593) 34.7  (31.7–38.0) 19,617  (17,032–22,548)  2,064 727  (696–759) 10,902  (10,441–11,382) 30,519  (27,473–33,931) 
2014 253,097 1,551 613  (583–644) 28.4  (26.3–30.6) 17,397  (15,347–19,700)  1,943 768  (734–803) 11,515  (11,015–12,039) 28,913  (26,361–31,739) 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; CI, confidence interval; PY, person-years. 
a Confidence intervals around mean prescription costs were calculated using bootstrapping with the percentile method. 
b The unit cost of a 25-OH-D test was priced at £15. 
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Figure 6.5  Time trends in healthcare costs arising from vitamin D prescriptions and 
tests, in the full THIN study cohort and in the linked THIN-HES study cohort.a 
 
a Combined costs of calciferol prescriptions and 25-OH-D tests are shown between 2000 and 
2014. 
 
 
 
 
6.4.4 National Cost Estimates for Healthcare Expenditure on Vitamin D Testing 
and Prescribing among Children in Primary Care in England in 2014 
 
Table 6.11 and 6.12 show the observed costs of vitamin D tests and prescriptions 
respectively in the linked THIN-HES study cohort in 2014, stratified by age group, sex, 
and ethnicity. They also show 2014 population estimates for each stratum in England, 
and estimated total costs of vitamin D tests and prescriptions nationally in each 
population stratum. The total cost of vitamin D prescriptions and tests for children in 
primary care in England in 2014 was estimated to be £4.29 million (95% CI: 2.94 to 
6.44), of which the cost of calciferol prescriptions was £2.60 million (95% CI: 1.64 to 
4.20) and the cost of 25-OH-D tests was £1.69 million (95% CI: 1.31 to 2.24). 
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Table 6.11  Stratified costs of vitamin D tests in the linked THIN-HES study cohort and national estimates for England in 2014. 
Stratum Stratified rates and costs of 25-OH-D tests in the study cohort in 2014 a National estimates for England in 2014 
Ethnicity Age group Sex PY of follow-up 
No. of 25-
OH-D tests 
Rate per 100,000 PY 
(95% CI) 
Cost per 100,000 PY, £ 
(95% CI) b 
Population 
estimate 
Cost of 25-OH-D tests, £ 
(95% CI) 
White 
0-4 years Male 27,535 49 178  (134–235) 2,669  (2,017–3,532) 1,337,468 35,701  (26,983–47,237) 
 Female 26,289 42 160  (118–216) 2,396  (1,771–3,243) 1,268,515 30,399  (22,465–41,134) 
5-9 years Male 29,154 69 237  (187–300) 3,550  (2,804–4,495) 1,298,411 46,096  (36,407–58,362) 
 Female 27,975 77 275  (220–344) 4,129  (3,302–5,162) 1,233,489 50,927  (40,733–63,672) 
10-14 years Male 25,984 99 381  (313–464) 5,715  (4,693–6,959) 1,224,417 69,976  (57,465–85,212) 
 Female 24,244 111 458  (380–551) 6,868  (5,702–8,272) 1,166,551 80,115  (66,515–96,495) 
15-17 years Male 15,878 70 441  (349–557) 6,613  (5,232–8,359) 802,058 53,041  (41,964–67,042) 
 Female 15,177 224 1,476  (1,295–1,682) 22,139  (19,421–25,236) 762,486 168,806  (148,086–192,424) 
Asian 
0-4 years Male 2,271 48 2,113  (1,593–2,804) 31,701  (23,890–42,066) 179,903 57,030  (42,978–75,677) 
 Female 2,299 37 1,609  (1,166–2,221) 24,139  (17,489–33,316) 172,680 41,683  (30,201–57,530) 
5-9 years Male 2,343 87 3,713  (3,009–4,581) 55,690  (45,136–68,713) 171,776 95,663  (77,533–118,032) 
 Female 2,180 97 4,449  (3,646–5,428) 66,733  (54,690–81,426) 164,570 109,822  (90,004–134,003) 
10-14 years Male 1,672 82 4,905  (3,951–6,091) 73,580  (59,260–91,361) 134,858 99,229  (79,917–123,208) 
 Female 1,709 121 7,080  (5,924–8,461) 106,196  (88,864–126,908) 127,544 135,447  (113,341–161,864) 
15-17 years Male 843 46 5,460  (4,089–7,289) 81,893  (61,340–109,332) 80,239 65,710  (49,218–87,727) 
 Female 834 117 14,029  (11,704–16,816) 210,433  (175,558–252,237) 74,448 156,663  (130,699–187,785) 
Black 
0-4 years Male 1,198 11 918  (508–1,658) 13,771  (7,626–24,866) 91,967 12,664  (7,014–22,868) 
 Female 1,150 17 1,478  (919–2,378) 22,176  (13,786–35,672) 89,322 19,808  (12,314–31,863) 
5-9 years Male 1,382 31 2,243  (1,578–3,190) 33,652  (23,666–47,850) 86,319 29,048  (20,428–41,304) 
 Female 1,401 30 2,141  (1,497–3,062) 32,116  (22,455–45,933) 84,422 27,113  (18,957–38,778) 
10-14 years Male 1,125 26 2,311  (1,574–3,394) 34,667  (23,604–50,916) 70,192 24,334  (16,568–35,739) 
 Female 1,099 58 5,279  (4,081–6,829) 79,187  (61,219–102,428) 69,190 54,789  (42,357–70,870) 
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Table 6.11  continued. 
Stratum Stratified rates and costs of 25-OH-D tests in the study cohort in 2014 a National estimates for England in 2014 
Ethnicity Age group Sex PY of follow-up 
No. of 25-
OH-D tests 
Rate per 100,000 PY 
(95% CI) 
Cost per 100,000 PY, £ 
(95% CI) b 
Population 
estimate 
Cost of 25-OH-D tests, £ 
(95% CI) 
Black 
15-17 years Male 688 13 1,891  (1,098–3,256) 28,361  (16,468–48,843) 42,733 12,120  (7,037–20,872) 
 Female 718 54 7,518  (5,758–9,816) 112,766  (86,367–147,236) 42,508 47,935  (36,713–62,587) 
Mixed 
0-4 years Male 1,083 4 369  (139–984) 5,540  (2,079–14,761) 113,209 6,272  (2,354–16,711) 
 Female 1,045 6 574  (258–1,278) 8,613  (3,869–19,171) 109,334 9,417  (4,231–20,961) 
5-9 years Male 1,153 10 867  (467–1,612) 13,007  (6,998–24,174) 89,212 11,604  (6,243–21,566) 
 Female 1,163 6 516  (232–1,149) 7,740  (3,477–17,229) 86,002 6,657  (2,991–14,817) 
10-14 years Male 683 12 1,758  (998–3,096) 26,371  (14,976–46,435) 67,736 17,862  (10,144–31,453) 
 Female 666 21 3,151  (2,055–4,833) 47,272  (30,821–72,502) 65,479 30,953  (20,182–47,473) 
15-17 years Male 318 6 1,887  (848–4,201) 28,310  (12,718–63,014) 38,506 10,901  (4,897–24,264) 
 Female 272 8 2,938  (1,469–5,875) 44,075  (22,042–88,132) 37,094 16,349  (8,176–32,692) 
Other 
0-4 years Male 654 6 918  (412–2,043) 13,766  (6,184–30,641) 35,194 4,845  (2,177–10,784) 
 Female 635 2 315  (79–1,259) 4,724  (1,182–18,890) 33,366 1,576  (394–6,303) 
5-9 years Male 561 8 1,427  (713–2,852) 21,398  (10,701–42,787) 29,430 6,297  (3,149–12,592) 
 Female 589 6 1,018  (457–2,266) 15,268  (6,860–33,986) 28,733 4,387  (1,971–9,765) 
10-14 years Male 579 11 1,899  (1,052–3,429) 28,488  (15,777–51,442) 24,294 6,921  (3,833–12,497) 
 Female 541 26 4,802  (3,270–7,053) 72,034  (49,046–105,797) 22,794 16,419  (11,179–24,115) 
15-17 years Male 441 7 1,587  (757–3,330) 23,810  (11,351–49,943) 18,551 4,417  (2,106–9,265) 
 Female 379 18 4,750  (2,993–7,540) 71,253  (44,893–113,093) 16,702 11,901  (7,498–18,889) 
TOTAL 225,910 1,773 - - 11,591,701 1,690,895 (1,307,422–2,236,434) 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D; CI, confidence interval; PY, person-years. 
a Missing data for ethnicity was handled using complete cases analysis. N = 268,221.  
b The unit cost of a 25-OH-D test was priced at £15. 
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Table 6.12  Stratified costs of vitamin D prescriptions in the linked THIN-HES study cohort and national estimates for England in 2014. 
Stratum Stratified rates and costs of calciferol prescriptions in the study cohort in 2014 a National estimates for England in 2014 
Ethnicity Age, years Sex 
PY of 
follow-up 
No. of 
prescriptions 
Rate per 100,000 PY 
(95% CI) 
Mean unit cost, 
£ (95% CI) b 
Cost per 100,000 PY, £ 
(95% CI) 
Population 
estimate 
Cost of calciferol 
prescriptions, £ (95% CI) 
White 
0–4 Male 27,535 29 105  (73–152) 57.3  (48.3–66.3)  6,037  (3,537–10,050) 1,337,468 80,743  (47,307–134,420) 
 Female 26,289 11 42  (23–76) 57.3  (48.3–66.3)  2,398  (1,120–5,010) 1,268,515 30,424  (14,205–63,556) 
5–9 Male 29,154 78 268  (214–334) 47.9  (41.8–54.0) 12,818  (8,967–18,030) 1,298,411 166,435  (116,430–234,101) 
 Female 27,975 31 111  (78–158) 47.9  (41.8–54.0) 5,309  (3,261–8,505) 1,233,489 65,487  (40,223–104,910) 
10–14 Male 25,984 114 439  (365–527) 22.6  (19.4–25.8) 9,904  (7,073–13,588) 1,224,417 121,265  (86,608–166,372) 
 Female 24,244 87 359  (291–443) 22.6  (19.4–25.8) 8,101  (5,634–11,413) 1,166,551 94,498  (65,722–133,139) 
15–17 Male 15,878 60 378  (293–487) 16.3  (13.9–18.6) 6,142  (4,092–9,033) 802,058 49,262  (32,821–72,450) 
 Female 15,177 148 975  (830–1,146) 16.3  (13.9–18.6) 15,850  (11,576–21,263) 762,486 120,851  (88,269–162,126) 
Asian 
0–4 Male 2,271 25 1,101  (744–1,629) 57.3  (48.3–66.3)  63,094  (35,944–108,023) 179,903 113,507  (64,664–194,337) 
 Female 2,299 19 826  (527–1,296) 57.3  (48.3–66.3)  47,368  (25,473–85,912) 172,680 81,795  (43,987–148,353) 
5–9 Male 2,343 55 2,347  (1,802–3,057) 47.9  (41.8–54.0) 112,450  (75,402–165,012) 171,776 193,163  (129,523–283,452) 
 Female 2,180 42 1,926  (1,424–2,607) 47.9  (41.8–54.0) 92,290  (59,568–140,694) 164,570 151,881  (98,031–231,540) 
10–14 Male 1,672 74 4,427  (3,525–5,560) 22.6  (19.4–25.8) 99,929  (68,279–143,307) 134,858 134,763  (92,080–193,262) 
 Female 1,709 129 7,548  (6,352–8,969) 22.6  (19.4–25.8) 170,383  (123,034–231,203) 127,544 217,313  (156,923–294,886) 
15–17 Male 843 45 5,341  (3,988–7,153) 16.3  (13.9–18.6) 86,806  (55,614–132,762) 80,239 69,652  (44,624–106,527) 
 Female 834 130 15,588  (13,126–18,511) 16.3  (13.9–18.6) 253,350  (183,059–343,567) 74,448 188,613  (136,284–255,778) 
Black 
0–4 Male 1,198 17 1,419  (882–2,282) 57.3  (48.3–66.3)  81,326  (42,625–151,346) 91,967 74,793  (39,201–139,188) 
 Female 1,150 7 609  (290–1,277) 57.3  (48.3–66.3)  34,894  (14,025–84,678) 89,322 31,168  (12,528–75,636) 
5–9 Male 1,382 21 1,520  (991–2,331) 47.9  (41.8–54.0) 72,812  (41,462–125,814) 86,319 62,850  (35,790–108,601) 
 Female 1,401 23 1,641  (1,091–2,470) 47.9  (41.8–54.0) 78,643  (45,643–133,330) 84,422 66,393  (38,533–112,561) 
10–14 Male 1,125 36 3,200  (2,308–4,436) 22.6  (19.4–25.8) 72,238  (44,714–114,355) 70,192 50,705  (31,385–80,268) 
 Female 1,099 65 5,916  (4,639–7,544) 22.6  (19.4–25.8) 133,552  (89,870–194,470) 69,190 92,405  (62,181–134,554) 
  231 
Table 6.12  continued. 
Stratum Stratified rates and costs of calciferol prescriptions in the study cohort in 2014 a National estimates for England in 2014 
Ethnicity Age, years Sex 
PY of 
follow-up 
No. of 
prescriptions 
Rate per 100,000 PY 
(95% CI) 
Mean unit cost, 
£ (95% CI) b 
Cost per 100,000 PY, £ 
(95% CI) 
Population 
estimate 
Cost of calciferol 
prescriptions, £ (95% CI) 
Black 
15–17 Male 688 13 1,891  (1,098–3,256) 16.3  (13.9–18.6) 30,731  (15,311–60,435) 42,733 13,132  (6,543–25,826) 
 Female 718 52 7,239  (5,516–9,500) 16.3  (13.9–18.6) 117,662  (76,935–176,325) 42,508 50,016  (32,704–74,953) 
Mixed 
0–4 Male 1,083 3 277  (89–859) 57.3  (48.3–66.3)  15,878  (4,318–56,955) 113,209 17,975  (4,888–64,478) 
 Female 1,045 7 670  (319–1,405) 57.3  (48.3–66.3)  38,398  (15,434–93,182) 109,334 41,983  (16,874–101,879) 
5–9 Male 1,153 10 867  (467–1,612) 47.9  (41.8–54.0) 41,544  (19,523–86,989) 89,212 37,062  (17,417–77,605) 
 Female 1,163 1 86  (12–611) 47.9  (41.8–54.0) 4,120  (507–32,955) 86,002 3,544  (436–28,341) 
10–14 Male 683 8 1,172  (586–2,344) 22.6  (19.4–25.8) 26,457  (11,354–60,410) 67,736 17,921  (7,691–40,919) 
 Female 666 15 2,251  (1,357–3,734) 22.6  (19.4–25.8) 50,814  (26,288–96,247) 65,479 33,273  (17,213–63,022) 
15–17 Male 318 9 2,831  (1,473–5,441) 16.3  (13.9–18.6) 46,012  (20,543–100,982) 38,506 17,717  (7,910–38,884) 
 Female 272 5 1,836  (764–4,412) 16.3  (13.9–18.6) 29,848  (10,660–81,888) 37,094 11,072  (3,954–30,376) 
Other 
0–4 Male 654 1 153  (22–1,086) 57.3  (48.3–66.3)  8,767  (1,041–72,005) 35,194 3,086  (366–25,341) 
 Female 635 2 315  (79–1,259) 57.3  (48.3–66.3)  18,053  (3,807–83,511) 33,366 6,024  (1,270–27,864) 
5–9 Male 561 7 1,248  (595–2,618) 47.9  (41.8–54.0) 59,802  (24,899–141,324) 29,430 17,600  (7,328–41,592) 
 Female 589 12 2,036  (1,156–3,585) 47.9  (41.8–54.0) 97,535  (48,377–193,492) 28,733 28,025  (13,900–55,596) 
10–14 Male 579 9 1,554  (809–2,986) 22.6  (19.4–25.8) 35,078  (15,662–76,982) 24,294 8,522  (3,805–18,702) 
 Female 541 21 3,879  (2,529–5,949) 22.6  (19.4–25.8) 87,559  (48,989–153,345) 22,794 19,958  (11,166–34,953) 
 15–17 Male 441 3 680  (219–2,109) 16.3  (13.9–18.6) 11,057  (3,060–39,147) 18,551 2,051  (568–7,262) 
  Female 379 12 3,167  (1,798–5,576) 16.3  (13.9–18.6) 51,471  (25,082–103,495) 16,702 8,597  (4,189–17,286) 
TOTAL 225,910 1,436 - - - 11,591,701 2,595,523 (1,635,542–4,204,896) 
Abbreviations: CI, confidence interval; PY, person-years. 
a Missing data for ethnicity was handled using complete cases analysis. N = 268,221.  
b The mean unit costs for calciferol prescriptions in each age group category, see Table 6.4. 
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6.5 Discussion 
 
 
6.5.1 Summary of Results and Comparison with Existing Studies 
 
Among children in the UK, a marked increase in healthcare expenditure on vitamin D 
tests and prescriptions in primary care was observed between 2008 and 2014. The 
magnitude of the increase was approximately 13-fold. This mirrors trends in the 
diagnosis of vitamin D deficiency in children in clinical practice over the same time-
period, described in chapter 5. Applying the observed rates of expenditure in the study 
cohort to national population estimates, the overall cost of vitamin D testing and 
prescribing for children in primary care in England in 2014 was estimated to be £4.29 
million (95% CI: 2.94 to 6.44). 
 
This is the first study to report estimates for healthcare expenditure related to vitamin D 
testing and treatment specifically among children. However previous publications, 
described below, have reported time trends in healthcare costs arising from vitamin D 
tests and prescriptions among general populations, including adults as well as children. 
These have generally reported a similar pattern to the results described in this chapter, 
with large increases in expenditure observed over the last decade. Overall NHS 
expenditure on vitamin D prescriptions dispensed by community pharmacies in 
England, reported in Prescription Cost Analysis data, increased from £28 million in 
2004 to £92 million in 2014 (HSCIC, 2005; 2015b). National healthcare expenditure on 
25-OH-D tests in Australia is reported to have increased from $1 million Australian 
dollars in 2000 to $95.6 million Australian dollars in 2010 (Bilinski & Boyages, 2012), 
whilst expenditure on vitamin D tests in the Ontario province of Canada increased from 
$38 million Canadian dollars in 2009 to a projected $150 million Canadian dollars in 
2012 (Bilinski & Boyages, 2012).  
 
Variation in the average cost of calciferol prescriptions for children was observed over 
the study period. Between 2003 to 2010 the mean prescription cost was greater than 
£100, and then decreased between 2011 and 2014 to £27.72. This may reflect efforts 
by local commissioning groups and pharmacy services in more recent years to 
encourage the prescription of less costly vitamin D products (Rehman & Rai, 2012). 
However, it should be noted that the unit costs for different calciferol preparations were 
kept constant at 2014 prices in the analyses, and therefore changes in the price of 
different preparations over time were not taken into account. This approach was taken 
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to ensure that that analysis of time-trends in expenditure represented changes in levels 
of healthcare activity over time rather than changes in the monetary value of drugs. 
 
 
6.5.2 Study Strengths 
 
THIN is a prospectively collected database of electronic healthcare records from UK 
primary care. As it contains routine consultation data, it is representative of real life, 
contemporary clinical practice. The longitudinal nature of the data allowed investigation 
of trends in the healthcare expenditure over time. The large sample size of the THIN 
database allowed stratification of rates of expenditure on vitamin D tests and 
prescriptions by several demographic factors (age group, sex, and ethnicity).  
 
The vast majority of the UK population is registered with a general practice, and the 
THIN cohort has been shown to be broadly representative of the UK population as a 
whole in terms of age and sex distribution, mortality rates, and the prevalence of 
various chronic medical conditions (Blak et al, 2011). Furthermore, the recording of 
consultations and prescriptions in THIN practices is comparable to national primary 
care statistics (Bourke et al, 2004). Therefore, the results of the study should be 
broadly generalisable to children in the UK as a whole. 
 
Medication prescriptions in primary care are particularly well recorded in THIN, as they 
are issued electronically by general practitioners (GPs) and automatically captured in 
the electronic patient record (Thiru et al, 2003). Laboratory test results are also well 
recorded, as the majority of THIN practices are electronically linked to pathology 
laboratories, with the results of tests requested in primary care sent electronically to 
practices and automatically stored in patients’ electronic health records (CSDMRUK, 
2010). Therefore, healthcare resource use regarding vitamin D prescription and testing 
in primary care is likely to have been accurately captured using the THIN data source. 
 
 
6.5.3 Study Limitations 
 
A key limitation of the study is that only healthcare costs are examined, without 
investigation of health benefits resulting from vitamin D testing and prescribing in 
children. Thus, the work represents a cost of illness study as opposed to a full health 
economic evaluation, and does not on its own provide information regarding whether or 
not the expenditure is an efficient use of healthcare resources (Byford et al, 2000). It 
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was not possible to estimate potential health benefits of treatment from the data 
available in the THIN database, as reliable information was not available regarding the 
clinical condition, or indications for testing and treatment, among cases (see chapter 
5.4.6). There are no previous studies that have investigated the clinical presentation of 
children diagnosed with vitamin D deficiency in primary care, and therefore this 
information was not available from existing work. 
 
A further important limitation of the study is that the results represent a proportion of, 
rather than total, direct healthcare costs for the NHS associated with vitamin D 
deficiency diagnosis and treatment in children. The study is limited to healthcare 
resource use in primary care, as the costs of vitamin D prescribing and testing in 
secondary care were not captured. Furthermore, reliable resource use data was not 
available regarding healthcare consultations arising as a direct consequence of the 
investigation or management of vitamin D deficiency. Although data regarding GP 
consultations and referrals to secondary care are recorded in THIN, information 
regarding the principal clinical reason for consultation episodes is not specifically 
coded. Therefore, it was not possible to reliably determine whether consultation 
episodes in patients’ medical records were primarily related to the investigation or 
management of vitamin D deficiency, or had arisen as a result of other clinical 
symptoms or comorbidities with vitamin D deficiency a secondary issue.  
 
There was a substantial degree of uncertainty, with relatively wide 95% confidence 
intervals, around the derived national cost estimates for children in England in 2014. 
This was particularly the case for the estimated cost of calciferol prescriptions. Factors 
contributing to this uncertainty included the small numbers of outcome events in some 
of the population strata, and the uncertainty around the mean calciferol prescription 
cost estimates. 
 
Other relevant limitations of THIN and HES data, including the under-representation of 
individuals from the most deprived areas of the country in THIN, and issues concerning 
the accuracy of ethnicity recording, have been discussed in chapter 5.5.3. 
 
 
6.5.4 Conclusion 
 
In summary, the results described in this chapter demonstrate that there has been a 
marked increase in healthcare expenditure on vitamin D tests and prescriptions for 
children in primary care in the UK between 2008 and 2014. The results do not 
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represent total NHS healthcare expenditure associated with the diagnosis and 
management of vitamin D deficiency among children. However, they do give some 
insight into the economic consequence of the increase in diagnosis of vitamin D 
deficiency among children in clinical practice over the last decade, described in chapter 
5. The implications of the work described in this chapter, with respect to health 
services, clinical practice and future research, are discussed in the final chapter of the 
thesis.  
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7.1 Introduction 
 
Vitamin D has attracted considerable clinical and academic interest over the last two 
decades. In relation to child health, there are concerns that clinical complications of 
vitamin D deficiency have increased in frequency among children in developed 
countries such as the UK, USA, and Australia (Ahmed et al, 2011; Allgrove, 2004; 
Holick, 2006; Robinson et al, 2006; Shaw & Pal, 2002). In the UK, this has generated 
criticism of national public health policy regarding the prevention of vitamin D deficiency 
(Davies & Shaw, 2011; Högler, 2015; Hyppönen & Boucher, 2010), and prompted the 
Department of Health to commission a review of the Healthy Start vitamin programme 
(Lemer, 2013; NICE, 2015). However, these concerns have largely been based upon 
anecdotal reports and local case series, and quantitative evaluation of the 
epidemiology of symptomatic vitamin D deficiency has been limited.  
 
There has also been considerable debate and controversy regarding the possibility that 
vitamin D may have clinically relevant physiological activity beyond its established role 
in calcium and bone metabolism, and that vitamin D deficiency may increase the risk of 
various non-musculoskeletal diseases (SACN, 2016; Theodoratou et al, 2014). As 
vitamin D has attracted increasing attention, large increases in vitamin D testing and 
prescribing have been reported in adult practice over the last decade, with significant 
associated healthcare costs (Bilinski & Boyages, 2012; 2013; HSCIC, 2005; 2015b). 
However, the influence of the increased interest in vitamin D on paediatric clinical 
practice has not been explored. 
 
The overall aims of the studies described in this thesis were to examine the 
epidemiology of symptomatic vitamin D deficiency in children, explore temporal trends 
in the diagnosis of vitamin D deficiency in clinical practice, and investigate healthcare 
expenditure related to vitamin D testing and prescribing in children. In this chapter, the 
main results from the work described in the thesis are summarised. The implications of 
the research findings for public health policy, health services and clinical practice are 
discussed, and recommendations for future research are made. 
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7.2 Summary of the Thesis and its Main Findings  
 
 
7.2.1 Epidemiology of Symptomatic Vitamin D Deficiency in Children 
 
Chapter 3 set out to systematically review the published literature regarding the 
incidence of symptomatic vitamin D deficiency among children worldwide, between 
1990 and 2016. Thirteen unique studies were identified, the majority of which 
originated from Europe and North America. There was considerable heterogeneity 
among the included studies with respect to their study populations, clinical outcomes, 
and methodological characteristics. There was also a large variation in the quality of 
included studies, and their assessed risk of bias. 
 
When considering the subset of higher-quality studies considered to have a lower risk 
of bias, it was possible to gain some insight into the epidemiology of symptomatic 
vitamin D deficiency among children from high-income countries with populations of 
predominantly Caucasian ethnicity. Data is lacking from other regions of the world, 
including Africa, Asia, the Middle East, and South America. Among studies that 
included both children presenting with musculoskeletal features of rickets and children 
with sequelae of hypocalcaemia, annual incidence estimates ranged between 2.2 to 
7.5 per 100,000 children. A pooled summary estimate for the annual incidence of 
symptomatic vitamin D deficiency, derived from four of the higher quality studies, was 
3.37 per 100,000 children aged from birth to adolescence (95% CI: 2.15 to 4.60). The 
pooled incidence estimate should be interpreted with caution, given the high level of 
statistical heterogeneity observed (I2 = 88%). 
 
Although few studies examined differences in the incidence of symptomatic vitamin D 
deficiency in relation to children’s demographic characteristics, the limited data 
available suggests that its incidence is considerably higher among young children aged 
≤2 years compared to older children, and among children from South Asian, black and 
Middle Eastern ethnic minority groups compared to white children. Although anecdotal 
reports and local case series have raised concerns that symptomatic vitamin D 
deficiency may have increased in frequency among children in high-income countries 
in recent decades, there is insufficient epidemiological data available to draw any 
conclusions regarding temporal trends in incidence over the last 25 years. 
 
Although the systematic review involved a comprehensive search of the published 
literature, using multiple bibliographic databases, unpublished literature was not 
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specifically sought, and study assessment was undertaken by a single researcher as 
opposed to independent double screening as recommended by published guidelines 
(Liberati et al, 2009). In view of the limited number of included studies, it was not 
possible to perform subgroup analysis to investigate sources of heterogeneity, or meta-
regression to examine differences in incidence rates in relation to demographic factors. 
 
The systematic review identified that the few existing studies investigating symptomatic 
vitamin D deficiency among UK children were regional studies, with limited 
generalisability to the national population. The prospective surveillance study described 
in chapter 4 set out to determine the incidence of one of the most common acute 
presentations of vitamin D deficiency, hypocalcaemic seizures, nationally among 
children across the UK and Ireland using the British Paediatric Surveillance Unit 
reporting system. There were 92 confirmed or probable cases reported over a 2-year 
study period between September 2011 to September 2013, equating to an overall 
annual incidence of 3.53 per million children aged 0 to 15 years (95% CI: 2.84 to 4.33). 
 
Hypocalcaemic seizures secondary to vitamin D deficiency were observed in two 
distinct age groups; young children aged between 0 to 2 years, and adolescents. The 
highest incidence was among infants aged <1 year. Incidence was 4-fold higher among 
males compared to females, and was considerably higher among children from South 
Asian and black ethnic groups compared to those from white ethnic backgrounds. 
Overall, clinical outcomes were good, with no deaths reported and one child reported 
to have sequelae at the time of discharge (an extravasation injury from intravenous 
calcium gluconate). In a minority of cases (13%), it was reported that children did not 
receive vitamin D replacement in the form of treatment doses of colecalciferol or 
ergocalciferol, as recommended by national and international guidelines, and instead 
received only multivitamin supplements or activated analogues of vitamin D. 
 
This is the first study in the UK to report national incidence estimates for any of the 
clinical manifestations of vitamin D deficiency. However, it is limited to one of the acute 
presentations of vitamin D deficiency, and does not represent the overall health burden 
caused by vitamin D deficiency in childhood. The main strength of the study was the 
use of an established active surveillance system, with national coverage, and 
consistently high response rates. However, a degree of under-ascertainment of cases 
is likely with any voluntary surveillance system, and there was no additional secondary 
source of case ascertainment available for the study outcome. Furthermore, it was not 
possible to confirm case status for a minority (7%) of reported cases. In some cases 
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pathology other than vitamin D deficiency may have contributed to the development of 
hypocalcaemia, such as immaturity of the parathyroid axis in neonates. 
 
 
 
7.2.2 Trends in the Diagnosis of Vitamin D Deficiency in Children, and 
Associated Cost Implications 
 
The cohort study described in chapter 5 set out to determine temporal trends in the 
diagnosis of vitamin D Deficiency in children in clinical practice, and explore differences 
in diagnosis by children’s socio-demographic characteristics. The study utilised 
prospectively collected electronic healthcare records from UK primary care, held in the 
Health Improvement Network (THIN) database. Linked Hospital Episode Statistics 
(HES) data, available for a subset of the cohort, was used to maximise the availability 
of data regarding ethnicity. Missing data for ethnicity was further minimised by linkage 
of children to mothers, and use of maternal ethnicity as a proxy measure for children 
whose ethnicity was not recorded. 
 
A marked increase in the diagnosis of vitamin D deficiency in clinical practice was 
observed among children in the UK over the past decade. Between 2000 and 2008, 
overall rates of diagnosis of vitamin D deficiency were below 10 per 100,000 person-
years. Between 2008 and 2013 this increased to over 200 per 100,000 person-years, 
after which rates plateaued between 2013 to 2014. After accounting for temporal 
changes in socio-demographic characteristics of the cohort, an increase in diagnosis of 
approximately 15-fold (95% CI: 10 to 21) was seen between 2008 to 2014. 
 
Vitamin D deficiency was diagnosed considerably more frequently in children from 
South Asian and black ethnic minority groups compared to those from white ethnic 
backgrounds. Diagnosis was more common in older compared to younger children, 
and among children from more deprived backgrounds. Among older children aged ≥10 
years, rates of diagnosis were higher in girls compared to boys. 
 
The THIN dataset is large and representative of real life clinical practice. The THIN 
cohort has been shown to be broadly representative of the UK population as a whole in 
terms of age and sex distribution, mortality rates, prevalence of chronic medical 
conditions, and primary care consultation and prescription rates. (Blak et al, 2011; 
Bourke et al, 2004). Therefore, the results of the study should be broadly generalisable 
to children in the UK as a whole. However, THIN has been shown to be somewhat 
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under-representative of individuals from the most deprived areas. Although vitamin D 
prescriptions and tests were included in the case definition to minimise case under-
ascertainment, it is possible that some cases may still have been missed. For example, 
children who were diagnosed and received their full course of treatment in secondary 
care would have been missed if the diagnosis was not subsequently entered into the 
primary care record from hospital correspondence. A key limitation of the data was 
poor recording of information regarding the clinical presentation of cases, which 
prevented meaningful exploration of the clinical indications prompting investigation of 
vitamin D status in children.  
 
The cohort study described in chapter 6 set out to the explore the economic 
implications of the change in diagnostic behaviour identified in chapter 5. Using the 
THIN database, the study examined longitudinal trends in healthcare expenditure 
arising from vitamin D testing and prescribing among children in primary care, and 
demonstrated a marked increase in expenditure of approximately 13-fold between 
2008 (£2,101 per 100,000 person-years,) and 2014 (£28,004 per 100,000 person-
years). Applying the observed rates of expenditure in the study cohort to national 
population estimates, the overall cost of vitamin D testing and prescribing for children in 
primary care in England in 2014 was estimated to be £4.29 million (95% CI: 2.94 to 
6.44). The observed increase in expenditure mirrors trends in healthcare spending on 
vitamin D tests and prescriptions reported in adult practice in England, Australia, and 
Canada over the last decade (Bilinski & Boyages, 2012; 2013; HSCIC, 2005; 2015b). 
 
Data regarding prescriptions issued in primary care and laboratory test results are 
particularly well recorded in THIN, as a result of computerised prescribing and 
electronic linkage with laboratory services. However, the study was limited to 
healthcare resource use in primary care, and did not capture the costs of vitamin D 
testing and prescribing in secondary care. Furthermore, reliable resource use data was 
not available for GP consultations, referrals to secondary care or hospital admissions, 
as it was not known whether episodes in patient’s medical records were primarily 
related to the investigation or management of vitamin D deficiency, or had arisen as a 
result of other clinical symptoms or comorbidities with vitamin D deficiency a secondary 
issue. Therefore, the results do not represent total National Health Service (NHS) 
healthcare expenditure associated with the diagnosis and management of vitamin D 
deficiency among children, although they do indicate a clear trend for increasing costs 
over the last decade. 
 
 
Chapter 7. Discussion 
 
 243 
7.3 Implications for Public Health  
 
The results from the systematic review and the BPSU surveillance study demonstrate 
that, whilst uncommon, symptomatic complications of vitamin D deficiency are 
occurring among children in the UK and in other high income countries with 
predominantly Caucasian populations. In these settings, children from high-risk ethnic 
minority groups, namely those from South Asian, black, and Middle Eastern 
backgrounds, are disproportionately affected. However, severe complications of 
vitamin D deficiency are not limited to children from high-risk ethnic groups and, 
although rare, also occur in children from white backgrounds.  
 
Although uncommon, symptomatic vitamin D deficiency can cause considerable 
morbidity amongst affected children. Almost all of the children with hypocalcaemic 
seizures in the BPSU study required admission to hospital, for a median duration of 3 
days, and many required treatment with medications such as intravenous calcium 
gluconate which are associated with a risk of complications. Children with rickets 
commonly experience debilitating symptoms such as chronic musculoskeletal pain, 
skeletal deformity, and delay in gross motor development. 
 
Whilst uncommon, symptomatic vitamin D deficiency is inherently preventable, 
provided that individuals either synthesise sufficient vitamin D endogenously in the skin 
through adequate sunlight exposure, or have adequate intake of vitamin D from 
fortified foods or supplements. The results from the BPSU surveillance study, and from 
the regional UK studies identified in the systematic review, suggest that the current 
implementation of public health policy in the UK is not effective in preventing children 
from developing significant clinical complications of vitamin D deficiency. Public health 
policy in this area should be reviewed and reconsidered, with the aim of achieving a 
reduction in the incidence of symptomatic vitamin D deficiency in children. 
 
The current public health approach regarding the prevention of vitamin D deficiency in 
the UK is based upon the recommendation of vitamin D supplementation for high-risk 
population groups (see chapter 2.8). Although the Department of Health (DoH) 
recommends that prophylactic vitamin D supplements are taken by all pregnant and 
lactating women, and all children from birth to 5 years who consume less than 500ml of 
infant formula milk per day, in most areas of the country supplements are provided free 
of charge only to low-income families through the Healthy Start scheme. Uptake rates 
for Healthy Start vitamins among eligible families have been reported to be very low 
(<10%) across the country (Jessiman et al, 2013; Moonan et al, 2012). Reasons that 
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have been suggested for the poor uptake of Healthy Start vitamins include poor 
accessibility with limited distribution points for the vitamins, a lack of awareness among 
eligible families, and poor promotion of the scheme by healthcare professionals 
(Jessiman et al, 2013). The overall use of vitamin supplements, whether Healthy Start 
or other brands, by children in the general population is also low, with only 9% to 14% 
of breastfed infants aged <1 year receiving vitamin drops (McAndrew et al, 2012). 
Knowledge regarding the DoH recommendations for vitamin D supplementation among 
various groups of health professionals involved in the care of pregnant women and 
young children, as well as among parents, has been shown to be limited (Cleghorn, 
2006; Jain et al, 2011; Sharma et al, 2011; Zipitis et al, 2011). 
 
In order for a prevention policy based upon vitamin D supplementation to be effective, 
it is clear that the uptake of supplements among pregnant women and children needs 
to be considerably higher than current rates. One approach that has been suggested to 
achieve this is to move from a policy of targeted provision of supplements based upon 
income, to universal provision of supplements to all pregnant women and young 
children. In response to a recommendation from the Child Medical Officer for England 
(Lemer, 2013), the DoH commissioned the National Institute for Health and Care 
Excellence (NICE) to examine the cost effectiveness of moving the Healthy Start 
vitamin programme from the current targeted offering to a universal scheme (NICE, 
2015). However, the analysis was limited by a lack of quality of life data for vitamin D 
deficiency, which meant that quality-adjusted life years (QALYs) could not be assigned 
to the effects of vitamin D supplementation in the model. As a result of this, the impact 
of folic acid supplementation had a dominant effect on the results of the cost-
effectiveness modelling. Folic acid is contained in the Healthy Start vitamin tablets for 
women, and supplementation prior to and during the early stages of pregnancy 
considerably reduces the risk of neural tube defects in offspring. QALY data was 
available for the most common type of neural tube defect, spina bifida. The results 
suggested that universal provision of Healthy Start vitamins could be cost effective, 
with an estimated incremental cost-effectiveness ratio (ICER) of £6,528 per QALY 
gained, provided that the scheme was extended to include women planning pregnancy 
and those less than 10 weeks pregnant, due to a reduction in children born with neural 
tube defects. NICE uses an ICER threshold range of between £20,000 to £30,000 per 
QALY gained for the assessment of the cost-effectiveness of healthcare interventions 
(McCabe et al, 2008). In view of the absence of health utility data for vitamin D 
deficiency, it was not possible for the authors to specifically model the cost-
effectiveness of universal provision of vitamin D supplements. 
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In a limited number of areas of the UK, local schemes have been introduced to make 
free of charge Healthy Start vitamin supplements universally available for all pregnant 
and lactating women and young children. One such programme was introduced in the 
Heart of Birmingham Primary Care Trust catchment area, in inner-city Birmingham, in 
2006 (Moy et al, 2012). Families were given an initial bottle of vitamins by their health 
visitor at the time of the first new baby home visit at 2 to 4 weeks of age, however they 
were required to obtain further bottles from certain issuing sites (health centres, 
children’s centres, and some community pharmacies and GP practices). In addition, 
the programme involved education of health care staff involved in the care of pregnant 
women and children, and targeted dissemination of information to the public through 
local media networks and Asian food retailers. The scheme achieved modest increases 
in uptake rates of Healthy Start vitamin supplements. Between 2 years (2008-2009) to 
6 years (2012-2013) after the introduction of the programme, uptake rates of children’s 
supplements increased from 7% to 20%, and of women’s supplements from 4% to 23% 
(McGee & Shaw, 2013). However, the impact of the publicity campaign on the uptake 
of other over the counter vitamin supplements could not be assessed. 
 
Assessment of a programme providing free vitamin D supplements to infants aged <1 
year in Quebec, which started in 1997, also reported low uptake rates (Millette et al, 
2014). The scheme included all infants covered by a public medication insurance 
programme, and the vitamin D supplements could only be obtained through 
prescription by a physician. Between 1998 to 2008, the average uptake rate for 
supplements by eligible families was only 17.9%. 
 
The assessment of the impact of the Birmingham and Quebec schemes suggests that 
the universal free availability of vitamin supplements is unlikely, on its own, to achieve 
high uptake rates. The methods of distribution and accessibility of the vitamin 
supplements are likely to have an important influence on uptake rates. In both of the 
above schemes, parents were required to proactively collect or request the vitamin 
supplements from issuing sites. It has been recommended that the distribution of 
vitamin D supplements should be incorporated into existing antenatal and childhood 
health care programmes (Munns et al, 2016), and this is one possible method by which 
supplementation schemes may achieve higher uptake rates. Qualitative research has 
suggested that parents are most likely to use Healthy Start vitamins if they are handed 
out directly by healthcare professionals, rather than when parents are required to 
collect them from distribution points (Jessiman et al, 2013). Consideration should be 
given to developing public health initiatives for vitamin D deficiency prevention which 
involve the universal free of charge distribution of vitamin supplements to pregnant 
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women and young children through existing NHS health care programmes. These 
could include routine antenatal care appointments, routine newborn physical 
examinations (shortly after birth, and at 6 to 8 weeks of life), routine childhood 
immunisation appointments, and routine health visitor appointments. Uptake rates for 
these established health care programmes are relatively high, for example 93% of 
infants in the UK complete the course of recommended immunisations in the first year 
of life (PHE, 2017), and uptake rates for health visitor appointments range from 88% at 
the new birth visit to 75% at the 2 to 2½ year review (PHE, 2016). 
 
NICE has undertaken a review to identify evidence-based approaches to increasing the 
use of vitamin D supplements among at-risk groups (NICE, 2014). Although the overall 
quality of the evidence base was considered to be poor (Morgan et al, 2014), the report 
made several recommendations for increasing vitamin D supplement uptake:  
 
i) Increasing accessibility of vitamin D supplements, including Healthy Start 
vitamins, by ensuring that low cost supplements are more widely distributed, 
sold, and promoted. Increasing the range of settings where supplements are 
available to include local pharmacies and supermarkets, children’s centres, 
midwifery and health vising services, GP practices, and schools. 
 
ii) Developing national and local activities to increase the population’s awareness 
of vitamin D, its importance for health, and advice regarding supplement use. 
 
iii) Consideration of providing vitamin supplements free of charge to all pregnant 
and breastfeeding women, and children aged under 5 years. 
 
iv) Education of health and social care professionals regarding the importance of 
vitamin D and national supplementation recommendations.  
 
v) Ensuring that health care professionals recommend vitamin D supplement use 
to relevant population groups during routine appointments. 
 
The age distribution of cases of hypocalcaemic seizures observed in the BPSU 
surveillance study, with the majority under 6 months (57%), supports the recent change 
in DoH guidance regarding vitamin D supplementation for this age group. Prior to the 
publication of updated recommendations by the Scientific Advisory Committee on 
Nutrition (SACN) regarding dietary reference values for vitamin D (SACN, 2016), DoH 
guidelines did not recommend routine vitamin D supplements for infants under 6 
months of age (DoH, 2009). However, in line with the recent recommendations by 
SACN, current DoH advice recommends that all breastfed babies should take a daily 
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supplement containing between 8.5 to 10mcg (300 to 400 units) of vitamin D (DoH, 
2016). 
 
A significant proportion of children with hypocalcaemic seizures identified in the BPSU 
study were neonates under one month of age (26%). More than half of the cases 
presenting as neonates were reported to be exclusively formula milk fed (54%). These 
results suggest that the vitamin D content of formula milk alone is not sufficient to 
prevent severe manifestations of vitamin D deficiency developing in neonates born to 
mothers with suboptimal vitamin D status during pregnancy, and highlights the 
importance of vitamin D supplementation during pregnancy in order to ensure 
adequate vitamin D status in newborns. It also questions whether current guidance that 
formula-fed infants do not require additional vitamin D supplementation is appropriate, 
particularly in cases where mothers have not taken supplements during pregnancy. 
Any public health initiatives that are developed with the aim of preventing symptomatic 
vitamin D deficiency in children must involve maternity as well as child health services, 
as infants born to mothers with severe vitamin D deficiency can develop clinical 
complications of hypocalcaemia very soon following birth, before post-natal 
interventions such as supplementation can have effect. 
 
 
 
7.4 Implications for Health Services and Clinical Practice  
 
In the BPSU surveillance study of hypocalcaemic seizures secondary to vitamin D 
deficiency, a minority of cases (13%) did not receive vitamin D replacement in the form 
recommended by UK and international guidelines (treatment dose colecalciferol or 
ergocalciferol). This suggests that the knowledge of guidelines regarding the treatment 
of vitamin D deficiency among paediatricians could be improved. The publication of 
guidance regarding vitamin D (RCPCH, 2013), and the development of an e-learning 
module (RCPCH, 2014), by the Royal College of Paediatrics and Child Health may 
help to address this. 
 
The cohort studies undertaken using the THIN database demonstrated that there has 
been a marked increase in the testing and diagnosis of vitamin D deficiency among 
children in UK clinical practice over the last decade, and that the cost implications of 
this change in clinicians’ diagnostic behaviour for the health service are not 
insignificant. 
 
Chapter 7. Discussion 
 
 248 
Given the magnitude of the increase in diagnosis over a relatively short period of time 
(15-fold between 2008 to 2013), it is highly unlikely to be explained by changes in 
population vitamin D levels, incidence of clinical complications of vitamin D deficiency, 
or population demographics. It is likely that the rise in testing and treatment has been 
driven by increased awareness and consideration of vitamin D deficiency among 
clinicians. There are several possible contributing factors for this: clinician education 
through the development of clinical guidelines and dissemination of Department of 
Health recommendations concerning vitamin D supplementation for high risk groups 
(Davies et al, 2012; DoH, 2009), reports of a rise in cases of rickets among children in 
the UK (Ahmed et al, 2011; Allgrove, 2004; Davies & Shaw, 2011; Shaw & Pal, 2002), 
and wide reporting in the general media and medical literature of research suggesting 
a link between vitamin D status and numerous non-musculoskeletal health outcomes 
(Harvey & Cooper, 2012; Holick, 2007; Pearce & Cheetham, 2010). 
 
The data available did not permit meaningful exploration of the reasons prompting 
investigation of vitamin D status among children in clinical practice. Therefore, it was 
not possible to determine how much the increase in diagnosis has been driven by 
improved recognition of children with symptomatic vitamin D deficiency, or by testing of 
vitamin D status in other clinical situations (for example screening of asymptomatic 
children, testing in children with non-specific symptoms, or testing prompted by the 
presence of non-musculoskeletal diseases that have been linked to vitamin D 
deficiency such as diabetes, atopic disorders, and infectious diseases). 
 
However, comparison of the observed rates of diagnosis of vitamin D deficiency with 
available incidence estimates for symptomatic complications of deficiency (see section 
7.2.1), suggests that considerably more children are currently being diagnosed with 
vitamin D deficiency than those who develop its recognised clinical complications. 
Whilst rates of diagnosis observed prior to 2008 (below 10 per 100,000 PYAR) were 
broadly comparable to available incidence estimates for symptomatic deficiency of 
between 2.2 to 7.5 per 100,000 children per year, it is clear that the rates of diagnosis 
in more recent years (over 200 per 100,000 PYAR in 2013 and 2014) were 
considerably higher than this. Furthermore, whilst symptomatic complications of vitamin 
D deficiency occur most frequently in young children in the first 3 years of life, overall 
rates of diagnosis of vitamin D deficiency were significantly higher among older 
children aged ≥10 years. This observation suggests that vitamin D testing and 
diagnosis among children in clinical practice is unlikely to be primarily focused upon 
individuals with recognised clinical complications of deficiency such as rickets and 
hypocalcaemia. 
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Insights may also be drawn from studies involving adult populations. In response to an 
increase in the number of vitamin D test requests being received by clinical pathology 
laboratories in Alberta, Canada, a province-wide change in test ordering procedures 
was introduced in April 2015 (Ferrari & Prosser, 2016). From that point on, a defined 
set of clinical criteria permitting 25-OH-D testing was introduced, and orders were only 
processed if one of the following indications was specified on the test request: 
metabolic bone disease, abnormal calcium level, malabsorption syndrome (e.g. coeliac 
disease, small-intestinal surgery, anticonvulsant agent), chronic renal disease, or liver 
disease. This resulted in a 92% reduction in the number of tests ordered (Figure 7.1), 
and annual cost savings of almost 4 million US dollars.  
 
 
Figure 7.1  25-OH-D test requests received by Alberta Health Services in 
Canada, before and after the introduction of a defined set of clinical criteria 
permitting 25-OH-D testing in April 2015.a 
 
Abbreviations: 25-OH-D, 25-hydroxyvitamin D. 
a The blue diamonds represent the actual number of 25-OH-D test requests received, 
whilst the orange triangles represent the predicted number of test requests based on 
historical data. Source: Ferrari & Prosser (2016). 
 
 
 
Chapter 7. Discussion 
 
 250 
These results suggest that, prior to the intervention, the majority of vitamin D tests were 
performed in individuals without specific clinical features or risk factors for deficiency. A 
similar response was seen after the introduction of a policy recommending targeted 
vitamin D testing among adults in Australia (Boyages, 2016), which advised that testing 
should only be undertaken in the following ‘high-risk’ groups: patients with 
osteoporosis, osteomalacia, disorders of calcium and parathyroid hormone, 
malabsorption, chronic renal disease, individuals with darker pigmented skin or 
reduced sun exposure, children under 16 years of age, and patients taking drugs 
known to reduce vitamin D levels. Following the introduction of the national policy in 
November 2014, there was a 42% reduction in healthcare expenditure on vitamin D 
tests over the subsequent 8 months compared to the same period in the preceding 
year. 
 
Although further studies are required to directly explore the reasons for investigation of 
vitamin D status in children in clinical practice, the observations described above 
suggest that is it unlikely that testing is focused upon children with recognised clinical 
complications of deficiency. Biochemical vitamin D deficiency, as defined by current 
guidelines, has a high prevalence in the general population, and testing in any patient 
group is likely to identify a significant proportion of abnormal results (see chapter 
2.7.1). The choice of threshold 25-OH-D levels used to define deficiency varies across 
guidelines internationally and has a limited evidence base in children (see chapter 2.4). 
Whilst the benefits of treatment with pharmacological doses of vitamin D are clear in 
children with symptomatic deficiency, there is no evidence that testing and treating 
asymptomatic individuals results in improved health outcomes compared with 
prophylaxis with low-dose supplements (SACN, 2016; Shaw & Mughal, 2013b).  
 
For these reasons, the UK Institute for Health and Care Excellence (NICE, 2014), US 
Endocrine Society (Holick et al, 2011), European Academy of Paediatrics (Grossman 
et al, 2017), and international paediatric consensus recommendations (Munns et al, 
2016) have all advised against the routine screening of vitamin D status. Authors have 
suggested that the primary reasons for requesting vitamin D measurement in children 
should relate to relate to symptoms and signs relating to the effects of vitamin D on the 
skeleton or muscle function (Shaw & Mughal, 2013b). A set of clinical indications for 
the measurement of 25-hydroxyvitamin D in children that has been proposed is shown 
in Table 7.1. 
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Table 7.1  Proposed clinical indications for the measurement of 25-hydroxyvitamin D in 
children.a 
Symptoms and signs of rickets / osteomalacia 
• Progressive bowing deformity of legs 
• Waddling gait 
• Abnormal knock knee deformity (intermalleolar distance >5 cm) 
• Swelling of wrists and costochondral junctions (rachitic rosary) 
• Prolonged bone pain (>3 months duration) 
Symptoms and signs of muscle weakness 
• Delayed walking 
• Difficulty climbing stairs 
• Cardiomyopathy in an infant 
Abnormal bone profile or x-rays 
• Low plasma calcium or phosphate 
• Raised alkaline phosphatase 
• Osteopenia or changes of rickets on x-ray 
• Pathological fractures 
Disorders impacting on vitamin D metabolism 
• Chronic renal failure 
• Chronic liver disease 
• Malabsorption syndromes, e.g. cystic fibrosis, Crohn’s disease, coeliac disease 
• Older anticonvulsants, e.g. phenobarbitone, phenytoin, carbamezapine 
Children with bone disease in whom correcting vitamin D deficiency prior to specific 
treatment would be indicated 
• Osteogenesis imperfecta 
• Idiopathic juvenile osteoporosis 
• Osteoporosis secondary to glucocorticoids, inflammatory disorders, immobility 
a Source: Shaw & Mughal (2013b). 
 
 
 
At the individual level, testing outside of this context requires careful consideration of 
whether vitamin D deficiency is related to the child’s presentation or is a coincidental 
finding. It also represents exposure of children to an unnecessary painful procedure 
without any clear benefit in terms of improving clinical management or health 
outcomes. From a health services perspective, unnecessary testing results in 
avoidable healthcare expenditure, with costs arising from the tests themselves, and 
from subsequent prescription of pharmacological doses of vitamin D and from follow-up 
consultations.  
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The identification of potential sources of cost savings, without adversely impacting 
upon patient care and health outcomes, is of increasing importance in the current 
climate of significant financial constraints in the National Health Service (NHS) 
(Iacobucci, 2017). On the basis of currently available evidence (SACN, 2016), the 
testing and treatment of vitamin D deficiency in asymptomatic individuals falls into this 
category. In view of the magnitude of the observed increase in diagnosis of vitamin D 
deficiency, and in healthcare spending on vitamin D tests and prescriptions, among 
children in clinical practice over the last decade, there is likely to be scope to 
significantly reduce expenditure if testing is limited to individuals with specific clinical 
indications (Table 7.1). The size of potential cost savings is not insignificant if adult 
practice is also considered; vitamin D prescriptions accounted for 1% (£92 million) of 
the total NHS expenditure on prescriptions issued by community pharmacies in 
England in 2014 (HSCIC, 2015b). 
 
Avoidance of routine screening of vitamin D levels is advocated by the Choosing 
Wisely campaigns in the USA (http://www.choosingwisely.org, accessed 21/08/2017), 
Canada (http://www.choosingwiselycanada.org, accessed 21/08/2017), and Australia 
(http://www.choosingwisely.org.au, accessed 21/08/2017). However, routine vitamin D 
testing was not included among the initial list of low value investigations and treatments 
compiled for the UK Choosing Wisely initiative led by the Academy of Medical Royal 
Colleges (http://www.choosingwisely.co.uk, accessed 21/08/2017). Given the large 
increase in testing observed among children in UK clinical practice over the last 
decade, untargeted vitamin D testing should be considered for inclusion in the UK 
Choosing Wisely campaign. NHS primary and secondary care services in the UK 
should consider the introduction of criteria-based approaches to limiting excessive 
vitamin D testing, as have been successfully implemented in Alberta, Canada (Ferrari 
& Prosser, 2016). 
 
 
 
7.5 Recommendations for Future Research  
 
The systematic review described in chapter 3 identified that the existing literature 
regarding the incidence of symptomatic vitamin D deficiency in children is limited in 
terms of the number, geographical coverage, and quality of existing studies. The 
number of studies considered to be of higher methodological quality was small (six), 
and provided data from only four countries (Canada, Denmark, New Zealand, and the 
UK). In order to minimise the risk of bias, future studies that are designed to investigate 
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the epidemiology of symptomatic vitamin D deficiency should have a clear case 
definition (to reduce the risk of case misclassification), should ascertain cases 
presenting to both outpatient and inpatient healthcare services and ideally from primary 
as well as secondary care (to reduce case under ascertainment), and should have 
national coverage so as to generate findings that are generalizable to the population as 
a whole. Future studies should report results stratified by age, sex, and ethnicity, which 
few existing studies have done, so that socio-demographic differences in the incidence 
of symptomatic vitamin D deficiency can be better understood.  
 
Existing studies are largely limited to high-income countries with predominantly 
Caucasian populations. Data is lacking from many regions of the world, including 
Africa, Asia, the Middle East, and South America. Future studies should address this 
gap in epidemiological evidence from low- and middle-income countries (LMIC). 
Undertaking studies which can provide reliable data regarding disease incidence in 
many LMIC is likely to be challenging, as existing mechanisms for prospective disease 
surveillance or the prospective collection of routine healthcare data may not exist. As 
dietary calcium deficiency is an important cause of rickets in many LMIC, studies 
conducted to investigate symptomatic vitamin D deficiency in these settings must 
include biochemical assessment, and ideally also assessment of dietary intake, in 
order to distinguish the relative contribution of vitamin D deficiency and dietary calcium 
deficiency in the aetiology of disease. 
 
Although anecdotal reports and local case series have raised concerns that 
symptomatic vitamin D deficiency may have increased in frequency among children in 
high-income countries in recent decades, data from existing studies are insufficient to 
draw any conclusions regarding temporal trends in incidence over the last 25 years. 
Consideration should be given to designing future studies with longer study periods, of 
at least 10 years, in order to investigate temporal trends in incidence and offer insight 
into the impact of any future changes in public health policy. This could be achieved 
through long-term prospective surveillance, such as the ongoing surveillance of 
perinatal HIV exposure and paediatric HIV infection undertaken by the British 
Paediatric Surveillance Unit (BPSU) and Royal College of Obstetricians and 
Gynaecologists since 1989 (Gibb et al, 2003). In countries where comprehensive 
healthcare administrative data records are available for research purposes, such as in 
various Scandinavian countries and records from large healthcare providers in the US, 
temporal trends in the incidence of symptomatic vitamin D deficiency could be 
investigated using existing data sources. 
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The BPSU surveillance study described in chapter 4 is the first study in the UK to 
report national incidence estimates for any of the clinical manifestations of vitamin D 
deficiency. However, it is limited to hypocalcaemic seizures, and captures only part of 
the health burden caused by vitamin D deficiency in childhood. Further studies are 
required to evaluate the epidemiology of symptomatic vitamin D deficiency more 
broadly in the UK. A separate BPSU study of nutritional rickets presenting to secondary 
care has recently been undertaken, with a 2-year surveillance period between March 
2015 to March 2017. The final results from the study have not yet been published, 
however preliminary data indicated that 59 confirmed cases were identified in the first 
13-months of surveillance (Julies & Blair, 2016). Based upon the findings of previous 
case series, musculoskeletal features of rickets and hypocalcaemic seizures represent 
the two most common modes of presentation of children to secondary care services 
with symptomatic vitamin D deficiency (see chapter 2.7.2). Taken together, the results 
from both BPSU surveillance studies will provide a reasonably comprehensive 
assessment of the incidence of symptomatic vitamin D deficiency presenting to 
paediatric secondary care services in the UK. It is likely that all children with acute 
presentations such as seizures, and the majority of children with rickets, will be referred 
to paediatric services. However, these studies will not capture children with more subtle 
symptoms, such as older children with non-specific musculoskeletal pain and muscle 
weakness, who may be managed in primary care. Future studies should attempt to 
investigate the burden of symptomatic vitamin D deficiency among children in primary 
care. 
 
The cohort study described in chapter 5 demonstrated that there has been a marked 
increase in the diagnosis of vitamin D deficiency among children in UK clinical practice 
over the last decade. Future research should be undertaken to explore the drivers for 
this change in clinician’s diagnostic behaviour. Studies should investigate the reasons 
prompting investigation of vitamin D status among children in clinical practice, and 
determine the extent to which testing is focused on children with clinical features 
consistent with symptomatic vitamin D deficiency, compared to the screening of vitamin 
D status in asymptomatic children. Both quantitative and qualitative methodologies 
would help to answer this research question. Studies should be undertaken in both 
primary care as well as secondary care, as the clinical indications for testing are likely 
to differ across these settings.  
 
The cohort study described in chapter 6 explored the economic implications of the 
increase in diagnosis of vitamin D deficiency, with respect to expenditure on vitamin D 
tests and prescriptions for children in primary care. Further work is required to 
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investigate other related costs which could not be ascertained by this study, including 
costs related to healthcare episodes such as GP consultations, and expenditure arising 
in secondary care. Future studies should also explore trends in the diagnosis of vitamin 
D deficiency, and associated healthcare costs, in adult practice, where the overall 
magnitude of expenditure is likely to be considerably greater than in children’s care. 
 
Should any health service interventions be introduced in the UK with the aim of limiting 
excessive vitamin D testing, as have been recently developed in Canada and Australia, 
their impact should be prospectively evaluated. 
 
Further research is necessary to identify effective interventions for increasing the 
uptake of vitamin D supplements among key population groups including pregnant 
women and young children, particularly those from high-risk ethnic backgrounds. The 
design of such interventions should incorporate evaluation of their cost-effectiveness. 
In order for the cost-effectiveness of public health interventions aimed at prevention of 
vitamin D deficiency to be evaluated, studies are required to determine the health utility 
impact (in terms of QALYs) of complications of vitamin D deficiency in childhood. 
 
 
 
7.6 Conclusion  
 
The studies described in this thesis have advanced knowledge regarding the 
epidemiology of symptomatic vitamin D deficiency in UK children, regarding the 
diagnosis of vitamin D deficiency in children in clinical practice, and regarding the 
economic implications of changes in clinical practice over the last 15 years. As vitamin 
D has become a ‘hot topic’, and generated considerable academic and clinical interest 
over the last two decades, the investigation and diagnosis of vitamin D deficiency 
among children in clinical practice has increased considerably, with important 
economic implications for the health service. However, despite this increased level of 
interest, children in the UK are continuing to develop significant, and preventable, 
clinical complications of vitamin D deficiency. When considered in the context of the 
existing literature, the results from this thesis suggest that vitamin D deficiency may be 
being over-tested and over-diagnosed, yet under-prevented, among children in the UK. 
These findings have implications for public health policy, clinical practice and health 
service delivery, and help to inform areas for future research. 
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Appendix A: Publications and Presentations Arising from the Work 
Described in the Thesis 
 
 
A.1 Publications 
 
1. Basatemur E, Sutcliffe A. Incidence of hypocalcemic seizures due to vitamin D 
deficiency in children in the United Kingdom and Ireland. Journal of Clinical 
Endocrinology and Metabolism. 2015;100(1), E91-5 
 
2. Basatemur E, Horsfall L, Marston L, Rait G, Sutcliffe A. Trends in the diagnosis of 
vitamin D deficiency. Pediatrics. 2017;139(3):e20162748 
 
3. Basatemur E, Hunter R, Horsfall L, Sutcliffe A, Rait G. Costs of vitamin D testing 
and prescribing among children in primary care. European Journal of Pediatrics. 
2017; doi:10.1007/s00431-017-2986-9 
 
 
A.2 National and International Presentations  
 
1. Basatemur E, Sutcliffe A. Surveillance of hypocalcaemic seizures secondary to 
vitamin D deficiency in children in the UK. Oral presentation. RCPCH Annual 
Conference, Glasgow, 7th June 2013. 
 
2. Basatemur E, Sutcliffe A. National surveillance study of hypocalcaemic seizures 
secondary to vitamin D deficiency in children in the UK. Poster presentation. 
Vitamin D and Human Health Conference, Queen Mary University, London, 23rd 
April 2014. 
 
3. Basatemur E, Horsfall L, Rait G, Sutcliffe A. Trends in the Diagnosis of Vitamin D 
Deficiency in UK Children between 2000-2014. Oral presentation. Academic 
Paediatric Association (APA) Conference, Liverpool, 15th April 2016. 
 
4. Basatemur E, Horsfall L, Rait G, Sutcliffe A. Trends in the Diagnosis of Vitamin D 
Deficiency in UK Children Between 2000-2014. Oral presentation. Pediatric 
Academic Societies (PAS) Conference, Baltimore, US, 2nd May 2016. 
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B.1 Ethics Approval for the BPSU study 
  
NRES Committee London - Central
Level 7N019, Maternity Block
Northwick Park Hospital
Watford Road
Harrow
Middx 
HA1 3UJ
Telephone: 020 8869 3775 
Facsimile: 020 8869 5222
05 July 2011
Dr Emre Basatemur
NIHR Academic Clinical Fellow in Paediatrics
Institute of Child Health, University College London
General and Adolescent Paediatric Unit, Institute of Child Health,
University College London,
30 Guilford Street, London
WC1N 1EH
Dear Dr Basatemur
Study title: British Paediatric Surveillance Unit Study of Hypocalcaemic 
Seizures due to Vitamin D Deficiency in Children
REC reference: 11/LO/0838
Protocol number: 1.0
The Research Ethics Committee reviewed the above application at the meeting held on 29 June 
2011. Thank you for attending to discuss the study.
Ethical opinion
The committee found no ethical issues with this study.
In discussion, the Committee found no ethical issues, and were pleased to see that the researcher had decided to 
contact charities to help disseminate future research findings. 
Members felt that the researcher was highly qualified and agreed that his application was well written and 
worthwhile.  
The Chair conveyed this to Dr Basatemur who was waiting in the adjoining room.
The members of the Committee present gave a favourable ethical opinion of the above research on 
the basis described in the application form, protocol and supporting documentation, subject to the 
conditions specified below.
Ethical review of research sites
NHS Sites
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
“Conditions of the favourable opinion” below). 
Conditions of the favourable opinion
The favourable opinion is subject to the following conditions being met prior to the start of the study.
Management permission or approval must be obtained from each host organisation prior to the start 
of the study at the site concerned.
Management permission (“R&D approval”) should be sought from all NHS organisations involved in 
the study in accordance with NHS research governance arrangements.
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Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.  
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought from the 
R&D office on the information it requires to give permission for this activity.
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
Sponsors are not required to notify the Committee of approvals from host organisations
It is responsibility of the sponsor to ensure that all the conditions are complied with before 
the start of the study or its initiation at a particular site (as applicable).
Approved documents
The documents reviewed and approved at the meeting were:
 
Document   Version   Date   
 Covering Letter  21 May 2011 
 Evidence of insurance or indemnity    
 Investigator CV    
 Other: Academic Supervisors CV  01 September 
2010 
 Other: Data protection register details  21 May 2011 
 Other: public Information sheet 1 24 May 2011 
 Other: case notification form 1 24 May 2011 
 Other: certificate from Sir P Tizard Research Bursary    
 Other: Letter from British Paediatric Surveillance Unit  11 October 2010 
 Other: Letter from British Paediatric Surveillance Unit  27 July 2010 
 Other: email from Professor Alan Emond  25 January 2011 
 Other: System Level Security Policy/appendix 1 1 24 May 2011 
 Protocol 1 28 March 2011 
 Questionnaire: Follow up questionnaire 1 24 May 2011 
 REC application  19 May 2011 
 
Membership of the Committee
The members of the Ethics Committee who were present at the meeting are listed on the attached 
sheet.
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees (July 2001) and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK.
After ethical review
Now that you have completed the application process please visit the National Research Ethics 
Service website > After Review
You are invited to give your view of the service that you have received from the National Research 
Ethics Service and the application procedure. If you wish to make your views known please use the 
feedback form available on the website.
The attached document “After ethical review – guidance for researchers” gives detailed guidance on 
reporting requirements for studies with a favourable opinion, including:
• Notifying substantial amendments
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• Adding new sites and investigators
• Progress and safety reports
• Notifying the end of the study
The NRES website also provides guidance on these topics, which is updated in the light of changes 
in reporting requirements or procedures.
We would also like to inform you that we consult regularly with stakeholders to improve our service. If 
you would like to join our Reference Group please email referencegroup@nres.npsa.nhs.uk.
11/LO/0838 Please quote this number on all correspondence
With the Committee’s best wishes for the success of this project
Yours sincerely
Dr John Keen
Chair
Email: Julie.kidd@nwlh.nhs.uk
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments
“After ethical review – guidance for researchers” 
Copy to: Nima Sharma, UCL - Institute of Child Health
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B.2 NIGB Approval for the BPSU study 
  
NIGB  
Ethics and Confidentiality Committee 
 
National Information Governance Board for Health and Social Care 
 
Dr Emre Basatemur 
Institute of Child Health, University College London 
General and Adolescent Paediatric Unit 
University College  
30 Guilford Street 
London 
WC1N 1EH 
 
 
15 July 2012 
 
Dear Dr Basatemur 
 
ECC/BPSU 6-02(FT7)/2011 Hypocalcaemic Seizures Due To Vitamin D Deficiency In 
Children  
 
Thank you for your application for support under section 251 of the NHS Act 2006 and the 
Health Service (Control of Patient Information) Regulations 2002 (‘section 251 support’) to 
process patient identifiable information without consent. This application followed the British 
Paediatric Surveillance Unit (BPSU) methodology and was therefore processed via the fast 
track procedure.  
 
Application context  
 
This application detailed a study using the BPSU orange card methodology in order to provide 
the incidence of hypocalcaemic seizures due to vitamin D deficiency in infants and children in 
the UK and Ireland. NHS Number, Hospital ID, date of birth, date of death and sector level 
postcode were required for de-duplication purposes and date of birth, date of death and sector 
level postcode would be retained for analysis purposes.  
 
Outcome  
 
The Committee agreed to recommend provisional approval under section 251 to this 
application. The Committee specified the following conditions of approval: 
 
1. The provision of a favourable REC opinion (received 8/7/2011) 
2. Confirmation of satisfactory security arrangements (approved 12/7/2011) 
 
As these conditions have been met this constitutes your final approval 
 
letter. I will arrange for 
our register of approved applications on our website to be updated shortly with details of your 
application. 
Annual Review  
 
Please note that your approval under section 251 is subject to submission of an annual review 
report to show how you have met the conditions or report plans, and action towards meeting  
them. It is also your responsibility to submit this report on the anniversary of this final approval 
letter and to report any changes such as to the purpose or design of the proposed activity, or 
to security and confidentiality arrangements. Please ensure that this is received approximately 
NHS Connecting for Health,  
Floor 7,  
New Kings Beam House,  
22 Upper Ground,  
London,  
SE1 9BW.  
Tel: (020) 7633 7052  
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NIGB  
Ethics and Confidentiality Committee 
 
National Information Governance Board for Health and Social Care 
8 weeks prior to this submission deadline. If section 251 support is no longer required prior to 
this please provide a report confirming all patient identifiable data has been destroyed. 
 
Please do not hesitate to contact me if you have any queries following this letter, I would be 
grateful if you could quote the above reference number in all future correspondence. 
 
 
Yours sincerely 
 
 
Claire Edgeworth 
Deputy Approvals Manager 
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B.3 BPSU Executive Committee approval for the BPSU study 
  
British Paediatric Surveillance Unit (BPSU) 
A unit within the research division 
Telephone: (020) 70926173/74     Fax: (020) 7092 6001 
E-mail: bpsu@rcpch.ac.uk  Website: http://bpsu.inopsu.com 
 
Registered Charity in England and Wales: 1057744 
Registered Charity in Scotland: SC038299  Website: www.rcpch.ac.uk  
   
 
 
Dr Emre Basatemur  
Academic Clinical Fellow 
General & Adolescent Unit  
UCL Institute of Child Health 
30 Guilford St 
London WC1N 1EH 
 
11th October 2010 
 
 
Dear Emre, 
 
RE: Phase 2 Application – Hypocalcaemic Seizures Secondary to Vitamin D Deficiency 
 
Thank you very much for submitting your Phase 2 application to the BPSU Executive Committee meeting 
of 30th September 2010. Members of the committee were very interested to talk with you about your 
proposal and were pleased to be able to congratulate you in person on winning the Sir Peter Tizard 
Bursary for 2010.  
 
Committee members discussed your Phase 2 application and supporting documentation in some detail 
and were grateful to you and Dr Sutcliffe for answering questions on your proposal. After deliberation, 
committee members considered that your Phase 2 application could be approved by Chair’s action if the 
following amendments, discussed with you at the meeting, were made to the study protocol, 
questionnaires and public information sheet:  
 
Study protocol 
1. Members suggested that the ‘background’ to the study could more clearly cite the NICE 
antenatal care guidelines in respect of known higher risk subgroups. In addition, the reference to 
Afro‐Caribbean as an ethnic subgroup should be changed to African‐Caribbean or African as 
these are terms used in census classifications. Moreover, vitamin D deficiency is more often a 
concern in UK populations of African rather than Caribbean origin. 
2. The statement that fits cause long‐term problems with ‘brain function’ in the lay summary be 
removed or amended as this is not sufficiently accurate as currently written and may be unduly 
alarming to lay readers.  
3. The study objectives should be amended to state that serum Vitamin D and calcium levels will be 
‘described’ rather than, as currently implied, that ‘levels at which fits occur’ will be defined. As 
discussed with you, members felt that defining a threshold for seizures would not be possible 
using observational data. 
Royal College of Paediatrics and Child Health 
5-11 Theobalds Road WC1X 8SH  
Telephone: 0207 092 6173/74   Fax: 0207 092 6001     E-mail:enquiries@rcpch.ac.uk 
 
 PATRON 
HRH The Princess Royal 
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British Paediatric Surveillance Unit (BPSU) 
A unit within the research division 
Telephone: (020) 70926173/74     Fax: (020) 7092 6001 
E-mail: bpsu@rcpch.ac.uk  Website: http://bpsu.inopsu.com 
 
Registered Charity in England and Wales: 1057744 
Registered Charity in Scotland: SC038299  Website: www.rcpch.ac.uk  
   
4. Committee members asked points 1 and 2 in the sectionof the case definition headed 
‘Exclusions’ should be removed from the reporting case definition and placed within the analytic 
case definition where they can be applied by the expert review panel. 
 
Public information sheet 
1. The public information sheet currently includes a statement ‘We hope that this study will 
provide us with important information about how many children are having fits as a result of 
vitamin D deficiency.’ It was felt by lay members that this was unduly alarming and perhaps 
should be omitted or changed to ‘We hope that this study will provide us with important 
information about how common it is to have fits as a result of vitamin D deficiency.’ 
 
Initial notification questionnaire: The following specific changes were suggested: 
1. Committee members suggested removal of the questions about who observed the seizure as 
they felt that answers to these would be difficult to interpret and were not relevant to the study 
objectives. 
2. Postcode data are not available in Ireland and you may wish to ask for ‘county of residence’ 
instead. You may also wish to consider in what detail regional or postcode data will be required 
as this would presumably be as a guide to sunlight exposure. Collection of unnecessary postcode 
details should be avoided in order to protect the anonymity of children notified to the study. 
3. Section C: You should clarify in Question 3.7 that you wish information on treatment at the first 
admission and not just at the time of the seizure as this may be otherwise misinterpreted.  
4. Section D: Long QT syndrome has recently been reported in a case series involving London 
infants with vitamin D deficiency (Daubeney) and it was suggested that you should include a 
question about whether an ECG was performed and the results of this in Section D. 
5. Section E: Committee members suggested that you add questions about parity, the use of 
sunscreens and maternal BMI to this section as maternal factors have significant impact on 
infant vitamin D levels at birth. 
6. Section F: In Question 6.1, you should ensure that you are satisfied that you will collect sufficient 
detail for the panel to determine whether a notified case meets the exclusion criteria. In 
Question 6.2, it would be preferable to specify in a ‘tick box’ list some conditions that you are 
particularly interested in, e.g. neurological outcomes, developmental delay and rickets or 
skeletal abnormalities). You may also wish to include cardiomyopathy in this list as this is a 
recognised association with vitamin D deficiency. 
 
Follow‐up questionnaire: The following specific changes were suggested: 
1. Committee members observed that Section B did not ask if the child had died, nor for the date 
and cause of death and suggested that this should be added as laid out in Section G of the initial 
questionnaire.   
2. It was suggested that relevant sections of Section F (Question 6.1 and 6.2) could be included in 
the follow‐up questionnaire also as sequelae of vitamin D deficiency may have become apparent 
in the months between completion of the first questionnaire and one year follow‐up.  
 
Appendices 
 284 
  
British Paediatric Surveillance Unit (BPSU) 
A unit within the research division 
Telephone: (020) 70926173/74     Fax: (020) 7092 6001 
E-mail: bpsu@rcpch.ac.uk  Website: http://bpsu.inopsu.com 
 
Registered Charity in England and Wales: 1057744 
Registered Charity in Scotland: SC038299  Website: www.rcpch.ac.uk  
   
If you have any questions or concerns about these changes, then please contact Dr Rachel Knowles who 
will be happy to discuss these with you. Your final paperwork (including dated and revised versions of 
the Phase 2 application, public information sheet and questionnaires) should be sent to the BPSU Office 
at your convenience. Once this has been approved by Professor Alan Emond, a date for commencement 
of surveillance using the Orange Card will be arranged with you. 
 
 
With kind regards, 
 
Yours sincerely, 
  
 
 
Dr Rachel Knowles, Senior Medical Adviser, BPSU  Professor Alan Emond, Chair, BPSU 
 
cc.  Mr Richard Lynn, BPSU Scientific Co‐ordinator 
  Ms Helen Friend, BPSU Research Facilitator 
  Dr Alastair Sutcliffe, Consultant/Academic Supervisor 
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B.4 Scientific Review Committee approval for the THIN study 
  
Page 1 
SRC Feedback 
 
Researcher Name: Dr Emre Basatemur 
Organisation: UCL 
SRC Reference Number: 14-013 
Date: 8th May 2014 
Study title: Childhood vitamin D deficiency in the UK: diagnosis, treatment and 
healthcare costs in primary and secondary care 
Committee opinion: Approved 
______________________________________________________________ 
 
The following feedback has been supplied by the SRC.  
 
Notes from the Chair:  
 
Approved 
______________________________________________________________ 
 
We are pleased to inform that you can proceed with the study as this is now approved. CSD 
Medical Research will let the relevant Ethics committee know this study has been approved 
by the SRC. 
 
Once the study has been completed and published, it is important for you to inform CSD 
Medical Research in order for us to advise the SRC and your reference number to be closed. 
 
References to all published studies are added to our website enabling other researchers to 
become aware of your work. Copies of publication(s), where available, will be appreciated.  
 
I wish you and your team all the best with the study progression.  
 
 
 
Mustafa Dungarwalla  
Research Associate 
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Table C.1  Search strategy used for the MEDLINE bibliographic database. 
Search 
No. Search Query 
a No. of Results 
1 exp Vitamin D Deficiency/ 24,196  
2 vitamin d deficiency.mp. 16,349  
3 exp Rickets/ 13,027  
4 rickets.mp. 8,914  
5 rachit*.mp. 1,776  
6 exp Osteomalacia/ 4,635  
7 osteomalacia.mp. 6,617  
8 hypovitaminosis d.mp. 1,377  
9 avitaminosis d.mp. 7  
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 31,455  
11 exp Incidence/ 221,915  
12 exp Prevalence/ 240,123  
13 exp Epidemiology/ 24,285  
14 incidence.mp. 730,403  
15 prevalence.mp. 579,035  
16 epidemiolog*.mp. 411,315  
17 11 or 12 or 13 or 14 or 15 or 16 1,528,512  
18 10 and 17 5,511  
19 exp Vitamin D Deficiency/ep [Epidemiology] 3,759  
20 exp Rickets/ep [Epidemiology] 603  
21 exp Osteomalacia/ep [Epidemiology] 131  
22 exp Child/ 1,749,773  
23 child*.mp. 2,192,212  
24 exp Infant/ 1,053,667  
25 infant*.mp. 1,160,013  
26 infancy.mp. 57,548  
27 neonat*.mp. 256,340  
28 newborn*.mp. 701,293  
29 exp Adolescent/ 1,835,172  
30 adolescen*.mp. 1,893,314  
31 teenage*.mp. 18,836  
32 toddler*.mp. 8,497  
33 babies.mp. 32,957  
34 baby.mp. 33,597  
35 young person*.mp. 3,102  
36 young people*.mp. 22,370  
37 youth.mp. 56,159  
38 exp Pediatrics/ 52,874  
39 p?ediatric*.mp. 324,473  
40 kid?.mp. 6,992  
41 juvenile*.mp. 81,622  
42 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 
34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 
3,930,286  
43 18 and 42 1,933  
44 limit 18 to (“all infant (birth to 23 months)” or “all child (0 to 18 years)” 
or “newborn infant (birth to 1 month)” or “infant (1 to 23 months)” or 
“preschool child (2 to 5 years)” or “child (6 to 12 years)” or “adolescent 
(13 to 18 years)”) 
1,491  
45 43 or 44 1,933  
46 19 or 20 or 21 or 45 4,772  
47 limit 46 to yr=”1990 – 2016” 4,300  
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Table C.1  continued. 
a exp denotes a subject heading search, where the specified subject heading is ‘exploded’ to 
include the specified subject heading as well as any subheadings. .mp. denotes a free-text 
(or text-word) search. The following search fields were included for free-text searches: 
abstract, title, keyword, heading word, subject heading word, original title.  
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Table C.2  Search strategy used for the EMBASE bibliographic database. 
Search 
No. Search Query 
a No. of Results 
1 exp vitamin D deficiency/ 24,276  
2 vitamin d deficiency.mp. 25,567  
3 exp rickets/ 9,414  
4 rickets.mp. 10,767  
5 rachit*.mp. 1,601  
6 exp osteomalacia/ 8,771  
7 osteomalacia.mp. 8,963  
8 hypovitaminosis d.mp. 2,283  
9 avitaminosis d.mp. 6  
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 40,505  
11 exp incidence/ 346,650  
12 exp prevalence/ 669,917  
13 exp epidemiology/ 2,949,552  
14 exp epidemiological data/ 2,970,461  
15 incidence.mp. 974,357  
16 prevalence.mp. 821,261  
17 epidemiolog*.mp. 1,413,009  
18 11 or 12 or 13 or 14 or 15 or 16 or 17 4,526,352  
19 exp vitamin D deficiency/ep [Epidemiology] 1,643  
20 exp rickets/ep [Epidemiology] 364  
21 exp osteomalacia/ep [Epidemiology] 117  
22 10 and 18 14,052  
23 limit 22 to (infant <to one year> or child <unspecified age> or 
preschool child <1 to 6 years> or school child <7 to 12 years> or 
adolescent <13 to 17 years>) 
3,110  
24 exp child/ 2,563,197  
25 child*.mp. 2,384,237  
26 exp infancy/ or exp infant/ 1,023,619  
27 infant*.mp. 819,883  
28 infancy.mp. 61,317  
29 exp newborn/ 546,079  
30 neonat*.mp. 304,206  
31 exp pediatrics/ 112,084  
32 newborn*.mp. 638,437  
33 p?ediatric*.mp. 492,298  
34 exp adolescence/ or exp adolescent/ or exp juvenile/ 3,331,916  
35 adolescen*.mp. 1,498,159  
36 teenage*.mp. 24,237  
37 toddler*.mp. 10,838  
38 babies.mp. 43,353  
39 baby.mp. 63,252  
40 young person*.mp. 4,103  
41 young people*.mp. 29,322  
42 youth.mp. 58,848  
43 kid?.mp. 9,410  
44 juvenile*.mp. 142,013  
45 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 
36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 
3,972,513  
46 22 and 45 4,217  
47 23 or 46 4,217  
48 19 or 20 or 21 or 47 5,329  
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Table C.2  continued. 
Search 
No. Search Query 
a No. of Results 
49 limit 48 to yr="1990 - 2016" 4,901  
a exp denotes a subject heading search, where the specified subject heading is ‘exploded’ to 
include the specified subject heading as well as any subheadings. .mp. denotes a free-text 
(or text-word) search. The following search fields were included for free-text searches: 
abstract, title, keyword, heading word, subject headings, original title.  
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Table C.3  Search strategy used for the PsycINFO bibliographic database. 
Search 
No. Search Query 
a No. of Results 
1 vitamin d deficiency.mp. 420  
2 rickets.mp. 101  
3 osteomalacia.mp. 23  
4 hypovitaminosis d.mp. 76  
5 avitaminosis d.mp. 0  
6 rachit*.mp. 26  
7 1 or 2 or 3 or 4 or 5 or 6 576  
8 exp epidemiology/ 44,959  
9 incidence.mp. 44,845  
10 prevalence.mp. 96,103  
11 epidemiolog*.mp. 85,787  
12 8 or 9 or 10 or 11 186,212  
13 7 and 12 188  
14 limit 13 to (childhood <birth to age 12 yrs> or neonatal <birth to age 1 
mo> or infancy <2 to 23 mo> or preschool age <age 2 to 5 yrs> or 
school age <age 6 to 12 yrs> or adolescence <age 13 to 17 yrs>) 
22  
15 child*.mp. 669,050  
16 infant*.mp. 84,793  
17 infancy.mp. 17,075  
18 exp neonatal period/ 1,521  
19 exp pediatrics/ 24,256  
20 neonat*.mp. 19,183  
21 newborn*.mp. 10,171  
22 p?ediatric*.mp. 39,545  
23 adolescen*.mp. 233,956  
24 teenage*.mp. 12,640  
25 toddler*.mp. 9,215  
26 babies.mp. 5,686  
27 baby.mp. 10,373  
28 young person*.mp. 2,257  
29 young people*.mp. 24,672  
30 youth.mp. 77,960  
31 kid?.mp. 4,284  
32 juvenile*.mp. 33,200  
33 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 
or 28 or 29 or 30 or 31 or 32 
899,070  
34 13 and 33 51  
35 14 or 34 53  
36 limit 35 to yr="1990 - 2016" 47  
a exp denotes a subject heading search, where the specified subject heading is ‘exploded’ to 
include the specified subject heading as well as any subheadings. .mp. denotes a free-text 
(or text-word) search. The following search fields were included for free-text searches: 
abstract, title, key concepts, table of contents, heading word, original title, tests & measures. 
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Table C.4  Search strategy used for the CINAHL Plus bibliographic database. 
Search 
No. Search Query 
a No. of Results 
S1 (MH "Vitamin D Deficiency+")  5,471 
S2 (MH "Rickets+")  849 
S3 (MH "Osteomalacia")  295 
S4 vitamin d deficiency  5,660 
S5 rickets  822 
S6 rachit*  37 
S7 osteomalacia  469 
S8 "hypovitaminosis-d"  322 
S9 avitaminosis-d  126 
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9  6,729 
S11 (MH "Incidence")  44,793 
S12 (MH "Prevalence")  60,448 
S13 (MH "Epidemiology+")  478,871 
S14 incidence  116,890 
S15 prevalence  131,784 
S16 epidemiolog*  337,392 
S17 S11 OR S12 OR S13 OR S14 OR S15 OR S16  739,322 
S18 S10 AND S17  2,593 
S19 limit S18 to SubjectAge: - infant, newborn: birth-1 month; - child, 
preschool: 2-5 years; - infant: 1-23 months; - all infant;  
- adolescent: 13-18 years: - child: 6-12 years: - all child 
765 
S20 (MH "Child+")  483,157 
S21 (MH "Infant+")  187,883 
S22 (MH "Adolescence+")  337,564 
S23 (MH "Pediatrics+")  14,961 
S24 child* OR infant* OR infancy OR neonat* OR newborn OR p#ediatric* 
OR adolescen* OR teenage* OR toddler* OR babies OR baby  
4,488,879 
S25 young person* OR young people* OR youth OR kid# OR juvenile*  54,199 
S26 S20 OR S21 OR S22 OR S23 OR S24 OR S25  4,490,259 
S27 S18 AND S26  2,484 
S28 S19 OR S27  2,484 
S29 (MH "Vitamin D Deficiency+/EP")  1,187 
S30 (MH "Rickets+/EP")  85 
S31 (MH "Osteomalacia/EP")  10 
S32 S28 OR S29 OR S30 OR S31  2,531 
S33 limit S36 to Publication Year: 1990-2016 2,481 
a MH denotes a subject heading search, and the + symbol specifies that the subject heading 
is ‘exploded’ to include any subheadings. The following search fields were included for free-
text searches: abstract, title, subject headings. 
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Table C.5  Search strategy used for the Web of Science bibliographic database. 
Search 
No. Search Query 
a No. of Results 
1 TS=("vitamin d deficiency") OR TS=(rickets) OR TS=(osteomalacia) 
OR TS=("hypovitaminosis d") OR TS=("avitaminosis d") 
20,807 
2 TS=(incidence) OR TS=(prevalence) OR TS=(epidemiolog*) 1,399,181 
3 TS=(child*) OR TS=(infant*) OR TS=(infancy) OR TS=(neonat*) OR 
TS=(newborn*) OR TS=(babies) OR TS=(baby) OR TS=(toddler*) OR 
TS=(adolescen*) OR TS=(teenage*) OR TS=("young person*) OR 
TS=("young people*) OR TS=(youth) OR TS=(p$ediatric*) OR 
TS=(kid$) OR TS=(juvenile*) 
2,425,818 
4 #3 AND #2 AND #1 1,494 
a The following search fields were included for free-text searches (TS): abstract, title, 
keywords. The search was limited to publications between 1990 to 2016. 
 
 
Table C.6  Search strategy used for the Global Health bibliographic database. 
Search 
No. Search Query 
a No. of Results 
1 vitamin d deficiency.mp. 5,098  
2 exp rickets/ 5,585  
3 rickets.mp. 6,187  
4 exp osteomalacia/ 1,061  
5 osteomalacia.mp. 1,536  
6 hypovitaminosis d.mp. 652  
7 avitaminosis d.mp. 8  
8 rachit*.mp. 2,652  
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 12,697  
10 exp incidence/ 90,025  
11 incidence.mp. 202,657  
12 exp disease prevalence/ 125,197  
13 prevalence.mp. 258,912  
14 exp epidemiology/ 279,477  
15 epidemiolog*.mp. 339,535  
16 10 or 11 or 12 or 13 or 14 or 15 570,591  
17 9 and 16 2,874  
18 exp childhood diseases/ 1,294  
19 exp children/ 286,033  
20 exp infants/ 117,021  
21 exp neonates/ 33,145  
22 exp paediatrics/ 2,781  
23 exp adolescents/ 48,751  
24 (child* or infant* or infancy or newborn* or neonat* or p?ediatric* or 
adolescen* or teenage* or toddler* or babies or baby or young person* 
or young people* or youth or kid? or juvenile*).mp. 
494,388  
25 18 or 19 or 20 or 21 or 22 or 23 or 24 494,388  
26 17 and 25 1,353  
27 limit 26 to yr="1990 - 2016" 720  
a exp denotes a subject heading search, where the specified subject heading is ‘exploded’ to 
include the specified subject heading as well as any subheadings. .mp. denotes a free-text 
(or text-word) search. The following search fields were included for free-text searches: 
abstract, title, broad terms, heading words, CABICODES, identifiers, original title.  
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D.1 Cover letter to reporting clinicians 
  
 
 
 
 
 
 
 
Name of Reporting Consultant 
Department Name 
Hospital Name 
       Date 
 
Dear Dr Consultant Name, 
 
Re: BPSU Study Investigating Hypocalcaemic Seizures Secondary to Vitamin D Deficiency 
 
Thank you very much for notifying us of a case for this study, which is being undertaken by the 
British Paediatrics Surveillance Unit at the RCPCH, and the UCL Institute of Child Health. We 
greatly value your contribution to the study. 
 
We are writing to gather further information about your patient on the enclosed questionnaire. We 
would be very grateful if you could complete it and return it in the enclosed postage-paid envelope. 
Please return the questionnaire, even if there are some sections you are unable to complete. We 
anticipate that it will take around 10-15 minutes to complete, with the child’s notes and laboratory 
results to hand when doing so. 
 
The study is funded by the Sir Peter Tizard Bursary from the RCPCH. It has been approved by the 
Central London Research Ethics Committee and by the National Information Governance Board. 
 
We will not be contacting your patient or his/her family at any time. Some patient identifiable data are 
needed to avoid duplication of reporting. These will be removed once the case has been confirmed to 
be a unique case, and all information you provide will be treated in strict confidence. 
 
Please do not hesitate to contact us (details below) if you have any queries about the questionnaire, 
eligibility of a particular case for inclusion in the study, or any other aspect of the study. Further 
information about the study is also available online at www.rcpch.ac.uk/bpsu. 
 
We are very grateful to you for reporting to the BPSU and for taking the time to provide further 
information about your patient. 
 
Finally, we will also ensure that you are sent a copy of the final report of the study once it is 
completed. 
 
With many thanks for your help, 
 
Yours sincerely, 
 
 
 
Dr Emre Basatemur     Dr Alastair Sutcliffe 
Academic Clinical Fellow    Reader in Child Health 
General & Adolescent Unit    General & Adolescent Unit 
UCL Institute of Child Health    UCL Institute of Child Health 
30 Guilford Street, London WC1N 1EH   30 Guilford Street, London WC1N 1EH 
emre.basatemur@ucl.ac.uk    a.sutcliffe@ucl.ac.uk 
Tel: 07585227463 
INSTITUTE OF CHILD HEALTH 
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D.2 Data collection form 
  
For$office$use$only: !!
Page!1"of!6!
 
 
 
Case notification form - Strictly Confidential 
!
Hypocalcaemic Seizures Secondary to Vitamin D Deficiency 
 
Please contact Dr Emre Basatemur (0778 695 6113 / emre.basatemur@ucl.ac.uk) if you have any questions 
 
 
Reporting Instructions: 
Please report any child under 16 years of age who has had a first episode of a hypocalcaemic seizure 
secondary to vitamin D deficiency within the last month. Please report all suspected cases, even if the 
results of investigations are pending. 
 
Case Definition: 
Any child under 16 years of age who develops a suspected seizure* in the presence of BOTH of the 
following biochemical criteria: 
 1. Low serum corrected calcium: < 2.0 mmol/L 
 2. Low serum 25-hydroxy vitamin D (25-OH-D) level: < 50 nmol/L (<20 ng/ml) 
 
Excluding children with a history of a previous hypocalcaemic seizure due to vitamin D deficiency (prior to 
this presentation) 
 
*Include cases where the event is felt to most likely represent a true seizure, as opposed to another paroxysmal event. A 
seizure can be defined as a  paroxysmal, time-limited change in motor activity and/or behaviour that results from abnormal 
electrical activity in the brain. 
 
 
 
Section A: Reporter Details 
1.1 Date of completion of questionnaire: 
 
1.2 Consultant responsible for case:  ______________________________________________________________________ 
1.3 Hospital name:  ______________________________________________________________________ 
1.4 Telephone number:  ________________________ Email: ____________________________________ 
1.5 Has the patient been referred from another centre? Yes:  No:  Not  known:  
  If yes: 1) please name centre: ____________________________________________________ 
    ____________________________________________________ 
   2) please name consultant: ____________________________________________________ 
!
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For$office$use$only: !
!
BPSU!Study!Questionnaire:!Hypocalcaemic!Seizures!Secondary!to!Vitamin!D!Deficiency! ! ! !  !!
Page!2!of!6!
 
 
This page of the case notification form will be stored separately from the rest of the questionnaire and 
personal identifying information for the case will be used only for linkage of records. 
 
 
 
 
 
 
 
Section B: Case Details  
2.1 NHS/CHI Number:   
 2.2 Local Hospital Number:  
2.3 Partial Postcode (first part only):    
2.4 Sex:   Male  Female     
2.5 Date of birth: 
 
 
2.6 Ethnicity: White   Asian or British Asian  
  Any White background   Indian  
     Pakistani  
  Mixed   Bangladeshi  
  White and Black Caribbean   
Any Other Asian background  
(please specify below)  
  White and Black African     
  White and Asian   Black or British Black  
  
Any Other Mixed background  
(please specify below)   Caribbean  
     African  
  Chinese or other ethnic group   
Any Other Black background  
(please specify below)  
  Chinese     
  Any Other (please specify below)     
  Please specify if any “Other” background: ____________________________________________________ 
!
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For$office$use$only: !
!
BPSU!Study!Questionnaire:!Hypocalcaemic!Seizures!Secondary!to!Vitamin!D!Deficiency! ! ! !  !!
Page!3!of!6!
 
 
 
Section C: Presentation & Initial Management 
3.1 Date of initial seizure:  
 
3.2 Date of admission to hospital:       Not admitted:   
3.3 Did the patient have any subsequent seizures? Yes:  No:  Don’t Know:  
  If yes, How many? 1:  2:  3:  4:  ≥ 5:   
3.4 Please describe the nature of the seizure(s) (as witnessed or described in the history):  
 _______________________________________________________________________________________ 
 _______________________________________________________________________________________ 
 _______________________________________________________________________________________ 
 _______________________________________________________________________________________ 
3.5 Estimated duration of longest seizure: ________________  minutes Not Known:  
3.6 Was any treatment given to terminate the seizure(s)?: Yes:  No:   Don’t know:  
  If yes, what treatment was given:     
  Benzodiazepine (lorazepam / diazepam / midazolam)  Phenytoin  
  Phenobarbitone  Paraldehyde  Sedation and ventilation  
  I.v. calcium gluconate  I.v. calcium chloride  I.v. / i.m. magnesium sulphate  
  Any other treatment:     
(please specify) 
____________________________________________________________________ 
  ____________________________________________________________________  
3.7 Did the child have evidence of other clinical manifestations of vitamin D deficiency? 
  Clinically evident rickets (e.g. bowing of leg, ricketary rosary, craniotabes)  
  Stunting of growth    
  Fracture    
  Cardiomyopathy     
  Other: _______________________________________________________________________________ 
   _______________________________________________________________________________ 
!
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For$office$use$only: !
!
BPSU!Study!Questionnaire:!Hypocalcaemic!Seizures!Secondary!to!Vitamin!D!Deficiency! ! ! !  !!
Page!4!of!6!
 
 
 
Section E: Maternal History 
5.1 If child < 2 years old, did the mother take vitamin D supplements (inlcuding multi-vitamin supplements 
containing vitamin D) at any time during pregnancy? 
  Yes:  No:  Don’t know:  
  If yes, which preparation and dose: __________________________________ Don’t know:  
5.2 If the mother is currently breastfeeding her baby, is she taking any vitamin D supplements (including multi-
vitamin supplements containing vitamin D)? 
  Yes:  No:  Not breastfeeding:  Don’t know:  
  If yes, which preparation and dose: __________________________________ Don’t know:  
5.3 Was the mother veiled / covered when you saw her? Yes:  No:  Don’t know:  
   If yes, was this: Full length / head-to-toe:  Head scarf only:  
!
Section D: Investigations 
 
Please indicate if any of the following tests were performed and their results: (Please report values taken 
prior to initiation of treatment where available)!
4.1 Serum calcium 
(Ca2+): 
Yes: corrected Ca2+:    No: !
Yes: uncorrected Ca2+:    Result pending:  
Result: ________________ Units of measurement: ____________!
 If only uncorrected calcium available, please also report the serum albumin: ____________ g/L!
4.2 Serum 25-
hydroxyvitamin D 
(25-OH-D): 
Yes:  No:  Result pending: !
Result: ________________ Units of measurement: ____________!
4.3 Serum alkaline 
phosphatase 
(ALP): 
Yes:  No:  Result pending: !
Result: ________________ Units of measurement: ____________!
4.4 Serum parathyroid 
hormone (PTH): 
Yes:  No:  Result pending:  
Result: ________________ Units of measurement: ____________ 
4.5 Serum phosphate: Yes:  No:  Result pending:  
Result: ________________ Units of measurement: ____________ 
4.6 X-ray of long bone 
(e.g. distal radius 
or femur): 
Yes:  No:    
If yes, were there any changes consistent with Rickets 
(i.e. cupping, widening, fraying of the metaphysis) ?  Yes:  No:  
4.7 Electrocardiogram 
(ECG): 
Yes:  No:   
If yes, was there: A prolonged QT interval: Yes:  No:  
   Any other abnormalities: _________________________________ 
4.8 Mother’s serum 
25-hydroxy vitamin 
D (25-OH-D): 
Yes:  No:  Result pending:  
Result: ________________ Units of measurement: ____________ 
!
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For$office$use$only: !
!
BPSU!Study!Questionnaire:!Hypocalcaemic!Seizures!Secondary!to!Vitamin!D!Deficiency! ! ! !  !!
Page!5!of!6!
 
 
* Inherited disorders of vitamin D metabolism include defects of 1-α hydroxylase, 25-α hydroxylase, and the vitamin D receptor 
(Vitamin D dependent rickets type 1 and 2) 
Section F: Medical & Nutritional History 
6.1 Does the child have any of the following medical conditions?  
  Gastrointestinal disease with fat malabsorption  Chronic renal disease  
  Inherited disorder of vitamin D metabolism*  Liver disease  
  A condition necessitating total parenteral nutrition  Epilepsy  
6.2 At the time of the seizure, did the child have any of the following medical conditions? 
  Intracranial haemorrhage (e.g. IVH)  Meningitis / encephalitis  
  Hypoxic ischaemic encephalopathy (HIE)  Cerebral infarction  
  Hypo- or hypernatraemia (<125mmol/l or >155 mmol/l)  Hypoglycaemia  
  An inborn error of metabolism  Drug withdrawal  
6.3 Does the child have any other medical condition(s)? Yes:   No:  Don’t know:  
  If yes, please specify: __________________________________________________________________ 
   __________________________________________________________________ 
   __________________________________________________________________ 
6.4 What was the child’s gestational age at birth?   
  ≥ 37 weeks:  32-36 weeks:  28 – 31 weeks:  < 28 weeks:  Don’t Know:  
6.5 Was the child on any medications at the time of admission? Yes:  No:  Not Known:  
 If yes, please specify: 
(including doses 
where known) 
__________________________________________________________________ 
 __________________________________________________________________ 
  __________________________________________________________________ 
6.6 Feeding history. Is the child: Exclusively breast fed:  Fed formula milk:  
   Mixed breast / formula milk:  Weaned onto solids:  
   Don’t Know:    
6.7 Does the child have any food allergies / intolerances? Yes:  No:  Don’t know:  
  If yes, please specify: ______________________________________________________________ 
6.8 If female, was the child veiled / covered when you saw her? Yes:  No:  Don’t know:  
  If yes, was this:  Full length / head-to-toe  Head scarf only   
!
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For$office$use$only: !
!
BPSU!Study!Questionnaire:!Hypocalcaemic!Seizures!Secondary!to!Vitamin!D!Deficiency! ! ! !  !!
Page!6!of!6!
 
!
Thank you for taking the time to complete the Questionnaire! 
Please return the completed form in the postage-paid self-addressed envelope to:   
 
Dr Emre Basatemur,  
General & Adolescent Paediatric Unit, UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH 
Alternatively, email the completed form to: emre.basatemur@ucl.ac.uk 
If you have any questions about the study please do not hesitate to contact Dr Emre Basatemur by email or 
telephone (0778 695 6113). 
!
Section G: Outcome 
7.1 Has the child been discharged? Yes:  If yes, date of discharge:  
   No:     
 If no, what happened? Still admitted:     
   Transferred:  Name of hospital: _______________________________ 
     Name of consultant _______________________________ 
  Died:  Date of death:  
   Was cause of death recorded? Yes:  No:  
   If yes, what: __________________________________________ 
7.2 If discharged, were there any sequlae at discharge? Yes:  No:  Don’t Know:  
  If yes, specify: _________________________________________________________________ 
   _________________________________________________________________ 
7.3 Was the child discharged on any treatment? Yes:  No:  Don’t Know:  
  If yes, what was prescribed?     
   Vitamin D:  If yes, which preparation? Colecalciferol  Adcal D3  
   Calcichew D3  Abidec  
   Dalivit  Calcitriol  
   Alfacalcidol  Ergocalciferol  
   Other preparation: ____________________ 
  Please specify the dose prescribed: ___________________________ 
  Calcium supplement  If yes, which preparation and dose: ___________________________ 
   Other medication:  If yes, please specify: ________________________________________ 
   ________________________________________ 
!
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Appendix E: Assessment for Interactions in Models Examining 
Rates of Diagnosis of Vitamin D Deficiency 
 
 
E.1 Assessment for interaction between sex and ethnicity................................ 303 
 
E.2 Assessment for interaction between age group and ethnicity...................... 305 
 
E.3 Assessment for interaction between ethnicity and Index of Multiple  
 Deprivation................................................................................................... 308 
 
E.4 Assessment for interaction between sex and Index of Multiple 
 Deprivation................................................................................................... 311 
 
E.5 Assessment for interaction between age group and Index of Multiple 
 Deprivation................................................................................................... 313 
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E.1 Asse ssme nt for  i nterac ti on be twee n s ex and et hnici ty  
Figure E.1  Adjusted predicted incidence rates for the diagnosis of vitamin D deficiency 
in children across categories of ethnicity, showing an interaction with sex.a 
 
Abbreviations: PYAR, person-years at risk. 
a Predicted margins were derived from a single-level multivariable Poisson regression model, at 
average values for the remaining covariates (age group, Index of Multiple Deprivation, and 
calendar year). The vertical bars represent 95% confidence intervals. Missing data was handled 
using complete cases analysis. n=414,182. 
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Table E.1  Inclusion of an interaction term between sex and ethnicity, in the single-
level Poisson regression model examining associations with the rate of diagnosis of 
vitamin D deficiency. 
Stratifying variable Effect of covariate RR for diagnosis of vitamin D deficiency (95% CI) a p-value 
b 
Ethnicity  Sex   
 White  Male Baseline - 
   Female 1.39  (1.18–1.63) <0.001 
 Asian or Asian British  Male Baseline - 
   Female 1.81  (1.58–2.08) <0.001 
 Black or black British  Male Baseline - 
   Female 1.57  (1.29–1.92) <0.001 
 Mixed  Male Baseline - 
   Female 1.83  (1.20–2.79) 0.005 
 Chinese or other  Male Baseline - 
   Female 1.73  (1.23–2.45) 0.002 
Sex Ethnicity   
 Male  White Baseline - 
   Asian or Asian British 19.0  (16.1–22.5) <0.001 
   Black or black British 13.2  (10.8–16.1) <0.001 
   Mixed 4.78  (3.34–6.84) <0.001 
   Chinese or other 7.81  (5.80–10.5) <0.001 
 Female  White Baseline - 
   Asian or Asian British 24.9  (21.7–28.6) <0.001 
   Black or black British 15.0  (12.7–17.7) <0.001 
   Mixed 6.30  (4.76–8.33) <0.001 
   Chinese or other 9.76  (7.65–12.5) <0.001 
Abbreviations: CI, confidence interval; RR, rate ratio. 
a Results from a single-level multivariable Poisson regression model, adjusted for the 
variables listed in the table in addition to age group, Index of Multiple Deprivation quintile, and 
calendar year. An interaction between sex and age group was included. Likelihood ratio test 
for interaction p-value 0.16. Missing data was handled using complete cases analysis. 
n=414,182. 
b p-value for the null hypothesis that the true rate ratio is equal to 1. 
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E.2 Asse ssme nt for  i nterac ti on be twee n a ge group and e thnici ty  
Figure E.2  Adjusted predicted incidence rates for the diagnosis of vitamin D deficiency 
in children across categories of ethnicity, showing an interaction with age group.a 
 
Abbreviations: PYAR, person-years at risk. 
a Predicted margins were derived from a single-level multivariable Poisson regression model, at 
average values for the remaining covariates (sex, Index of Multiple Deprivation, and calendar 
year). The vertical bars represent 95% confidence intervals. Missing data was handled using 
complete cases analysis. n=414,182. 
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Table E.2  Inclusion of an interaction term between age group and ethnicity, in the 
single-level Poisson regression model examining associations with the rate of 
diagnosis of vitamin D deficiency. 
Stratifying variable Effect of covariate RR for diagnosis of vitamin D deficiency (95% CI) a p-value 
b 
Ethnicity  Age group   
 White  0 – 4 years Baseline - 
   5 – 9 years 1.12  (0.84–1.51) 0.435 
   10 – 14 years 2.51  (1.94–3.24) <0.001 
   15 – 17 years 4.46  (3.46–5.75) <0.001 
 Asian or Asian British  0 – 4 years Baseline - 
   5 – 9 years 1.86  (1.47–2.35) <0.001 
   10 – 14 years 4.77  (3.86–5.91) <0.001 
   15 – 17 years 5.59  (4.44–7.06) <0.001 
 Black or black British  0 – 4 years Baseline - 
   5 – 9 years 1.19  (0.84–1.69) 0.316 
   10 – 14 years 3.64  (2.70–4.90) <0.001 
   15 – 17 years 3.49  (2.52–4.84) <0.001 
 Mixed  0 – 4 years Baseline - 
   5 – 9 years 0.98  (0.46–2.06) 0.954 
   10 – 14 years 4.50  (2.45–8.26) <0.001 
   15 – 17 years 8.04  (4.33–14.9) <0.001 
 Chinese or other  0 – 4 years Baseline - 
   5 – 9 years 1.83  (0.93–3.60) 0.078 
   10 – 14 years 4.38  (2.40–7.98) <0.001 
   15 – 17 years 4.90  (2.61–9.20) <0.001 
Age Group Ethnicity   
 0 – 4 years  White Baseline - 
   Asian or Asian British 14.9  (11.2–19.9) <0.001 
   Black or black British 13.1  (9.35–18.4) <0.001 
   Mixed 3.97  (2.29–6.88) <0.001 
   Chinese or other 6.42  (3.58–11.5) <0.001 
 5 – 9 years  White Baseline - 
   Asian or Asian British 24.7  (19.3–31.6) <0.001 
   Black or black British 13.9  (10.3–18.9) <0.001 
   Mixed 3.46  (1.94–6.17) <0.001 
   Chinese or other 10.5  (6.69–16.4) <0.001 
 10 – 14 years  White Baseline - 
   Asian or Asian British 28.5  (23.9–33.9) <0.001 
   Black or black British 19.0  (15.5–23.4) <0.001 
   Mixed 7.13  (4.95–10.3) <0.001 
   Chinese or other 11.2  (8.38–15.0) <0.001 
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Table E.2  Continued. 
Stratifying variable Effect of covariate RR for diagnosis of vitamin D deficiency (95% CI) a p-value 
b 
Age Group Ethnicity   
 15 – 17 years  White Baseline - 
   Asian or Asian British 18.7  (15.4–22.7) <0.001 
   Black or black British 10.3  (8.04–13.1) <0.001 
   Mixed 7.16  (4.88–10.5) <0.001 
   Chinese or other 7.05  (4.99–9.96) <0.001 
Abbreviations: CI, confidence interval; RR, rate ratio. 
a Results from a single-level multivariable Poisson regression model, adjusted for the 
variables listed in the table in addition to sex, Index of Multiple Deprivation quintile, and 
calendar year. An interaction between age group and ethnicity was included. Likelihood ratio 
test for interaction p-value <0.001. Missing data was handled using complete cases analysis. 
n=414,182. 
b p-value for the null hypothesis that the true rate ratio is equal to 1. 
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E.3 Asse ssme nt for  i nterac ti on be twee n e thnic ity and I ndex of Mul tip le De priva tion  
Figure E.3  Adjusted predicted incidence rates for the diagnosis of vitamin D deficiency 
in children across categories of Index of Multiple Deprivation, showing an interaction 
with ethnicity.a 
 
Abbreviations: PYAR, person-years at risk. 
a Predicted margins were derived from a single-level multivariable Poisson regression model, at 
average values for the remaining covariates (sex, age group, and calendar year). Missing data 
was handled using complete cases analysis. n=414,182. 
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Table E.3  Inclusion of an interaction term between ethnicity and Index of Multiple 
Deprivation, in the single-level Poisson regression model examining associations with 
the rate of diagnosis of vitamin D deficiency. 
Stratifying variable Effect of covariate RR for diagnosis of vitamin D deficiency (95% CI) a p-value 
b 
Ethnicity  IMD quintile   
 White  1 (least deprived) Baseline - 
   2 1.45  (1.10–1.90) 0.008 
   3 1.89  (1.46–2.45) <0.001 
   4 2.15  (1.67–2.78) <0.001 
   5 (most deprived) 2.13  (1.60–2.82) <0.001 
 Asian or Asian British  1 (least deprived) Baseline - 
   2 3.26  (2.27–4.68) <0.001 
   3 3.10  (2.19–4.42) <0.001 
   4 3.51  (2.48–4.98) <0.001 
   5 (most deprived) 4.45  (3.16–6.27) <0.001 
 Black or black British  1 (least deprived) Baseline - 
   2 5.14  (1.55–17.1) 0.008 
   3 9.02  (2.85–28.6) <0.001 
   4 9.20  (2.92–28.9) <0.001 
   5 (most deprived) 18.6  (5.93–58.1) <0.001 
 Mixed  1 (least deprived) Baseline - 
   2 2.16  (0.75–6.21) 0.154 
   3 3.93  (1.48–10.4) 0.006 
   4 4.76  (1.85–12.3) 0.001 
   5 (most deprived) 4.96  (1.89–13.0) 0.001 
 Chinese or other  1 (least deprived) Baseline - 
   2 1.45  (0.66–3.15) 0.352 
   3 2.41  (1.23–4.72) 0.010 
   4 3.06  (1.59–5.90) 0.001 
   5 (most deprived) 3.03  (1.48–6.23) 0.002 
IMD quintile Ethnicity   
 1 (least deprived)  White Baseline - 
   Asian or Asian British 13.1  (8.97–19.1) <0.001 
   Black or black British 2.76  (0.88–8.72) 0.083 
   Mixed 2.95  (1.20–7.24) 0.018 
   Chinese or other 7.01  (3.76–13.1) <0.001 
 2  White Baseline - 
   Asian or Asian British 29.5  (23.0–37.9) <0.001 
   Black or black British 9.82  (6.31–15.3) <0.001 
   Mixed 4.40  (2.37–8.18) <0.001 
   Chinese or other 7.02  (4.09–12.0) <0.001 
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Table E.3  Continued. 
Stratifying variable Effect of covariate RR for diagnosis of vitamin D deficiency (95% CI) a p-value 
b 
IMD quintile Ethnicity   
 3  White Baseline - 
   Asian or Asian British 21.6  (17.3–26.9) <0.001 
   Black or black British 13.2  (9.96–17.5) <0.001 
   Mixed 6.13  (3.91–9.63) <0.001 
   Chinese or other 8.96  (6.25–12.8) <0.001 
 4  White Baseline - 
   Asian or Asian British 21.4  (17.3–26.4) <0.001 
   Black or black British 11.8  (9.27–15.0) <0.001 
   Mixed 6.52  (4.40–9.66) <0.001 
   Chinese or other 9.97  (7.17–13.9) <0.001 
 5 (most deprived)  White Baseline - 
   Asian or Asian British 27.4  (21.7–34.6) <0.001 
   Black or black British 24.1  (18.8–31.0) <0.001 
   Mixed 6.88  (4.39–10.8) <0.001 
   Chinese or other 10.0  (6.35–15.8) <0.001 
Abbreviations: CI, confidence interval; IMD, Index of Multiple Deprivation; RR, rate ratio. 
a Results from a single-level multivariable Poisson regression model, adjusted for the 
variables listed in the table in addition to sex, age group, and calendar year. An interaction 
between ethnicity and Index of Multiple Deprivation was included. Likelihood ratio test for 
interaction p-value <0.001. Missing data was handled using complete cases analysis. 
n=414,182. 
b p-value for the null hypothesis that the true rate ratio is equal to 1. 
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E.4 Asse ssme nt for  i nterac ti on be twee n s ex and Inde x o f M ult ipl e De privat ion  
Figure E.4  Adjusted predicted incidence rates for the diagnosis of vitamin D deficiency 
in children across categories of Index of Multiple Deprivation, showing an interaction 
with sex.a 
 
Abbreviations: PYAR, person-years at risk. 
a Predicted margins were derived from a single-level multivariable Poisson regression model, at 
average values for the remaining covariates (age group, ethnicity, and calendar year). The 
vertical bars represent 95% confidence intervals. Missing data was handled using complete 
cases analysis. n=414,182. 
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Table E.4  Inclusion of an interaction term between sex and Index of Multiple 
Deprivation, in the single-level Poisson regression model examining associations with 
the rate of diagnosis of vitamin D deficiency. 
Stratifying variable Effect of covariate RR for diagnosis of vitamin D deficiency (95% CI) a p-value 
b 
IMD Quintile  Sex   
 1 (least deprived)  Male Baseline - 
   Female 1.47  (1.07–2.03) 0.018 
 2  Male Baseline - 
   Female 1.53  (1.21–1.93) <0.001 
 3  Male Baseline - 
   Female 1.53  (1.27–1.84) <0.001 
 4  Male Baseline - 
   Female 1.71  (1.44–2.02) <0.001 
 5 (most deprived)  Male Baseline - 
   Female 1.74  (1.47–2.05) <0.001 
Sex IMD Quintile   
 Male  1 (least deprived) Baseline - 
   2 1.94  (1.43–2.63) <0.001 
   3 2.34  (1.76–3.12) <0.001 
   4 2.45  (1.85–3.25) <0.001 
   5 (most deprived) 3.21  (2.42–4.25) <0.001 
 Female  1 (least deprived) Baseline - 
   2 2.01  (1.56–2.59) <0.001 
   3 2.43  (1.92–3.09) <0.001 
   4 2.83  (2.24–3.57) <0.001 
   5 (most deprived) 3.78  (3.00–4.76) <0.001 
Abbreviations: CI, confidence interval; IMD, Index of Multiple Deprivation; RR, rate ratio. 
a Results from a single-level multivariable Poisson regression model, adjusted for the 
variables listed in the table in addition to age group, ethnicity, and calendar year. An 
interaction between sex and Index of Multiple Deprivation was included. Likelihood ratio test 
for interaction p-value 0.75. Missing data was handled using complete cases analysis. 
n=414,182. 
b p-value for the null hypothesis that the true rate ratio is equal to 1. 
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E.5 Asse ssme nt for  i nterac ti on be twee n a ge group and I ndex of Mul tip le De priva tion  
Figure E.5  Adjusted predicted incidence rates for the diagnosis of vitamin D deficiency 
in children across categories of Index of Multiple Deprivation, showing an interaction 
with age group.a 
 
Abbreviations: PYAR, person-years at risk. 
a Predicted margins were derived from a single-level multivariable Poisson regression model, at 
average values for the remaining covariates (sex, ethnicity, and calendar year). The vertical 
bars represent 95% confidence intervals. Missing data was handled using complete cases 
analysis. n=414,182. 
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Table E.5  Inclusion of an interaction term between age group and Index of Multiple 
Deprivation, in the single-level Poisson regression model examining associations with 
the rate of diagnosis of vitamin D deficiency. 
Stratifying variable Effect of covariate RR for diagnosis of vitamin D deficiency (95% CI) a p-value 
b 
IMD quintile  Age group   
 1 (least deprived)  0 – 4 years Baseline - 
   5 – 9 years 0.95  (0.52–1.76) 0.877 
   10 – 14 years 2.81  (1.68–4.71) <0.001 
   15 – 17 years 5.91  (3.57–9.80) <0.001 
 2  0 – 4 years Baseline - 
   5 – 9 years 1.79  (1.15–2.78) 0.009 
   10 – 14 years 4.11  (2.76–6.12) <0.001 
   15 – 17 years 7.28  (4.87–10.9) <0.001 
 3  0 – 4 years Baseline - 
   5 – 9 years 1.18  (0.87–1.61) 0.286 
   10 – 14 years 3.08  (2.36–4.03) <0.001 
   15 – 17 years 4.05  (3.05–5.38) <0.001 
 4  0 – 4 years Baseline - 
   5 – 9 years 1.61  (1.20–2.15) 0.001 
   10 – 14 years 4.06  (3.13–5.28) <0.001 
   15 – 17 years 4.53  (3.42–6.00) <0.001 
 5 (most deprived)  0 – 4 years Baseline - 
   5 – 9 years 1.58  (1.18–2.11) 0.002 
   10 – 14 years 4.42  (3.42–5.71) <0.001 
   15 – 17 years 4.76  (3.60–6.27) <0.001 
Age Group IMD quintile   
 0 – 4 years  1 (least deprived) Baseline - 
   2 1.46  (0.83–2.56) 0.189 
   3 2.54  (1.55–4.15) <0.001 
   4 2.32  (1.42–3.81) 0.001 
   5 (most deprived) 2.94  (1.80–4.82) <0.001 
 5 – 9 years  1 (least deprived) Baseline - 
   2 2.74  (1.66–4.53) <0.001 
   3 3.15  (1.95–5.08) <0.001 
   4 3.92  (2.46–6.25) <0.001 
   5 (most deprived) 4.87  (3.06–7.76) <0.001 
 10 – 14 years  1 (least deprived) Baseline - 
   2 2.13  (1.53–2.96) <0.001 
   3 2.78  (2.04–3.79) <0.001 
   4 3.35  (2.48–4.54) <0.001 
   5 (most deprived) 4.62  (3.42–6.23) <0.001 
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Table E.2  Continued. 
Stratifying variable Effect of covariate RR for diagnosis of vitamin D deficiency (95% CI) a p-value 
b 
Age Group IMD quintile   
 15 – 17 years  1 (least deprived) Baseline - 
   2 1.80  (1.31–2.47) <0.001 
   3 1.74  (1.28–2.36) <0.001 
   4 1.78  (1.32–2.41) <0.001 
   5 (most deprived) 2.37  (1.75–3.19) <0.001 
Abbreviations: CI, confidence interval; IMD, Index of Multiple Deprivation; RR, rate ratio. 
a Results from a single-level multivariable Poisson regression model, adjusted for the 
variables listed in the table in addition to sex, ethnicity, and calendar year. An interaction 
between age group and Index of Multiple Deprivation was included. Likelihood ratio test for 
interaction p-value 0.016. Missing data was handled using complete cases analysis. 
n=414,182. 
b p-value for the null hypothesis that the true rate ratio is equal to 1. 
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Appendix F: Proximity Rules for Child to Mother Linkage 
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F.1 Prox imity ru les for  c hil d t o mother linkage using pregna ncy or  deliv ery relat ed AHD  code s  
Table F.1  Proximity rules for child to mother linkage using pregnancy or delivery 
related AHD codes. 
AHD code Description 
Proximity rule for children 
with month of birth (MOB) 
available b 
Proximity rule for children 
with only year of birth (YOB) 
available c 
1001400092 Pregnancy test d - Record date 0-9 months 
before MOB 
- None e 
1001400161 Maternity ultra sound 
scan 
- EDD 4 months before to 2 
months after MOB 
- If EDD not available, record 
date 0-8 months before MOB 
- EDD in same year as YOB 
- If EDD not available and 
record date between Jan to 
June, if record in same year 
as YOB 
- If EDD not available and 
record date between July to 
Dec, if record in previous 
year to YOB. 
1001400306 Ante natal blood tests - Record date 0-9 months 
before MOB 
- If record date between Jan 
to July and in same year as 
YOB. 
- If record date between Aug 
to Dec and in previous year 
to YOB 
1009800000 CHS – APGAR Score 
At 1 Minute 
- Record date 0-2 months 
after MOB 
- Record in same year as 
YOB 
1009810000 CHS – APGAR Score 
At 5 Minutes 
- Record date 0-2 months 
after MOB 
- Record in same year as 
YOB 
1015000000 Maternity outcome f - Delivery date 0-2 months 0-2 
months after MOB 
- If delivery date not available, 
record date 0-2 months after 
MOB 
- Delivery date in same year 
as YOB 
- If delivery date not available, 
record in same year as YOB 
1040000000 Ante natal booking - EDD 1 month before to 2 
months after MOB 
- If EDD not available, record 
date 0-9 months before MOB 
- EDD in same year as YOB 
- If EDD not available and 
record date between Jan to 
June, if record in same year 
as YOB 
- If EDD not available and 
record date between July to 
Dec, if record in previous 
year to YOB. 
1041000000 Ante natal 
consultation 
- EDD 1 month before to 2 
months after MOB 
- If EDD not available, record 
date 0-8 months before MOB 
- EDD in same year as YOB 
- No match if EDD not 
available e 
1044000000 Postnatal 
examination 
- Delivery date 1 month before 
to 2 months after MOB 
- If delivery date not available, 
record date 0-4 months after 
MOB 
- Delivery date in same year 
as YOB 
- If delivery date not available 
and record date between 
Jan to Feb, if record in 
previous year to YOB 
- If delivery date not available 
and record date between 
March to Dec, if record in 
same year as YOB 
1044100000 Postnatal visit - Delivery date 1 month before 
to 1 month after MOB 
- If delivery date not available, 
record date 0-2 months after 
MOB 
- Delivery date in same year 
as YOB 
- If delivery date not available, 
record in same year as YOB 
1046100000 Ante natal fetal 
examination 
- Record date 0-8 months 
before MOB 
- If record date between Jan 
to Oct and in same year as 
YOB 
- If record date between Nov 
to Dec and in previous year 
to YOB 
1047000000 Maternity outcome 
gestational age of 
baby 
- Record date 1 month before 
to 2 months after MOB 
- Record in same year as 
YOB 
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Table F.1  Continued. 
AHD code Description 
- Proximity rule for children 
with month of birth (MOB) 
available b 
- Proximity rule for children 
with only year of birth 
(YOB) available c 
1048000000 Maternity pregnancy 
dates – event date = 
LMP date 
- EDD 1 month before to 1 
month after MOB 
- EDD in same year as YOB 
1048100000 Maternity delivery 
details baby f 
- Record date 0-2 months 
after MOB 
- Record in same year as 
YOB 
1048200000 Maternity placenta - Record date 0-2 months 
after MOB 
- Record in same year as 
YOB 
1049000000 CHS – gestation - Record date 0-2 months 
after MOB 
- Record in same year as 
YOB 
1050300000 Maternity feeding - Record date 0-3 months 
after MOB 
- Record in same year as 
YOB 
1052500000 Maternity infant 
details f 
- Record date 0-3 months 
after MOB 
- Record in same year as 
YOB 
1055400000 Maternity perineum - Record date 0-2 months 
after MOB 
- Record in same year as 
YOB 
1055405000 Maternity care plan - Record date 0-9 months 
before MOB 
- If record date between Jan 
to June and in same year as 
YOB 
- If record date between July 
to Dec and in previous year 
to YOB 
1055500000 CHS – delivery 
details f 
- Record date 0-1 months 
after MOB 
- Record in same year as 
YOB 
1055520000 Maternity stages of 
labour 
- Record date 0-2 months 
after MOB 
- Record in same year as 
YOB 
Abbreviations: AHD, additional health data; EDD, estimated date of delivery; MOB, month of birth; YOB, 
year of birth. 
a Where the AHD code provides information regarding the EDD or actual delivery date, the proximity 
rule refers to the difference in time between the child’s month or year of birth and the EDD or actual 
delivery date. Where information regarding the EDD or actual delivery date is not recorded, the 
proximity rule refers to the difference in time between the child’s month or year of birth and the AHD 
code record date. The proximity rules were applied where women who had a pregnancy or delivery 
related AHD code in their medical record were registered with the same general practice as a child in 
the study cohort with overlapping periods of active registration, shared an identical ‘household’ identifier 
with the child, and were between 14 to 50 older than the child. 
b Month of birth was available for children below 15 years of age at February 2015. 
c Year of birth only was available for children 15 years of age or older at February 2015.  
d Only included in linkage if the test was specified as being positive. 
e The distribution of timing of records in relation to children’s birth was considered to be too wide to 
allow reliable matching of records when only the year of birth was available for children.  
f Not included in linkage if the outcome was specified as being a stillbirth, miscarriage, or neonatal 
death. 
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F.2 Prox imity ru les for  c hil d t o mother linkage using pregna ncy or  deliv ery relat ed R ea d c odes groups  
Table F.2  Proximity rules for child to mother linkage using pregnancy or delivery 
related Read code groups. 
Read code group Proximity rule for children with month of birth (MOB) available b 
Proximity rule for children with 
only year of birth (YOB) available 
c 
Pregnant - Record date 0-9 months before 
MOB 
- If record date between Jan to May 
and in same year as YOB 
- If record date between June to 
Dec and in previous year to YOB 
Pregnancy Test - Record date 5-9 months before 
MOB 
- If record date between Jan to 
April and in same year as YOB 
- If record date between May to 
Dec and in previous year to YOB 
Antenatal ultrasound 
scan 
- Record date 1-8 months before 
MOB 
- If record date between Jan to May 
and in same year as YOB. 
- If record date between June to 
Dec and in previous year to YOB 
Antenatal examination - Record date 0-8 months before 
MOB 
- If record date between Jan to Nov 
and in same year as YOB. 
- If record date in Dec and in 
previous year to YOB 
Antenatal care - Record date 0-9 months before 
MOB 
- If record date between Jan to 
June and in same year as YOB. 
- If record date between July to 
Dec and in previous year to YOB 
Antenatal screening or 
test 
- Record date 0-8 months before 
MOB 
- If record date between Jan to July 
and in same year as YOB. 
- If record date between August to 
Dec and in previous year to YOB 
Delivery booking - Record date 0-8 months before 
MOB 
- If record date between Jan to 
June and in same year as YOB. 
- If record date between July to 
Dec and in previous year to YOB 
Estimated delivery date - Record date 9 months before to 1 
month after MOB 
- If record date between Jan to July 
and in same year as YOB. 
- If record date between August to 
Dec and in previous year to YOB 
Amniocentesis - Record date 3-7 months before 
MOB 
- If record date between Jan to July 
and in same year as YOB. 
- If record date between August to 
Dec and in previous year to YOB 
Birth or delivery - Record date 0-2 months after MOB - Record in same year as YOB 
Length of labour - Record date in same month as MOB - Record in same year as YOB 
Mode of birth - Record date 0-1 months after MOB - Record in same year as YOB 
Sex of baby - Record date 0-1 months after MOB - Record in same year as YOB 
Gestational age - Record date in same month as MOB - Record in same year as YOB 
Postnatal visit - Record date 0-1 months after MOB - Record in same year as YOB 
Postnatal care - Record date 0-1 months after MOB - Record in same year as YOB 
Postnatal examination - Record date 0-3 months after MOB - If record date between Jan to Feb 
and in subsequent year to YOB. 
- If record date between March to 
Dec and in the same year to YOB 
Hearing screen - Record date in same month as MOB - Record in same year as YOB 
Newborn registration - Record date 0-1 months after MOB - Record in same year as YOB 
Abbreviations: MOB, month of birth; YOB, year of birth. 
a The proximity rule refers to the difference in time between the child’s month or year of birth and the 
Read code record date. The proximity rules were applied where women who had a pregnancy or 
delivery related Read code (see appendix G.3) in their medical record were registered with the same 
general practice as a child in the study cohort with overlapping periods of active registration, shared an 
identical ‘household’ identifier with the child, and were between 14 to 50 older than the child. 
b Month of birth was available for children below 15 years of age at February 2015. 
c Year of birth only was available for children 15 years of age or older at February 2015. 
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G.1 Drug Codes  Ref err ing to P ure Prepara tions of  Calci fero l  
Table G.9  Drug codes referring to pure preparations of calciferol. 
Drug 
code Code description 
Dosage 
unit 
IU of 
calciferol 
per dosage 
unit 
52073979 Colecalciferol 40,000unit capsules tablet / cap 40000 
52074979 Colecalciferol 40,000unit capsules tablet / cap 40000 
52154979 Colecalciferol 20,000unit capsules tablet / cap 20000 
53089979 Colecalciferol 15,000units/5ml oral solution ml 3000 
53090979 Colecalciferol 15,000units/5ml oral solution ml 3000 
53091979 Colecalciferol 15,000units/5ml oral solution ml 3000 
53092979 Colecalciferol 15,000units/5ml oral solution ml 3000 
53322979 Ergocalciferol 125microgram tablets tablet / cap 5000 
53356979 Colecalciferol 30,000unit capsules tablet / cap 30000 
53357979 Colecalciferol 5,000unit capsules tablet / cap 5000 
53359979 Ergocalciferol 12.5microgram tablets tablet / cap 500 
53362979 Colecalciferol 400unit capsules tablet / cap 400 
53365979 Colecalciferol 1,000unit capsules tablet / cap 1000 
53366979 Colecalciferol 600unit capsules tablet / cap 600 
53367979 Colecalciferol 2,200unit capsules tablet / cap 2200 
53368979 Colecalciferol 10,000unit capsules tablet / cap 10000 
53370979 Colecalciferol 20,000unit capsules tablet / cap 20000 
53371979 Colecalciferol 50,000unit capsules tablet / cap 50000 
53641979 Ergocalciferol 250microgram tablets tablet / cap 10000 
53650979 Ergocalciferol 1.25mg capsules tablet / cap 50000 
54637979 Colecalciferol 500unit capsules tablet / cap 500 
54638979 Colecalciferol 500unit capsules tablet / cap 500 
54716979 Colecalciferol 1,000unit capsules tablet / cap 1000 
54889979 Colecalciferol 3,000units/ml oral solution ml 3000 
54890979 Colecalciferol 2,000units/ml oral solution ml 2000 
54891979 Colecalciferol 2,000units/ml oral solution ml 2000 
54916979 COLECALCIFEROL 800iu tablets tablet / cap 800 
54917979 Colecalciferol 800unit tablets tablet / cap 800 
55053979 Colecalciferol 3,000unit tablets tablet / cap 3000 
55054979 Colecalciferol 20,000unit tablets tablet / cap 20000 
55055979 Colecalciferol 2,200unit tablets tablet / cap 2200 
55056979 Colecalciferol 10,000unit tablets tablet / cap 10000 
55060979 Colecalciferol 5,000unit tablets tablet / cap 5000 
55061979 Ergocalciferol 3,000units/ml oral solution ml 3000 
55062979 Ergocalciferol 3,000units/ml oral solution sugar free ml 3000 
55064979 Colecalciferol 3,000units/ml oral solution sugar free ml 3000 
55065979 Colecalciferol 20,000units/ml oral solution sugar free ml 20000 
55066979 Colecalciferol 30,000unit capsules tablet / cap 30000 
55067979 Colecalciferol 30,000unit capsules tablet / cap 30000 
55068979 Colecalciferol 5,000unit capsules tablet / cap 5000 
55070979 Colecalciferol 400unit capsules tablet / cap 400 
55072979 Colecalciferol 1,000unit capsules tablet / cap 1000 
55074979 Colecalciferol 2,200unit capsules tablet / cap 2200 
55076979 Colecalciferol 10,000unit capsules tablet / cap 10000 
55077979 Colecalciferol 20,000unit capsules tablet / cap 20000 
55078979 Colecalciferol 50,000unit capsules tablet / cap 50000 
55079979 Colecalciferol 50,000unit capsules tablet / cap 50000 
55558979 Ergocalciferol 50,000unit capsules tablet / cap 50000 
56123979 Ergocalciferol 1.25mg capsules tablet / cap 50000 
56242979 Colecalciferol 3,000unit tablets tablet / cap 3000 
56244979 Colecalciferol 20,000unit tablets tablet / cap 20000 
56246979 Colecalciferol 2,200unit tablets tablet / cap 2200 
56248979 Colecalciferol 10,000unit tablets tablet / cap 10000 
56310979 Colecalciferol 400unit tablets tablet / cap 400 
56313979 Colecalciferol 1,000unit tablets tablet / cap 1000 
57965979 Colecalciferol 20,000unit capsules tablet / cap 20000 
58139979 Colecalciferol 5,000unit tablets tablet / cap 5000 
58209979 Ergocalciferol 3,000units/ml oral solution ml 3000 
58346979 Colecalciferol 800unit capsules tablet / cap 800 
58349979 Colecalciferol 5,000unit capsules tablet / cap 5000 
58353979 Colecalciferol 1,000unit capsules tablet / cap 1000 
58355979 Colecalciferol 20,000unit capsules tablet / cap 20000 
58356979 Colecalciferol 20,000unit capsules tablet / cap 20000 
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Table G.1  Continued. 
Drug 
code Code description 
Dosage 
unit 
IU of 
calciferol 
per 
dosage 
unit 
58768979 Colecalciferol 2,000units/ml oral solution sugar free ml 2000 
58769979 Colecalciferol 2,000units/ml oral solution sugar free ml 2000 
58782979 Colecalciferol 3,000units/ml oral solution sugar free ml 3000 
59769979 Colecalciferol 800units/ml oral drops sugar free ml 800 
59770979 Colecalciferol 800units/ml oral drops sugar free ml 800 
59771979 Colecalciferol 400units/dose oral spray sugar free spray 400 
59772979 Colecalciferol 400units/dose oral spray sugar free spray 400 
59843979 Colecalciferol 20,000unit capsules tablet / cap 20000 
59981979 Ergocalciferol 15,000units/5ml oral solution ml 3000 
60056979 Ergocalciferol 300,000units/1ml solution for injection ampoules ml 300000 
60225979 Colecalciferol 300,000units/1ml solution for injection ampoules ml 300000 
60568979 Ergocalciferol 20,000units/ml oral solution sugar free ml 20000 
60572979 Colecalciferol 20,000units/ml oral solution sugar free ml 20000 
60594979 Colecalciferol 1,000unit tablets tablet / cap 1000 
61563979 Colecalciferol 30,000units/5ml oral solution ml 6000 
61592979 Colecalciferol 2,000units/ml oral drops sugar free ml 2000 
61593979 Colecalciferol 2,000units/ml oral drops sugar free ml 2000 
61910979 Colecalciferol 400unit tablets tablet / cap 400 
61911979 Colecalciferol 400unit tablets tablet / cap 400 
62001979 Colecalciferol 1,000units/ml oral solution ml 1000 
62002979 Colecalciferol 1,000units/ml oral solution ml 1000 
62088979 Colecalciferol 10,000units/ml oral solution ml 10000 
62116979 Colecalciferol 5,000unit capsules tablet / cap 5000 
62118979 Colecalciferol 3,000unit capsules tablet / cap 3000 
62152979 Colecalciferol 6,000units/5ml oral suspension ml 1200 
62324979 Colecalciferol 20,000units/ml oral drops ml 20000 
62356979 Ergocalciferol 12.5microgram tablets tablet / cap 500 
62357979 Ergocalciferol 12.5microgram tablets tablet / cap 500 
62536979 Colecalciferol 400unit capsules tablet / cap 400 
62622979 Colecalciferol 1,000unit tablets tablet / cap 1000 
62626979 Colecalciferol 1,000unit capsules tablet / cap 1000 
62643979 Colecalciferol 600unit capsules tablet / cap 600 
62645979 Colecalciferol 2,200unit capsules tablet / cap 2200 
62986979 Colecalciferol 20,000unit capsules tablet / cap 20000 
63201979 Colecalciferol 2,000unit capsules tablet / cap 2000 
68364979 Ergocalciferol 400units/5ml oral solution ml 80 
68382979 Ergocalciferol 20,000units/5ml oral suspension ml 4000 
68384979 Ergocalciferol 20,000units/5ml oral solution ml 4000 
68392979 Ergocalciferol 120units/5ml oral solution ml 24 
68396979 Ergocalciferol 100,000units/5ml oral solution ml 20000 
78390978 Colecalciferol 2,000unit orodispersible tablets sugar free tablet / cap 2000 
78426978 Colecalciferol 2,200unit tablets tablet / cap 2200 
78428978 Colecalciferol 5,000unit tablets tablet / cap 5000 
78719978 Colecalciferol 2,000unit tablets tablet / cap 2000 
78720978 Colecalciferol 2,000unit tablets tablet / cap 2000 
79322978 Colecalciferol 200units/drop oral drops sugar free drops 200 
79338978 Ergocalciferol 6,000units/5ml oral solution ml 1200 
79960978 Colecalciferol 280unit chewable tablets tablet / cap 280 
79961978 Colecalciferol 280unit chewable tablets tablet / cap 280 
79993978 Colecalciferol 20,000unit tablets tablet / cap 20000 
80016978 Colecalciferol 400unit capsules tablet / cap 400 
80022978 Colecalciferol 20,000unit capsules tablet / cap 20000 
80153979 Ergocalciferol 50,000units/5ml oral suspension ml 10000 
80157979 Ergocalciferol 30,000units/5ml oral suspension ml 6000 
80169979 Ergocalciferol 10,000units/5ml oral suspension ml 2000 
80416979 Colecalciferol 15,000units/5ml oral suspension ml 3000 
80883998 Colecalciferol 3,000units/ml oral solution sugar free ml 3000 
80885998 Colecalciferol 3,000units/ml oral solution sugar free ml 3000 
80886998 Colecalciferol 20,000units/ml oral solution sugar free ml 20000 
80887998 Colecalciferol 20,000units/ml oral solution sugar free ml 20000 
80914998 Colecalciferol 2,000units/ml oral drops sugar free ml 2000 
80915998 Colecalciferol 2,000units/ml oral drops sugar free ml 2000 
80947998 Ergocalciferol 20,000units/ml oral solution sugar free ml 20000 
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Drug 
code Code description 
Dosage 
unit 
IU of 
calciferol 
per 
dosage 
unit 
80952998 COLECALCIFEROL 800iu capsules tablet / cap 800 
80958998 Colecalciferol 20,000unit capsules tablet / cap 20000 
81004998 Colecalciferol 30,000unit capsules tablet / cap 30000 
81007998 Colecalciferol 30,000unit capsules tablet / cap 30000 
81009998 Colecalciferol 10,000unit capsules tablet / cap 10000 
81010998 Colecalciferol 10,000unit capsules tablet / cap 10000 
81011998 Colecalciferol 2,500unit capsules tablet / cap 2500 
81012998 Colecalciferol 2,500unit capsules tablet / cap 2500 
81013998 Colecalciferol 1,000unit capsules tablet / cap 1000 
81014998 Colecalciferol 1,000unit capsules tablet / cap 1000 
81015998 Colecalciferol 400unit capsules tablet / cap 400 
81074998 Colecalciferol 5,000unit capsules tablet / cap 5000 
81138998 Colecalciferol 500 units tablets tablet / cap 500 
81252998 Colecalciferol 1,000unit tablets tablet / cap 1000 
81253998 Colecalciferol 1,000unit tablets tablet / cap 1000 
81328998 Colecalciferol 800unit capsules tablet / cap 800 
81329998 Colecalciferol 800unit capsules tablet / cap 800 
81335998 Colecalciferol 20,000unit capsules tablet / cap 20000 
81464998 Colecalciferol 400unit capsules tablet / cap 400 
81568998 Colecalciferol 10000units/ml oral solution ml 10000 
81612998 Colecalciferol 1,000unit tablets tablet / cap 1000 
81624998 Colecalciferol 10,000units/5ml oral suspension ml 2000 
81631998 Colecalciferol 2,200unit capsules tablet / cap 2200 
81710998 Colecalciferol 50,000unit capsules tablet / cap 50000 
82283998 Colecalciferol 15,000units/5ml oral solution ml 3000 
82513998 Colecalciferol 20,000unit capsules tablet / cap 20000 
82514998 Ergocalciferol 1.25mg capsules tablet / cap 50000 
82946978 Colecalciferol 20,000unit tablets tablet / cap 20000 
82956978 Colecalciferol 20,000unit capsules tablet / cap 20000 
83393978 Colecalciferol 50,000unit tablets tablet / cap 50000 
83468978 COLECALCIFEROL 20,000iu tabs tablet / cap 20000 
83744978 Colecalciferol 5,000units/5ml oral solution ml 1000 
83746978 Colecalciferol 5,000units/5ml oral solution ml 1000 
83747978 Colecalciferol 10,000units/5ml oral solution ml 2000 
83748978 Colecalciferol 10,000units/5ml oral solution ml 2000 
83750978 Colecalciferol 10,000units/5ml oral solution ml 2000 
84072978 Colecalciferol 5,000unit tablets tablet / cap 5000 
84414978 Ergocalciferol 1,500units/ml oral solution sugar free ml 1500 
84586978 Colecalciferol 20,000unit tablets tablet / cap 20000 
84592978 Colecalciferol 400unit tablets tablet / cap 400 
84600978 Colecalciferol 1,000unit tablets tablet / cap 1000 
84680998 Colecalciferol oral liquid ml - 
85005998 Ergocalciferol oral liquid ml - 
85220998 Ergocalciferol 600,000units/2ml solution for injection ampoules ml 300000 
85224998 Ergocalciferol 300,000units/1ml solution for injection ampoules ml 300000 
86614979 Ergocalciferol 300,000units/1ml solution for injection ampoules ml 300000 
86615979 Ergocalciferol 300,000units/1ml solution for injection ampoules ml 300000 
93163990 Ergocalciferol 600,000units/2ml solution for injection ampoules ml 300000 
93164990 Ergocalciferol 300,000units/1ml solution for injection ampoules ml 300000 
93384992 CALCIFEROL 10 MCG TAB tablet / cap 400 
93390992 CALCIFEROL 1,000 IU I/U TAB tablet / cap 1000 
93401992 CALCIFEROL 5000 I/U TAB tablet / cap 5000 
94809990 Ergocalciferol 1.25mg tablets tablet / cap 50000 
94810990 Ergocalciferol 250microgram tablets tablet / cap 10000 
95606992 ERGOCALCIF 600ku/1.5mL soln ml 400000 
95872992 CALCIFEROL 3,000 IU TAB tablet / cap 3000 
95873992 CALCIFEROL 30,000 IU/ML INJ ml 30000 
95875992 CALCIFEROL SOLN 400U/5ML IN ARACHIS OIL SOL ml 80 
95877992 CALCIFEROL 40,000 IU/ML INJ ml 40000 
95878992 CALCIFEROL 400 IU/ML SOL ml 400 
96131992 CALCIFEROL 400 IU/ML I/U SYR ml 400 
96132992 CALCIFEROL .25 MG CAP tablet / cap 10000 
96133992 CALCIFEROL 1 MG CAP tablet / cap 40000 
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96134992 CALCIFEROL 1,000 IU I/U CAP tablet / cap 1000 
96599992 CALCIFEROL 75 MCG INJ - 3000 
96600992 CALCIFEROL STRONG MG TAB tablet / cap 10000 
96601992 CALCIFEROL 20,000 IU CAP tablet / cap 20000 
96788998 Ergocalciferol 400000units/ml oral solution ml 400000 
97023992 CALCIFEROL 100,000 IU/ML INJ ml 100000 
97024992 CALCIFEROL 600,000 IU/ML INJ ml 600000 
97032992 CALCIFEROL 300 IU/ML I/U SYR ml 300 
97033992 CALCIFEROL DROPS LIQ ml - 
97034992 CALCIFEROL 400 I/U INJ ml 400 
97035992 CALCIFEROL 9,000 IU/ML LIQ ml 9000 
97036992 CALCIFEROL 1,000 IU/5ML SOL ml 200 
97037992 CALCIFEROL 300 MG TAB tablet / cap 12000 
97038992 CALCIFEROL 15 MCG TAB tablet / cap 600 
97238989 Ergocalciferol 1.25mg tablets tablet / cap 50000 
97238990 Ergocalciferol 250microgram tablets tablet / cap 10000 
97767998 Calciferol BP 3000units/ml solution ml 3000 
98374992 VITAMIN D2 TAB tablet / cap - 
98421997 Ergocalciferol 1.25mg tablets tablet / cap 50000 
98421998 Ergocalciferol 250microgram tablets tablet / cap 10000 
98422997 Ergocalciferol 1,000units/5ml oral suspension ml 200 
98422998 Ergocalciferol 3,000units/ml oral solution sugar free ml 3000 
98925998 Calciferol 300,000 units/ml BP solution ml 300000 
99763990 Calciferol 300,000 units/ml BP solution ml 300000 
59525978 Colecalciferol 40,000unit capsules tablet / cap 40000 
60566979 Ergocalciferol 3,000units/ml oral solution sugar free ml 3000 
73128978 Colecalciferol 10,000unit capsules tablet / cap 10000 
80018978 Colecalciferol 1,000unit tablets tablet / cap 1000 
73011978 Colecalciferol 25,000units/ml oral solution sugar free 1ml unit dose ampoules ml 25000 
83743978 Ergocalciferol 1,000units/5ml oral solution ml 200 
70249978 Ergocalciferol 1.25mg capsules tablet / cap 50000 
79935978 Ergocalciferol 600,000units/1.5ml solution for injection ampoules ml 400000 
73301978 Colecalciferol 20,000units/ml oral solution ml 20000 
99763988 Ergocalciferol 250microgram tablets tablet / cap 10000 
73012978 Colecalciferol 25,000units/ml oral solution sugar free 1ml unit dose ampoules ml 25000 
53321979 Ergocalciferol 125microgram tablets tablet / cap 5000 
83469978 Colecalciferol 10,000unit tablets tablet / cap 10000 
73392978 Colecalciferol 3,200unit capsules tablet / cap 3200 
60224979 Colecalciferol 300,000units/1ml solution for injection ampoules ml 300000 
54790979 Ergocalciferol 1.25mg capsules tablet / cap 50000 
59528978 Colecalciferol 20,000unit capsules tablet / cap 20000 
62087979 Colecalciferol 10,000units/ml oral solution ml 10000 
60374979 Colecalciferol 800unit capsules tablet / cap 800 
60373979 Colecalciferol 800unit capsules tablet / cap 800 
73102978 Colecalciferol 3,200unit capsules tablet / cap 3200 
78388978 Colecalciferol 500unit orodispersible tablets sugar free tablet / cap 500 
78389978 Colecalciferol 2,000unit orodispersible tablets sugar free tablet / cap 2000 
59522978 Colecalciferol 2,000unit tablets tablet / cap 2000 
73391978 Colecalciferol 3,200unit capsules tablet / cap 3200 
53353979 Colecalciferol 5,000unit tablets tablet / cap 5000 
80151979 Ergocalciferol 6,000units/5ml oral suspension ml 1200 
78441978 Colecalciferol 1,000unit capsules tablet / cap 1000 
83392978 Colecalciferol 50,000unit tablets tablet / cap 50000 
80019978 Colecalciferol 1,000unit capsules tablet / cap 1000 
78387978 Colecalciferol 500unit orodispersible tablets sugar free tablet / cap 500 
73129978 Colecalciferol 20,000unit capsules tablet / cap 20000 
53358979 Colecalciferol 3,000unit capsules tablet / cap 3000 
Abbreviations: IU, international units; cap, capsule 
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G.2 Re ad codes re lat ed to et hni city , nati onalit y, c ountry of bir t h, or  language, c oded usi ng  ONS 20 01 C ens us cla ssif ica tions  
Table G.2  Read codes related to ethnicity, nationality, country of birth, or language, 
coded using ONS 2001 Census classifications.  
Read 
code Code description 
5-category 
ethnicity 
group 
16-category 
ethnicity group 
Codes referring to ethnicity, nationality, or race 
134..00 Country of origin - - 
1341.00 European origin White Other white 
1342.00 African origin Black African 
1343.00 Asian origin Asian - 
1344.00 North American origin White Other white 
1345.00 South American origin Other Other 
1346.00 Australian origin White Other white 
1347.00 Indian origin Asian Indian 
1348.00 Middle Eastern origin Other Other 
1349.00 Far Eastern origin Other Other 
134A.00 West Indian origin Black Caribbean 
134B.00 RACE: Caucasian White - 
134C.00 RACE: Arab Other Other 
134D.00 RACE: Chinese Other Chinese 
134E.00 RACE: Japanese Other Other 
134F.00 RACE: Korean Other Other 
134G.00 RACE: Oriental Other Other 
134H.00 RACE: Afro-caribbean Black - 
134I.00 RACE: Bangladeshi Asian Bangladeshi 
134J.00 RACE: Mixed Mixed - 
134K.00 RACE: West indian Black Caribbean 
134L.00 RACE: Afro-caucasian Mixed Other mixed 
134M.00 RACE: Pakistani Asian Pakistani 
134N.00 RACE: White White - 
134O.00 RACE: Unknown - - 
134P.00 RACE: Not stated - - 
134P.11 RACE: Other - - 
134Z.00 Country of origin NOS - - 
1X...00 NHS Sickle Cell Thalassaemia Screening Program family - - 
1X0..00 Sick Cell Thalas Scr Prog fam orig African or African Black African 
1X00.00 NHS Sick Cell Thal Scr Prog Caribbean Islands family Black Caribbean 
1X01.00 NHS Sick Cell Thalassaemia Screen Prog African family Black African 
1X1..00 Sick Cell Thalas Scr Prog fam orig South Asia (Asian) Asian - 
1X10.00 NHS Sic Cel Th Sc Prog India or African-Indian family Asian Indian 
1X11.00 NHS Sickle Cell Thal Screening Prog Pakistan family o Asian Pakistani 
1X12.00 NHS Sickle Cell Thal Screening Prog Bangladesh family Asian Bangladeshi 
1X2..00 NHS Sick Cell Thal Scr Prog fam orig South East Asia Other Other 
1X20.00 NHS Sickle Cel Thal Screening Program Chinese family Other Chinese 
1X21.00 N Sic Cell Th Scr P Thailand, Indonesia, Burma family Other Other 
1X22.00 NSCTSP Malaysia, Vietnam, Philippin, Cambodia, Laos f Other Other 
1X3..00 NHS Sickle Cell Thal Scr Prog fam origin other non-Eu - - 
1X30.00 NHS Sickle Cell Thalass Scr Prog North Africa family Other Other 
1X31.00 NHS Sickle Cell Thal Scr Program South America family Other Other 
1X32.00 NHS Sickle Cell Thal Scr Prog Middle East family orig Other Other 
1X4..00 NHS Sic Cel Th Scr Prog fam orig Southern and other E White Other white 
1X40.00 NHS Sickle Cell Thal Scr Prog Sardinia family origin White Other white 
1X41.00 NSCTSP Greece, Turkey, Cyprus family origin White Other white 
1X42.00 NSCTSP Italy, Portugal, Spain family origin White Other white 
1X5..00 NHS Sick Cel Thal Scr Prog fam origin United Kingdom White British 
1X6..00 NHS Sic Cel Thal Scr Prog fam orig Northern European White Other white 
1X60.00 NSCTSP Austr, Belg, Ire, Fr, Germ, Netherland family White Other white 
1X61.00 NSCTSP Scandinavia, Switzerland family origin White Other white 
226..00 O/E - ethnic group - - 
226..11 O/E - ethnic origin - - 
2261.00 O/E - Europeanoid White - 
2262.00 O/E - Negroid Black - 
2263.00 O/E - Mongoloid origin Other Other 
2263.11 O/E - Asian origin Asian - 
2264.00 O/E - Australoid Other Other 
226Z.00 O/E - ethnic group NOS - - 
916E.00 Patient ethnicity unknown - - 
9S...00 Ethnic groups (census) - - 
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Read 
code Code description 
5-category 
ethnicity 
group 
16-category 
ethnicity 
group 
9S1..00 White White - 
9S10.00 White British White British 
9S11.00 White Irish White Irish 
9S12.00 Other white ethnic group White Other white 
9S13.00 White Scottish White British 
9S14.00 Other white British ethnic group White British 
9S2..00 Black Caribbean Black Caribbean 
9S3..00 Black African Black African 
9S4..00 Black, other, non-mixed origin Black Other black 
9S41.00 Black British Black Other black 
9S42.00 Black Caribbean/W.I./Guyana Black Caribbean 
9S42.11 Black Caribbean Black Caribbean 
9S42.12 Black West Indian Black Caribbean 
9S42.13 Black Guyana Black Caribbean 
9S43.00 Black N African/Arab/Iranian Black Other black 
9S43.11 Black North African Black Other black 
9S43.12 Black Arab Black Other black 
9S43.13 Black Iranian Black Other black 
9S44.00 Black - other African country Black African 
9S45.00 Black E Afric Asia/Indo-Caribb Black Other black 
9S45.11 Black East African Asian Black African 
9S45.12 Black Indo-Caribbean Black Caribbean 
9S46.00 Black Indian sub-continent Black Other black 
9S47.00 Black - other Asian Black Other black 
9S48.00 Black Black - other Black Other black 
9S5..00 Black - other, mixed Mixed Other mixed 
9S51.00 Other Black - Black/White orig Mixed Other mixed 
9S52.00 Other Black - Black/Asian orig Mixed Other mixed 
9S6..00 Indian Asian Indian 
9S7..00 Pakistani Asian Pakistani 
9S8..00 Bangladeshi Asian Bangladeshi 
9S9..00 Chinese Other Chinese 
9SA..00 Other ethnic non-mixed (NMO) Other Other 
9SA1.00 Brit. ethnic minor. spec.(NMO) - - 
9SA2.00 Brit. ethnic minor. unsp (NMO) - - 
9SA3.00 Caribbean I./W.I./Guyana (NMO) Black Caribbean 
9SA3.11 Caribbean Island (NMO) Black Caribbean 
9SA3.12 West Indian (NMO) Black Caribbean 
9SA3.13 Guyana (NMO) Black Caribbean 
9SA4.00 N African Arab/Iranian (NMO) Other Other 
9SA4.11 North African Arab (NMO) Other Other 
9SA4.12 Iranian (NMO) Other Other 
9SA5.00 Other African countries (NMO) Black African 
9SA6.00 E Afric Asian/Indo-Carib (NMO) Asian Other Asian 
9SA6.11 East African Asian (NMO) Asian Other Asian 
9SA6.12 Indo-Caribbean (NMO) Asian Other Asian 
9SA7.00 Indian sub-continent (NMO) Asian - 
9SA8.00 Other Asian (NMO) Asian Other Asian 
9SA9.00 Irish (NMO) White Irish 
9SAA.00 Greek/Greek Cypriot (NMO) White Other white 
9SAA.11 Greek (NMO) White Other white 
9SAA.12 Greek Cypriot (NMO) White Other white 
9SAB.00 Turkish/Turkish Cypriot (NMO) White Other white 
9SAB.11 Turkish (NMO) White Other white 
9SAB.12 Turkish Cypriot (NMO) White Other white 
9SAC.00 Other European (NMO) White Other white 
9SAD.00 Other ethnic NEC (NMO) Other Other 
9SB..00 Other ethnic, mixed origin Mixed Other mixed 
9SB1.00 Other ethnic, Black/White orig Mixed Other mixed 
9SB2.00 Other ethnic, Asian/White orig Mixed White & Asian 
9SB3.00 Other ethnic, mixed white orig Mixed Other mixed 
9SB4.00 Other ethnic, other mixed orig Mixed Other mixed 
9SB5.00 Black Caribbean and White Mixed White & Caribb. 
9SB6.00 Black African and White Mixed White & African 
9SC..00 Vietnamese Other Other 
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Read 
code Code description 
5-category 
ethnicity 
group 
16-category 
ethnicity group 
9SD..00 Ethnic group not given - patient refused - - 
9SE..00 Ethnic group not recorded - - 
9SG..00 Other black ethnic group Black Other black 
9SH..00 Other Asian ethnic group Asian Other Asian 
9SI..00 Irish traveller White Other white 
9SJ..00 Other ethnic group Other Other 
9SZ..00 Ethnic groups (census) NOS - - 
9T...00 Ethnicity and other related nationality data - - 
9T1..00 New Zealand ethnic groups - - 
9T11.00 New Zealand European White Other white 
9T11.11 Pakeha White Other white 
9T12.00 Other European in New Zealand White Other white 
9T13.00 New Zealand Maori Other Other 
9T14.00 Samoan Other Other 
9T15.00 Cook Island Maori Other Other 
9T16.00 Tongan Other Other 
9T17.00 Niuean Other Other 
9T18.00 Tokelauan Other Other 
9T19.00 Fijian Other Other 
9T1A.00 Other Pacific ethnic group Other Other 
9T1B.00 South East Asian Other Other 
9T1C.00 Chinese Other Chinese 
9T1D.00 Indian Asian Indian 
9T1E.00 Other Asian Asian Other Asian 
9T1Y.00 Other New Zealand ethnic group Other Other 
9T1Z.00 New Zealand ethnic group NOS - - 
9T2..00 Traveller - gypsy White Other white 
9T3..00 Yemeni Other Other 
9T4..00 Romanian White Other white 
9T5..00 Bulgarian White Other white 
9T6..00 Czech White Other white 
9T7..00 Slovak White Other white 
9T8..00 Portuguese White Other white 
9T9..00 Nepali Asian Other Asian 
9i...00 Ethnic category - 2001 census - - 
9i0..00 British or mixed British - ethnic category 2001 censu White British 
9i00.00 White British - ethnic category 2001 census White British 
9i1..00 Irish - ethnic category 2001 census White Irish 
9i10.00 White Irish - ethnic category 2001 census White Irish 
9i2..00 Other White background - ethnic category 2001 census White Other white 
9i20.00 English - ethnic category 2001 census White British 
9i21.00 Scottish - ethnic category 2001 census White British 
9i22.00 Welsh - ethnic category 2001 census White British 
9i23.00 Cornish - ethnic category 2001 census White British 
9i24.00 Northern Irish - ethnic category 2001 census White Other white 
9i25.00 Ulster Scots - ethnic category 2001 census White Other white 
9i26.00 Cypriot (part not stated) – ethnic category 2001 cens White Other white 
9i27.00 Greek – ethnic category 2001 census White Other white 
9i28.00 Greek Cypriot – ethnic category 2001 census White Other white 
9i29.00 Turkish – ethnic category 2001 census White Other white 
9i2A.00 Turkish Cypriot – ethnic category 2001 census White Other white 
9i2B.00 Italian – ethnic category 2001 census White Other white 
9i2C.00 Irish Traveller – ethnic category 2001 census White Other white 
9i2D.00 Traveller – ethnic category 2001 census White Other white 
9i2E.00 Gypsy/Romany – ethnic category 2001 census White Other white 
9i2F.00 Polish – ethnic category 2001 census White Other white 
9i2G.00 Baltic Estonian/Latvian/Lithuanian – ethn categ 2001 White Other white 
9i2H.00 Commonwealth (Russian) Indep States – ethn categ 2001 White Other white 
9i2J.00 Kosovan – ethnic category 2001 census White Other white 
9i2K.00 Albanian – ethnic category 2001 census White Other white 
9i2L.00 Bosnian – ethnic category 2001 census White Other white 
9i2M.00 Croatian – ethnic category 2001 census White Other white 
9i2N.00 Serbian – ethnic category 2001 census White Other white 
9i2P.00 Other republics former Yugoslavia – ethnic categ 2001 White Other white 
9i2Q.00 Mixed Irish and other White – ethnic category 2001 ce White Other white 
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code Code description 
5-category 
ethnicity 
group 
16-category 
ethnicity group 
9i2R.00 Oth White European/European unsp/Mixed European 2001 White Other white 
9i2S.00 Other mixed White – ethnic category 2001 census White Other white 
9i2T.00 Other White or White unspecified ethnic category 2001 White Other white 
9i3..00 White and Black Caribbean – ethnic category 2001 cens Mixed White & Caribb. 
9i4..00 White and Black African – ethnic category 2001 census Mixed White & African 
9i5..00 White and Asian – ethnic category 2001 census Mixed White & Asian 
9i6..00 Other Mixed background – ethnic category 2001 census Mixed Other mixed 
9i60.00 Black and Asian – ethnic category 2001 census Mixed Other mixed 
9i61.00 Black and Chinese – ethnic category 2001 census Mixed Other mixed 
9i62.00 Black and White – ethnic category 2001 census Mixed Other mixed 
9i63.00 Chinese and White – ethnic category 2001 census Mixed Other mixed 
9i64.00 Asian and Chinese – ethnic category 2001 census Mixed Other mixed 
9i65.00 Other Mixed or Mixed unspecified ethnic category 2001 Mixed Other mixed 
9i7..00 Indian or British Indian – ethnic category 2001 censu Asian Indian 
9i8..00 Pakistani or British Pakistani – ethnic category 2001 Asian Pakistani 
9i9..00 Bangladeshi or British Bangladeshi – ethn categ 2001 Asian Bangladeshi 
9iA..00 Other Asian background – ethnic category 2001 census Asian Other Asian 
9iA1.00 Punjabi – ethnic category 2001 census Asian Other Asian 
9iA2.00 Kashmiri – ethnic category 2001 census Asian Other Asian 
9iA3.00 East African Asian – ethnic category 2001 census Asian Other Asian 
9iA4.00 Sri Lankan – ethnic category 2001 census Asian Other Asian 
9iA5.00 Tamil – ethnic category 2001 census Asian Other Asian 
9iA6.00 Sinhalese – ethnic category 2001 census Asian Other Asian 
9iA7.00 Caribbean Asian – ethnic category 2001 census Asian Other Asian 
9iA8.00 British Asian – ethnic category 2001 census Asian Other Asian 
9iA9.00 Mixed Asian – ethnic category 2001 census Asian Other Asian 
9iAA.00 Other Asian or Asian unspecified ethnic category 2001 Asian Other Asian 
9iB..00 Caribbean – ethnic category 2001 census Black Caribbean 
9iC..00 African – ethnic category 2001 census Black African 
9iD..00 Other Black background – ethnic category 2001 census Black Other black 
9iD0.00 Somali – ethnic category 2001 census Black African 
9iD1.00 Nigerian – ethnic category 2001 census Black African 
9iD2.00 Black British – ethnic category 2001 census Black Other black 
9iD3.00 Mixed Black – ethnic category 2001 census Black Other black 
9iD4.00 Other Black or Black unspecified ethnic category 2001 Black Other black 
9iE..00 Chinese – ethnic category 2001 census Other Chinese 
9iF..00 Other – ethnic category 2001 census Other Other 
9iF0.00 Vietnamese – ethnic category 2001 census Other Other 
9iF1.00 Japanese – ethnic category 2001 census Other Other 
9iF2.00 Filipino – ethnic category 2001 census Other Other 
9iF3.00 Malaysian – ethnic category 2001 census Other Other 
9iF4.00 Buddhist – ethnic category 2001 census - - 
9iF5.00 Hindu – ethnic category 2001 census - - 
9iF6.00 Jewish – ethnic category 2001 census - - 
9iF7.00 Muslim – ethnic category 2001 census - - 
9iF8.00 Sikh – ethnic category 2001 census - - 
9iF9.00 Arab - ethnic category 2001 census Other Other 
9iFA.00 North African - ethnic category 2001 census Other Other 
9iFB.00 Mid East (excl Israeli, Iranian & Arab) - eth cat 200 Other Other 
9iFC.00 Israeli - ethnic category 2001 census Other Other 
9iFD.00 Iranian - ethnic category 2001 census Other Other 
9iFE.00 Kurdish - ethnic category 2001 census Other Other 
9iFF.00 Moroccan - ethnic category 2001 census Other Other 
9iFG.00 Latin American - ethnic category 2001 census Other Other 
9iFH.00 South and Central American - ethnic category 2001 cen Other Other 
9iFJ.00 Mauritian/Seychellois/Maldivian/St Helena eth cat 200 Other Other 
9iFK.00 Any other group - ethnic category 2001 census Other Other 
9iG..00 Ethnic category not stated - 2001 census - - 
Codes referring to country of birth 
134..11 Born in - country - - 
13d..00 Country of birth (European) - - 
13d0.00 Born in Albania White Other white 
13d1.00 Born in Andorra White Other white 
13d2.00 Born in Austria White Other white 
13d3.00 Born in Azerbaijan Other Other 
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13d4.00 Born in Belgium White Other white 
13d5.00 Born in Belorussia White Other white 
13d6.00 Born in Bosnia - Herzegovnia White Other white 
13d7.00 Born in Bulgaria White Other white 
13d8.00 Born in Croatia White Other white 
13d9.00 Born in Cyprus White Other white 
13dA.00 Born in Czech Republic White Other white 
13dB.00 Born in Denmark White Other white 
13dC.00 Born in England - - 
13dD.00 Born in Estonia White Other white 
13dE.00 Born in Finland White Other white 
13dF.00 Born in France White Other white 
13dG.00 Born in Germany White Other white 
13dH.00 Born in Greece White Other white 
13dI.00 Born in Hungary White Other white 
13dJ.00 Born in Iceland White Other white 
13dK.00 Born in Ireland White Irish 
13dL.00 Born in Italy White Other white 
13dM.00 Born in Kosovo White Other white 
13dN.00 Born in Latvia White Other white 
13dO.00 Born in Liechtenstein White Other white 
13dP.00 Born in Lithuania White Other white 
13dQ.00 Born in Luxembourg White Other white 
13dR.00 Born in Malta White Other white 
13dS.00 Born in Moldavia White Other white 
13dT.00 Born in Monaco White Other white 
13dU.00 Born in Northern Ireland White Other white 
13dV.00 Born in Norway White Other white 
13dW.00 Born in Poland White Other white 
13dX.00 Born in Portugal White Other white 
13dY.00 Born in Republic of Ireland White Irish 
13dZ.00 Born in Romania White Other white 
13da.00 Born in San Marino White Other white 
13db.00 Born in Scotland White British 
13dc.00 Born in Slovakia White Other white 
13dd.00 Born in Slovenia White Other white 
13de.00 Born in Spain White Other white 
13df.00 Born in Sweden White Other white 
13dg.00 Born in Switzerland White Other white 
13dh.00 Born in The Netherlands White Other white 
13di.00 Born in Ukraine White Other white 
13dj.00 Born in Vatican City White Other white 
13dk.00 Born in Wales White British 
13dl.00 Born in Yugoslavia White Other white 
13dm.00 Born in former Yugoslav Republic of Macedonia White Other white 
13dn.00 Born in Serbia White Other white 
13e..00 Country of birth (Asian) - - 
13e0.00 Born in Afghanistan Other Other 
13e1.00 Born in Armenia White Other white 
13e2.00 Born in Bahrain Other Other 
13e3.00 Born in Bangladesh Asian Bangladeshi 
13e4.00 Born in Bhutan Other Other 
13e5.00 Born in Brunei Other Other 
13e6.00 Born in Burma Other Other 
13e7.00 Born in Chechnya White Other white 
13e8.00 Born in China Other Chinese 
13e9.00 Born in Democratic People's Republic of Korea Other Other 
13eA.00 Born in East Timor Other Other 
13eB.00 Born in Georgia White Other white 
13eC.00 Born in Hong Kong Other Chinese 
13eD.00 Born in India Asian Indian 
13eE.00 Born in Indonesia Other Other 
13eF.00 Born in Iran Other Other 
13eG.00 Born in Iraq Other Other 
13eH.00 Born in Israel Other Other 
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13eI.00 Born in Japan Other Other 
13eJ.00 Born in Jordan Other Other 
13eK.00 Born in Kazakhstan Other Other 
13eL.00 Born in Kuwait Other Other 
13eM.00 Born in Kyrgyzstan Other Other 
13eN.00 Born in Laos Other Other 
13eO.00 Born in Lebanon Other Other 
13eP.00 Born in Malaysia Other Other 
13eQ.00 Born in Maldives Other Other 
13eR.00 Born in Mali Other Other 
13eS.00 Born in Mongolia Other Other 
13eT.00 Born in Nepal Asian Other Asian 
13eU.00 Born in North Korea Other Other 
13eV.00 Born in Oman Other Other 
13eW.00 Born in Pakistan Asian Pakistani 
13eX.00 Born in Palestine Other Other 
13eY.00 Born in Philippines Other Other 
13eZ.00 Born in Qatar Other Other 
13ea.00 Born in Republic of Korea Other Other 
13eb.00 Born in Russia White Other white 
13ec.00 Born in Saudi Arabia Other Other 
13ed.00 Born in Singapore Other Other 
13ee.00 Born in South Korea Other Other 
13ef.00 Born in Sri Lanka Asian Other Asian 
13eg.00 Born in Syria Other Other 
13eh.00 Born in Taiwan Other Other 
13ei.00 Born in Tajikistan Other Other 
13ej.00 Born in Thailand Other Other 
13ek.00 Born in Turkey White Other white 
13el.00 Born in Turkmenistan Other Other 
13em.00 Born in United Arab Emirates Other Other 
13en.00 Born in Uzbekistan Other Other 
13eo.00 Born in Vietnam Other Other 
13ep.00 Born in Yemen Other Other 
13f..00 Country of birth (American) - - 
13f0.00 Born in Argentina Other Other 
13f1.00 Born in Belize Other Other 
13f2.00 Born in Bolivia Other Other 
13f3.00 Born in Brazil Other Other 
13f4.00 Born in British Guyana Other Other 
13f5.00 Born in Canada White Other white 
13f6.00 Born in Chile Other Other 
13f7.00 Born in Columbia Other Other 
13f8.00 Born in Costa Rica Other Other 
13f9.00 Born in Ecuador Other Other 
13fA.00 Born in El Salvador Other Other 
13fB.00 Born in Grenada Other Other 
13fC.00 Born in Guatemala Other Other 
13fD.00 Born in Guyana Other Other 
13fE.00 Born in Honduras Other Other 
13fF.00 Born in Mexico Other Other 
13fG.00 Born in Nicaragua Other Other 
13fH.00 Born in Panama Other Other 
13fI.00 Born in Paraguay Other Other 
13fJ.00 Born in Peru Other Other 
13fK.00 Born in Suriname Other Other 
13fL.00 Born in USA White Other white 
13fM.00 Born in Uruguay Other Other 
13fN.00 Born in Venezuela Other Other 
13g..00 Country of birth (African) - - 
13g0.00 Born in Algeria Other Other 
13g1.00 Born in Angola Black African 
13g2.00 Born in Benin Black African 
13g3.00 Born in Botswana Black African 
13g4.00 Born in Burkina Faso Black African 
Appendices 
 331 
Table G.2  Continued. 
Read 
code Code description 
5-category 
ethnicity 
group 
16-category 
ethnicity group 
13g5.00 Born in Burundi Black African 
13g6.00 Born in Cambodia Other Other 
13g7.00 Born in Cameroon Black African 
13g8.00 Born in Cape Verde Islands Black African 
13g9.00 Born in Central African Republic Black African 
13gA.00 Born in Chad Black African 
13gB.00 Born in Comoros Islands Black African 
13gC.00 Born in Congo Black African 
13gD.00 Born in Djibouti Black African 
13gE.00 Born in Egypt Other Other 
13gF.00 Born in Equatorial Guinea Black African 
13gG.00 Born in Ethiopia Black African 
13gH.00 Born in Gabon Black African 
13gI.00 Born in Gambia Black African 
13gJ.00 Born in Ghana Black African 
13gK.00 Born in Guinea Bissau Black African 
13gL.00 Born in Guinea Republic Black African 
13gM.00 Born in Ivory Coast Black African 
13gN.00 Born in Kenya Black African 
13gO.00 Born in Lesotho Black African 
13gP.00 Born in Liberia Black African 
13gQ.00 Born in Libya Other Other 
13gR.00 Born in Madagascar Black African 
13gS.00 Born in Malawi Black African 
13gT.00 Born in Mauritania Black African 
13gU.00 Born in Mauritius Asian Other Asian 
13gV.00 Born in Morocco Other Other 
13gW.00 Born in Mozambique Black African 
13gX.00 Born in Namibia Black African 
13gY.00 Born in Niger Black African 
13gZ.00 Born in Nigeria Black African 
13ga.00 Born in Rwanda Black African 
13gb.00 Born in Sao Tome and Principe Black African 
13gc.00 Born in Senegal Black African 
13gd.00 Born in Sierra Leone Black African 
13ge.00 Born in Somalia Black African 
13gf.00 Born in South Africa - - 
13gg.00 Born in Sudan Other Other 
13gh.00 Born in Swaziland Black African 
13gi.00 Born in Tanzania Black African 
13gj.00 Born in The Gambia Black African 
13gk.00 Born in Tunisia Other Other 
13gl.00 Born in Uganda Black African 
13gm.00 Born in Zaire Black African 
13gn.00 Born in Zambia Black African 
13go.00 Born in Zimbabwe Black African 
13gp.00 Born in Eritrea Black African 
13h..00 Country of birth (Australasian) - - 
13h0.00 Born in Australia White Other white 
13h1.00 Born in New Zealand White Other white 
13j..00 Country of birth (Atlantic) - - 
13j0.00 Born in Antigua and Barbuda Black Caribbean 
13j1.00 Born in Bahamas Black Caribbean 
13j2.00 Born in Barbados Black Caribbean 
13j3.00 Born in Cuba Black Caribbean 
13j4.00 Born in Dominican Republic Black Caribbean 
13j5.00 Born in Haiti Black Caribbean 
13j6.00 Born in Jamaica Black Caribbean 
13j7.00 Born in Puerto Rico Black Caribbean 
13j8.00 Born in St. Kitts and Nevis Black Caribbean 
13j9.00 Born in St. Lucia Black Caribbean 
13jA.00 Born in St. Vincent Black Caribbean 
13jB.00 Born in Togo Black African 
13jC.00 Born in Trinidad and Tobago Black Caribbean 
13jD.00 Born in Dominica Black Caribbean 
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13jE.00 Born in Aruba Black Caribbean 
13k..00 Country of birth (Pacific) - - 
13k0.00 Born in Fiji Other Other 
13k1.00 Born in Kiribati Other Other 
13k2.00 Born in Nauru Other Other 
13k3.00 Born in Papua New Guinea Other Other 
13k4.00 Born in Seychelles Other Other 
13k5.00 Born in Solomon Islands Other Other 
13k6.00 Born in Tonga Other Other 
13k7.00 Born in Tuvalu Other Other 
13k8.00 Born in Vanuatu Other Other 
13k9.00 Born in Western Samoa Other Other 
13t..00 Born in British overseas territory - - 
13t0.00 Born in Montserrat - - 
13t1.00 Born in Bermuda - - 
13t2.00 Born in Anguilla - - 
13v..00 Born French overseas region department collectivity t - - 
13v0.00 Born in Martinique Black Caribbean 
13do.00 Born in Montenegro White Other white 
13dp.00 Born in Belarus White Other white 
13dq.00 Born in Republic of Moldova White Other white 
13dr.00 Born in Guernsey White British 
13ds.00 Born in Jersey White British 
13dt.00 Born in Isle of Man White British 
13du.00 Born in Faroe Islands White Other white 
13dv.00 Born in Greenland White Other white 
13dw.00 Born in Svalbard and Jan Mayen White Other white 
13dx.00 Born in Aland Islands White Other white 
13eq.00 Born in Christmas Island Other Chinese 
13er.00 Born in Cocos (Keeling) Islands Other Other 
13es.00 Born in Macao Other Chinese 
13gq.00 Born in Democratic Republic of Congo Black African 
13gr.00 Born in Western Sahara Other Other 
13jF.00 Born in United States Virgin Islands Black Caribbean 
13jG.00 Born in Saint Vincent and the Grenadines Black Caribbean 
13jH.00 Born in Sint Maarten Black Caribbean 
13jJ.00 Born in Saint-Martin Black Caribbean 
13jK.00 Born in Bonaire, Sint Eustatius and Saba Black Caribbean 
13jL.00 Born in Curacao Black Caribbean 
13kA.00 Born in Samoa Other Other 
13kB.00 Born in American Samoa Other Other 
13kC.00 Born in United States Minor Outlying Islands - - 
13kD.00 Born in Tokelau Other Other 
13kE.00 Born in Cook Islands Other Other 
13kF.00 Born in Guam Other Other 
13kG.00 Born in Federated States of Micronesia Other Other 
13kH.00 Born in Marshall Islands Other Other 
13kJ.00 Born in Niue Other Other 
13kK.00 Born in Norfolk Island White Other white 
13kL.00 Born in Northern Mariana Islands Other Other 
13kM.00 Born in Palau Other Other 
13kN.00 Born in Antarctica - - 
13t3.00 Born in British Virgin Islands Black Caribbean 
13t4.00 Born in Turks and Caicos Islands Black Caribbean 
13t5.00 Born in Saint Helena, Ascension and Tristan da Cunha Black Caribbean 
13t6.00 Born in South Georgia and the South Sandwich Islands - - 
13t7.00 Born in Falkland Islands White British 
13t8.00 Born in British Indian Ocean Territory - - 
13t9.00 Born in Cayman Islands Mixed White & African 
13tA.00 Born in Pitcairn Islands White Other white 
13v1.00 Born in Saint Pierre and Miquelon White Other white 
13v2.00 Born in Wallis and Futuna Other Other 
13v3.00 Born in French Polynesia Other Other 
13v4.00 Born in French Guiana Other Other 
13v5.00 Born in French Southern Territories - - 
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13v6.00 Born in Mayotte Other Other 
13v7.00 Born in Guadeloupe Black Caribbean 
13v8.00 Born in Reunion - - 
13v9.00 Born in New Caledonia Other Other 
Codes referring to spoken or read language, or the need for an interpreter 
13Z6.00 Language spoken - - 
13Z6.11 Language - - 
13Z6000 English as a second language - - 
13Z6100 Language Bengali Asian - 
13Z6200 Language Gujurati Asian - 
13Z6300 Language Hindi Asian - 
13Z6400 Language Pashtu Other Other 
13Z6500 Language Punjabi Asian - 
13Z6600 Language Urdu Asian - 
13Z6700 Speaks English well - - 
13Z6800 Speaks English poorly - - 
13Z6Z00 Language NOS - - 
13b..00 World languages - - 
13b0.00 Vietnamese language Other Other 
13b1.00 Cantonese Chinese dialect Other Chinese 
13b2.00 Sylhety Asian - 
13b3.00 Creole language - - 
13b4.00 Mirpuri language Asian - 
13l..00 Main spoken language - - 
13l0.00 Main spoken language Arabic - - 
13l1.00 Main spoken language Bengali Asian - 
13l2.00 Main spoken language Cantonese Other Chinese 
13l3.00 Main spoken language Czech White Other white 
13l4.00 Main spoken language English - - 
13l5.00 Main spoken language French - - 
13l6.00 Main spoken language Gujerati Asian - 
13l7.00 Main spoken language Hausa Black African 
13l8.00 Main spoken language Hindi Asian - 
13l9.00 Main spoken language Iba - - 
13l9.11 Main spoken language Iban Other Other 
13lA.00 Main spoken language Kutchi Asian - 
13lB.00 Main spoken language Mandarin Other Chinese 
13lC.00 Main spoken language Polish White Other white 
13lD.00 Main spoken language Portuguese - - 
13lE.00 Main spoken language Punjabi Asian - 
13lE.11 Main spoken language Panjabi Asian - 
13lF.00 Main spoken language Russian White Other white 
13lG.00 Main spoken language Somali Black African 
13lH.00 Main spoken language Spanish - - 
13lI.00 Main spoken language Swahili Black African 
13lJ.00 Main spoken language Sylheti Asian - 
13lK.00 Main spoken language Tamil Asian - 
13lL.00 Main spoken language Urdu Asian - 
13lM.00 Main spoken language Yoruba Black African 
13lN.00 Main spoken language Kurdish Other Other 
13lO.00 Main spoken language Farsi Other Other 
13lO.11 Main spoken language Persian Other Other 
13lP.00 Main spoken language Shona Black African 
13lQ.00 Main spoken language Italian White Other white 
13lR.00 Main spoken language German White Other white 
13lS.00 Main spoken language Albanian White Other white 
13lT.00 Main spoken language Croatian White Other white 
13lT.11 Main spoken language Serbo-Croatian White Other white 
13lV.00 Main spoken language Greek White Other white 
13lW.00 Main spoken language Japanese Other Other 
13lX.00 Main spoken language Korean Other Other 
13lY.00 Main spoken language Lithuanian White Other white 
13lZ.00 Main spoken language Turkish White Other white 
13la.00 Main spoken language Ukrainian White Other white 
13lc.00 Main spoken language Akan Black African 
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13ld.00 Main spoken language Amharic Black African 
13le.00 Main spoken language Brawa Black African 
13lf.00 Main spoken language Dutch White Other white 
13lg.00 Main spoken language Ethiopian Black African 
13lh.00 Main spoken language Flemish White Other white 
13li.00 Main spoken language French Creole - - 
13lj.00 Main spoken language Gaelic White - 
13lk.00 Main spoken language Hakka Asian - 
13ll.00 Main spoken language Hebrew - - 
13lm.00 Main spoken language Igbo Black African 
13ln.00 Main spoken language Lingala Black African 
13lo.00 Main spoken language Luganda Black African 
13lp.00 Main spoken language Malayalam Asian - 
13lq.00 Main spoken language Norwegian White Other white 
13lr.00 Main spoken language Pashto Other Other 
13ls.00 Main spoken language Patois - - 
13lt.00 Main spoken language Serbian White Other white 
13lt.11 Main spoken language Serbo-Croatian White Other white 
13lu.00 Main spoken language Sinhala Asian - 
13lu.11 Main spoken language Sinhalese Asian - 
13lv.00 Main spoken language Swedish White Other white 
13lw.00 Main spoken language Tagalog Other Other 
13lx.00 Main spoken language Thai Other Other 
13ly.00 Main spoken language Tigrinya Black African 
13lz.00 Main spoken language Welsh White British 
13n..00 Language read - - 
13n0.00 Reads Arabic - - 
13n1.00 Reads Portuguese - - 
13n2.00 Reads Punjabi Asian - 
13n3.00 Reads Russian White Other white 
13n4.00 Reads Somali Black African 
13n5.00 Reads Spanish - - 
13n6.00 Reads Tamil Asian - 
13n7.00 Reads Urdu Asian - 
13n8.00 Reads Bengali Asian - 
13n9.00 Reads Cantonese Other Chinese 
13nA.00 Reads Czech White Other white 
13nB.00 Reads English - - 
13nC.00 Reads French - - 
13nD.00 Reads Hindi Asian - 
13nE.00 Reads Chinese Other Chinese 
13nF.00 Reads Polish White Other white 
13nG.00 Reads Lithuanian White Other white 
13nH.00 Reads Farsi Other Other 
13nJ.00 Reads Chinese - Traditional Other Chinese 
13nK.00 Reads Gujarati Asian - 
13nL.00 Reads Hausa Black African 
13nM.00 Reads Chinese - Simplified Other Chinese 
13nN.00 Reads Swahili Black African 
13nP.00 Reads Yoruba Black African 
13nQ.00 Reads Kurdish Other Other 
13nR.00 Reads Italian White Other white 
13nS.00 Reads German White Other white 
13nT.00 Reads Albanian White Other white 
13nV.00 Reads Croatian White Other white 
13nW.00 Reads Greek White Other white 
13nX.00 Reads Japanese Other Other 
13nY.00 Reads Turkish White Other white 
13nZ.00 Reads Vietnamese Other Other 
13na.00 Reads Amharic Black African 
13nb.00 Reads Lingala Black African 
13nc.00 Reads Pashto Other Other 
13nd.00 Reads Serbian White Other white 
13ne.00 Reads Sinhala Asian - 
13nf.00 Reads Tigrinya Black African 
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13ng.00 Reads Bulgarian White Other white 
13nh.00 Reads Burmese Other Other 
13ni.00 Reads Chechen White Other white 
13nj.00 Reads Indonesian Other Other 
13nk.00 Reads Kinyarwanda Black African 
13nl.00 Reads Kurmanji Other Other 
13nm.00 Reads Malay Other Other 
13nn.00 Reads Mongolian Other Other 
13no.00 Reads Ndebele Black African 
13np.00 Reads Braille - - 
13nq.00 Reads Welsh White British 
13s..00 Second language - - 
13s0.00 Akan as a second language Black African 
13s1.00 Albanian as a second language White Other white 
13s2.00 Amharic as a second language Black African 
13s3.00 Arabic as a second language - - 
13s4.00 Bengali as a second language Asian - 
13s5.00 Italian as a second language White Other white 
13s6.00 Chinese as a second language Other Chinese 
13s7.00 Croatian as a second language White Other white 
13s8.00 Czech as a second language White Other white 
13s9.00 Dutch as a second language White Other white 
13sA.00 English as a second language - - 
13sB.00 German as a second language White Other white 
13sC.00 Ukrainian as a second language White Other white 
13sD.00 French as a second language - - 
13sE.00 Vietnamese as a second language Other Other 
13sF.00 Irish Gaelic as a second language White Irish 
13sG.00 Greek as a second language White Other white 
13sH.00 Gujarati as a second language Asian - 
13sI.00 Tamil as a second language Asian - 
13sJ.00 Urdu as a second language Asian - 
13sK.00 Hausa as a second language Black African 
13sL.00 Hebrew as a second language - - 
13sM.00 Hindi as a second language Asian - 
13sN.00 Yoruba as a second language Black African 
13sO.00 Tagalog as a second language Other Other 
13sP.00 Igbo as a second language Black African 
13sQ.00 Japanese as a second language Other Other 
13sR.00 Korean as a second language Other Other 
13sS.00 Kurdish as a second language Other Other 
13sT.00 Lingala as a second language Black African 
13sU.00 Turkish as a second language White Other white 
13sV.00 Lithuanian as a second language White Other white 
13sW.00 Shona as a second language Black African 
13sX.00 Malayalam as a second language Asian - 
13sY.00 Norwegian as a second language White Other white 
13sZ.00 Polish as a second language White Other white 
13sa.00 Portuguese as a second language - - 
13sb.00 Thai as a second language Other Other 
13sc.00 Russian as a second language White Other white 
13sd.00 Serbian as a second language White Other white 
13se.00 Tigrinya as a second language Black African 
13sf.00 Somali as a second language Black African 
13sg.00 Spanish as a second language - - 
13sh.00 Swahili as a second language Black African 
13si.00 Swedish as a second language White Other white 
13sj.00 Welsh as a second language White British 
13sk.00 Scottish Gaelic as a second language White British 
13u..00 Additional main spoken language - - 
13u0.00 Main spoken language Bulgarian White Other white 
13u1.00 Main spoken language Romanian White Other white 
13u2.00 Main spoken language Oromo Black African 
13u3.00 Main spoken language Abkhazian White Other white 
13u4.00 Main spoken language Afar Black African 
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13u5.00 Main spoken language Afrikaans - - 
13u6.00 Main spoken language Armenian White Other white 
13u7.00 Main spoken language Assamese Asian - 
13u8.00 Main spoken language Aymara Other Other 
13u9.00 Main spoken language Azerbaijani Other Other 
13uA.00 Main spoken language Bashkir White Other white 
13uB.00 Main spoken language Basque White Other white 
13uC.00 Main spoken language Dzongkha Other Other 
13uD.00 Main spoken language Bihari - - 
13uE.00 Main spoken language Bislama Other Other 
13uF.00 Main spoken language Breton White Other white 
13uG.00 Main spoken language Burmese Other Other 
13uH.00 Main spoken language Belarusian White Other white 
13uJ.00 Main spoken language Central Khmer Other Other 
13uK.00 Main spoken language Catalan White Other white 
13uL.00 Main spoken language Slovak White Other white 
13uM.00 Main spoken language Corsican White Other white 
13uN.00 Main spoken language Danish White Other white 
13uP.00 Main spoken language Esperanto - - 
13uQ.00 Main spoken language Estonian White Other white 
13uR.00 Main spoken language Faeroese White Other white 
13uS.00 Main spoken language Fijian Other Other 
13uT.00 Main spoken language Finnish White Other white 
13uV.00 Main spoken language Frisian White Other white 
13uW.00 Main spoken language Galician White Other white 
13uX.00 Main spoken language Georgian White Other white 
13uY.00 Main spoken language Kalaallisut Other Other 
13uY.11 Main spoken language Greenlandic Other Other 
13uZ.00 Main spoken language Guarani Other Other 
13ua.00 Main spoken language Hungarian White Other white 
13ub.00 Main spoken language Icelandic White Other white 
13uc.00 Main spoken language Indonesian Other Other 
13ud.00 Main spoken language Interlingua - - 
13ue.00 Main spoken language Interlingue - - 
13uf.00 Main spoken language Inupiaq Other Other 
13ug.00 Main spoken language Inuktitut Other Other 
13uh.00 Main spoken language Irish White Irish 
13ui.00 Main spoken language Javanese White Other white 
13uj.00 Main spoken language Kannada Asian Indian 
13uk.00 Main spoken language Kashmiri Asian - 
13ul.00 Main spoken language Kazakh Other Other 
13um.00 Main spoken language Kinyarwanda Black African 
13un.00 Main spoken language Kirghiz Other Other 
13uo.00 Main spoken language Rundi Black African 
13up.00 Main spoken language Lao Other Other 
13uq.00 Main spoken language Bamun Black African 
13uq.11 Main spoken language Bamoun Black African 
13ur.00 Main spoken language Latvian White Other white 
13us.00 Main spoken language Macedonian White Other white 
13ut.00 Main spoken language Malagasy Black African 
13uu.00 Main spoken language Malay Other Other 
13uv.00 Main spoken language Maltese White Other white 
13uw.00 Main spoken language Maori Other Other 
13ux.00 Main spoken language Marathi Asian Indian 
13uy.00 Main spoken language Moldavian White Other white 
13uz.00 Main spoken language Mongolian Other Other 
13w..00 Supplemental main language spoken - - 
13w0.00 Main spoken language Nauru Other Other 
13w1.00 Main spoken language Nepali Other Other 
13w2.00 Main spoken language Occitan White Other white 
13w3.00 Main spoken language Oriya Asian Indian 
13w4.00 Main spoken language Filipino Other Other 
13w5.00 Main spoken language Quechua Other Other 
13w6.00 Main spoken language Romansh White Other white 
13w7.00 Main spoken language Samoan Other Other 
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13w8.00 Main spoken language Sango Black African 
13w9.00 Main spoken language Hindko Asian - 
13wA.00 Main spoken language Dari Other Other 
13wB.00 Main spoken language Southern Sotho Black African 
13wC.00 Main spoken language Tswana Black African 
13wD.00 Main spoken language Sindhi Asian - 
13wE.00 Main spoken language Ndebele Black African 
13wF.00 Main spoken language Swati Black African 
13wG.00 Main spoken language Slovenian White Other white 
13wH.00 Main spoken language Sundanese Black African 
13wJ.00 Main spoken language Tajik Other Other 
13wK.00 Main spoken language Tatar White Other white 
13wL.00 Main spoken language Telugu Asian Indian 
13wM.00 Main spoken language Tibetan Other Other 
13wN.00 Main spoken language Tongan Other Other 
13wP.00 Main spoken language Tsonga Black African 
13wQ.00 Main spoken language Turkmen Other Other 
13wR.00 Main spoken language Twi Black African 
13wS.00 Main spoken language Uighur Other Chinese 
13wT.00 Main spoken language Uzbek Other Other 
13wV.00 Main spoken language Tetum Other Other 
13wW.00 Main spoken language Wolof Black African 
13wX.00 Main spoken language Xhosa Black African 
13wY.00 Main spoken language Yiddish - - 
13wZ.00 Main spoken language Zhuang Other Chinese 
13wa.00 Main spoken language Zulu Black African 
13wb.00 Main spoken language Konkani Asian Indian 
13wc.00 Main spoken language Aragonese White Other white 
9NU..00 Need for interpreter - - 
9NU0.00 Interpreter needed - - 
9NU1.00 Interpreter not needed - - 
9NU2.00 Interpreter needed - Akan Black African 
9NU3.00 Interpreter needed - Albanian White Other white 
9NU4.00 Interpreter needed - Amharic Black African 
9NU5.00 Interpreter needed - Arabic - - 
9NU6.00 Interpreter needed - Bengali Asian - 
9NU7.00 Interpreter needed - Italian White Other white 
9NU8.00 Interpreter needed - Cantonese Other Chinese 
9NU9.00 Interpreter needed - Croatian White Other white 
9NU9.11 Serbo-Croatian language interpreter needed White Other white 
9NUA.00 Interpreter needed - Czech White Other white 
9NUB.00 Interpreter needed - Dutch White Other white 
9NUC.00 Interpreter needed - Farsi Other Other 
9NUC.11 Persian language interpreter needed Other Other 
9NUD.00 Interpreter needed - French - - 
9NUE.00 Interpreter needed - French Creole - - 
9NUF.00 Interpreter needed - Igbo Black African 
9NUG.00 Interpreter needed - German White Other white 
9NUH.00 Interpreter needed - Greek White Other white 
9NUJ.00 Interpreter needed - Gujarati Asian - 
9NUK.00 Interpreter needed - Hakka Other - 
9NUL.00 Interpreter needed - Hausa Black African 
9NUM.00 Interpreter needed - Hebrew - - 
9NUN.00 Interpreter needed - Hindi Asian - 
9NUP.00 Interpreter needed - Japanese Other Other 
9NUQ.00 Interpreter needed - Korean Other Other 
9NUR.00 Interpreter needed - Kurdish Other Other 
9NUS.00 Interpreter needed - Lingala Black African 
9NUT.00 Interpreter needed - Lithuanian White Other white 
9NUV.00 Interpreter needed - Ganda Black African 
9NUW.00 Interpreter needed - Malayalam Asian Indian 
9NUX.00 Interpreter needed - Mandarin Other Chinese 
9NUY.00 Interpreter needed - Norwegian White Other white 
9NUZ.00 Interpreter needed - Pashto Other Other 
9NUa.00 Interpreter needed - Polish White Other white 
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Read 
code Code description 
5-category 
ethnicity 
group 
16-category 
ethnicity group 
9NUb.00 Interpreter needed - Portuguese - - 
9NUc.00 Interpreter needed - Panjabi Asian - 
9NUc.11 Punjabi language interpreter needed Asian - 
9NUd.00 Interpreter needed - Russian White Other white 
9NUe.00 Interpreter needed - Serbian White Other white 
9NUe.11 Serbo-Croatian language interpreter needed White Other white 
9NUf.00 Interpreter needed - Shona Black African 
9NUg.00 Interpreter needed - Sinhala Asian Other Asian 
9NUh.00 Interpreter needed - Somali Black African 
9NUi.00 Interpreter needed - Spanish - - 
9NUj.00 Interpreter needed - Swahili Black African 
9NUk.00 Interpreter needed - Swedish White Other white 
9NUl.00 Interpreter needed - Sylheti Asian - 
9NUm.00 Interpreter needed - Tagalog Other Other 
9NUn.00 Interpreter needed - Tamil Asian - 
9NUo.00 Interpreter needed - Thai Other Other 
9NUp.00 Interpreter needed - Tigrinya Black African 
9NUq.00 Interpreter needed - Turkish White Other white 
9NUr.00 Interpreter needed - Ukrainian White Other white 
9NUs.00 Interpreter needed - Urdu Asian - 
9NUt.00 Interpreter needed - Vietnamese Other Other 
9NUu.00 Interpreter needed - Welsh White British 
9NUv.00 Interpreter needed - Yoruba Black African 
9NUw.00 Interpreter needed - British Sign Language - - 
9NUx.00 Interpreter needed - Makaton Sign Language - - 
9NUy.00 Romanian language interpreter needed White Other white 
9NUz.00 Bulgarian language interpreter needed White Other white 
9Nm..00 Other interpreter needed - - 
9Nm0.00 Mongolian language interpreter needed Other Other 
9Nm1.00 Moldavian language interpreter needed White Other white 
9Nm2.00 Marathi language interpreter needed Asian Indian 
9Nm3.00 Maltese language interpreter needed White Other white 
9Nm4.00 Luganda language interpreter needed Black African 
9Nm5.00 Ethiopian language interpreter needed Black African 
9Nm6.00 Brawa language interpreter needed - - 
9Nm7.00 Kirghiz language interpreter needed Other Other 
9Nm8.00 Iban language interpreter needed Other Other 
9Nm9.00 Maori language interpreter needed Other Other 
9NmA.00 Macedonian language interpreter needed White Other white 
9NmB.00 Malagasy language interpreter needed Other Other 
9NmC.00 Latvian language interpreter needed White Other white 
9NmD.00 Kannada language interpreter needed Asian Indian 
9NmE.00 Kinyarwanda language interpreter needed Black African 
9NmF.00 Malay language interpreter needed Other Other 
9NmG.00 Kashmiri language interpreter needed Asian - 
9NmH.00 Kazakh language interpreter needed Other Other 
9NmJ.00 Inupiaq language interpreter needed Other Other 
9NmK.00 Javanese language interpreter needed Other Other 
9NmL.00 Inuktitut language interpreter needed Other Other 
9NmM.00 Interlingue language interpreter needed - - 
9NmN.00 Lao language interpreter needed Other Other 
9NmP.00 Icelandic language interpreter needed White Other white 
9NmQ.00 Hungarian language interpreter needed White Other white 
9NmR.00 Guarani language interpreter needed Other Other 
9NmS.00 Georgian language interpreter needed White Other white 
9NmT.00 Frisian language interpreter needed White Other white 
9NmV.00 Faeroese language interpreter needed White Other white 
9NmW.00 Fijian language interpreter needed Other Other 
9NmX.00 Galician language interpreter needed White Other white 
9NmY.00 Esperanto language interpreter needed - - 
9NmZ.00 Estonian language interpreter needed White Other white 
9Nma.00 Corsican language interpreter needed White Other white 
9Nmb.00 Danish language interpreter needed White Other white 
9Nmc.00 Kalaallisut language interpreter needed Other Other 
9Nmc.11 Greenlandic language interpreter needed Other Other 
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Read 
code Code description 
5-category 
ethnicity 
group 
16-category 
ethnicity group 
9Nmd.00 Catalan language interpreter needed White Other white 
9Nme.00 Belarusian language interpreter needed White Other white 
9Nmf.00 Indonesian language interpreter needed Other Other 
9Nmg.00 Breton language interpreter needed White Other white 
9Nmh.00 Bislama language interpreter needed Other Other 
9Nmi.00 Bihari language interpreter needed Asian - 
9Nmj.00 Assamese language interpreter needed Asian - 
9Nmk.00 Armenian language interpreter needed White Other white 
9Nml.00 Central Khmer language interpreter needed Other Other 
9Nmm.00 Burmese language interpreter needed Other Other 
9Nmn.00 Aymara language interpreter needed Other Other 
9Nmo.00 Afrikaans language interpreter needed - - 
9Nmp.00 Azerbaijani language interpreter needed Other Other 
9Nmq.00 Basque language interpreter needed White Other white 
9Nmr.00 Afar language interpreter needed Black African 
9Nms.00 Abkhazian language interpreter needed White Other white 
9Nmt.00 Dzongkha language interpreter needed Other Other 
9Nmu.00 Zulu language interpreter needed Black African 
9Nmv.00 Zhuang language interpreter needed Other Chinese 
9Nmw.00 Uzbek language interpreter needed Other Other 
9Nmx.00 Oromo language interpreter needed Black African 
9Nmy.00 Yiddish language interpreter needed - - 
9Nmz.00 Rundi language interpreter needed Black African 
9Nn..00 Further interpreter needed - - 
9Nn0.00 Tibetan language interpreter needed Other Other 
9Nn1.00 Tsonga language interpreter needed Black African 
9Nn2.00 Tatar language interpreter needed White Other white 
9Nn3.00 Twi language interpreter needed Black African 
9Nn4.00 Telugu language interpreter needed Asian Indian 
9Nn5.00 Tongan language interpreter needed Other Other 
9Nn6.00 Turkmen language interpreter needed Other Other 
9Nn7.00 Slovenian language interpreter needed White Other white 
9Nn8.00 Swati language interpreter needed Black African 
9Nn9.00 Southern Sotho language interpreter needed Black African 
9NnA.00 Tajik language interpreter needed Other Other 
9NnB.00 Sindhi language interpreter needed Asian - 
9NnC.00 Sundanese language interpreter needed Black African 
9NnD.00 Samoan language interpreter needed Other Other 
9NnE.00 Tswana language interpreter needed Black African 
9NnF.00 Quechua language interpreter needed Other Other 
9NnG.00 Sango language interpreter needed Black African 
9NnH.00 Uighur language interpreter needed Other - 
9NnJ.00 Oriya language interpreter needed Asian Indian 
9NnK.00 Nepali language interpreter needed Other Other 
9NnL.00 Occitan language interpreter needed White Other white 
9NnM.00 Nauru language interpreter needed Other Other 
9NnN.00 Romansh language interpreter needed White Other white 
9NnP.00 Xhosa language interpreter needed Black African 
Abbreviations: ONS, Office for National Statistics; White & Caribb., White and Black Caribbean; White & 
African, White and Black African. 
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G.3 Re ad codes re lat ed to pregna ncy  or  deliv ery  
Table G.3  Read codes related to pregnancy or delivery, grouped into categories.  
Read 
code Code description Category 
13H8.00 Illegitimate pregnancy Pregnant 
13Hd.00 Teenage pregnancy Pregnant 
13If000 Unborn child is cause for safeguarding concern Pregnant 
13S..00 Pregnancy benefits Pregnant 
13SZ.00 Pregnancy benefit NOS Pregnant 
615C.00 IUD failure - pregnant Pregnant 
615C.11 Pregnant, IUD failure Pregnant 
6166.00 Pregnant, diaphragm failure Pregnant 
6174.00 Pregnant, sheath failure Pregnant 
62...00 Patient pregnant Pregnant 
621..00 Patient currently pregnant Pregnant 
621..11 Pregnancy confirmed Pregnant 
6213.00 Pregnant - V.E. confirms Pregnant 
6214.00 Pregnant - on history Pregnant 
6215.00 Pregnant - on abdom. palpation Pregnant 
6216.00 Pregnant - planned Pregnant 
6217.00 Pregnant - unplanned - wanted Pregnant 
621A.00 Pregnancy unplanned ? wanted Pregnant 
621B.00 Pregnant - ? planned Pregnant 
621C.00 Unplanned pregnancy Pregnant 
621D.00 Concealed pregnancy Pregnant 
621Z.00 Patient pregnant NOS Pregnant 
62O7.00 Pregnancy prolonged - 41 weeks Pregnant 
62O8.00 Pregnancy prolonged - 42 weeks Pregnant 
8B68.00 Pregnancy prophylactic therapy Pregnant 
8B7..11 Pregnancy vitamin/iron prophyl Pregnant 
8B74.00 Iron supplement in pregnancy Pregnant 
8B75.00 Vitamin supplement - pregnancy Pregnant 
L13..00 Excessive pregnancy vomiting Pregnant 
L13..12 Hyperemesis of pregnancy Pregnant 
L132.00 Late vomiting of pregnancy Pregnant 
L132000 Late pregnancy vomiting unspecified Pregnant 
L132100 Late pregnancy vomiting - delivered Pregnant 
L132200 Late pregnancy vomiting - not delivered Pregnant 
L132z00 Late pregnancy vomiting NOS Pregnant 
L13y.00 Other pregnancy vomiting Pregnant 
L13y000 Other pregnancy vomiting unspecified Pregnant 
L13y100 Other pregnancy vomiting - delivered Pregnant 
L13y200 Other pregnancy vomiting - not delivered Pregnant 
L13yz00 Other pregnancy vomiting NOS Pregnant 
L13z.00 Unspecified pregnancy vomiting Pregnant 
L13z000 Unspecified pregnancy vomiting unspecified Pregnant 
L13z100 Unspecified pregnancy vomiting - delivered Pregnant 
L13z200 Unspecified pregnancy vomiting - not delivered Pregnant 
L13zz00 Unspecified pregnancy vomiting NOS Pregnant 
L161.00 Oedema or excessive weight gain in pregnancy no 
hypertension 
Pregnant 
L161.11 Excessive weight gain in pregnancy Pregnant 
L161000 Oedema or excessive weight gain in pregnancy, unspecified Pregnant 
L161100 Oedema or excessive weight gain in pregnancy, delivered Pregnant 
L161300 Oedema or excessive weight gain in pregnancy - not delivered Pregnant 
L161z00 Oedema or excessive weight gain in pregnancy NOS Pregnant 
L168.00 Fatigue during pregnancy Pregnant 
L168000 Fatigue during pregnancy unspecified Pregnant 
L168100 Fatigue during pregnancy - delivered Pregnant 
L168200 Fatigue during pregnancy - delivered with postnatal comp Pregnant 
L168300 Fatigue during pregnancy - not delivered Pregnant 
L168400 Fatigue during pregnancy with postnatal complication Pregnant 
L168z00 Fatigue during pregnancy NOS Pregnant 
L16D.00 Excessive weight gain in pregnancy Pregnant 
L16E.00 Pregnancy pruritus Pregnant 
L2...00 Risk factors in pregnancy Pregnant 
L21..00 Multiple pregnancy Pregnant 
L210.00 Twin pregnancy Pregnant 
L210000 Twin pregnancy unspecified Pregnant 
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Table G.3  Continued. 
Read 
code Code description Category 
L210200 Twin pregnancy with antenatal problem Pregnant 
L210z00 Twin pregnancy NOS Pregnant 
L211.00 Triplet pregnancy Pregnant 
L211000 Triplet pregnancy unspecified Pregnant 
L211200 Triplet pregnancy with antenatal problem Pregnant 
L211z00 Triplet pregnancy NOS Pregnant 
L212.00 Quadruplet pregnancy Pregnant 
L212000 Quadruplet pregnancy unspecified Pregnant 
L212200 Quadruplet pregnancy with antenatal problem Pregnant 
L212z00 Quadruplet pregnancy NOS Pregnant 
L21y.00 Other multiple pregnancy Pregnant 
L21y000 Other multiple pregnancy unspecified Pregnant 
L21y200 Other multiple pregnancy with antenatal problem Pregnant 
L21yz00 Other multiple pregnancy NOS Pregnant 
L21z.00 Multiple pregnancy NOS Pregnant 
L21z000 Multiple pregnancy NOS, unspecified Pregnant 
L21z200 Multiple pregnancy NOS with antenatal problem Pregnant 
L21zz00 Multiple pregnancy NOS Pregnant 
L222000 Breech presentation unspecified Pregnant 
L228.00 Multiple pregnancy with malpresentation Pregnant 
L228000 Multiple pregnancy with malpresentation unspecified Pregnant 
L228z00 Multiple pregnancy with malpresentation NOS Pregnant 
L22y.00 Other fetal malposition and malpresentation Pregnant 
L22y000 Other fetal malposition and malpresentation unspecified Pregnant 
L22y200 Other fetal malposition and malpresentation with a/n prob Pregnant 
L22yz00 Other fetal malposition and malpresentation NOS Pregnant 
L22z.00 Fetal malposition and malpresentation NOS Pregnant 
L22z000 Fetal malposition and malpresentation NOS, unspecified Pregnant 
L22z200 Fetal malposition and malpresentation NOS with a/n problem Pregnant 
L22zz00 Fetal malposition and malpresentation NOS Pregnant 
L265.00 Small-for-dates fetus in pregnancy Pregnant 
L266.00 Large-for-dates fetus in pregnancy Pregnant 
L2B..00 Low weight gain in pregnancy Pregnant 
L2C..00 Malnutrition in pregnancy Pregnant 
L2y..00 Other specified risk factors in pregnancy Pregnant 
L2z..00 Risk factors in pregnancy NOS Pregnant 
Z2...00 Pregnancy, childbirth and puerperium observations Pregnant 
Z22..00 Pregnancy observations Pregnant 
Z225.00 Normal pregnancy Pregnant 
Z226.00 Pregnancy problem Pregnant 
Z227.00 Confirmation of pregnancy Pregnant 
Z229.00 Observation of position of pregnancy Pregnant 
Z229100 Intrauterine pregnancy Pregnant 
Z22A.00 Observation of pattern of pregnancy Pregnant 
Z22A100 Low risk pregnancy Pregnant 
Z22A200 High risk pregnancy Pregnant 
Z22A211 HRP - High risk pregnancy Pregnant 
Z22A300 Concealed pregnancy Pregnant 
Z22A400 Early stage of pregnancy Pregnant 
Z22A500 Biochemical pregnancy Pregnant 
Z22A600 Teenage pregnancy Pregnant 
Z22A800 Undiagnosed pregnancy Pregnant 
Z22AA00 Wanted pregnancy Pregnant 
Z22AB00 Unplanned pregnancy Pregnant 
Z22AB11 Accidental pregnancy Pregnant 
Z22AC00 Pregnancy with uncertain dates Pregnant 
Z22AD00 Presentation of pregnancy Pregnant 
Z22AD11 Reported conception - pregnancy Pregnant 
Z22B.00 Observation of quantity of pregnancy Pregnant 
Z22B100 Single pregnancy Pregnant 
Z22B500 Quintuplet pregnancy Pregnant 
Z22B600 Sextuplet pregnancy Pregnant 
Z22B700 Septulet pregnancy Pregnant 
Z22B800 Undiagnosed multiple pregnancy Pregnant 
Z22B900 Continuing pregnancy after abortion of sibling fetus Pregnant 
Z22BA00 Contin pregnancy after intrauterine death of sibling fetus Pregnant 
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Read 
code Code description Category 
Z22C311 Pregnancy duration Pregnant 
Z22C313 Duration of pregnancy Pregnant 
Z22C314 Weeks pregnant Pregnant 
Z22D100 Viable pregnancy Pregnant 
ZV22.00 [V]Normal pregnancy Pregnant 
ZV22.11 [V]Supervision of normal pregnancy Pregnant 
ZV22000 [V]First normal pregnancy supervision Pregnant 
ZV22100 [V]Other normal pregnancy supervision Pregnant 
ZV22200 [V]Pregnancy confirmed Pregnant 
ZV22300 [V]Pregnant state, incidental Pregnant 
ZV22400 [V]Supervision of other normal pregnancy Pregnant 
ZV22y00 [V]Other specified pregnant state Pregnant 
ZV22z00 [V]Unspecified pregnant state Pregnant 
ZV23.00 [V]High-risk pregnancy supervision Pregnant 
ZV23000 [V]Pregnancy with history of infertility Pregnant 
ZV23400 [V]Pregnancy with other poor obstetric history Pregnant 
ZV23500 [V]Pregnancy with other poor reproductive history Pregnant 
ZV23600 [V]Supervisn/pregnancy wth history insufficnt antenatal care Pregnant 
ZV23800 [V]Supervision of high-risk pregnancy due to social problems Pregnant 
ZV23y00 [V]Other specified high-risk pregnancy Pregnant 
ZV23z00 [V]Unspecified high-risk pregnancy Pregnant 
ZVu2300 [X]Supervision of other normal pregnancy Pregnant 
ZVu2500 [X]Supervision of other high-risk pregnancies Pregnant 
4453.00 Serum pregnancy test positive Pregnancy Test 
4654.00 Urine pregnancy test positive Pregnancy Test 
6211.00 Pregnant - urine test confirms Pregnancy Test 
6212.00 Pregnant - blood test confirms Pregnancy Test 
584..11 Fetal U-S scan Antenatal ultrasound scan 
5845.00 U-S scan - fetal cephalometry Antenatal ultrasound scan 
5846.00 U-S scan - fetal maturity Antenatal ultrasound scan 
5849.00 U-S scan - fetal presentation Antenatal ultrasound scan 
584C.00 Antenatal ultrasound result received Antenatal ultrasound scan 
584D.00 Antenatal ultrasound confirms intra-uterine pregnancy Antenatal ultrasound scan 
62G..00 Antenatal ultrasound scan Antenatal ultrasound scan 
62G6.00 A/N U/S scan normal += dates Antenatal ultrasound scan 
62G7.00 A/N U/S scan normal +? dates Antenatal ultrasound scan 
62GB.00 Antenatal ultrasounds scan at 4-8 weeks Antenatal ultrasound scan 
62GC.00 Antenatal ultrasound scan at 9-16 weeks Antenatal ultrasound scan 
62GD.00 Antenatal ultrasound scan at 17-22 weeks Antenatal ultrasound scan 
62GE.00 Antenatal ultrasound scan at 22-40 weeks Antenatal ultrasound scan 
62GZ.00 Antenatal ultrasound scan NOS Antenatal ultrasound scan 
7F27.00 Non routine obstetric scan for fetal observations Antenatal ultrasound scan 
7F27200 Fetal biometry Antenatal ultrasound scan 
7F27y00 OS non routine obstetric scan for fetal observations Antenatal ultrasound scan 
7F27z00 Non routine obstetric scan for fetal observations NOS Antenatal ultrasound scan 
7F2B100 Ultrasound monitoring of early pregnancy Antenatal ultrasound scan 
272..00 O/E - fetal presentation Antenatal examination 
2726.00 O/E -fetal presentation unsure Antenatal examination 
272Z.00 O/E - fetal presentation NOS Antenatal examination 
274Z.00 O/E - fetal station NOS Antenatal examination 
275..00 O/E - fetal movements Antenatal examination 
2751.00 O/E - no fetal movements Antenatal examination 
2752.00 O/E - fetal movements seen Antenatal examination 
2753.00 O/E - fetal movements felt Antenatal examination 
2755.00 O/E - fetal movemnt.diminished Antenatal examination 
275Z.00 O/E - fetal movements NOS Antenatal examination 
276..00 O/E - fetal heart heard Antenatal examination 
2764.00 O/E - fetal heart 80-100 Antenatal examination 
2765.00 O/E - fetal heart 100-120 Antenatal examination 
2766.00 O/E - fetal heart 120-160 Antenatal examination 
2767.00 O/E - fetal heart 160-180 Antenatal examination 
2768.00 O/E - fetal heart 180-200 Antenatal examination 
2769.00 O/E - fetal heart > 200 Antenatal examination 
276A.00 O/E - fetal heart -type 1 dips Antenatal examination 
276B.00 O/E - fetal heart -type 2 dips Antenatal examination 
276Z.00 O/E - fetal heart NOS Antenatal examination 
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code Code description Category 
62N..00 Antenatal examinations Antenatal examination 
62N1.00 A/N booking examination Antenatal examination 
62N2.00 A/N 12 weeks examination Antenatal examination 
62N3.00 A/N 16 week examination Antenatal examination 
62N4.00 A/N 20 week examination Antenatal examination 
62N5.00 A/N 24 week examination Antenatal examination 
62N6.00 A/N 28 week examination Antenatal examination 
62N7.00 A/N 30 week examination Antenatal examination 
62N8.00 A/N 32 week examination Antenatal examination 
62N9.00 A/N 34 week examination Antenatal examination 
62NA.00 A/N 35 week examination Antenatal examination 
62NB.00 A/N 36 week examination Antenatal examination 
62NC.00 A/N 37 week examination Antenatal examination 
62ND.00 A/N 38 week examination Antenatal examination 
62NE.00 A/N 39 week examination Antenatal examination 
62NF.00 A/N 40 week examination Antenatal examination 
62NG.00 A/N 41 week examination Antenatal examination 
62NH.00 A/N 42 week examination Antenatal examination 
62NJ.00 Antenatal 22 week examination Antenatal examination 
62NK.00 Antenatal 25 week examination Antenatal examination 
62NL.00 Antenatal 31 week examination Antenatal examination 
62NZ.00 Antenatal examination NOS Antenatal examination 
62O1.00 Fetal movements felt Antenatal examination 
62O2.00 Fetal movements seen Antenatal examination 
Z235.00 Observation of shape of pregnant abdomen Antenatal examination 
Z235100 Ovoid pregnant abdomen Antenatal examination 
Z235200 Rounded pregnant abdomen Antenatal examination 
Z235211 Globular pregnant abdomen Antenatal examination 
Z235300 Transversely enlarged pregnant abdomen Antenatal examination 
Z235400 Pendulous pregnant abdomen Antenatal examination 
Z236300 Pregnant uterus displaced laterally Antenatal examination 
Z23D100 Girth of pregnant abdomen Antenatal examination 
Z23D200 Pregnant abdomen observation Antenatal examination 
38B6.00 Antenatal risk assessment Antenatal care 
62...11 Antenatal care Antenatal care 
62...13 Pregnancy care Antenatal care 
622..00 Antenatal care: gravida No. Antenatal care 
6221.00 Antenatal care: primigravida Antenatal care 
6222.00 Antenatal care: 2nd pregnancy Antenatal care 
6223.00 Antenatal care: 3rd pregnancy Antenatal care 
6224.00 Antenatal care: multip Antenatal care 
622Z.00 Antenatal care: gravida NOS Antenatal care 
623..00 A/N care: obstetric risk Antenatal care 
6231.00 A/N care: uncertain dates Antenatal care 
6233.00 A/N care: grand multip Antenatal care 
6236.00 A/N care: poor obstetr history Antenatal care 
623Z.00 A/N care: obstetric risk NOS Antenatal care 
624..00 A/N care: precious pregnancy Antenatal care 
6241.00 A/N care: elderly primip. Antenatal care 
624Z.00 A/N care: precious preg. NOS Antenatal care 
625..00 A/N care: social risk Antenatal care 
6251.00 A/N care: poor home conditions Antenatal care 
6252.00 A/N care: poor A/N attender Antenatal care 
6253.00 A/N care: late booker Antenatal care 
625Z.00 A/N care: social risk NOS Antenatal care 
626..00 A/N care: medical risk Antenatal care 
627..00 A/N care: gynae. risk Antenatal care 
628..00 A/N care: risk NOS Antenatal care 
6281.00 A/N care: under 5ft tall Antenatal care 
6282.00 A/N care:10yrs+since last preg Antenatal care 
6283.00 A/N care: primip. < 17 years Antenatal care 
6284.00 A/N care: primip. > 30 years Antenatal care 
6285.00 A/N care: multip. > 35 years Antenatal care 
628Z.00 A/N risk NOS Antenatal care 
62A..00 A/N care provider Antenatal care 
62A1.00 A/N care from G.P. Antenatal care 
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code Code description Category 
62A2.00 A/N care from consultant Antenatal care 
62A3.00 A/N - shared care Antenatal care 
62A4.00 A/N care midwifery led Antenatal care 
62AZ.00 A/N care provider NOS Antenatal care 
62O..00 Misc. antenatal data Antenatal care 
62O..11 Fetal maturity - A/N Antenatal care 
62O3.00 Fetal maturity: dates = size Antenatal care 
62O4.00 Fetal maturity: dates not=size Antenatal care 
62OZ.00 Misc. antenatal data NOS Antenatal care 
62Y..00 Routine antenatal care Antenatal care 
62a..00 Pregnancy review Antenatal care 
62a..11 Review of pregnancy Antenatal care 
6B22.00 Sure Start antenatal visit Antenatal care 
8HT9.00 Referral to antenatal clinic Antenatal care 
9N1N.00 Seen in antenatal clinic Antenatal care 
9NFV.00 Health visitor antenatal visit Antenatal care 
9NV1.00 Antenatal clinic Antenatal care 
9Nil.00 Did not attend antenatal appointment Antenatal care 
L263800 Maternal care for fetal decelerations during pregnancy Antenatal care 
L263900 Maternal care for fetal tachycardia during pregnancy Antenatal care 
L263A00 Maternal care for fetal bradycardia during pregnancy Antenatal care 
L263A11 Maternal care for reduced fetal heart rate during pregnancy Antenatal care 
L263B00 Maternal care for fetal acidosis during pregnancy Antenatal care 
Z212.00 Antenatal care Antenatal care 
Z212.11 Pregnancy care Antenatal care 
62I..11 AFP test - antenatal Antenatal screening or test 
62K..00 Antenatal syphilis screen Antenatal screening or test 
62KZ.00 Antenatal syphilis screen NOS Antenatal screening or test 
62L..00 Antenatal blood group screen Antenatal screening or test 
62M..00 Antenatal sickle cell screen Antenatal screening or test 
62W..00 Antenatal blood tests Antenatal screening or test 
62b..00 Antenatal HIV screening Antenatal screening or test 
62c..00 Antenatal screening Antenatal screening or test 
65QG.00 Antenatal screening shows non sig haemoglobinopathy carrier Antenatal screening or test 
68b..00 Antenatal screening status Antenatal screening or test 
68b6.00 Antenatal screening declined Antenatal screening or test 
ZV28.00 [V]Antenatal screening Antenatal screening or test 
ZV28600 [V]Antenatal screening for chromosomal anomalies Antenatal screening or test 
ZV28y00 [V]Other specified antenatal screening Antenatal screening or test 
ZV28z00 [V]Unspecified antenatal screening Antenatal screening or test 
ZVu2900 [X]Other antenatal screening Antenatal screening or test 
62B1.00 Delivery: no place booked Delivery booking 
62B2.00 Home delivery booked Delivery booking 
62B3.00 G.P. unit delivery booking Delivery booking 
62B5.00 Private home delivery booking Delivery booking 
62B6.00 Delivery booking place changed Delivery booking 
62B8.00 Midwife unit delivery booking Delivery booking 
62BZ.00 Delivery booking - place NOS Delivery booking 
62C1.00 Short stay delivery booking Delivery booking 
62C2.00 Full stay delivery booking Delivery booking 
62CZ.00 Delivery booking - stay NOS Delivery booking 
62V..00 Delivery place planned Delivery booking 
62V0.00 Home delivery planned Delivery booking 
Z212100 Delivery place planned Delivery booking 
Z212200 Home delivery planned Delivery booking 
Z212300 Delivery place booked Delivery booking 
1514.12 Estimated date of delivery Estimated delivery date 
1514000 Estimated date of delivery from last period Estimated delivery date 
1514100 Estimated date of delivery by antenatal ultrasound scan Estimated delivery date 
Z22C100 Estimated date of delivery from last period Estimated delivery date 
Z22C200 Estimated date of delivery from last normal period Estimated delivery date 
62F..00 Antenatal amniocentesis Amniocentesis 
62F6.00 A/N amniocentesis - normal Amniocentesis 
62FZ.00 Antenatal amniocentesis NOS Amniocentesis 
ZVu2600 [X]Other antenatal screening based on amniocentesis Amniocentesis 
63...00 Birth details Birth or delivery 
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631..00 Place of birth Birth or delivery 
631..11 Born - place delivered Birth or delivery 
6311.00 Home birth Birth or delivery 
6312.00 GP unit birth Birth or delivery 
6313.00 Consultant unit birth Birth or delivery 
6314.00 Nursing home birth Birth or delivery 
6315.00 Ambulance birth Birth or delivery 
6316.00 Born before arrival Birth or delivery 
6317.00 Born in transit to hospital Birth or delivery 
6318.00 Born in hospital Birth or delivery 
631Z.00 Place of birth NOS Birth or delivery 
633..00 Outcome of delivery Birth or delivery 
633..11 Livebirth Birth or delivery 
633..13 Triplet birth Birth or delivery 
633..14 Twin birth Birth or delivery 
6331.00 Single live birth Birth or delivery 
6333.00 Twins - both live born Birth or delivery 
6334.00 Twins - 1 still + 1 live born Birth or delivery 
6336.00 Triplets - all live born Birth or delivery 
6337.00 Triplets -2 live+ 1 still born Birth or delivery 
6338.00 Triplets-1 live+ 2 still born Birth or delivery 
633D.00 Order of birth at delivery Birth or delivery 
633Z.00 Outcome of delivery NOS Birth or delivery 
633a.00 Birth of child Birth or delivery 
63CL.00 One of multiple birth Birth or delivery 
63D7.00 Complete placenta at delivery Birth or delivery 
63E..00 Labour details Birth or delivery 
63E1.00 Spontaneous onset of labour Birth or delivery 
63E2.00 Normal birth Birth or delivery 
63E3.00 Normal labour Birth or delivery 
63F..00 Birth details not known Birth or delivery 
63G..00 Uterine membrane observations Birth or delivery 
63G0.00 Membranes complete Birth or delivery 
63G1.00 Membranes incomplete Birth or delivery 
63H..00 Time of delivery Birth or delivery 
63Z..00 Birth details NOS Birth or delivery 
7F...11 Childbirth operations Birth or delivery 
7F...12 Pregnancy operations Birth or delivery 
7F...13 Puerperium operations Birth or delivery 
7F06012 Shirodkar suture in pregnancy Birth or delivery 
7F1..00 Induction and delivery operations Birth or delivery 
7F1..11 Labour operations Birth or delivery 
7F10.00 Surgical induction of labour Birth or delivery 
7F10y00 Other specified surgical induction of labour Birth or delivery 
7F10z00 Surgical induction of labour NOS Birth or delivery 
7F11.00 Other induction of labour Birth or delivery 
7F11000 Oxytocic induction of labour Birth or delivery 
7F11100 Induction of labour using prostaglandins Birth or delivery 
7F11200 Syntocinon induction of labour Birth or delivery 
7F11300 Medical induction of labour Birth or delivery 
7F11y00 Other specified other induction of labour Birth or delivery 
7F11z00 Other induction of labour NOS Birth or delivery 
7F12.00 Elective caesarean delivery Birth or delivery 
7F12000 Elective upper uterine segment caesarean delivery Birth or delivery 
7F12100 Elective lower uterine segment caesarean delivery Birth or delivery 
7F12111 Elective lower uterine segment caesarean section (LSCS) Birth or delivery 
7F12y00 Other specified elective caesarean delivery Birth or delivery 
7F12z00 Elective caesarean delivery NOS Birth or delivery 
7F13.00 Other caesarean delivery Birth or delivery 
7F13000 Upper uterine segment caesarean delivery NEC Birth or delivery 
7F13100 Lower uterine segment caesarean delivery NEC Birth or delivery 
7F13111 Lower uterine segment caesarean section (LSCS) NEC Birth or delivery 
7F13200 Extraperitoneal caesarean section Birth or delivery 
7F13300 Emergency caesarean section Birth or delivery 
7F13y00 Other specified other caesarean delivery Birth or delivery 
7F13z00 Other caesarean delivery NOS Birth or delivery 
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7F14.00 Breech extraction delivery Birth or delivery 
7F14000 Breech extraction delivery with version Birth or delivery 
7F14100 Forceps to aftercoming head (breech) Birth or delivery 
7F14y00 Other specified breech extraction delivery Birth or delivery 
7F14z00 Breech extraction delivery NOS Birth or delivery 
7F15.00 Other breech delivery Birth or delivery 
7F15000 Spontaneous breech delivery Birth or delivery 
7F15100 Assisted breech delivery Birth or delivery 
7F15y00 Other specified other breech delivery Birth or delivery 
7F15z00 Other breech delivery NOS Birth or delivery 
7F16.00 Forceps cephalic delivery Birth or delivery 
7F16000 High forceps cephalic delivery with rotation Birth or delivery 
7F16100 High forceps cephalic delivery NEC Birth or delivery 
7F16200 Mid forceps cephalic delivery with rotation Birth or delivery 
7F16300 Mid forceps cephalic delivery NEC Birth or delivery 
7F16400 Low forceps cephalic delivery Birth or delivery 
7F16500 Trial of forceps delivery Birth or delivery 
7F16600 Failed forceps delivery Birth or delivery 
7F16700 Barton forceps cephalic delivery with rotation Birth or delivery 
7F16800 Dehee forceps cephalic delivery with rotation Birth or delivery 
7F16900 Kielland forceps cephalic delivery with rotation Birth or delivery 
7F16A00 Scanzoni forceps cephalic delivery with rotation Birth or delivery 
7F16B00 Piper forceps delivery Birth or delivery 
7F16y00 Other specified forceps cephalic delivery Birth or delivery 
7F16z00 Forceps cephalic delivery NOS Birth or delivery 
7F17.00 Vacuum delivery Birth or delivery 
7F17.11 Ventouse delivery Birth or delivery 
7F17.12 Ventouse extraction Birth or delivery 
7F17000 High vacuum delivery Birth or delivery 
7F17100 Low vacuum delivery Birth or delivery 
7F17200 Vacuum delivery before full dilation of cervix Birth or delivery 
7F17300 Trial of vacuum delivery Birth or delivery 
7F17y00 Other specified vacuum delivery Birth or delivery 
7F17z00 Vacuum delivery NOS Birth or delivery 
7F18.00 Cephalic vaginal deliv abnorm presentation head - no instrum Birth or delivery 
7F18000 Manip cephalic vaginal deliv abnorm pres head without instrm Birth or delivery 
7F18100 Nonmanip cephal vagin deliv abnorm pres head without 
instrum 
Birth or delivery 
7F18y00 Cephalic vagin deliv abnorm pres head without instrument OS Birth or delivery 
7F18z00 Cephalic vagin deliv abnorm pres head without instrument 
NOS 
Birth or delivery 
7F19.00 Normal delivery Birth or delivery 
7F19000 Manually assisted vaginal delivery Birth or delivery 
7F19100 Water birth delivery Birth or delivery 
7F19y00 Other specified normal delivery Birth or delivery 
7F19z00 Normal delivery NOS Birth or delivery 
7F1A.00 Other methods of delivery Birth or delivery 
7F1A000 Caesarean hysterectomy Birth or delivery 
7F1A400 Trial of labour NEC Birth or delivery 
7F1Ay00 Other specified other method of delivery Birth or delivery 
7F1Az00 Other method of delivery NOS Birth or delivery 
7F1B.00 Other operations to facilitate delivery Birth or delivery 
7F1B000 Episiotomy to facilitate delivery Birth or delivery 
7F1B100 Symphysiotomy to facilitate delivery Birth or delivery 
7F1B200 Pubiotomy to facilitate delivery Birth or delivery 
7F1B400 Incision of cervix to facilitate delivery Birth or delivery 
7F1By00 Other specified other operation to facilitate delivery Birth or delivery 
7F1Bz00 Other operation to facilitate delivery NOS Birth or delivery 
7F1y.00 Other specified induction or delivery operations Birth or delivery 
7F1z.00 Induction and delivery operations NOS Birth or delivery 
7F25.11 Fetal monitoring Birth or delivery 
7F25.13 Monitoring during labour Birth or delivery 
7F25000 Fetal heart monitoring NEC Birth or delivery 
7F25100 Fetal heart monitoring in labour Birth or delivery 
7Fy..00 Other specified obstetric operations Birth or delivery 
7Fz..00 Obstetric operations NOS Birth or delivery 
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7L16000 Intravenous induction of labour Birth or delivery 
7M35000 Gas and air analgesia in labour Birth or delivery 
7M35011 Entonox analgesia in labour Birth or delivery 
8HE7.00 Discharged from hospital within 6 hours of delivery Birth or delivery 
L030000 Delivery of viable fetus in abdominal pregnancy Birth or delivery 
L142.00 Early onset of delivery Birth or delivery 
L142.11 Premature delivery Birth or delivery 
L142000 Early onset of delivery unspecified Birth or delivery 
L142100 Early onset of delivery - delivered Birth or delivery 
L142z00 Early onset of delivery NOS Birth or delivery 
L143.00 Premature labour and delivery Birth or delivery 
L143100 Premature labour with premature delivery Birth or delivery 
L143200 Premature labour with term delivery Birth or delivery 
L143300 Premature delivery without labour Birth or delivery 
L15..00 Prolonged or post-term pregnancy Birth or delivery 
L15..11 Post-term pregnancy Birth or delivery 
L150.00 Post-term pregnancy Birth or delivery 
L150000 Post-term pregnancy unspecified Birth or delivery 
L150100 Post-term pregnancy - delivered Birth or delivery 
L150200 Post-term pregnancy - not delivered Birth or delivery 
L150z00 Post-term pregnancy NOS Birth or delivery 
L15z.00 Prolonged pregnancy NOS Birth or delivery 
L20..00 Normal delivery in a completely normal case Birth or delivery 
L20..11 Spontaneous vaginal delivery Birth or delivery 
L200.00 Normal delivery but ante- or post- natal conditions present Birth or delivery 
L20z.00 Normal delivery in completely normal case NOS Birth or delivery 
L210100 Twin pregnancy - delivered Birth or delivery 
L211100 Triplet pregnancy - delivered Birth or delivery 
L212100 Quadruplet pregnancy - delivered Birth or delivery 
L213.00 Multiple delivery Birth or delivery 
L213000 Multiple delivery, all spontaneous Birth or delivery 
L213100 Multiple delivery, all by forceps and vacuum extractor Birth or delivery 
L213200 Multiple delivery, all by caesarean section Birth or delivery 
L21y100 Other multiple pregnancy - delivered Birth or delivery 
L21z100 Multiple pregnancy NOS - delivered Birth or delivery 
L222.11 Assisted breech delivery Birth or delivery 
L222.12 Breech delivery Birth or delivery 
L222.13 Spontaneous breech delivery Birth or delivery 
L228100 Multiple pregnancy with malpresentation - delivered Birth or delivery 
L22y100 Other fetal malposition and malpresentation - delivered Birth or delivery 
L22z100 Fetal malposition and malpresentation NOS - delivered Birth or delivery 
L296.00 Vaginal delivery following previous caesarean section Birth or delivery 
L395.00 Forceps delivery Birth or delivery 
L395.11 Keilland's forceps delivery Birth or delivery 
L395.12 Neville - Barnes forceps delivery Birth or delivery 
L395.13 Simpson's forceps delivery Birth or delivery 
L395000 Forceps delivery unspecified Birth or delivery 
L395100 Forceps delivery - delivered Birth or delivery 
L395200 Low forceps delivery Birth or delivery 
L395300 Mid-cavity forceps delivery Birth or delivery 
L395400 Delivery by combination of forceps and vacuum extractor Birth or delivery 
L395500 Mid-cavity forceps with rotation Birth or delivery 
L395z00 Forceps delivery NOS Birth or delivery 
L396.00 Vacuum extractor delivery Birth or delivery 
L396.11 Ventouse delivery Birth or delivery 
L396000 Vacuum extractor delivery unspecified Birth or delivery 
L396100 Vacuum extractor delivery - delivered Birth or delivery 
L396z00 Vacuum extractor delivery NOS Birth or delivery 
L397.00 Breech extraction Birth or delivery 
L397000 Breech extraction unspecified Birth or delivery 
L397100 Breech extraction - delivered Birth or delivery 
L397z00 Breech extraction NOS Birth or delivery 
L398.00 Caesarean delivery Birth or delivery 
L398000 Caesarean delivery unspecified Birth or delivery 
L398100 Caesarean delivery - delivered Birth or delivery 
L398200 Caesarean section - pregnancy at term Birth or delivery 
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L398300 Delivery by elective caesarean section Birth or delivery 
L398400 Delivery by emergency caesarean section Birth or delivery 
L398500 Delivery by caesarean hysterectomy Birth or delivery 
L398600 Caesarean delivery following previous Caesarean delivery Birth or delivery 
L398z00 Caesarean delivery NOS Birth or delivery 
Ly0..00 Spontaneous vertex delivery Birth or delivery 
Ly1..00 Spontaneous breech delivery Birth or delivery 
Lyu5.00 [X]Delivery Birth or delivery 
Lyu5000 [X]Other single spontaneous delivery Birth or delivery 
Lyu5100 [X]Other and unspecified forceps delivery Birth or delivery 
Lyu5200 [X]Other single delivery by caesarean section Birth or delivery 
Lyu5300 [X]Other assisted breech delivery Birth or delivery 
Lyu5400 [X]Other manipulation-assisted delivery Birth or delivery 
Lyu5500 [X]Other specified assisted single delivery Birth or delivery 
Lyu5600 [X]Other multiple delivery Birth or delivery 
Lyu5700 [X]Assisted single delivery, unspecified Birth or delivery 
Lyu5800 [X]Multiple delivery, unspecified Birth or delivery 
Q432.00 Preterm delivery associated jaundice Birth or delivery 
Z1H4.00 Pain relief in labour Birth or delivery 
Z213.00 Care of mother in labour Birth or delivery 
Z23B400 Contraction of uterus during labour Birth or delivery 
Z23G.00 Uterine observation in labour Birth or delivery 
Z24..00 Labour observations Birth or delivery 
Z241.00 Labour established Birth or delivery 
Z241100 Onset of labour induced Birth or delivery 
Z243.00 Observation of first stage of labour Birth or delivery 
Z243100 First stage of labour established Birth or delivery 
Z243300 Progress of labour - first stage Birth or delivery 
Z243400 Rapid first stage of labour Birth or delivery 
Z243411 Rapid progress in first stage of labour Birth or delivery 
Z243500 Normal length of first stage of labour Birth or delivery 
Z243600 Slow progress in first stage of labour Birth or delivery 
Z243700 Normal first stage of labour Birth or delivery 
Z243800 First stage of labour problem Birth or delivery 
Z244.00 Observation of pattern of labour Birth or delivery 
Z244100 Observation of duration of labour Birth or delivery 
Z244200 Long duration of labour Birth or delivery 
Z244300 Short duration of labour Birth or delivery 
Z244400 Late onset of labour Birth or delivery 
Z244411 Postmature labour Birth or delivery 
Z244500 Relation of onset of labour to due date Birth or delivery 
Z245.00 Observation of blood loss in labour Birth or delivery 
Z246.00 Observation of measures of labour Birth or delivery 
Z246100 Duration of labour Birth or delivery 
Z246111 Length of labour Birth or delivery 
Z246200 Onset of labour first stage Birth or delivery 
Z246211 Start of labour Birth or delivery 
Z246311 Onset of labour pains Birth or delivery 
Z246700 Onset of second stage of labour Birth or delivery 
Z246900 Duration of second stage of labour Birth or delivery 
Z246A00 Total duration of labour Birth or delivery 
Z247.00 Device-associated observation of labour Birth or delivery 
Z247100 Expulsion of IUCD during third stage of labour Birth or delivery 
Z248.00 Normal labour Birth or delivery 
Z249.00 Labour problem Birth or delivery 
Z25..00 Delivery observations Birth or delivery 
Z251.00 Mother delivered Birth or delivery 
Z253.00 Observation of speed of delivery Birth or delivery 
Z253.11 Speed of delivery Birth or delivery 
Z253.12 Rate of delivery Birth or delivery 
Z253100 Slow rate of delivery Birth or delivery 
Z253200 Rapid rate of delivery Birth or delivery 
Z253211 Precipitate delivery Birth or delivery 
Z253300 Normal rate of delivery Birth or delivery 
Z254.00 Observation of pattern of delivery Birth or delivery 
Z254100 Deliveries by forceps - delivered Birth or delivery 
Appendices 
 349 
Table G.3  Continued. 
Read 
code Code description Category 
Z254200 Delivered by low forceps delivery Birth or delivery 
Z254300 Delivered by mid-cavity forceps delivery Birth or delivery 
Z254400 Deliveries by breech extraction Birth or delivery 
Z254500 Delivered by caesarean section - pregnancy at term Birth or delivery 
Z254600 Deliv caes following prev caes Birth or delivery 
Z254700 Deliveries by vacuum extractor Birth or delivery 
Z254800 Deliveries by spontaneous breech delivery Birth or delivery 
Z254900 Vaginal delivery Birth or delivery 
Z254A00 Abnormal delivery Birth or delivery 
Z254B00 Brow delivery Birth or delivery 
Z254C00 Face delivery Birth or delivery 
Z254D00 Face to pubes birth Birth or delivery 
Z254E00 Multiple birth Birth or delivery 
Z254E11 Multiple birth delivery Birth or delivery 
Z255.00 Observation of second stage of labour Birth or delivery 
Z255100 Second stage of labour established Birth or delivery 
Z255200 Second stage of labour not established Birth or delivery 
Z255300 Progess of second stage of labour Birth or delivery 
Z255311 Progess of delivery Birth or delivery 
Z255400 Rapid second stage of labour Birth or delivery 
Z255600 Normal length of second stage of labour Birth or delivery 
Z255700 Failure to progress in second stage of labour Birth or delivery 
Z255711 No progress with delivery Birth or delivery 
Z255712 No progress in second stage of labour Birth or delivery 
Z255800 Second stage of labour problem Birth or delivery 
Z255900 Normal second stage of labour Birth or delivery 
Z255A00 Observation of delivery push in labour Birth or delivery 
Z255B11 Wants to push in labour Birth or delivery 
Z255C00 No desire to push in labour Birth or delivery 
Z255D00 Ability to push in labour Birth or delivery 
Z255D11 Observation of ability to push in labour Birth or delivery 
Z255E00 Pushing effectively in labour Birth or delivery 
Z255E11 Pushing well in labour Birth or delivery 
Z255F00 Not pushing well in labour Birth or delivery 
Z255G00 Urge to push in labour Birth or delivery 
Z255H00 Reluctant to push in labour Birth or delivery 
Z255I00 Pushing voluntarily in labour Birth or delivery 
Z255J00 Pushing involuntarily in labour Birth or delivery 
Z256.00 Observation of third stage of labour Birth or delivery 
Z256100 Normal length of third stage of labour Birth or delivery 
Z256200 Prolonged third stage of labour Birth or delivery 
Z256300 Speed of delivery of placenta Birth or delivery 
Z256311 Rate of delivery of placenta Birth or delivery 
Z257.00 Delivery normal Birth or delivery 
Z257.11 Normal delivery Birth or delivery 
Z257.12 Spontaneous vaginal delivery Birth or delivery 
Z257.13 SVD - Spontaneous vaginal delivery Birth or delivery 
Z257.14 FTND - Full term normal delivery Birth or delivery 
Z257.15 ND - Normal delivery Birth or delivery 
Z257100 Spontaneous vertex delivery Birth or delivery 
Z258.00 Delivery problem Birth or delivery 
Z262600 Complete placenta at delivery Birth or delivery 
Z262700 Incomplete placenta at delivery Birth or delivery 
Z262711 Incomplete delivery of placenta Birth or delivery 
Z263300 Condition of membranes at delivery Birth or delivery 
Z265900 Umbilical cord not around baby's neck at delivery Birth or delivery 
ZV24000 [V]Examination immediately after delivery Birth or delivery 
ZV27.00 [V]Outcome of delivery Birth or delivery 
ZV27.11 [V]Live birth Birth or delivery 
ZV27.13 [V]Birth - type Birth or delivery 
ZV27000 [V]Single live birth Birth or delivery 
ZV27200 [V]Twins, both live born Birth or delivery 
ZV27300 [V]Twins, one live born and one stillborn Birth or delivery 
ZV27500 [V]Other multiple birth, all live born Birth or delivery 
ZV27600 [V]Other multiple birth, some live born Birth or delivery 
ZV27y00 [V]Other specified outcome of delivery Birth or delivery 
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ZV27z00 [V]Unspecified delivery outcome Birth or delivery 
ZV3..00 [V]Healthy liveborn infants according to type of birth Birth or delivery 
ZV31.00 [V]Twin, mate live born Birth or delivery 
ZV31000 [V]Twin, born in hospital, mate live born Birth or delivery 
ZV31100 [V]Twin, born before admission to hospital, mate live born Birth or delivery 
ZV31200 [V]Twin, not hospitalised, mate live born Birth or delivery 
ZV31z00 [V]Twin, mate liveborn, NOS Birth or delivery 
ZV34.00 [V]Other multiple birth, mates live born Birth or delivery 
ZV34000 [V]Other multiple birth, born in hospital, mates live born Birth or delivery 
ZV34100 [V]Other multiple birth, born before hospital, mates live Birth or delivery 
ZV34200 [V]Other multiple birth, not hospitalised, mates live born Birth or delivery 
ZV34z00 [V]Other multiple birth, mates live born, NOS Birth or delivery 
ZV36.00 [V]Other multiple birth, mates live and stillborn Birth or delivery 
ZV36000 [V]Other multiple birth, born in hospital, mates live+still Birth or delivery 
ZV36z00 [V]Other multiple birth, mates live and stillborn NOS Birth or delivery 
ZV3y.00 [V]Other multiple birth, unspecified Birth or delivery 
ZV3y000 [V]Other multiple birth, unspecified, born in hospital Birth or delivery 
ZV3y100 [V]Other multiple birth, unspecified, born before hospital Birth or delivery 
ZV3y200 [V]Other multiple birth, unspecified, not hospitalised Birth or delivery 
ZV3yz00 [V]Other multiple birth, unspecified, NOS Birth or delivery 
ZV3z.00 [V]Unspecified birth Birth or delivery 
ZV3z000 [V]Unspecified birth, born in hospital Birth or delivery 
ZV3z100 [V]Unspecified birth, born before admission to hospital Birth or delivery 
ZV3z200 [V]Unspecified birth, not hospitalised Birth or delivery 
ZV3zz00 [V]Unspecified birth, NOS Birth or delivery 
ZVu2A00 [X]Other multiple births, all liveborn Birth or delivery 
ZVu2B00 [X]Other multiple births, some liveborn Birth or delivery 
ZVu2D00 [X]Other multiple liveborn infants, born in hospital Birth or delivery 
ZVu2E00 [X]Other multiple liveborn infants, born outside hospital Birth or delivery 
ZVu2F00 [X]Oth multip liveborn infants, unspec as to place of birth Birth or delivery 
632..00 Length of labour Length of labour 
6321.00 1st stage of labour length Length of labour 
6322.00 2nd stage of labour length Length of labour 
6323.00 3rd stage of labour length Length of labour 
632Z.00 Length of labour NOS Length of labour 
14Y0.00 Born by caesarean section Mode of birth 
14Y1.00 Born by forceps delivery Mode of birth 
14Y2.00 Born by elective caesarean section Mode of birth 
14Y3.00 Born by normal vaginal delivery Mode of birth 
14Y4.00 Born by breech delivery Mode of birth 
14Y5.00 Born by ventouse delivery Mode of birth 
14Y6.00 Born by emergency caesarean section Mode of birth 
634..00 Sex of baby Sex of baby 
634..11 Delivery - sex of baby Sex of baby 
634..12 Female baby Sex of baby 
634..13 Male baby Sex of baby 
6341.00 Baby male Sex of baby 
6342.00 Baby female Sex of baby 
6343.00 2 male babies Sex of baby 
6344.00 2 female babies Sex of baby 
6345.00 1 male + 1 female baby Sex of baby 
6346.00 3 male babies Sex of baby 
6347.00 2 male + 1 female babies Sex of baby 
6348.00 1 male + 2 female babies Sex of baby 
6349.00 3 female babies Sex of baby 
634Z.00 Sex of baby NOS Sex of baby 
6351.00 Baby premature 36-38 weeks Gestational age 
6352.00 Baby v. premature 32-36 weeks Gestational age 
6353.00 Baby extremely prem.28-32 week Gestational age 
6354.00 Baby full term maturity Gestational age 
6355.00 Baby post-mature Gestational age 
6356.00 Baby premature 26-28 weeks Gestational age 
6357.00 Baby premature 24-26 weeks Gestational age 
6358.00 Baby premature 39 weeks Gestational age 
6359.00 Baby premature 38 weeks Gestational age 
635A.00 Baby premature 37 weeks Gestational age 
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635B.00 Baby premature 36 weeks Gestational age 
635C.00 Preterm infant status Gestational age 
635C.11 Preterm Gestational age 
635Z.00 Baby maturity NOS Gestational age 
62R..12 New birth visit Postnatal visit 
62R1.00 P/N - first day visit Postnatal visit 
62R2.00 P/N - second day visit Postnatal visit 
62R3.00 P/N - third day visit Postnatal visit 
62R4.00 P/N - fourth day visit Postnatal visit 
62R5.00 P/N - fifth day visit Postnatal visit 
62R6.00 P/N - sixth day visit Postnatal visit 
62R7.00 P/N - seventh day visit Postnatal visit 
62R8.00 P/N - eighth day visit Postnatal visit 
62R9.00 P/N - ninth day visit Postnatal visit 
62RA.00 P/N - tenth day visit Postnatal visit 
9NFS.00 Health visitor new birth visit Postnatal visit 
44qW100 Completion of newborn blood spot screening card Postnatal care 
62RB.00 P/N care started at birth Postnatal care 
62RC.00 P/N care <48hrs after birth Postnatal care 
62RD.00 P/N care >48hrs after birth Postnatal care 
62S..00 Maternal P/N 6 week exam. Postnatal examination 
62S..11 Postnatal exam. - maternal Postnatal examination 
62S5.00 Maternal P/N exam. done Postnatal examination 
62SZ.00 Maternal P/N 6 week exam. NOS Postnatal examination 
68Y..00 Newborn hearing screening Hearing screen 
9Oq9G00 Newborn hearing screening not done Hearing screen 
9114.11 FP58 - newborn registration Newborn registration 
9114.12 GP58 - newborn registration Newborn registration 
9G7..00 Notification of birth Newborn registration 
 
  
Appendices 
 352 
G.4 Re ad codes re lat ed to l iver  dise ase  
Table G.4  Read codes related to liver disease. 
Read code Code description 
14S8.00 H/O: liver recipient 
67P4200 Discussion about liver transplantation 
7800.00 Transplantation of liver 
7800000 Orthotopic transplantation of liver 
7800100 Heterotopic transplantation of liver 
7800111 Auxillary liver transplant 
7800112 Piggy back liver transplant 
7800200 Replacement of previous liver transplant 
7800300 Transplantation of liver cells 
7800400 Orthotopic transplantation of whole liver 
7800500 Orthotopic transplantation of liver NEC 
7800y00 Other specified transplantation of liver 
7800z00 Transplantation of liver NOS 
7805211 Exploration of liver transplant 
7822011 Kasai hepatojejunostomy + insertion tubal prosthesis 
7824400 Roux-en-y procedure for biliary atresia 
7824411 Sawaguchi roux-en-y procedure for biliary atresia 
7L1f.00 Compensation for liver failure 
7L1fy00 Other specified compensation for liver failure 
7L1fz00 Compensation for liver failure NOS 
8LH..00 Liver transplant planned 
9kR..00 Chronic hepatitis annual review - enhanced services admin 
9kR..11 Chronic hepatitis annual review 
A707.00 Chronic viral hepatitis 
A707000 Chronic viral hepatitis B with delta-agent 
A707100 Chronic viral hepatitis B without delta-agent 
A707200 Chronic viral hepatitis C 
A707300 Chronic viral hepatitis B 
A707X00 Chronic viral hepatitis, unspecified 
AC11.11 Chinese liver fluke disease 
AyuB100 [X]Other chronic viral hepatitis 
AyuB200 [X]Chronic viral hepatitis, unspecified 
C310400 Glycogenosis with hepatic cirrhosis 
C350000 Haemochromatosis 
C350012 Pigmentary cirrhosis of liver 
C370700 Liver disease due to cystic fibrosis 
C370800 Cystic fibrosis related cirrhosis 
C376100 Alpha-1-antitrypsin hepatitis 
C376200 Alpha-1-antitrypsin deficiency 
D307000 Deficiency of coagulation factor due to liver disease 
G820.00 Budd - Chiari syndrome (hepatic vein thrombosis) 
G852200 Oesophageal varices in cirrhosis of the liver 
G852300 Oesophageal varices in alcoholic cirrhosis of the liver 
J6...00 Liver, biliary, pancreas + gastrointestinal diseases NEC 
J60..00 Acute and subacute liver necrosis 
J600.00 Acute necrosis of liver 
J600000 Acute hepatic failure 
J600011 Acute liver failure 
J600100 Acute hepatitis - noninfective 
J600200 Acute yellow atrophy 
J600z00 Acute necrosis of liver NOS 
J601.00 Subacute necrosis of liver 
J601000 Subacute hepatic failure 
J601100 Subacute hepatitis - noninfective 
J601200 Subacute yellow atrophy 
J601z00 Subacute necrosis of liver NOS 
J60z.00 Acute and subacute liver necrosis NOS 
J61..00 Cirrhosis and chronic liver disease 
J610.00 Alcoholic fatty liver 
J611.00 Acute alcoholic hepatitis 
J612.00 Alcoholic cirrhosis of liver 
J612.11 Florid cirrhosis 
J612.12 Laennec's cirrhosis 
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J612000 Alcoholic fibrosis and sclerosis of liver 
J613.00 Alcoholic liver damage unspecified 
J613000 Alcoholic hepatic failure 
J614.00 Chronic hepatitis 
J614000 Chronic persistent hepatitis 
J614100 Chronic active hepatitis 
J614111 Autoimmune chronic active hepatitis 
J614200 Chronic aggressive hepatitis 
J614300 Recurrent hepatitis 
J614400 Chronic lobular hepatitis 
J614y00 Chronic hepatitis unspecified 
J614z00 Chronic hepatitis NOS 
J615.00 Cirrhosis - non alcoholic 
J615.11 Portal cirrhosis 
J615000 Unilobular portal cirrhosis 
J615100 Multilobular portal cirrhosis 
J615111 Postnecrotic cirrhosis of liver 
J615200 Mixed portal cirrhosis 
J615300 Diffuse nodular cirrhosis 
J615400 Fatty portal cirrhosis 
J615500 Hypertrophic portal cirrhosis 
J615600 Capsular portal cirrhosis 
J615700 Cardiac portal cirrhosis 
J615711 Congestive cirrhosis 
J615800 Juvenile portal cirrhosis 
J615811 Childhood function cirrhosis 
J615812 Indian childhood cirrhosis 
J615900 Pigmentary portal cirrhosis 
J615A00 Pipe-stem portal cirrhosis 
J615B00 Toxic portal cirrhosis 
J615C00 Xanthomatous portal cirrhosis 
J615D00 Bacterial portal cirrhosis 
J615E00 Cardituberculous cirrhosis 
J615F00 Syphilitic portal cirrhosis 
J615G00 Zooparasitic portal cirrhosis 
J615H00 Infectious cirrhosis NOS 
J615y00 Portal cirrhosis unspecified 
J615z00 Non-alcoholic cirrhosis NOS 
J615z11 Macronodular cirrhosis of liver 
J615z12 Cryptogenic cirrhosis of liver 
J615z13 Cirrhosis of liver NOS 
J615z14 Laennec's cirrhosis, non-alcoholic 
J615z15 Hepatic fibrosis 
J616.00 Biliary cirrhosis 
J616000 Primary biliary cirrhosis 
J616100 Secondary biliary cirrhosis 
J616200 Biliary cirrhosis of children 
J616z00 Biliary cirrhosis NOS 
J617.00 Alcoholic hepatitis 
J617000 Chronic alcoholic hepatitis 
J61y.00 Other non-alcoholic chronic liver disease 
J61y000 Chronic yellow liver atrophy 
J61y100 Non-alcoholic fatty liver 
J61y200 Hepatosplenomegaly 
J61y300 Portal fibrosis without cirrhosis 
J61y400 Hepatic fibrosis 
J61y500 Hepatic sclerosis 
J61y600 Hepatic fibrosis with hepatic sclerosis 
J61y700 Steatosis of liver 
J61y800 Nonalcoholic steatohepatitis 
J61y900 Fatty change of liver 
J61y911 Fatty liver 
J61yz00 Other non-alcoholic chronic liver disease NOS 
J61z.00 Chronic liver disease NOS 
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Read code Code description 
J62..00 Liver abscess and sequelae of chronic liver disease 
J620.00 Liver abscess - excluding amoebic liver abscess 
J620000 Liver abscess due to portal pyaemia 
J620100 Liver abscess due to cholangitis 
J620200 Liver abscess via hepatic artery 
J620300 Liver abscess via umbilicus 
J620400 Liver abscess due to direct extension 
J620z00 Liver abscess NOS 
J621.00 Portal pyaemia 
J621.11 Phlebitis of portal vein 
J622.00 Hepatic coma 
J622.11 Encephalopathy - hepatic 
J623.00 Portal hypertension 
J624.00 Hepatorenal syndrome 
J625.00 [X] Hepatic failure 
J625.11 [X] Liver failure 
J62y.00 Other sequelae of chronic liver disease 
J62y.11 Hepatic failure NOS 
J62y.12 Liver failure NOS 
J62y.13 Hepatic failure 
J62z.00 Liver abscess and chronic liver disease causing sequelae NOS 
J635.00 Toxic liver disease 
J635000 Toxic liver disease with cholestasis 
J635100 Toxic liver disease with hepatic necrosis 
J635200 Toxic liver disease with acute hepatitis 
J635300 Toxic liver disease with chronic persistent hepatitis 
J635400 Toxic liver disease with chronic lobular hepatitis 
J635500 Toxic liver disease with chronic active hepatitis 
J635600 Toxic liver disease with fibrosis and cirrhosis of liver 
J635700 Acute hepatic failure due to drugs 
J635X00 Toxic liver disease, unspecified 
J637.00 Hepatic veno-occlusive disease 
J63B.00 Autoimmune hepatitis 
J66..00 Other biliary tract disorders 
J660.00 Postcholecystectomy syndrome 
J661.00 Cholangitis 
J661000 Acute cholangitis 
J661100 Chronic cholangitis 
J661200 Recurrent cholangitis 
J661300 Suppurative cholangitis 
J661400 Ascending cholangitis 
J661500 Cholangitis lenta 
J661600 Obliterative cholangitis 
J661700 Primary sclerosing cholangitis 
J661800 Secondary sclerosing cholangitis 
J661900 Sclerosing cholangitis unspecified 
J661y00 Other cholangitis 
J661z00 Cholangitis NOS 
J662.00 Obstruction of bile duct 
J662000 Occlusion of bile duct 
J662100 Stricture of bile duct 
J662z00 Obstruction of bile duct NOS 
J663.00 Perforation of bile duct 
J664.00 Fistula of bile duct 
J664000 Choledochoduodenal fistula 
J664z00 Fistula of bile duct NOS 
J665.00 Spasm of sphincter of Oddi 
J666.00 Biliary sepsis 
J66y.00 Other bile duct disorders 
J66y000 Adhesions of bile duct 
J66y100 Atrophy of bile duct 
J66y200 Cyst of bile duct 
J66y300 Hypertrophy of bile duct 
J66y400 Stasis of bile duct 
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Read code Code description 
J66y500 Ulcer of bile duct 
J66y600 Obstructive jaundice NOS 
J66y700 Post cholecystectomy bile leakage 
J66yz00 Other bile duct disorder NOS 
J66z.00 Bile duct disorder NOS 
J6y..00 Liver, biliary, pancreas + gastrointestinal diseases OS 
J6z..00 Liver, biliary, pancreas + gastrointestinal diseases NOS 
Jyu7.00 [X]Diseases of the liver 
Jyu7000 [X]Toxic liver disease with other disorders of liver 
Jyu7100 [X]Other and unspecified cirrhosis of liver 
Jyu7200 [X]Other specified inflammatory liver diseases 
Jyu7300 [X]Other specified diseases of liver 
Jyu7400 [X]Liver disorders in infectious and parasitic diseases CE 
Jyu7500 [X]Liver disorders in other diseases classified elsewhere 
Jyu7600 [X]Toxic liver disease, unspecified 
Jyu7700 [X]Granulomatous hepatitis, not elsewhere classified 
PB6..00 Liver and biliary system anomalies 
PB6..11 Bile duct anomalies 
PB6..12 Biliary anomalies 
PB6..13 Gallbladder anomalies 
PB6..14 Liver anomalies 
PB60.00 Liver and biliary system anomalies, unspecified 
PB60000 Liver anomaly, unspecified 
PB60100 Gallbladder anomaly, unspecified 
PB60200 Bile duct anomaly, unspecified 
PB60z00 Unspecified liver and biliary system anomaly NOS 
PB61.00 Biliary atresia 
PB61.11 Bile duct atresia 
PB61000 Congenital absence of bile duct 
PB61011 Agenesis of bile duct 
PB61100 Congenital hypoplasia of bile duct 
PB61200 Congenital obstruction of bile duct 
PB61300 Congenital stricture of bile duct 
PB61311 Congenital stricture of common bile duct 
PB61400 Atresia of bile duct 
PB61411 Intrahepatic atresia of bile duct 
PB61412 Extrahepatic atresia of bile duct 
PB61500 Congenital absence of hepatic ducts 
PB61511 Agenesis of hepatic ducts 
PB61600 Atresia of hepatic ducts 
PB61z00 Biliary atresia NOS 
PB62.00 Congenital cystic liver disease 
PB62.11 Congenital hepatic cyst 
PB62000 Congenital polycystic liver disease 
PB62100 Fibrocystic liver disease 
PB62z00 Congenital cystic liver disease NOS 
PB63.00 Congenital absence of liver and gallbladder 
PB63000 Congenital absence of gallbladder 
PB63011 Agenesis of gallbladder 
PB63100 Congenital absence of liver lobe 
PB63111 Congenital agenesis of liver lobe 
PB63200 Congenital small left lobe of liver 
PB63300 Riedel's lobe liver 
PB63400 Congenital absence of liver,total 
PB63411 Congenital agenesis liver,total 
PB63500 Alagille syndrome 
PB63z00 Absence of liver or gallbladder NOS 
PB64.00 Liver and biliary duplication 
PB64000 Duplication of biliary duct 
PB64100 Duplication of cystic duct 
PB64200 Duplication of gallbladder 
PB64300 Duplication of liver 
PB64311 Accessory liver 
PB64400 Accessory hepatic ducts 
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PB64z00 Liver or biliary duplication NOS 
PB6y.00 Other liver and biliary anomalies 
PB6y000 Congenital choledochal cyst 
PB6y100 Congenital hepatomegaly 
PB6y200 Congenital floating gallbladder 
PB6y300 Congenital floating liver 
PB6y400 Intrahepatic gallbladder 
PB6y500 Hypoplasia of gallbladder 
PB6y600 Atrophy of left lobe of liver 
PB6y700 Congenital dilation of bile duct 
PB6y800 Congenital diverticulum of bile duct 
PB6y900 Liver hyperplasia 
PB6yw00 Other congenital anomaly of liver 
PB6yw11 Liver hamartoma 
PB6yw12 Abnormal liver lobulation 
PB6yw13 Trilobular liver 
PB6yx00 Other congenital anomaly of gallbladder 
PB6yy00 Other congenital anomaly of hepatic or bile ducts 
PB6yy11 Congenital kink of cystic duct 
PB6yz00 Other liver or biliary system anomalies NOS 
PB6z.00 Liver or biliary system anomalies NOS 
SP08600 Liver transplant failure and rejection 
SP14200 Hepatic failure as a complication of care 
SP14211 Liver failure as a complication of care 
TB00200 Liver transplant with complication, without blame 
ZC2CH11 Dietary advice for liver disease 
ZV42700 [V]Liver transplanted 
ZV7C000 [V]Assessment for liver transplant 
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G.5 Re ad codes re lat ed to chronic  ki dne y d ise ase  
Table G.5  Read codes related to chronic kidney disease. 
Read code Code description 
14S2.00 H/O: kidney recipient 
14V2.00 H/O: renal dialysis 
14V2.11 H/O: kidney dialysis 
1Z1..00 Chronic renal impairment 
1Z10.00 Chronic kidney disease stage 1 
1Z11.00 Chronic kidney disease stage 2 
1Z12.00 Chronic kidney disease stage 3 
1Z13.00 Chronic kidney disease stage 4 
1Z14.00 Chronic kidney disease stage 5 
1Z15.00 Chronic kidney disease stage 3A 
1Z16.00 Chronic kidney disease stage 3B 
1Z17.00 Chronic kidney disease stage 1 with proteinuria 
1Z17.11 CKD stage 1 with proteinuria 
1Z18.00 Chronic kidney disease stage 1 without proteinuria 
1Z18.11 CKD stage 1 without proteinuria 
1Z19.00 Chronic kidney disease stage 2 with proteinuria 
1Z19.11 CKD stage 2 with proteinuria 
1Z1A.00 Chronic kidney disease stage 2 without proteinuria 
1Z1A.11 CKD stage 2 without proteinuria 
1Z1B.00 Chronic kidney disease stage 3 with proteinuria 
1Z1B.11 CKD stage 3 with proteinuria 
1Z1C.00 Chronic kidney disease stage 3 without proteinuria 
1Z1C.11 CKD stage 3 without proteinuria 
1Z1D.00 Chronic kidney disease stage 3A with proteinuria 
1Z1D.11 CKD stage 3A with proteinuria 
1Z1E.00 Chronic kidney disease stage 3A without proteinuria 
1Z1E.11 CKD stage 3A without proteinuria 
1Z1F.00 Chronic kidney disease stage 3B with proteinuria 
1Z1F.11 CKD stage 3B with proteinuria 
1Z1G.00 Chronic kidney disease stage 3B without proteinuria 
1Z1G.11 CKD stage 3B without proteinuria 
1Z1H.00 Chronic kidney disease stage 4 with proteinuria 
1Z1H.11 CKD stage 4 with proteinuria 
1Z1J.00 Chronic kidney disease stage 4 without proteinuria 
1Z1J.11 CKD stage 4 without proteinuria 
1Z1K.00 Chronic kidney disease stage 5 with proteinuria 
1Z1K.11 CKD stage 5 with proteinuria 
1Z1L.00 Chronic kidney disease stage 5 without proteinuria 
1Z1L.11 CKD stage 5 without proteinuria 
661M200 Chronic kidney disease self-management plan agreed 
661N200 Chronic kidney disease self-management plan review 
66i..00 Chronic kidney disease monitoring 
67P4100 Discussion about kidney transplantation 
6AA..00 Chronic kidney disease annual review 
7A60600 Creation of graft fistula for dialysis 
7A61900 Ligation of arteriovenous dialysis fistula 
7A61A00 Ligation of arteriovenous dialysis graft 
7B00.00 Transplantation of kidney 
7B00000 Autotransplant of kidney 
7B00100 Transplantation of kidney from live donor 
7B00111 Allotransplantation of kidney from live donor 
7B00200 Transplantation of kidney from cadaver 
7B00211 Allotransplantation of kidney from cadaver 
7B00212 Cadaveric renal transplant 
7B00300 Allotransplantation of kidney from cadaver, heart-beating 
7B00400 Allotransplantation kidney from cadaver, heart non-beating 
7B00500 Allotransplantation of kidney from cadaver NEC 
7B00600 Xenograft renal transplant 
7B00y00 Other specified transplantation of kidney 
7B00z00 Transplantation of kidney NOS 
7B01511 Excision of rejected transplanted kidney 
7B01900 Excision of rejected transplanted kidney 
7B03300 Rovsing's operation for polycystic kidney 
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Read code Code description 
7B06300 Exploration of renal transplant 
7B0F.00 Interventions associated with transplantation of kidney 
7B0F100 Pre-transplantation of kidney work-up, recipient 
7B0F300 Post-transplantation of kidney examination, recipient 
7B0Fy00 OS interventions associated with transplantation of kidney 
7B0Fz00 Interventions associated with transplantation of kidney NOS 
7L1A.00 Compensation for renal failure 
7L1A.11 Dialysis for renal failure 
7L1A000 Renal dialysis 
7L1A011 Thomas intravascular shunt for dialysis 
7L1A100 Peritoneal dialysis 
7L1A200 Haemodialysis NEC 
7L1A400 Automated peritoneal dialysis 
7L1A500 Continuous ambulatory peritoneal dialysis 
7L1A600 Peritoneal dialysis NEC 
7L1Ay00 Other specified compensation for renal failure 
7L1Az00 Compensation for renal failure NOS 
7L1B.00 Placement ambulatory apparatus compensation renal failure 
7L1B.11 Placement ambulatory dialysis apparatus - compens renal fail 
7L1B000 Insertion of ambulatory peritoneal dialysis catheter 
7L1B100 Removal of ambulatory peritoneal dialysis catheter 
7L1B200 Flushing of peritoneal dialysis catheter 
7L1By00 Placement ambulatory apparatus- compensate renal failure OS 
7L1Bz00 Placement ambulatory apparatus- compensate renal failure NOS 
7L1C.00 Placement other apparatus for compensation for renal failure 
7L1C000 Insertion of temporary peritoneal dialysis catheter 
7L1Cy00 Placement other apparatus- compensate for renal failure OS 
7L1Cz00 Placement other apparatus- compensate for renal failure NOS 
8L50.00 Renal transplant planned 
9Ni9.00 Did not attend chronic kidney disease monitoring clinic 
9Ot..00 Chronic kidney disease monitoring administration 
9Ot0.00 Chronic kidney disease monitoring first letter 
9Ot1.00 Chronic kidney disease monitoring second letter 
9Ot2.00 Chronic kidney disease monitoring third letter 
9Ot3.00 Chronic kidney disease monitoring verbal invite 
9Ot4.00 Chronic kidney disease monitoring telephone invite 
9Ot5.00 Predicted stage chronic kidney disease 
9hE..00 Exception reporting: chronic kidney disease quality indicato 
9hE0.00 Except chronic kidney disease qual indic: Patient unsuitable 
9hE1.00 Exc chronic kidney disease quality indicators: Inform dissen 
A160000 Tuberculous nephropathy 
A844100 Plasmodium malariae malaria with nephropathy 
C300D00 Infantile nephropathic cystinosis 
C300y12 Hypophosphataemic rickets with nephrotic-glycosuric dwarfism 
C353600 Renal failure-associated hyperphosphataemia 
C354C00 Cortical nephrocalcinosis 
C373412 Amyloid nephropathy with deafness and urticaria 
C373L00 Amyloid nephropathy of Ostertag 
D215.00 Anaemia secondary to renal failure 
D215000 Anaemia secondary to chronic renal failure 
G22..00 Hypertensive renal disease 
G22..11 Nephrosclerosis 
G220.00 Malignant hypertensive renal disease 
G221.00 Benign hypertensive renal disease 
G222.00 Hypertensive renal disease with renal failure 
G22z.00 Hypertensive renal disease NOS 
G22z.11 Renal hypertension 
G23..00 Hypertensive heart and renal disease 
G230.00 Malignant hypertensive heart and renal disease 
G231.00 Benign hypertensive heart and renal disease 
G232.00 Hypertensive heart&renal dis wth (congestive) heart failure 
G233.00 Hypertensive heart and renal disease with renal failure 
G234.00 Hyperten heart&renal dis+both(congestv)heart and renal fail 
G23z.00 Hypertensive heart and renal disease NOS 
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Read code Code description 
G721100 Congenital renal artery aneurysm 
G72C.00 Ruptured aneurysm of dialysis vascular access 
G72D.00 Aneurysm of dialysis arteriovenous fistula 
G72D000 Aneurysm of superficialised artery of dialysis AV fistula 
G72D100 Aneurysm of needle site of dialysis arteriovenous fistula 
G72D200 Aneurysm of anastomotic site of dialysis AV fistula 
G72E.00 Aneurysm of dialysis vascular access 
G752111 Antiglomerular basement membrane disease 
G752112 Anti GBM disease - Antiglomerular basement membrane disease 
Gy1..00 Stenosis of dialysis vascular access 
Gy10.00 Stenosis of dialysis arteriovenous graft 
Gy11.00 Stenosis of dialysis arteriovenous shunt 
Gy11000 Stenosis of arterial side of dialysis arteriovenous shunt 
Gy11100 Stenosis of venous side of dialysis arteriovenous shunt 
Gy2..00 Thrombosis of dialysis vascular access 
Gy20.00 Thrombosis of dialysis arteriovenous graft 
Gy21.00 Thrombosis of dialysis arteriovenous fistula 
Gy22.00 Thrombosis of dialysis arteriovenous shunt 
Gy3..00 Occlusion of dialysis vascular access 
Gy30.00 Occlusion of dialysis arteriovenous graft 
Gy31.00 Occlusion of dialysis arteriovenous fistula 
Gy32.00 Occlusion of dialysis arteriovenous shunt 
Gy4..00 Infection of dialysis vascular access 
Gy40.00 Infection of dialysis arteriovenous graft 
Gy41.00 Infection of dialysis arteriovenous fistula 
Gy42.00 Infection of dialysis arteriovenous shunt 
Gy5..00 Haemorrhage of dialysis vascular access 
Gy50.00 Haemorrhage of dialysis arteriovenous graft 
Gy51.00 Haemorrhage of dialysis arteriovenous fistula 
Gy52.00 Haemorrhage of dialysis arteriovenous shunt 
Gy6..00 Rupture of dialysis vascular access 
Gy60.00 Rupture of dialysis arteriovenous graft 
Gy61.00 Rupture of dialysis arteriovenous fistula 
Gy62.00 Rupture of dialysis arteriovenous shunt 
K0...00 Nephritis, nephrosis and nephrotic syndrome 
K000100 Crescentic glomerulonephritis 
K000111 CGN - Crescentic glomerulonephritis 
K01..00 Nephrotic syndrome 
K010.00 Nephrotic syndrome with proliferative glomerulonephritis 
K011.00 Nephrotic syndrome with membranous glomerulonephritis 
K012.00 Nephrotic syndrome+membranoproliferative glomerulonephritis 
K013.00 Nephrotic syndrome with minimal change glomerulonephritis 
K013.11 Lipoid nephrosis 
K013.12 Steroid sensitive nephrotic syndrome 
K014.00 Nephrotic syndrome, minor glomerular abnormality 
K015.00 Nephrotic syndrome, focal and segmental glomerular lesions 
K016.00 Nephrotic syndrome, diffuse membranous glomerulonephritis 
K017.00 Nephrotic syn difus mesangial prolifertiv glomerulonephritis 
K018.00 Nephrotic syn,difus endocapilary proliftv glomerulonephritis 
K019.00 Nephrotic syn,diffuse mesangiocapillary glomerulonephritis 
K01A.00 Nephrotic syndrome, dense deposit disease 
K01B.00 Nephrotic syndrome, diffuse crescentic glomerulonephritis 
K01w.00 Congenital nephrotic syndrome 
K01w000 Finnish nephrosis syndrome 
K01w011 Microcystic type congenital nephrotic syndrome 
K01w012 Congenital Finnish nephrosis 
K01w100 Drash syndrome 
K01w111 Nephrotic syndrome with pseudohermaphroditism 
K01w112 Wilms' tumour + nephrotic syndrome + pseudohermaphroditism 
K01w200 Congenital nephrotic syndrome with focal glomerulosclerosis 
K01wz00 Congenital nephrotic syndrome NOS 
K01x.00 Nephrotic syndrome in diseases EC 
K01x000 Nephrotic syndrome in amyloidosis 
K01x100 Nephrotic syndrome in diabetes mellitus 
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K01x111 Kimmelstiel - Wilson disease 
K01x200 Nephrotic syndrome in malaria 
K01x300 Nephrotic syndrome in polyarteritis nodosa 
K01x400 Nephrotic syndrome in systemic lupus erythematosus 
K01x411 Lupus nephritis 
K01xz00 Nephrotic syndrome in diseases EC NOS 
K01y.00 Nephrotic syndrome with other pathological kidney lesions 
K01z.00 Nephrotic syndrome NOS 
K02..00 Chronic glomerulonephritis 
K02..11 Nephritis - chronic 
K02..12 Nephropathy - chronic 
K020.00 Chronic proliferative glomerulonephritis 
K021.00 Chronic membranous glomerulonephritis 
K022.00 Chronic membranoproliferative glomerulonephritis 
K023.00 Chronic rapidly progressive glomerulonephritis 
K024.00 Thin basement membrane disease 
K02y.00 Other chronic glomerulonephritis 
K02y000 Chronic glomerulonephritis + diseases EC 
K02y100 Chronic exudative glomerulonephritis 
K02y200 Chronic focal glomerulonephritis 
K02y300 Chronic diffuse glomerulonephritis 
K02y400 Chronic radiation nephritis 
K02yz00 Other chronic glomerulonephritis NOS 
K02z.00 Chronic glomerulonephritis NOS 
K03..00 Nephritis and nephropathy unspecified 
K03..11 Nephritis and nephropathy unspecified 
K03..12 Nephropathy, unspecified 
K030.00 Proliferative nephritis unspecified 
K031.00 Membranous nephritis unspecified 
K032.00 Membranoproliferative nephritis unspecified 
K032000 Focal membranoproliferative glomerulonephritis 
K032200 Focal glomerulon + focal recurr macroscop glomerulonephritis 
K032300 Anaphylactoid glomerulonephritis 
K032400 Familial glomerulonephritis in Alport's syndrome 
K032500 Other familial glomerulonephritis 
K032600 Berger's IgA or IgG nephropathy 
K032y00 Nephritis unsp+OS membranoprolif glomerulonephritis lesion 
K032y11 Hypocomplementaemic persistent glomerulonephritis NEC 
K032y12 Lobular glomerulonephritis NEC 
K032y13 Mesangioproliferative glomerulonephritis NEC 
K032y14 Mesangiocapillary glomerulonephritis NEC 
K032y15 Mixed membranous and proliferative glomerulonephritis NEC 
K032z00 Nephritis unsp+membranoprolif glomerulonephritis lesion NOS 
K033.00 Rapidly progressive nephritis unspecified 
K034.00 Renal cortical necrosis unspecified 
K035.00 Renal medullary necrosis unspecified 
K036.00 Cryoglobulinaemic glomerulonephritis 
K03T.00 Tubulo-interstit nephritis, not specif as acute or chron 
K03U.00 Unspecif nephr synd, diff concentric glomerulonephritis 
K03V.00 Unspecified nephritic syndrome, dense deposit disease 
K03W.00 Unsp nephrit synd, diff endocap prolif glomerulonephritis 
K03X.00 Unsp nephrit synd, diff mesang prolif glomerulonephritis 
K03y.00 Other nephritis and nephrosis unspecified 
K03y000 Other nephritis and nephrosis in diseases EC 
K03y100 Other exudative nephritis 
K03y200 Other interstitial nephritis 
K03yz00 Other nephritis and nephrosis NOS 
K03z.00 Unspecified glomerulonephritis NOS 
K05..00 Chronic renal failure 
K05..11 Chronic uraemia 
K05..12 End stage renal failure 
K05..13 Chronic kidney disease 
K050.00 End stage renal failure 
K051.00 Chronic kidney disease stage 1 
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K052.00 Chronic kidney disease stage 2 
K053.00 Chronic kidney disease stage 3 
K054.00 Chronic kidney disease stage 4 
K055.00 Chronic kidney disease stage 5 
K06..00 Renal failure unspecified 
K06..11 Uraemia NOS 
K06..12 Kidney failure unspecified 
K060.00 Renal impairment 
K060.11 Impaired renal function 
K07..00 Renal sclerosis unspecified 
K070.00 Atrophy of kidney 
K071.00 Renal fibrosis 
K072.00 Glomerulosclerosis 
K073.00 Diffuse mesangial sclerosis with ocular abnormalities 
K07z.00 Renal sclerosis NOS 
K08..00 Impaired renal function disorder 
K080.00 Renal osteodystrophy 
K080000 Phosphate-losing tubular disorders 
K080100 Renal dwarfism 
K080200 Renal infantilism 
K080300 Renal rickets 
K080z00 Renal osteodystrophy NOS 
K081100 Congenital nephrogenic diabetes insipidus 
K08y000 Hypokalaemic nephropathy 
K08y211 Albright's renal tubular acidosis 
K08y300 Renal function impairment with growth failure 
K08y400 Renal tubular acidosis 
K08y412 Renal tubular acidaemia 
K08y800 Renal tubular acidosis with progressive nerve deafness 
K08y900 Classic distal renal tubular acidosis 
K08yB00 Hyperkalaemic renal tubular acidosis 
K08yB11 Type IV renal tubular acidosis 
K08yC00 Proximal renal tubular acidosis 
K08yC11 Type II renal tubular acidosis 
K08yD00 Distal renal tubular acidosis 
K08yE00 Mixed renal tubular acidosis 
K08yE11 Type III renal tubular acidosis 
K08yH00 Familial renal hypouricaemia 
K08yz12 Renotubular acidaemia 
K08z.00 Impaired renal function disorder NOS 
K0A..00 Glomerular disease 
K0A1.00 Rapidly progressive nephritic syndrome 
K0A1000 Rapid progres neph syndrome, minor glomerular abnormality 
K0A1100 Rapid progres nephritic syn focal+segmental glomerulr lesion 
K0A1200 Rapid progres neph syn diffuse membranous glomerulonephritis 
K0A1300 Rpd prog neph syn df mesangial prolifratv glomerulonephritis 
K0A1400 Rapid progres neph syn df endocapilary prolifv glomnephritis 
K0A1500 Rapid prog neph syn df mesangiocapillary glomerulonephritis 
K0A1600 Rapid progressive nephritic syndrome, dense deposit disease 
K0A1700 Rapid progres nephritic syn df crescentic glomerulonephritis 
K0A2000 Recurrent+persistnt haematuria minor glomerular abnormality 
K0A2100 Recur+persist haematuria, focal+segmental glomerular lesions 
K0A2200 Recur+persist haematuria difus membranous glomerulonephritis 
K0A2300 Recur+persist haemuria df mesangial prolif glomerulnephritis 
K0A2400 Recur+persist haemuria df endocaplry prolifrtv glomeruloneph 
K0A2500 Recur+persist hmuria df mesangiocapilary glomerulonephritis 
K0A2700 Recur+persist haematuria difus crescentic glomerulonephritis 
K0A2800 IgA nephropathy 
K0A3.00 Chronic nephritic syndrome 
K0A3000 Chronic nephritic syndrome, minor glomerular abnormality 
K0A3100 Chronic nephritic syndrm focal+segmental glomerular lesions 
K0A3200 Chron nephritic syndrom difuse membranous glomerulonephritis 
K0A3300 Chron neph syn difus mesangial prolifrtiv glomerulonephritis 
K0A3400 Chron neph syn difuse endocap prolifrativ glomerulonephritis 
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Read code Code description 
K0A3500 Chronic neph syn difus mesangiocapillary glomerulonephritis 
K0A3600 Chronic nephritic syndrome, dense deposit disease 
K0A3700 Chronic nephritic syn diffuse crescentic glomerulonephritis 
K0A5.00 Hereditary nephropathy not elsewhere classified 
K0A5000 Hereditary nephropathy NEC, minor glomerular abnormality 
K0A5100 Hereditary nephropathy NEC,focal+segmnt glomerular lesion 
K0A5200 Hereditry nephropathy NEC,difus membran glomerulnephritis 
K0A5300 Heredtry nephrpthy NEC difus mesangial prolif glomnephrit 
K0A5400 Heredtry nephrpthy NEC difus endocapil prolif glomnephrit 
K0A5500 [X]Heredtry nephrpthy NEC difus mesangiocapilry glomneph 
K0A5600 Hereditary nephropathy, NEC, dense deposit disease 
K0A5700 Hereditary nephropathy,NEC,difus crescentic glomnephritis 
K0A5X00 Hereditary nephropathy, unspecif morphological changes 
K0A6.00 Glomerular disorders in neoplastic diseases 
K0A8.00 Rapidly progressive glomerulonephritis 
K0A9.00 Cytomegalovirus-induced glomerulonephritis 
K0B..00 Renal tubulo-interstitial disorders in diseases EC 
K0B0.00 Ren tubulo-interstital disord infect and parasitic dis EC 
K0B1.00 Renal tubulo-interstitial disorder/ neoplastic diseases 
K0B2.00 Ren tub-interst disordr/blood dis+disordr inv immune mech 
K0B3.00 Renal tubulo-interstitial disorders in metabolic diseases 
K0B4.00 Ren tub-interstitl disordr/systemc connectv tiss disorder 
K0B4000 Renal tubulo-interstitial disorder in SLE 
K0B5.00 Renal tubulo-interstitial disordrs in transplant rejectn 
K0B6.00 Balkan nephropathy 
K0C..00 Drug/heavy-metal-induced tubulo-interstitial and tub conditn 
K0C0.00 Analgesic nephropathy 
K0C1.00 Nephropathy induced by other drugs meds and biologl substncs 
K0C2.00 Nephropathy induced by unspec drug medicament or biol subs 
K0C3.00 Nephropathy induced by heavy metals 
K0C3400 Chronic interstitial nephritis due to heavy metals 
K0C3500 Chronic lead nephropathy 
K0C3600 Chronic mercury nephropathy 
K0C3700 Chronic cadmium nephropathy 
K0C3800 Saturnine nephropathy 
K0C4.00 Toxic nephropathy, not elsewhere classified 
K0C6.00 Chronic lithium nephrotoxicity 
K0D..00 End-stage renal disease 
K0E..00 Acute-on-chronic renal failure 
K0G..00 Sickle cell nephropathy 
K0J..00 Renal disorders in systemic disease 
K0J0.00 Renal involvement in scleroderma 
K0J1.00 Renal involvement in malignant disease 
K0y..00 Other specified nephritis, nephrosis or nephrotic syndrome 
K0y1.00 Acquired magnesium-losing nephropathy 
K0z..00 Nephritis, nephrosis and nephrotic syndrome NOS 
K132.11 Acquired renal cystic disease 
K138600 Renal vascular disease 
K13C.00 Chronic drug-induced renal disease 
K13yB00 Ischaemic nephropathy 
K13z.00 Kidney and ureter disease NOS 
K196.11 Obstructive uropathy, unspecified 
K19C.00 Other obstructive and reflux uropathy 
K19X.00 Obstructive and reflux uropathy, unspecified 
Kyu0.00 [X]Glomerular diseases 
Kyu0000 [X]Glomerular disorders in infectious+parasitic diseases CE 
Kyu0100 [X]Glomerular disorders in neoplastic diseases CE 
Kyu0200 [X]Glomerulr disordrs/bld dis+disordr inv immune mechansm CE 
Kyu0300 [X]Glomerular disorders in diabetes mellitus 
Kyu0400 [X]Glomerulr disordr/oth endocrine,nutritnl+metabolic dis CE 
Kyu0500 [X]Glomerular disordrs/systemic disordrs/connectiv tissue CE 
Kyu0600 [X]Glomerular disorders in other diseases CE 
Kyu0700 [X]Rapidly progressive nephritic syndrome, other 
Kyu0800 [X]Unspecif nephritic syndr, minor glomerular abnormality 
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Table G.5  Continued. 
Read code Code description 
Kyu0900 [X]Unsp nephrit synd, diff mesang prolif glomerulonephritis 
Kyu0A00 [X]Unsp nephrit synd, diff endocap prolif glomerulonephritis 
Kyu0B00 [X]Unspecified nephritic syndrome, dense deposit disease 
Kyu0C00 [X]Unspecif nephr synd, diff concentric glomerulonephritis 
Kyu0F00 [X]Hereditary nephropathy, unspecif morphological changes 
Kyu1.00 [X]Renal tubulo-interstitial diseases 
Kyu1000 [X]Other chronic tubulo-interstitial nephritis 
Kyu1100 [X]Other and unspecified hydronephrosis 
Kyu1200 [X]Other obstructive and reflux uropathy 
Kyu1300 [X]Obstructive and reflux uropathy, unspecified 
Kyu1400 [X]Nephropathy induced by other drugs+biological substances 
Kyu1500 [X]Toxic nephropathy, not elsewhere classified 
Kyu1600 [X]Other specified renal tubulo-interstitial diseases 
Kyu1700 [X]Renal tubulo-interstitial disordr/infect+parasitic dis CE 
Kyu1800 [X]Renal tubulo-interstitial disordrs/neoplastic diseases CE 
Kyu1900 [X]Renal tub-interstl disord/bld dis+disord invl imm mech CE 
Kyu1A00 [X]Renal tubulo-interstitial disorders/metabolic diseases CE 
Kyu1B00 [X]Renal tubul-interstitl disordrs/connectv tissu disordr CE 
Kyu1C00 [X]Renal tubulo-interstitial disorders/transplant rejection 
Kyu1D00 [X]Renal tubulo-interstitial disorders in other diseases CE 
Kyu1E00 [X]Tubulo-interstit nephritis, not specif as acute or chron 
Kyu2.00 [X]Renal failure 
Kyu2100 [X]Other chronic renal failure 
Kyu4000 [X]Other disorders resulting/impaired renal tubular function 
Kyu4200 [X]Oth disordrs/kidney+ureter/infects+parasitic diseases CE 
Kyu4300 [X]Other disorders of kidney+ureter in other diseases CE 
L093300 Renal tubular necrosis following abortive pregnancy 
L162.00 Unspecified renal disease in pregnancy 
L162.12 Nephropathy NOS in pregnancy without hypertension 
L162000 Unspecified renal disease in pregnancy unspecified 
L162100 Unspecified renal disease in pregnancy - delivered 
L162200 Unspecified renal disease in pregnancy - del with p/n comp 
L162300 Unspecified renal disease in pregnancy - not delivered 
L162400 Unspecified renal disease in pregnancy with p/n complication 
L162z00 Unspecified renal disease in pregnancy NOS 
PD00200 Unilat renal agenesis with contralat hypoplasia/dysplasia 
PD03.00 Hypoplasia of kidney 
PD03000 Bilateral renal hypoplasia 
PD03100 Unilateral renal hypoplasia 
PD03200 Segmental renal hypoplasia 
PD04.00 Dysplasia of kidney 
PD04000 Bilateral renal dysplasia 
PD04100 Unilateral renal dysplasia 
PD04200 Renal dysplasia and retinal aplasia 
PD04z00 Dysplasia of kidney NOS 
PD1..00 Congenital cystic kidney disease 
PD1..11 Congenital cystic renal disease 
PD1..12 Fibrocystic kidney 
PD1..13 Polycystic kidney 
PD1..14 Sponge kidney 
PD11.00 Polycystic kidney disease 
PD11000 Polycystic kidneys, infantile type 
PD11011 Autosomal recessive polycystic kidney disease 
PD11100 Polycystic kidneys, adult type 
PD11111 Autosomal dominant polycystic kidney disease 
PD11z00 Polycystic kidney disease NOS 
PD11z11 Cystic kidney disease NEC 
PD12.00 Medullary cystic disease 
PD12000 Medullary cystic disease, juvenile type 
PD12011 Nephronophthisis 
PD12012 Autosomal recessive medullary cystic disease 
PD12100 Medullary cystic disease, adult type 
PD12111 Medullary sponge kidney 
PD12200 Nephronophthisis - medullary cystic disease 
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Table G.5  Continued. 
Read code Code description 
PD12211 Autosomal dominant medullary cystic disease 
PD12y00 Medullary cystic disease OS 
PD12z00 Medullary cystic disease NOS 
PD13.00 Multicystic renal dysplasia 
PD13.11 Multicystic kidney 
PD1y.00 Other specified congenital cystic kidney disease 
PD1y000 Fibrocystic kidney disease 
PD1y011 Fibrocystic renal degeneration 
PD1y100 Cortical cystic disease 
PD1yz00 Other congenital cystic kidney disease NOS 
PD1z.00 Congenital cystic kidney disease NOS 
PD39.00 Hyperplasia of kidney 
PD8..00 Congenital abnormality of the kidney 
PD80.00 Duplex kidney 
PKy5E00 Branchio-otorenal dysplasia 
Pyu7000 [X]Other cystic kidney diseases 
Q48y000 Congenital renal failure 
SK05.00 Renal failure following crush syndrome 
SK05.11 Renal failure after crushing 
SP01500 Mechanical complication of dialysis catheter 
SP05613 [X] Peritoneal dialysis associated peritonitis 
SP06B00 Continuous ambulatory peritoneal dialysis associated perit 
SP07G00 Stenosis of arteriovenous dialysis fistula 
SP08300 Kidney transplant failure and rejection 
SP08C00 Accelerated rejection of renal transplant 
SP08D00 Acute-on-chronic rejection of renal transplant 
SP08E00 Acute rejection of renal transplant - grade I 
SP08F00 Acute rejection of renal transplant - grade II 
SP08G00 Acute rejection of renal transplant - grade III 
SP08H00 Acute rejection of renal transplant 
SP08J00 Chronic rejection of renal transplant 
SP08J11 Chronic transplant nephropathy 
SP08K00 Chronic rejection of renal transplant - grade 1 
SP08L00 Chronic rejection of renal transplant - grade II 
SP08M00 Chronic rejection of renal transplant - grade III 
SP08N00 Unexplained episode of renal transplant dysfunction 
SP08P00 Stenosis of vein of transplanted kidney 
SP08Q00 Aneurysm of artery of transplanted kidney 
SP08R00 Renal transplant rejection 
SP08S00 Aneurysm of vein of transplanted kidney 
SP08T00 Urological complication of renal transplant 
SP08V00 Very mild acute rejection of renal transplant 
SP08W00 Vascular complication of renal transplant 
SP08X00 Rupture of artery of transplanted kidney 
SP08Y00 Rupture of vein of transplanted kidney 
SP08Z00 Thrombosis of artery of transplanted kidney 
SP08a00 Thrombosis of vein of transplanted kidney 
SP08b00 De novo glomerulonephritis 
SP0E.00 Disorders associated with peritoneal dialysis 
SP0E000 Bloodstained peritoneal dialysis effluent 
SP0E100 Thrombus in peritoneal dialysis catheter 
SP0F.00 Haemodialysis first use syndrome 
SP0G.00 Anaphylactoid reaction due to haemodialysis 
SP0H.00 Disorder associated with dialysis 
SP0H000 Dialysis disequilibrium 
SP15400 Renal failure as a complication of care 
SP15411 Kidney failure as a complication of care 
SP15412 Post operative renal failure 
SP3y900 Acute hypercalcaemia of dialysis 
TA02.00 Accid cut,puncture,perf,h'ge - kidney dialysis/oth perfusion 
TA02000 Accid cut,puncture,perf,h'ge - kidney dialysis 
TA02011 Accidental cut/puncture/perf/haem'ge during renal dialysis 
TA12000 Foreign object left in body during kidney dialysis 
TA12011 Foreign object left in body during renal dialysis 
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Table G.5  Continued. 
Read code Code description 
TA22000 Failure of sterile precautions during kidney dialysis 
TA22011 Failure of sterile precautions during renal dialysis 
TA42000 Mechanical failure of apparatus during kidney dialysis 
TA42011 Mechanical failure of apparatus during renal dialysis 
TB00100 Kidney transplant with complication, without blame 
TB00111 Renal transplant with complication, without blame 
TB11.00 Kidney dialysis with complication, without blame 
TB11.11 Renal dialysis with complication, without blame 
U612200 [X]Failure sterile precautions dur kidney dialys/other perf 
U641.00 [X]Kidny dialysis caus abn reac pt/lat comp no misad at time 
Z1A..00 Dialysis training 
Z1A1.00 Peritoneal dialysis training 
Z1A1.11 PD - Peritoneal dialysis training 
Z1A2.00 Haemodialysis training 
Z1A2.11 HD - Haemodialysis training 
Z919.00 Care of haemodialysis equipment 
Z919100 Priming haemodialysis lines 
Z919200 Washing back through haemodialysis lines 
Z919300 Reversing haemodialysis lines 
Z919400 Recirculation of the dialysis machine 
Z91A.00 Peritoneal dialysis bag procedure 
Z91A100 Putting additive into peritoneal dialysis bag 
ZC2CL11 Dietary advice kidney disease 
ZV42000 [V]Kidney transplanted 
ZV45100 [V]Renal dialysis status 
ZV56.00 [V]Aftercare involving intermittent dialysis 
ZV56000 [V]Aftercare involving extracorporeal dialysis 
ZV56011 [V]Aftercare involving renal dialysis NOS 
ZV56100 [V]Preparatory care for dialysis 
ZV56y00 [V]Other specified aftercare involving intermittent dialysis 
ZV56y11 [V]Aftercare involving peritoneal dialysis 
ZV56z00 [V]Unspecified aftercare involving intermittent dialysis 
ZVu3G00 [X]Other dialysis 
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G.6 Re ad codes re lat ed to condi ti ons  ass oc iat ed w it h gastro in tes tinal mala bs orpt ion  
Table G.6  Read codes related to conditions associated with gastrointestinal 
malabsorption. 
Read code Code description 
13YB.00 Coeliac UK member 
14CH.00 History of chronic pancreatitis 
6648.00 Coeliac disease monitoring 
6648000 Coeliac disease annual review 
66k..00 Cystic fibrosis monitoring 
66k0.00 Cystic fibrosis annual review 
7Q09600 Total parenteral nutrition 
8CA4W00 Dietary education for inflammatory bowel disease 
8Cc5.00 Management of inflammatory bowel disease 
8Cc5.11 Management of IBD (inflammatory bowel disease) 
8IAp.00 Coeliac disease annual review declined 
9Ngq.00 On parenteral nutrition 
9No7.00 Seen in cystic fibrosis clinic 
9mB..00 Coeliac disease monitoring invitation 
9mB0.00 Coeliac disease monitoring telephone invitation 
9mB1.00 Coeliac disease monitoring invitation first letter 
9mB2.00 Coeliac disease monitoring invitation second letter 
9mB3.00 Coeliac disease monitoring invitation third letter 
C10N100 Cystic fibrosis related diabetes mellitus 
C370.00 Cystic fibrosis 
C370000 Cystic fibrosis with no meconium ileus 
C370100 Cystic fibrosis with meconium ileus 
C370111 Meconium ileus in cystic fibrosis 
C370200 Cystic fibrosis with pulmonary manifestations 
C370300 Cystic fibrosis with intestinal manifestations 
C370400 Arthropathy in cystic fibrosis 
C370500 Cystic fibrosis with distal intestinal obstruction syndrome 
C370700 Liver disease due to cystic fibrosis 
C370800 Cystic fibrosis related cirrhosis 
C370900 Exacerbation of cystic fibrosis 
C370y00 Cystic fibrosis with other manifestations 
C370y11 Cystic fibrosis with combined manifestations 
C370z00 Cystic fibrosis NOS 
J08z900 Orofacial Crohn's disease 
J4...12 Inflammatory bowel disease 
J40..00 Regional enteritis - Crohn's disease 
J40..11 Crohn's disease 
J400200 Crohn's disease of the terminal ileum 
J400300 Crohn's disease of the ileum unspecified 
J400400 Crohn's disease of the ileum NOS 
J400500 Exacerbation of Crohn's disease of small intestine 
J400z00 Crohn's disease of the small bowel NOS 
J401200 Exacerbation of Crohn's disease of large intestine 
J401z00 Crohn's disease of the large bowel NOS 
J401z11 Crohn's colitis 
J40z.11 Crohn's disease NOS 
J41..12 Ulcerative colitis and/or proctitis 
J410.00 Ulcerative proctocolitis 
J410000 Ulcerative ileocolitis 
J410100 Ulcerative colitis 
J410200 Ulcerative rectosigmoiditis 
J410300 Ulcerative proctitis 
J410400 Exacerbation of ulcerative colitis 
J410z00 Ulcerative proctocolitis NOS 
J411.00 Ulcerative (chronic) enterocolitis 
J412.00 Ulcerative (chronic) ileocolitis 
J413.00 Ulcerative pancolitis 
J671.00 Chronic pancreatitis 
J671000 Alcohol-induced chronic pancreatitis 
J671100 Gallstone chronic pancreatitis 
J67y500 Pancreatic insufficiency 
J67y600 Exocrine pancreatic insufficiency 
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Table G.6  Continued. 
Read code Code description 
J69..00 Intestinal malabsorption 
J690.00 Coeliac disease 
J690.11 Coeliac rickets 
J690.12 Gee - Herter disease 
J690.13 Gluten enteropathy 
J690.14 Sprue - nontropical 
J690.16 Villous atrophy 
J690.17 Partial villous atrophy 
J690000 Congenital coeliac disease 
J690100 Acquired coeliac disease 
J690z00 Coeliac disease NOS 
J691.00 Tropical sprue 
J692.00 Blind loop syndrome 
J693.00 Other postsurgical nonabsorption 
J693.11 Postsurgical malabsorption - other 
J693000 Post gastrointestinal tract surgery hypoglycaemia 
J693100 Post gastrointestinal tract surgery malnutrition 
J693z00 Postsurgical nonabsorption NOS 
J694.00 Pancreatic steatorrhoea 
J69y.00 Other intestinal malabsorption 
J69y000 Chronic steatorrhoea 
J69y011 Malabsorption due to intolerance to fat 
J69y200 Intestinal malabsorption of protein 
J69y600 Intestinal malabsorption of fat 
J69yz00 Other gastrointestinal tract malabsorption NOS 
J69yz13 Malabsorption syndrome NOS 
J69z.00 Intestinal malabsorption NOS 
Jyu4000 [X]Other Crohn's disease 
Jyu4100 [X]Other ulcerative colitis 
Jyu8400 [X]Other chronic pancreatitis 
Jyu9000 [X]Other intestinal malabsorption 
N031000 Arthropathy in ulcerative colitis 
N031100 Arthropathy in Crohn's disease 
N045300 Juvenile arthritis in Crohn's disease 
N045400 Juvenile arthritis in ulcerative colitis 
PB5z.12 Short bowel syndrome 
PJ53500 Shwachman-Diamond syndrome 
ZC2C200 Dietary advice for coeliac disease 
ZC32.49 TPN - Total parenteral nutrition 
ZC64.00 Parenteral nutrition 
ZC64.11 Parenteral alimentation 
ZC64.12 IV - Intravenous feeding 
ZC64.13 Intravenous feeding 
ZC64.14 Parenteral feeding 
ZC64.15 PN - Parenteral nutrition 
ZC64100 Central line feeding 
ZC64200 Peripheral line feeding 
ZC64300 Total parenteral nutrition 
ZC64311 TPN - Total parenteral nutrition 
ZR3S.00 Crohn's disease activity index 
ZR3S.11 CDAI - Crohn's disease activity index 
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G.7 Identification of Read Codes Referring to Symptoms and Clinical 
Complications of Vitamin D Deficiency 
 
 
G.7.1 Identification of Read Codes Related to Musculoskeletal and Non-Specific  
 Pain 
 
The following truncated search terms were used to identify Read codes related to 
musculoskeletal and non-specific pain: ‘pain’, ‘ache’, ‘aching’, ‘arthralgia’, ‘arthropathy’, 
‘cramp’, ‘cervicalgia’, ‘musculo’, ‘myalgia’. Common code stems were used to identify 
additional relevant codes. A total of 175 relevant codes were identified. The final list of 
included codes is shown in Table G.7. 
 
Table G.7  Read codes related to musculoskeletal and non-specific pain. 
Read code Code description 
16C..00 Backache symptom 
16C2.00 Backache 
16C3.00 Backache with radiation 
16C4.00 Back pain worse on sneezing 
16C5.00 C/O - low back pain 
16C6.00 Back pain without radiation NOS 
16C7.00 C/O - upper back ache 
16C9.00 Chronic low back pain 
16CA.00 Mechanical low back pain 
16CZ.00 Backache symptom NOS 
16Z2.00 Growing pains 
16Z2.11 Growing pains symptom 
182B.00 Rib pain 
182B000 Costal margin chest pain 
182C.00 Chest wall pain 
1D13.00 C/O: a pain 
1D13.11 Pain 
1D13.12 C/O - an ache 
1D13000 C/O - pain in toes 
1D13100 C/O - pain in hallux 
1D13111 C/O - pain in big toe 
1DC2.00 Aching pain 
1DC8.00 Generalised pain [symptom] 
1DCC.00 Aching muscles 
1M0..00 Pain in upper limb 
1M00.00 Pain in elbow 
1M00.11 Elbow pain 
1M01.00 Pain in wrist 
1M1..00 Pain in lower limb 
1M10.00 Knee pain 
1M11.00 Foot pain 
1M12.00 Anterior knee pain 
1M13.00 Ankle pain 
N065.00 Unspecified polyarthropathy or polyarthritis 
N065.11 Polyarthropathy NEC 
N065000 Unspecified polyarthropathy of unspecified site 
N065100 Unspecified polyarthropathy of the shoulder region 
N065200 Unspecified polyarthropathy of the upper arm 
N065300 Unspecified polyarthropathy of the forearm 
N065400 Unspecified polyarthropathy of the hand 
N065500 Unspecified polyarthropathy of the pelvic region and thigh 
N065600 Unspecified polyarthropathy of the lower leg 
N065700 Unspecified polyarthropathy of the ankle and foot 
N065800 Unspecified polyarthropathy of other specified site 
N065900 Unspecified polyarthropathy of multiple sites 
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Table G.7  Continued. 
Read code Code description 
N065z00 Unspecified polyarthropathy or polyarthritis NOS 
N06y.00 Other specified arthropathy 
N06y000 Other specified arthropathy of unspecified site 
N06y100 Other specified arthropathy of the shoulder region 
N06y200 Other specified arthropathy of the upper arm 
N06y300 Other specified arthropathy of the forearm 
N06y400 Other specified arthropathy of the hand 
N06y500 Other specified arthropathy of the pelvic region and thigh 
N06y600 Other specified arthropathy of the lower leg 
N06y700 Other specified arthropathy of the ankle and foot 
N06y800 Other specified arthropathy of other specified site 
N06y900 Other specified arthropathy of multiple sites 
N06yz00 Other specified arthropathy NOS 
N06z.00 Arthropathy NOS 
N06z000 Arthropathy NOS, of unspecified site 
N06z100 Arthropathy NOS, of the shoulder region 
N06z200 Arthropathy NOS, of the upper arm 
N06z300 Arthropathy NOS, of the forearm 
N06z400 Arthropathy NOS, of the hand 
N06z500 Arthropathy NOS, of the pelvic region and thigh 
N06z600 Arthropathy NOS, of the lower leg 
N06z700 Arthropathy NOS, of the ankle and foot 
N06z800 Arthropathy NOS, of other specified site 
N06z900 Arthropathy NOS, of multiple sites 
N06zz00 Arthropathy NOS 
N094.00 Pain in joint - arthralgia 
N094.11 Ache in joint 
N094000 Arthralgia of unspecified site 
N094100 Arthralgia of the shoulder region 
N094111 Shoulder joint pain 
N094200 Arthralgia of the upper arm 
N094211 Elbow joint pain 
N094300 Arthralgia of the forearm 
N094311 Wrist joint pain 
N094400 Arthralgia of the hand 
N094411 Hand joint pain 
N094500 Arthralgia of the pelvic region and thigh 
N094511 Coxalgia 
N094512 Hip joint pain 
N094600 Arthralgia of the lower leg 
N094611 Knee joint pain 
N094700 Arthralgia of the ankle and foot 
N094711 Ankle joint pain 
N094800 Arthralgia of other specified site 
N094900 Arthralgia of multiple joints 
N094A00 Arthralgia of shoulder 
N094B00 Arthralgia of sternoclavicular joint 
N094C00 Arthralgia of acromioclavicular joint 
N094D00 Arthralgia of elbow 
N094D11 Elbow joint pain 
N094E00 Arthralgia of distal radio-ulnar joint 
N094F00 Arthralgia of wrist 
N094F11 Wrist pain 
N094G00 Arthralgia of MCP joint 
N094H00 Arthralgia of PIP joint of finger 
N094J00 Arthralgia of DIP joint of finger 
N094K00 Arthralgia of hip 
N094K11 Coxalgia 
N094K12 Hip pain 
N094L00 Arthralgia of sacro-iliac joint 
N094M00 Arthralgia of knee 
N094N00 Arthralgia of tibio-fibular joint 
N094P00 Arthralgia of ankle 
N094Q00 Arthralgia of subtalar joint 
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Table G.7  Continued. 
Read code Code description 
N094R00 Arthralgia of talonavicular joint 
N094S00 Arthralgia of other tarsal joint 
N094T00 Arthralgia of 1st MTP joint 
N094U00 Arthralgia of lesser MTP joint 
N094V00 Arthralgia of IP joint of toe 
N094W00 Anterior knee pain 
N094z00 Arthralgia NOS 
N096.12 Musculoskeletal pain - joints 
N131.00 Cervicalgia - pain in neck 
N131.11 Pain in cervical spine 
N134.13 Cervical root pain 
N138.00 Cervicalgia 
N141.00 Pain in thoracic spine 
N141.11 Acute back pain - thoracic 
N142.00 Pain in lumbar spine 
N142.11 Low back pain 
N142.12 Lumbalgia 
N142.13 Acute back pain - lumbar 
N142.14 Lumbago 
N142000 Lumbago with sciatica 
N143.11 Acute back pain with sciatica 
N144011 Thoracic nerve root pain 
N145.00 Backache, unspecified 
N145.11 Acute back pain - unspecified 
N145.12 Back pain, unspecified 
N147211 Pain in coccyx 
N241.00 Myalgia and myositis unspecified 
N241000 Myalgia unspecified 
N241012 Muscle pain 
N241z00 Myalgia or myositis NOS 
N245.00 Pain in limb 
N245.11 Ankle pain 
N245.12 Arm pain 
N245.13 Foot pain 
N245.14 Hand pain 
N245.15 Heel pain 
N245.16 Leg pain 
N245.17 Shoulder pain 
N245.18 Thigh pain 
N245.19 Pain in buttock 
N245000 Hand pain 
N245011 Thumb pain 
N245012 Finger pain 
N245100 Foot pain 
N245111 Toe pain 
N245200 Pain in leg 
N245211 Aching leg syndrome 
N245300 Pain in arm 
N245400 Calf pain 
N245500 Axillary pain 
N245700 Shoulder pain 
N247.00 Other musculoskeletal limb symptoms 
N247100 Leg cramps 
N247111 Night cramps 
N247200 Cramp 
N247z00 Musculoskeletal limb symptoms NOS 
N247z11 Hand cramps 
N33A.00 Bone pain 
N33A000 Bony pelvic pain 
N33A100 Clavicle pain 
R00z200 [D]Pain, generalized 
R00z211 [D]General aches and pains 
R01..11 [D]Musculoskeletal symptoms 
R01z100 [D]Growing pains - limbs 
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Table G.7  Continued. 
Read code Code description 
R01z200 [D]Musculoskeletal pain 
R065A00 [D]Musculoskeletal chest pain 
 
 
 
G.7.2 Identification of Read Codes Related to Tiredness and Fatigue 
 
The following truncated search terms were used to identify Read codes related to 
tiredness and fatigue: ‘tired’, ‘letharg’, ‘malaise’, ‘fatigue’, ‘energy’, ‘asthenia’, 
‘lassitude’. Common code stems were used to identify additional relevant codes. A total 
of 33 relevant codes were identified. The final list of included codes is shown in Table 
G.8. 
 
Table G.8  Read codes related to tiredness and fatigue. 
Read code Code description 
168..00 Tiredness symptom 
168..11 Fatigue - symptom 
168..12 Lethargy - symptom 
168..13 Malaise - symptom 
1682.00 Fatigue 
1683.00 Tired all the time 
1683.11 C/O - "tired all the time" 
1684.00 Malaise/lethargy 
1684.11 C/O - debility - malaise 
168Z.00 Tiredness symptom NOS 
E205.12 Tired all the time 
Eu46011 [X]Fatigue syndrome 
F286.00 Chronic fatigue syndrome 
F286.11 CFS - Chronic fatigue syndrome 
F286.12 Postviral fatigue syndrome 
F286.13 PVFS - Postviral fatigue syn 
F286.14 Post-viral fatigue syndrome 
F286.15 Myalgic encephalomyelitis 
F286.16 ME - Myalgic encephalomyelitis 
F286000 Mild chronic fatigue syndrome 
F286100 Moderate chronic fatigue synd 
F286200 Severe chronic fatigue synd 
R007.00 [D]Malaise and fatigue 
R007000 [D]Malaise 
R007100 [D]Fatigue 
R007200 [D]Asthenia NOS 
R007211 [D]General weakness 
R007300 [D]Lethargy 
R007400 [D]Postviral (asthenic) syndrome 
R007411 [D]Post viral debility 
R007500 [D]Tiredness 
R007z00 [D]Malaise and fatigue NOS 
R007z11 [D]Lassitude 
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G.7.3 Identification of Read Codes Related to Skeletal Deformity 
 
The following truncated search terms were used to identify Read codes related to 
skeletal deformity: ‘bow AND leg’, ‘bowed’, ‘bowing’, ‘genu’, ‘varum’, ‘varus’, ‘valgum’, 
‘valgus’, ‘knock AND knee’, ‘deform’, ‘abnormal AND bone’, ‘abnormal AND leg’, 
‘craniotab’, ‘ping AND pong’, ‘kypho’, ‘scolio’, ‘spine’, ‘spinal’, ‘rosary’, ‘ricket’, ‘rachit’, 
‘bead’. Common code stems were used to identify additional relevant codes. A total of 
93 relevant codes were identified. The final list of included codes is shown in Table 
G.9. 
 
Table G.9  Read codes related to skeletal deformity. 
Read code Code description 
1D16.00 C/O: a deformity 
2HA..00 O/E - bone abnormal 
2HA..12 O/E - leg bone abnormal 
2HA8.00 O/E - thigh bone abnormal 
2HA9.00 O/E - lower leg bone abnormal 
2HAZ.00 O/E - bone abnormal NOS 
2HB..00 O/E - bone abnormality 
2HB2.00 O/E - bone deformed 
2HBZ.00 O/E - bone abnormality NOS 
2I13.00 O/E - a deformity 
Nyu3400 [X]Other specified acquired deformities of limbs 
NyuE000 [X]Oth specified acquired deformities/musculoskeletal system 
N36..00 Other acquired limb deformity 
N364.00 Acquired genu valgum and varum 
N364000 Acquired genu valgum 
N364011 Knock knee 
N364100 Acquired genu varum 
N364111 Bow legged 
N364z00 Acquired genu valgum or varum NOS 
N365.00 Genu recurvatum - acquired 
N36y.00 Acquired deformity of other limb parts 
N36y.12 Other deformity of bone 
N36y200 Deformity of bone 
N36yC00 Deformity of femur 
N36yE00 Deformity of tibia 
N36yF00 Deformity of fibula 
N36yz00 Acquired limb deformity NEC 
N36z.00 Acquired limb deformity NOS 
N38..00 Other acquired deformity 
N38y.00 Other acquired deformity 
N38yz00 Other acquired deformity NOS 
N38z.00 Acquired deformity NOS 
PE4..00 Genu recurvatum and long leg bone bowing 
PE4..11 Congenital leg bone bowing 
PE40.00 Congenital genu recurvatum 
PE42.00 Congenital bowing of femur 
PE43.00 Congenital bowing of tibia and fibula 
PE43000 Congenital bowing of tibia 
PE43100 Congenital bowing of fibula 
PE44.00 Congenital bowing of long leg bone, unspecified 
PE44.11 Bow legs NOS 
PE4z.00 Genu recurvatum and long leg bone bowing NOS 
PE9..00 Other musc skeletal deformity 
PE9..11 Other congenital musculoskeletal deformity 
PEz..00 Congenital musculoskeletal deformity NOS 
PF64100 Congenital genu valgum - knock-knee 
PF64200 Congenital genu varum - bowleg 
Q48y411 Neonatal "craniotabes" 
2374.00 O/E - rickety rosary 
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Read code Code description 
2376.00 O/E - kyphoscoliotic chest def 
2H8..00 O/E - spine abnormal 
2H82.00 O/E - cervical spine abnormal 
2H83.00 O/E - thoracic spine abnormal 
2H84.00 O/E - lumbar spine abnormal 
2H8Z.00 O/E - spine abnormal NOS 
Nyu5000 [X]Other secondary kyphosis 
Nyu5100 [X]Other and unspecified kyphosis 
Nyu5300 [X]Other idiopathic scoliosis 
Nyu5400 [X]Other secondary scoliosis 
Nyu5500 [X]Other forms of scoliosis 
N37..00 Curvature of spine 
N370.00 Adolescent postural kyphosis 
N371.00 Acquired kyphosis 
N371000 Acquired postural kyphosis 
N371z00 Acquired kyphosis NOS 
N373.00 Kyphoscoliosis and scoliosis 
N373000 Idiopathic scoliosis 
N373100 Idiopathic kyphoscoliosis 
N373200 Resolving infantile idiopathic scoliosis 
N373300 Progressive infantile idiopathic scoliosis 
N373500 Thoracogenic scoliosis 
N373600 Postural scoliosis 
N373700 Adolescent idiopathic scoliosis 
N373z00 Kyphoscoliosis or scoliosis NOS 
N374.00 Curvature of spine associated with other conditions 
N374.11 Kyphosis, scoliosis, and lordosis associated with oth cond 
N374000 Curvature of spine, unspecified 
N374100 Kyphosis associated with other condition 
N374300 Scoliosis associated with other condition 
N374X00 Other and unspecified kyphosis 
N374z00 Curvature of spine associated with other conditions NOS 
N37y.00 Other curvatures of spine 
N37z.00 Curvature of spine NOS 
N37zz00 Curvature of spine NOS 
N385.00 Acquired deformity of spine NOS 
PE2..00 Congenital spine deformity 
PE20.00 Congenital spine deformity, unspecified 
PE22.00 Congenital postural scoliosis 
PE23.00 Congenital scoliosis due to congenital bony malformation 
PE2z.00 Congenital spine deformity NOS 
PE2z.11 Congenital postural curvature of spine NOS 
PG18.00 Congenital kyphosis 
PG18.11 Congenital kyphoscoliosis 
 
 
 
 
G.7.4 Identification of Read Codes Related to Bone Fracture 
 
The following truncated search term was used to identify Read codes related to bone 
fracture: ‘fracture’. Common code stems were used to identify additional relevant 
codes. A total of 1,560 relevant codes were identified. The final list of included codes is 
shown in Table G.10. 
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Table G.10  Read codes related to bone fracture. 
Read code Code description 
N331.00 Pathological fracture 
N331.13 Sponanteous fracture 
N331000 Pathological fracture of thoracic vertebra 
N331100 Pathological fracture of lumbar vertebra 
N331200 Postoophorectomy osteoporosis with pathological fracture 
N331300 Osteoporosis of disuse with pathological fracture 
N331400 Postsurgical malabsorption osteoporosis with path fracture 
N331500 Drug-induced osteoporosis with pathological fracture 
N331600 Idiopathic osteoporosis with pathological fracture 
N331700 Fracture of bone in neoplastic disease 
N331800 Osteoporosis + pathological fracture lumbar vertebrae 
N331900 Osteoporosis + pathological fracture thoracic vertebrae 
N331A00 Osteoporosis + pathological fracture cervical vertebrae 
N331B00 Postmenopausal osteoporosis with pathological fracture 
N331C00 Pathological fracture of cervical vertebra 
N331M00 Fragility fracture due to unspecified osteoporosis 
N331M11 Minimal trauma fracture due to unspecified osteoporosis 
N331N00 Fragility fracture 
N331N11 Minimal trauma fracture 
N331y00 Other specified pathological fracture 
N331z00 Pathological fracture NOS 
Q202.00 Fracture of clavicle due to birth trauma 
Q203.11 Other fractures due to birth trauma 
Q203.12 Other birth fracture 
Q203000 Fracture of humerus due to birth trauma 
Q203100 Fracture of radius or ulna due to birth trauma 
Q203111 Birth fracture of radius 
Q203112 Birth fracture of ulna 
Q203200 Fracture of femur due to birth trauma 
Q203300 Fracture of tibia or fibula due to birth trauma 
Q203400 Fracture of skull due to birth trauma 
Q203y11 Fracture due to birth trauma NEC 
Q203y12 Fracture of nose due to birth trauma 
Q204100 Spine fracture due to birth trauma 
S0...00 Fracture of skull 
S00..00 Fracture of vault of skull 
S00..11 Frontal bone fracture 
S00..12 Parietal bone fracture 
S000.00 Closed fracture vault of skull without intracranial injury 
S000000 Closed #skull vlt no intracranial injury, unspec state consc 
S000100 Closed #skull vlt no intracranial injury, no loss of consc 
S000200 Closed #skull vlt no intracranial injury, <1hr loss of consc 
S000300 Closed #skull vlt no intracranial injury, 1-24hr loss consc 
S000400 Closed #skull vlt no intracranial injury, >24hr LOC+recovery 
S000500 Closed #skull vlt no intracranial inj,>24hr LOC not restored 
S000600 Closed #skull vlt no intracranial inj, LOC unspec duration 
S000z00 Closed #skull vlt no intracranial injury + concussion unspec 
S001.00 Closed fracture vault of skull with intracranial injury 
S001000 Closed #skull vlt + intracranial injury, unspec state consc 
S001100 Closed #skull vlt + intracranial injury, no loss of consc 
S001200 Closed #skull vlt + intracranial injury, <1hr loss of consc 
S001300 Closed #skull vlt + intracranial injury, 1-24hr loss consc 
S001400 Closed #skull vlt + intracranial injury, >24hr LOC+recovery 
S001500 Closed #skull vlt + intracranial inj, >24hr LOC not restored 
S001600 Closed #skull vlt + intracranial injury, LOC unspec duration 
S001z00 Closed #skull vlt with intracranial injury+concussion unspec 
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Read code Code description 
S002.00 Open fracture vault of skull without intracranial injury 
S002000 Open #skull vlt no intracranial injury, unspec state consc 
S002100 Open #skull vlt no intracranial injury, no loss of consc 
S002200 Open #skull vlt no intracranial injury, <1hr loss of consc 
S002300 Open #skull vlt no intracranial injury, 1-24hr loss of consc 
S002400 Open #skull vlt no intracranial injury, >24hr LOC+recovery 
S002500 Open #skull vlt no intracranial inj, >24hr LOC not restored 
S002600 Open #skull vlt no intracranial injury, LOC unspec duration 
S002z00 Open #skull vlt no intracranial injury + concussion unspec 
S003.00 Open fracture vault of skull with intracranial injury 
S003000 Open #skull vlt + intracranial injury, unspec state of consc 
S003100 Open #skull vlt + intracranial injury, no loss of consc 
S003200 Open #skull vlt + intracranial injury, <1hr loss of consc 
S003300 Open #skull vlt + intracranial injury, 1-24hr loss of consc 
S003400 Open #skull vlt + intracranial injury, >24hr LOC + recovery 
S003500 Open #skull vlt + intracranial inj, >24hr LOC not restored 
S003600 Open #skull vlt + intracranial injury, LOC unspec duration 
S003z00 Open #skull vlt with intracranial injury + concussion unspec 
S00z.00 Fracture of vault of skull NOS 
S01..00 Fracture of base of skull 
S01..11 Anterior fossa fracture 
S01..12 Ethmoid sinus fracture 
S01..13 Frontal sinus fracture 
S01..14 Middle fossa fracture 
S01..15 Occiput bone fracture 
S01..16 Orbital roof fracture 
S01..17 Posterior fossa fracture 
S01..18 Sphenoid bone fracture 
S01..19 Temporal bone fracture 
S010.00 Closed fracture base of skull without intracranial injury 
S010000 Closed #skull bse no intracranial injury, unspec state consc 
S010100 Closed #skull bse no intracranial injury, no loss of consc 
S010200 Closed #skull bse no intracranial injury, <1hr loss of consc 
S010300 Closed #skull bse no intracranial injury, 1-24hr loss consc 
S010400 Closed #skull bse no intracranial injury, >24hr LOC+recovery 
S010500 Closed #skull bse no intracranial inj,>24hr LOC not restored 
S010600 Closed #skull bse no intracranial inj, LOC unspec duration 
S010z00 Closed #skull bse no intracranial injury + concussion unspec 
S011.00 Closed fracture base of skull with intracranial injury 
S011000 Closed #skull bse + intracranial inj, unspec state of consc 
S011100 Closed #skull bse + intracranial injury, no loss of consc 
S011200 Closed #skull bse + intracranial injury, <1hr loss of consc 
S011300 Closed #skull bse + intracranial injury, 1-24hr loss consc 
S011400 Closed #skull bse + intracranial injury, >24hr LOC+recovery 
S011500 Closed #skull bse + intracranial inj, >24hr LOC not restored 
S011600 Closed #skull bse + intracranial injury, LOC unspec duration 
S011z00 Closed #skull bse + intracranial injury + concussion unspec 
S012.00 Open fracture base skull without mention intracranial injury 
S012000 Open #skull bse no intracranial inj, unspec state of consc 
S012100 Open #skull bse no intracranial injury, no loss of consc 
S012200 Open #skull bse no intracranial injury, <1hr loss of consc 
S012300 Open #skull bse no intracranial injury, 1-24hr loss of consc 
S012400 Open #skull bse no intracranial injury, >24hr LOC+recovery 
S012500 Open #skull bse no intracranial inj, >24hr LOC not restored 
S012600 Open #skull bse no intracranial injury, LOC unspec duration 
S012z00 Open #skull bse no intracranial injury + concussion unspec 
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Read code Code description 
S013.00 Open fracture base of skull with intracranial injury 
S013000 Open #skull bse + intracranial injury, unspec state of consc 
S013100 Open #skull bse + intracranial injury, no loss of consc 
S013200 Open #skull bse + intracranial injury, <1hr loss of consc 
S013300 Open #skull bse + intracranial injury, 1-24hr loss of consc 
S013400 Open #skull bse + intracranial injury, >24hr LOC + recovery 
S013500 Open #skull bse + intracranial inj, >24hr LOC not restored 
S013600 Open #skull bse + intracranial injury, LOC unspec duration 
S013z00 Open #skull bse + intracranial injury + concussion unspec 
S01z.00 Fracture of base of skull NOS 
S02..00 Fracture of face bones 
S020.00 Closed fracture nose 
S020.11 Closed fracture nasal bone 
S021.00 Open fracture nose 
S021.11 Open fracture nasal bone 
S022.00 Fracture of mandible, closed 
S022.11 Fracture of inferior maxilla, closed 
S022.12 Fracture of lower jaw, closed 
S022000 Closed fracture mandible (site unspecified) 
S022100 Closed fracture of mandible, condylar process 
S022200 Closed fracture of mandible, subcondylar 
S022300 Closed fracture of mandible, coronoid process 
S022400 Closed fracture of mandible, ramus, unspecified 
S022500 Closed fracture of mandible, angle of jaw 
S022600 Closed fracture of mandible, symphysis of body 
S022700 Closed fracture of mandible, alveolar border of body 
S022800 Closed fracture of mandible, body, other and unspecified 
S022x00 Closed fracture of mandible, multiple sites 
S022z00 Fracture of mandible, closed, NOS 
S023.00 Fracture of mandible, open 
S023.11 Fracture of lower jaw, open 
S023000 Open fracture mandible (site unspecified) 
S023100 Open fracture of mandible, condylar process 
S023200 Open fracture of mandible, subcondylar 
S023300 Open fracture of mandible, coronoid process 
S023400 Open fracture of mandible, ramus, unspecified 
S023500 Open fracture of mandible, angle of jaw 
S023600 Open fracture of mandible, symphysis of body 
S023700 Open fracture of mandible, alveolar border of body 
S023800 Open fracture of mandible, body, other and unspecified 
S023x00 Open fracture of mandible, multiple sites 
S023z00 Fracture of mandible, open, NOS 
S024.00 Fracture of malar or maxillary bones, closed 
S024.11 Fracture of upper jaw, closed 
S024000 Closed fracture maxilla 
S024100 Closed fracture zygoma 
S024z00 Fracture of malar or maxillary bones, closed, NOS 
S025.00 Fracture of malar or maxillary bones, open 
S025.11 Fracture of upper jaw, open 
S025000 Open fracture maxilla 
S025100 Open fracture zygoma 
S025z00 Fracture of malar or maxillary bones, open, NOS 
S026.00 Closed orbital blow-out fracture 
S027.00 Open orbital blow-out fracture 
S028.00 Fracture of skull and facial bones 
S028000 Fracture of nasal bones 
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Read code Code description 
S028100 Fracture of orbital floor 
S028200 Fracture of malar and maxillary bones 
S028300 Fracture of mandible 
S02A.00 Le Fort I fracture maxilla 
S02B.00 Le Fort II fracture maxilla 
S02C.00 Le Fort III fracture maxilla 
S02x.00 Closed fracture other facial bone 
S02x000 Fracture of alveolus, closed 
S02x100 Fracture of orbit NOS, closed 
S02x200 Fracture of palate, closed 
S02xz00 Fracture of other facial bones, closed, NOS 
S02y.00 Open fracture other facial bone 
S02y000 Fracture of alveolus, open 
S02y100 Fracture of orbit NOS, open 
S02y200 Fracture of palate, open 
S02yz00 Fracture of other facial bones,open, NOS 
S02z.00 Fracture of facial bone NOS 
S02z.11 Jaw fracture NOS 
S03..00 Other and unqualified skull fractures 
S030.00 Closed fracture of skull NOS without intracranial injury 
S030000 Closed #skull NOS no intracranial inj, unspec state of consc 
S030100 Closed #skull NOS no intracranial inj, no loss of consc 
S030200 Closed #skull NOS no intracranial inj, <1hr loss of consc 
S030300 Closed #skull NOS no intracranial inj, 1-24hr loss of consc 
S030400 Closed #skull NOS no intracranial inj, >24hrs LOC + recovery 
S030500 Closed #skull NOS no intracranial inj,>24hr LOC not restored 
S030600 Closed #skull NOS no intracranial inj, LOC unspec duration 
S030z00 Closed #skull NOS no intracranial inj + concussion unspec 
S031.00 Closed fracture of skull NOS with intracranial injury 
S031000 Closed #skull NOS + intracranial inj, unspec state of consc 
S031100 Closed #skull NOS + intracranial inj, no loss of consc 
S031200 Closed #skull NOS + intracranial inj, <1hr loss of consc 
S031300 Closed #skull NOS + intracranial inj, 1-24hrs loss of consc 
S031400 Closed #skull NOS + intracranial inj, >24hrs LOC + recovery 
S031500 Closed #skull NOS + intracranial inj, >24hr LOC not restored 
S031600 Closed #skull NOS + intracranial inj, LOC unspec duration 
S031z00 Closed #skull NOS + intracranial inj + concussion unspec 
S032.00 Open #skull NOS without mention of intracranial injury 
S032000 Open #skull NOS no intracranial inj, unspec state of consc 
S032100 Open #skull NOS no intracranial inj, no loss of consc 
S032200 Open #skull NOS no intracranial inj, <1hr loss of consc 
S032300 Open #skull NOS no intracranial inj, 1-24hrs loss of consc 
S032400 Open #skull NOS no intracranial inj, >24hrs LOC + recovery 
S032500 Open #skull NOS no intracranial inj, >24hrs LOC not restored 
S032600 Open #skull NOS no intracranial inj, LOC unspec duration 
S032z00 Open #skull NOS no intracranial inj + concussion unspec 
S033.00 Open fracture of skull NOS with intracranial injury 
S033000 Open #skull NOS + intracranial inj, unspec state of consc 
S033100 Open #skull NOS + intracranial inj, no loss of consc 
S033200 Open #skull NOS + intracranial inj, <1hr loss of consc 
S033300 Open #skull NOS + intracranial inj, 1-24hrs loss of consc 
S033400 Open #skull NOS + intracranial inj, >24hrs LOC + recovery 
S033500 Open #skull NOS + intracranial inj, >24hrs LOC not restored 
S033600 Open #skull NOS + intracranial inj, LOC unspec duration 
S033z00 Open #skull NOS + intracranial inj + concussion unspec 
S03z.00 Skull fracture NOS 
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S03z.11 Depressed skull fracture NOS 
S04..00 Multiple fractures involving skull or face with other bones 
S04..11 Multiple face fractures 
S04..12 Multiple skull fractures 
S040.00 Mult #skull/face+other bones, closed, no intracranial injury 
S040000 Closed #skull/face, mult, no intracranial inj, unspec consc 
S040100 Closed #skull/face, mult, no intracranial inj, no loss consc 
S040200 Closed #skull/face, mult, no intracranial inj, <1hr LOC 
S040300 Closed #skull/face, mult, no intracranial inj, 1-24hrs LOC 
S040400 Closed #skull/face, mult,no intracran inj,>24hr LOC+recovery 
S040500 Closed #skull/face,mult,no intracran inj,>24hr LOC-restored 
S040600 Closed #skull/face,mult,no intracran inj,LOC unspec duration 
S040z00 Closed #skull/face,mult,no intracran inj, concussion unspec 
S041.00 Mult #skull/face+other bones, closed + intracranial injury 
S041000 Closed #skull/face, mult + intracranial inj, unspec consc 
S041100 Closed #skull/face, mult + intracranial inj, no loss consc 
S041200 Closed #skull/face, mult + intracranial inj, <1hr LOC 
S041300 Closed #skull/face, mult + intracranial inj, 1-24hrs LOC 
S041400 Closed #skull/face, mult+intracran inj, >24hr LOC+recovery 
S041500 Closed #skull/face, multi+intracran inj, >24hr LOC-restored 
S041600 Closed #skull/face,mult + intracran inj, LOC unspec duration 
S041z00 Closed #skull/face,mult + intracran inj, concussion unspec 
S042.00 Mult #skull/face + other bones, open, no intracranial injury 
S042000 Open #skull/face, mult, no intracranial inj, unspec consc 
S042100 Open #skull/face, mult, no intracranial inj, no loss consc 
S042200 Open #skull/face, mult, no intracranial inj, <1hr LOC 
S042300 Open #skull/face, mult, no intracranial inj, 1-24hrs LOC 
S042400 Open #skull/face, mult, no intracran inj, >24hr LOC+recovery 
S042500 Open #skull/face,mult,no intracran inj,>24hr LOC no restored 
S042600 Open #skull/face,mult,no intracran inj, LOC unspec duration 
S042z00 Open #skull/face,mult,no intracran inj, concussion unspec 
S043.00 Mult #skull/face + other bones, open + intracranial injury 
S043000 Open #skull/face, mult + intracranial inj, unspec consc 
S043100 Open #skull/face, mult + intracranial inj, no loss consc 
S043200 Open #skull/face, mult + intracranial inj, <1hr LOC 
S043300 Open #skull/face, mult + intracranial inj, 1-24hrs LOC 
S043400 Open #skull/face, mult + intracran inj, >24hr LOC + recovery 
S043500 Open #skull/face,mult + intracran inj, >24hr LOC no restored 
S043600 Open #skull/face, mult + intracran inj, LOC unspec duration 
S043z00 Open #skull/face, mult + intracran inj + concussion, unspec 
S044.00 Multiple fractures involving skull and facial bones 
S04z.00 Multiple fractures involving skull/face with other bones NOS 
S0z..00 Fracture of skull NOS 
S1…00 Fracture of neck and trunk 
S10..00 Fracture of spine without mention of spinal cord injury 
S10..11 Fracture of transverse process spine – no spinal cord lesion 
S10..12 Fracture of vertebra without spinal cord lesion 
S100.00 Closed fracture of cervical spine 
S100.11 Closed fracture of atlas without spinal cord lesion 
S100.12 Closed fracture of axis without spinal cord lesion 
S100000 Closed fracture of unspecified cervical vertebra 
S100100 Closed fracture atlas 
S100111 C1 vertebra closed fracture – no spinal cord lesion 
S100200 Closed fracture axis 
S100211 C2 vertebra closed fracture without spinal cord lesion 
S100300 Closed fracture of third cervical vertebra 
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S100311 C3 vertebra closed fracture without spinal cord lesion 
S100400 Closed fracture of fourth cervical vertebra 
S100411 C4 vertebra closed fracture without spinal cord lesion 
S100500 Closed fracture of fifth cervical vertebra 
S100511 C5 vertebra closed fracture without spinal cord lesion 
S100600 Closed fracture of sixth cervical vertebra 
S100611 C6 vertebra closed fracture without spinal cord lesion 
S100700 Closed fracture of seventh cervical vertebra 
S100711 C7 vertebra closed fracture without spinal cord lesion 
S100800 Closed fracture atlas, isolated arch or articular process 
S100900 Closed fracture atlas, comminuted 
S100A00 Closed fracture axis, odontoid process 
S100B00 Closed fracture axis, spondylolysis 
S100C00 Closed fracture axis, spinous process 
S100D00 Closed fracture axis, transverse process 
S100E00 Closed fracture axis, posterior arch 
S100F00 Closed fracture axis, tricolumnar 
S100G00 Closed fracture cervical vertebra, burst 
S100H00 Closed fracture cervical vertebra, wedge 
S100J00 Closed fracture cervical vertebra, spondylolysis 
S100K00 Closed fracture cervical vertebra, spinous process 
S100L00 Closed fracture cervical vertebra, transverse process 
S100M00 Closed fracture cervical vertebra, posterior arch 
S100N00 Closed fracture cervical vertebra, tricolumnar 
S100x00 Multiple closed fractures of cervical vertebrae 
S100z00 Closed fracture of cervical spine not otherwise specified 
S101.00 Open fracture of cervical spine 
S101.11 Open fracture of atlas without spinal cord lesion 
S101.12 Open fracture of axis without spinal cord lesion 
S101000 Open fracture of unspecified cervical vertebra 
S101100 Open fracture atlas 
S101111 C1 vertebra open fracture without spinal cord lesion 
S101200 Open fracture axis 
S101211 C2 vertebra open fracture without spinal cord lesion 
S101300 Open fracture of third cervical vertebra 
S101311 C3 vertebra open fracture without spinal cord lesion 
S101400 Open fracture of fourth cervical vertebra 
S101411 C4 vertebra open fracture without spinal cord lesion 
S101500 Open fracture of fifth cervical vertebra 
S101511 C5 vertebra open fracture without spinal cord lesion 
S101600 Open fracture of sixth cervical vertebra 
S101611 C6 vertebra open fracture without spinal cord lesion 
S101700 Open fracture of seventh cervical vertebra 
S101711 C7 vertebra open fracture without spinal cord lesion 
S101800 Open fracture atlas, isolated arch or articular process 
S101900 Open fracture atlas, comminuted 
S101A00 Open fracture axis, odontoid process 
S101B00 Open fracture axis, spondylolysis 
S101C00 Open fracture axis, spinous process 
S101D00 Open fracture axis, transverse process 
S101E00 Open fracture axis, posterior arch 
S101F00 Open fracture axis, tricolumnar 
S101G00 Open fracture cervical vertebra, burst 
S101H00 Open fracture cervical vertebra, wedge 
S101J00 Open fracture cervical vertebra, spondylolysis 
S101K00 Open fracture cervical vertebra, spinous process 
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S101L00 Open fracture cervical vertebra, transverse process 
S101M00 Open fracture cervical vertebra, posterior arch 
S101N00 Open fracture cervical vertebra, tricolumnar 
S101x00 Multiple open fractures of cervical vertebrae 
S101z00 Open fracture of cervical spine not otherwise specified 
S102.00 Closed fracture thoracic vertebra 
S102000 Closed fracture thoracic vertebra, burst 
S102100 Closed fracture thoracic vertebra, wedge 
S102200 Closed fracture thoracic vertebra, spondylolysis 
S102300 Closed fracture thoracic vertebra, spinous process 
S102400 Closed fracture thoracic vertebra, transverse process 
S102500 Closed fracture thoracic vertebra, posterior arch 
S102600 Closed fracture thoracic vertebra, tricolumnar 
S102y00 Other specified closed fracture thoracic vertebra 
S102z00 Closed fracture thoracic vertebra not otherwise specified 
S103.00 Open fracture thoracic vertebra 
S103000 Open fracture thoracic vertebra, burst 
S103100 Open fracture thoracic vertebra, wedge 
S103200 Open fracture thoracic vertebra, spondylolysis 
S103300 Open fracture thoracic vertebra, spinous process 
S103400 Open fracture thoracic vertebra, transverse process 
S103500 Open fracture thoracic vertebra, posterior arch 
S103600 Open fracture thoracic vertebra, tricolumnar 
S104.00 Closed fracture lumbar vertebra 
S104000 Closed fracture lumbar vertebra, burst 
S104100 Closed fracture lumbar vertebra, wedge 
S104200 Closed fracture lumbar vertebra, spondylolysis 
S104300 Closed fracture lumbar vertebra, spinous process 
S104400 Closed fracture lumbar vertebra, transverse process 
S104500 Closed fracture lumbar vertebra, posterior arch 
S104600 Closed fracture lumbar vertebra, tricolumnar 
S105.00 Open fracture lumbar vertebra 
S105000 Open fracture lumbar vertebra, burst 
S105100 Open fracture lumbar vertebra, wedge 
S105200 Open fracture lumbar vertebra, spondylolysis 
S105300 Open fracture lumbar vertebra, spinous process 
S105400 Open fracture lumbar vertebra, transverse process 
S105500 Open fracture lumbar vertebra, posterior arch 
S105600 Open fracture lumbar vertebra, tricolumnar 
S106.00 Closed fracture sacrum 
S106000 Closed compression fracture sacrum 
S106100 Closed vertical fracture of sacrum 
S107.00 Open fracture sacrum 
S107000 Open compression fracture sacrum 
S107100 Open vertical fracture of sacrum 
S108.00 Closed fracture pelvis, coccyx 
S109.00 Open fracture pelvis, coccyx 
S10A.00 Fracture of neck 
S10A000 Fracture of first cervical vertebra 
S10A100 Fracture of second cervical vertebra 
S10A200 Multiple fractures of cervical spine 
S10B.00 Fracture of lumbar spine and pelvis 
S10B000 Fracture of lumbar vertebra 
S10B100 Fracture of sacrum 
S10B200 Fracture of coccyx 
S10B300 Fracture of ilium 
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S10B400 Fracture of acetabulum 
S10B500 Fracture of pubis 
S10B600 Multiple fractures of lumbar spine and pelvis 
S10x.00 Closed fracture of spine, unspecified, 
S10y.00 Open fracture of spine, unspecified, 
S10z.00 Fracture of spine without mention of spinal cord lesion NOS 
S11..00 Fracture of spine with spinal cord lesion 
S11..11 Fracture of transverse process of spine + spinal cord lesion 
S11..12 Fracture of vertebra with spinal cord lesion 
S110.00 Closed fracture of cervical spine with cord lesion 
S110000 Cls spinal fracture with unspec cervical cord lesion, C1-4 
S110100 Cls spinal fracture with complete cervcl cord lesion, C1-4 
S110200 Cls spinal fracture with anterior cervcl cord lesion, C1-4 
S110300 Cls spinal fracture with central cervical cord lesion, C1-4 
S110400 Cls spinal fracture with posterior cervcl cord lesion, C1-4 
S110500 Cls spinal # with incomplete cervical cord lesion, C1-4 NOS 
S110600 Cls spinal fracture with unspec cervical cord lesion, C5-7 
S110700 Cls spinal fracture with complete cervcl cord lesion, C5-7 
S110800 Cls spinal fracture with anterior cervcl cord lesion, C5-7 
S110900 Cls spinal fracture with central cervical cord lesion, C5-7 
S110A00 Cls spinal fracture with posterior cervcl cord lesion, C5-7 
S110B00 Cls spinal # with incomplete cervical cord lesion, C5-7 NOS 
S110z00 Closed fracture of cervical spine with cord lesion NOS 
S111.00 Open fracture of cervical spine with spinal cord lesion 
S111000 Opn spinal fracture with unspec cervical cord lesion, C1-4 
S111100 Opn spinal fracture with complete cervcl cord lesion, C1-4 
S111200 Opn spinal fracture with anterior cervcl cord lesion, C1-4 
S111300 Open spinal fracture with central cervical cord lesion, C1-4 
S111400 Opn spinal fracture with posterior cervcl cord lesion, C1-4 
S111500 Opn spinal # with incomplete cervical cord lesion, C1-4 NOS 
S111600 Opn spinal fracture with unspec cervical cord lesion, C5-7 
S111700 Opn spinal fracture with complete cervcl cord lesion, C5-7 
S111800 Opn spinal fracture with anterior cervcl cord lesion, C5-7 
S111900 Open spinal fracture with central cervical cord lesion, C5-7 
S111A00 Opn spinal fracture with posterior cervcl cord lesion, C5-7 
S111B00 Opn spinal # with incomplete cervical cord lesion, C5-7 NOS 
S111z00 Open fracture of cervical spine with spinal cord lesion NOS 
S112.00 Closed fracture of thoracic spine with spinal cord lesion 
S112000 Cls spinal fracture with unspec thoracic cord lesion,T1-6 
S112100 Cls spinal fracture wth complete thoracic cord lesion,T1-6 
S112200 Cls spinal fracture wth anterior thoracic cord lesion,T1-6 
S112300 Cls spinal fracture with central thoracic cord lesion, T1-6 
S112400 Cls spinal fracture with posterior thorac cord lesion, T1-6 
S112500 Cls spinal # with incomplete thoracic cord lesion, T1-6 NOS 
S112600 Cls spinal fracture with unspec thoracic cord lesion, T7-12 
S112700 Cls spinal fracture with complete thorac cord lesion, T7-12 
S112800 Cls spinal fracture with anterior thorac cord lesion, T7-12 
S112900 Cls spinal fracture with central thoracid cord lesion, T7-12 
S112A00 Cls spinal fracture with posterior thorac cord lesion, T7-12 
S112B00 Cls spinal # with incomplete thoracid cord lesion, T7-12 NOS 
S112z00 Closed fracture of thoracic spine with cord lesion NOS 
S113.00 Open fracture of thoracic spine with spinal cord lesion 
S113000 Opn spinal fracture with unspec thoracic cord lesion, T1-6 
S113100 Opn spinal fracture with complete thorac cord lesion, T1-6 
S113200 Opn spinal fracture with anterior thorac cord lesion, T1-6 
S113300 Open spinal fracture with central thoracic cord lesion, T1-6 
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S113400 Opn spinal fracture with posterior thorac cord lesion, T1-6 
S113500 Opn spinal # with incomplete thoracic cord lesion, T1-6 NOS 
S113600 Opn spinal fracture with unspec thoracic cord lesion, T7-12 
S113700 Opn spinal fracture with complete thorac cord lesion, T7-12 
S113800 Opn spinal fracture with anterior thorac cord lesion, T7-12 
S113900 Op spinal fracture with central thoracic cord lesion, T7-12 
S113A00 Opn spinal fracture with posterior thorac cord lesion, T7-12 
S113B00 Opn spinal # with incomplete thoracic cord lesion, T7-12 NOS 
S113z00 Open fracture of thoracic spine with spinal cord lesion NOS 
S114.00 Closed fracture of lumbar spine with spinal cord lesion 
S114000 Closed spinal fracture with unspecified lumbar cord lesion 
S114100 Closed spinal fracture with complete lumbar cord lesion 
S114200 Closed spinal fracture with anterior lumbar cord lesion 
S114300 Closed spinal fracture with central lumbar cord lesion 
S114400 Closed spinal fracture with posterior lumbar cord lesion 
S114500 Closed spinal fracture with cauda 382quine lesion 
S115.00 Open fracture of lumbar spine with spinal cord lesion 
S115000 Open spinal fracture with unspecified lumbar cord lesion 
S115100 Open spinal fracture with complete lumbar cord lesion 
S115200 Open spinal fracture with anterior lumbar cord lesion 
S115300 Open spinal fracture with central lumbar cord lesion 
S115400 Open spinal fracture with posterior lumbar cord lesion 
S115500 Open spinal fracture with cauda 382quine lesion 
S115z00 Open spinal fracture with incomplete lumbar cord lesion NOS 
S116.00 Closed fracture of sacrum with spinal cord lesion 
S116000 Closed fracture of sacrum with unspec spinal cord lesion 
S116100 Closed fracture of sacrum with complete cauda 382quine lesion 
S116200 Closed fracture of sacrum with other cauda 382quine injury 
S116300 Closed fracture of sacrum with other spinal cord injury 
S116z00 Closed fracture of sacrum with spinal cord lesion NOS 
S117.00 Open fracture of sacrum with spinal cord lesion 
S117000 Open fracture of sacrum with unspecified spinal cord lesion 
S117100 Open fracture of sacrum with complete cauda 382quine lesion 
S117200 Open fracture of sacrum with other cauda 382quine injury 
S117300 Open fracture of sacrum with other spinal cord injury 
S117z00 Open fracture of sacrum with spinal cord lesion NOS 
S118.00 Closed fracture of coccyx with spinal cord lesion 
S118000 Closed fracture of coccyx with unspec spinal cord lesion 
S118100 Closed fracture of coccyx with complete cauda 382quine lesion 
S118200 Closed fracture of coccyx with other cauda 382quine injury 
S118300 Closed fracture of coccyx with other spinal cord injury 
S118z00 Closed fracture of coccyx with spinal cord lesion NOS 
S119.00 Open fracture of coccyx with spinal cord lesion 
S119000 Open fracture of coccyx with unspecified spinal cord lesion 
S119100 Open fracture of coccyx with complete cauda 382quine lesion 
S119200 Open fracture of coccyx with other cauda 382quine injury 
S119300 Open fracture of coccyx with other spinal cord injury 
S119z00 Open fracture of coccyx with spinal cord lesion NOS 
S11x.00 Closed fracture of spine with spinal cord lesion unspecified 
S11y.00 Open fracture of spine with spinal cord lesion unspecified 
S11z.00 Fracture of spine with spinal cord lesion NOS 
S12..00 Fracture of rib(s), sternum, larynx and trachea 
S120.00 Closed fracture rib 
S120000 Closed fracture of rib, unspecified 
S120100 Closed fracture of one rib 
S120200 Closed fracture of two ribs 
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S120300 Closed fracture of three ribs 
S120400 Closed fracture of four ribs 
S120500 Closed fracture of five ribs 
S120600 Closed fracture of six ribs 
S120700 Closed fracture of seven ribs 
S120800 Closed fracture of eight or more ribs 
S120900 Closed fracture multiple ribs 
S120A00 Cough fracture 
S120z00 Closed fracture of rib(s) NOS 
S121.00 Open fracture rib 
S121000 Open fracture of rib, unspecified 
S121100 Open fracture of one rib 
S121200 Open fracture of two ribs 
S121300 Open fracture of three ribs 
S121400 Open fracture of four ribs 
S121500 Open fracture of five ribs 
S121600 Open fracture of six ribs 
S121700 Open fracture of seven ribs 
S121800 Open fracture of eight or more ribs 
S121900 Open fracture multiple ribs 
S121z00 Open fracture of rib(s) NOS 
S122.00 Closed fracture sternum 
S123.00 Open fracture sternum 
S124.00 Flail chest 
S124000 Closed flail chest 
S124100 Open flail chest 
S125.00 Closed fracture larynx and trachea 
S125000 Closed fracture larynx 
S125100 Closed fracture of hyoid bone 
S125200 Closed fracture of thyroid cartilage 
S125300 Closed fracture of trachea 
S125z00 Closed fracture of larynx and trachea NOS 
S126.00 Open fracture larynx and trachea 
S126000 Open fracture larynx 
S126100 Open fracture of hyoid bone 
S126200 Open fracture of thyroid cartilage 
S126300 Open fracture of trachea 
S126z00 Open fracture of larynx and trachea NOS 
S127.00 Fracture of rib 
S127000 Multiple fractures of ribs 
S127100 Cough fracture of ribs 
S128.00 Fracture of sternum 
S12X.00 Fracture of bony thorax, part unspecified 
S12X000 Closed fracture of bony thorax part unspecified 
S12X100 Open fracture of bony thorax part unspecified 
S12y.00 Fracture of other parts of bony thorax 
S12y000 Closed fracture of other parts of bony thorax 
S12y100 Open fracture of other parts of bony thorax 
S12z.00 Fracture of rib(s), sternum, larynx or trachea NOS 
S12z.11 Rib fracture NOS 
S12z.12 Sternum fracture NOS 
S13..00 Fracture or disruption of pelvis 
S130.00 Closed fracture acetabulum 
S130000 Closed fracture acetabulum, anterior lip alone 
S130100 Closed fracture acetabulum, posterior lip alone 
S130200 Closed fracture acetabulum, anterior column 
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S130300 Closed fracture acetabulum, posterior column 
S130400 Closed fracture acetabulum, floor 
S130500 Closed fracture acetabulum, double column transverse 
S130600 Closed fracture acetabulum, double column unspecified 
S130y00 Other specified closed fracture acetabulum 
S130z00 Closed fracture acetabulum NOS 
S131.00 Open fracture acetabulum 
S131000 Open fracture acetabulum, anterior lip alone 
S131100 Open fracture acetabulum, posterior lip alone 
S131200 Open fracture acetabulum, anterior column 
S131300 Open fracture acetabulum, posterior column 
S131400 Open fracture acetabulum, floor 
S131500 Open fracture acetabulum, double column transverse 
S131600 Open fracture acetabulum, double column unspecified 
S131y00 Other specified open fracture acetabulum 
S131z00 Open fracture acetabulum NOS 
S132.00 Closed fracture pubis 
S132000 Closed fracture pelvis, single pubic ramus 
S132100 Closed fracture pelvis, multiple pubic rami – stable 
S132200 Closed fracture pelvis, multiple pubic rami – unstable 
S132y00 Other specified closed fracture pubis 
S132z00 Closed fracture pubis NOS 
S133.00 Open fracture of pubis 
S133000 Open fracture pelvis, single pubic ramus 
S133100 Open fracture pelvis, multiple pubic rami – stable 
S133200 Open fracture pelvis, multiple pubic rami – unstable 
S133y00 Other specified open fracture of pubis 
S133z00 Open fracture of pubis NOS 
S134.00 Other or multiple closed fracture of pelvis 
S134000 Closed fracture of ilium, unspecified 
S134100 Closed fracture pelvis, ischium 
S134200 Closed multiple disruptions of pelvis 
S134300 Closed fracture pelvis, ischial tuberosity 
S134400 Closed fracture pelvis, anterior superior iliac spine 
S134500 Closed fracture pelvis, anterior inferior iliac spine 
S134600 Closed fracture pelvis, iliac wing 
S134700 Closed vertical fracture of ilium 
S134800 Closed fracture dislocation of sacro-iliac joint 
S134z00 Other or multiple closed fracture of pelvis NOS 
S135.00 Other or multiple open fracture of pelvis 
S135000 Open fracture of ilium, unspecified 
S135100 Open fracture pelvis, ischium 
S135200 Open multiple disruptions of pelvis 
S135300 Open fracture pelvis, ischial tuberosity 
S135400 Open fracture pelvis, anterior superior iliac spine 
S135500 Open fracture pelvis, anterior inferior iliac spine 
S135600 Open fracture pelvis, iliac wing 
S135700 Open vertical fracture of ilium 
S135800 Open fracture dislocation of sacro-iliac joint 
S135y00 Other open fracture of pelvis 
S135z00 Other/multiple open fracture of pelvis NOS 
S136.00 Closed complete rupture of pelvic ring 
S136000 Closed complete rupture pubic symphysis 
S136100 Closed complete rupture sacro-iliac joint 
S137.00 Open complete rupture of pelvic ring 
S137000 Open complete rupture pubic symphysis 
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S137100 Open complete rupture of sacro-iliac joint 
S138.00 Traumatic rupture of symphysis pubis 
S13y.00 Closed fracture of pelvis NOS 
S13z.00 Open fracture of pelvis NOS 
S14..00 Fracture of ill-defined bones of trunk 
S140.00 Closed fracture of ill-defined bone of trunk 
S141.00 Open fracture of ill-defined bone of trunk 
S14z.00 Fracture of ill-defined bone of trunk NOS 
S15..00 Fracture of thoracic vertebra 
S150.00 Multiple fractures of thoracic spine 
S150000 Closed multiple fractures of thoracic spine 
S150100 Open multiple fracture of thoracic spine 
S1z..00 Fracture of neck and trunk NOS 
S2…00 Fracture of upper limb 
S2…11 Arm fracture 
S20..00 Fracture of clavicle 
S20..11 Collar bone fracture 
S200.00 Closed fracture of clavicle 
S200000 Closed fracture of clavicle, unspecified part 
S200100 Closed fracture clavicle, medial end 
S200200 Closed fracture clavicle, shaft 
S200300 Closed fracture clavicle, lateral end 
S200z00 Closed fracture of clavicle NOS 
S201.00 Open fracture of clavicle 
S201000 Open fracture of clavicle, unspecified part 
S201100 Open fracture clavicle, medial end 
S201200 Open fracture clavicle, shaft 
S201300 Open fracture clavicle, lateral end 
S201z00 Open fracture of clavicle NOS 
S20z.00 Fracture of clavicle NOS 
S21..00 Fracture of scapula 
S21..11 Shoulder blade fracture 
S210.00 Closed fracture of scapula 
S210000 Closed fracture of scapula, unspecified part 
S210100 Closed fracture scapula, acromion 
S210200 Closed fracture scapula, coracoid 
S210300 Closed fracture scapula, glenoid 
S210400 Closed fracture scapula, blade 
S210500 Closed fracture scapula, spine 
S210600 Closed fracture scapula, neck 
S210z00 Closed fracture of scapula NOS 
S211.00 Open fracture of scapula 
S211000 Open fracture of scapula, unspecified part 
S211100 Open fracture scapula, acromion 
S211200 Open fracture scapula, coracoid 
S211300 Open fracture scapula, glenoid 
S211400 Open fracture scapula, blade 
S211500 Open fracture scapula, spine 
S211600 Open fracture scapula, neck 
S211z00 Open fracture of scapula NOS 
S21z.00 Fracture of scapula NOS 
S22..00 Fracture of humerus 
S220.00 Closed fracture of the proximal humerus 
S220000 Closed fracture of proximal humerus, unspecified part 
S220100 Closed fracture proximal humerus, neck 
S220200 Closed fracture of proximal humerus, anatomical neck 
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S220300 Closed fracture proximal humerus, greater tuberosity 
S220400 Closed fracture proximal humerus, head 
S220500 Closed fracture of humerus, upper epiphysis 
S220600 Closed fracture proximal humerus, three part 
S220700 Closed fracture proximal humerus, four part 
S220z00 Closed fracture of proximal humerus not otherwise specified 
S221.00 Open fracture of the proximal humerus 
S221.11 Shoulder fracture – open 
S221000 Open fracture of proximal humerus, unspecified part 
S221100 Open fracture proximal humerus, neck 
S221200 Open fracture of proximal humerus, anatomical neck 
S221300 Open fracture proximal humerus, greater tuberosity 
S221400 Open fracture proximal humerus, head 
S221500 Open fracture of humerus, upper epiphysis 
S221600 Open fracture proximal humerus, three part 
S221700 Open fracture proximal humerus, four part 
S221z00 Open fracture of proximal humerus not otherwise specified 
S222.00 Closed fracture of humerus, shaft or unspecified part 
S222000 Closed fracture of humerus NOS 
S222100 Closed fracture of humerus, shaft 
S222z00 Closed fracture of humerus, shaft or unspecified part NOS 
S223.00 Open fracture of humerus, shaft or unspecified part 
S223000 Open fracture of humerus NOS 
S223100 Open fracture of humerus, shaft 
S223z00 Open fracture of humerus, shaft or unspecified part NOS 
S224.00 Closed fracture of the distal humerus 
S224.11 Elbow fracture – closed 
S224000 Closed fracture of elbow, unspecified part 
S224100 Closed fracture distal humerus, supracondylar 
S224200 Closed fracture distal humerus, lateral condyle 
S224300 Closed fracture distal humerus, medial condyle 
S224400 Closed fracture of distal humerus, condyle(s) unspecified 
S224500 Closed fracture of distal humerus, trochlea 
S224600 Closed fracture distal humerus, lateral epicondyle 
S224700 Closed fracture distal humerus, medial epicondyle 
S224800 Closed fracture distal humerus, capitellum 
S224900 Closed fracture distal humerus, bicondylar (T-Y fracture) 
S224x00 Closed fracture of distal humerus, multiple 
S224z00 Closed fracture of distal humerus, not otherwise specified 
S225.00 Open fracture of the distal humerus 
S225.11 Elbow fracture – open 
S225000 Open fracture of elbow, unspecified part 
S225100 Open fracture distal humerus, supracondylar 
S225200 Open fracture distal humerus, lateral condyle 
S225300 Open fracture distal humerus, medial condyle 
S225400 Open fracture of distal humerus, condyle(s) unspecified 
S225500 Open fracture of distal humerus, trochlea 
S225600 Open fracture distal humerus, lateral epicondyle 
S225700 Open fracture distal humerus, medial epicondyle 
S225800 Open fracture distal humerus, capitellum 
S225900 Open fracture distal humerus, bicondylar (T-Y fracture) 
S225x00 Open fracture of distal humerus, multiple 
S225z00 Open fracture of distal humerus, not otherwise specified 
S226.00 Fracture of upper end of humerus 
S227.00 Fracture of shaft of humerus 
S228.00 Fracture of lower end of humerus 
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S22z.00 Fracture of humerus NOS 
S23..00 Fracture of radius and ulna 
S23..11 Forearm fracture 
S230.00 Closed fracture of proximal radius and ulna 
S230000 Closed fracture of proximal forearm, unspecified part 
S230100 Closed fracture olecranon, extra-articular 
S230200 Closed fracture of ulna, coronoid 
S230300 Closed Monteggia’s fracture 
S230400 Closed fracture of proximal ulna, comminuted 
S230500 Closed fracture of the proximal ulna 
S230600 Closed fracture radius, head 
S230700 Closed fracture radius, neck 
S230711 Closed # radius neck 
S230800 Closed fracture proximal radius, comminuted 
S230900 Closed fracture of the proximal radius 
S230A00 Closed fracture radius and ulna, proximal 
S230B00 Closed fracture olecranon, intra-articular 
S230z00 Closed fracture of proximal forearm not otherwise specified 
S231.00 Open fracture of proximal radius and ulna 
S231000 Open fracture of proximal forearm, unspecified 
S231100 Open fracture olecranon, extra-articular 
S231200 Open fracture of ulna, coronoid 
S231300 Open Monteggia’s fracture 
S231400 Open fracture proximal ulna, comminuted 
S231500 Open fracture of the proximal ulna 
S231600 Open fracture radial head 
S231700 Open fracture radial neck 
S231800 Open fracture proximal radius, comminuted 
S231900 Open fracture of the proximal radius 
S231A00 Open fracture radius and ulna, proximal 
S231B00 Open fracture olecranon, intra-articular 
S231z00 Open fracture of forearm, upper end, NOS 
S232.00 Closed fracture of radius and ulna, shaft 
S232000 Closed fracture of radius, shaft, unspecified 
S232100 Closed fracture of the radial shaft 
S232200 Closed fracture of the ulnar shaft 
S232300 Closed fracture radius and ulna, middle 
S232z00 Closed fracture of radius and ulna, shaft, NOS 
S233.00 Open fracture of radius and ulna, shaft 
S233000 Open fracture of radius, shaft, unspecified 
S233100 Open fracture of the radial shaft 
S233200 Open fracture of the ulnar shaft 
S233300 Open fracture radius and ulna, middle 
S233z00 Open fracture of radius and ulna, shaft, NOS 
S234.00 Closed fracture of radius and ulna, lower end 
S234.11 Wrist fracture – closed 
S234000 Closed fracture of forearm, lower end, unspecified 
S234100 Closed Colles’ fracture 
S234111 Smith’s fracture – closed 
S234200 Closed fracture of the distal radius, unspecified 
S234211 Dupuytren’s fracture, radius – closed 
S234300 Closed fracture of ulna, styloid process 
S234400 Closed fracture of ulna, lower epiphysis 
S234500 Closed fracture distal ulna, unspecified 
S234600 Closed fracture radius and ulna, distal 
S234700 Closed Smith’s fracture 
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S234800 Closed Galeazzi fracture 
S234900 Closed volar Barton’s fracture 
S234911 Closed volar Barton’s fracture-dislocation 
S234912 Closed volar Barton fracture-subluxation 
S234A00 Closd dorsal Barton’s fracture 
S234A11 Closed dorsal Barton’s fracture-dislocation 
S234A12 Closed dorsal Barton fracture-subluxation 
S234B00 Closed fracture radial styloid 
S234C00 Closed fracture distal radius, intra-articular, die-punch 
S234D00 Closed fracture distal radius, extra-articular, other type 
S234E00 Closed fracture distal radius, intra-articular, other type 
S234F00 Closed Barton’s fracture 
S234G00 Greenstick fracture of distal radius 
S234z00 Closed fracture of forearm, lower end, NOS 
S235.00 Open fracture of radius and ulna, lower end 
S235.11 Wrist fracture – open 
S235000 Open fracture of forearm, lower end, unspecified 
S235100 Open Colles’ fracture 
S235111 Smith’s fracture – open 
S235200 Open fracture of the distal radius, unspecified 
S235211 Dupuytren’s fracture, radius – open 
S235300 Open fracture of ulna, styloid process 
S235400 Open fracture of ulna, lower epiphysis 
S235500 Open fracture distal ulna – other 
S235600 Open fracture radius and ulna, distal 
S235700 Open Smith’s fracture 
S235800 Open Galeazzi fracture 
S235900 Open volar Barton’s fracture 
S235911 Open volar Barton fracture-dislocation 
S235912 Open volar Barton fracture-subluxation 
S235A00 Open dorsal Barton’s fracture 
S235A11 Open dorsal Barton’s fracture-dislocation 
S235A12 Open dorsal Barton’s fracture-subluxation 
S235B00 Open fracture radial styloid 
S235C00 Open fracture distal radius, intra-articular, die-punch 
S235D00 Open fracture distal radius, extra-articular other type 
S235E00 Open fracture distal radius, intra-articular other type 
S235F00 Open Barton’s fracture 
S235z00 Open fracture of forearm, lower end, NOS 
S236.00 Fracture of upper end of ulna 
S237.00 Fracture of upper end of radius 
S238.00 Fracture of shaft of ulna 
S239.00 Fracture of shaft of radius 
S23A.00 Fracture of shafts of both ulna and radius 
S23B.00 Fracture of lower end of radius 
S23C.00 Fracture of lower end of both ulna and radius 
S23x.00 Closed fracture of radius and ulna, unspecified part 
S23x000 Closed fracture of forearm, unspecified 
S23x100 Closed fracture of radius (alone), unspecified 
S23x111 Fracture of radius NOS 
S23x200 Closed fracture of ulna (alone), unspecified 
S23x211 Fracture of ulna NOS 
S23x300 Closed fracture of the radius and ulna 
S23xz00 Closed fracture of radius and ulna, NOS 
S23y.00 Open fracture of radius and ulna, unspecified part 
S23y000 Open fracture of forearm, unspecified 
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S23y100 Open fracture of radius (alone), unspecified 
S23y200 Open fracture of ulna (alone), unspecified 
S23y300 Open fracture of the radius and ulna 
S23yz00 Open fracture of radius and ulna, NOS 
S23z.00 Fracture of radius and ulna, NOS 
S24..00 Fracture of carpal bone 
S24..11 Hand fracture – carpal bone 
S240.00 Closed fracture of carpal bone 
S240000 Closed fracture of carpal bone, unspecified 
S240100 Closed fracture of the scaphoid 
S240200 Closed fracture lunate 
S240300 Closed fracture triquetral 
S240400 Closed fracture pisiform 
S240500 Closed fracture trapezium 
S240600 Closed fracture trapezoid 
S240700 Closed fracture capitate 
S240800 Closed fracture hamate 
S240900 Closed fracture hamate, hook 
S240A00 Closed fracture scaphoid, proximal pole 
S240B00 Closed fracture scaphoid, waist, transverse 
S240C00 Closed fracture scaphoid, waist, oblique 
S240D00 Closed fracture scaphoid, waist, comminuted 
S240E00 Closed fracture scaphoid, tuberosity 
S240F00 Closed fracture carpal bones, multiple 
S240y00 Closed fracture of other carpal bone 
S240z00 Closed fracture of carpal bone NOS 
S241.00 Open fracture of carpal bone 
S241000 Open fracture of carpal bone, unspecified 
S241100 Open fracture of the scaphoid 
S241200 Open fracture lunate 
S241300 Open fracture triquetral 
S241400 Open fracture pisiform 
S241500 Open fracture trapezium 
S241600 Open fracture trapezoid 
S241700 Open fracture capitate 
S241800 Open fracture hamate 
S241900 Open fracture hamate, hook 
S241A00 Open fracture scaphoid, proximal pole 
S241B00 Open fracture scaphoid, waist, transverse 
S241C00 Open fracture scaphoid, waist, oblique 
S241D00 Open fracture scaphoid, waist, comminuted 
S241E00 Open fracture scaphoid, tuberosity 
S241F00 Open fracture carpal bones, multiple 
S241y00 Open fracture of other carpal bone 
S241z00 Open fracture of carpal bone NOS 
S242.00 Fracture at wrist and hand level 
S242000 Fracture of scaphoid 
S242100 Fracture of first metacarpal bone 
S242200 Fracture of other metacarpal bone 
S242300 Multiple fractures of metacarpal bones 
S24z.00 Fracture of carpal bone NOS 
S25..00 Fracture of metacarpal bone 
S25..11 Hand fracture – metacarpal bone 
S250.00 Closed fracture of metacarpal bone(s) 
S250000 Closed fracture of metacarpal bone (s), site unspecified 
S250100 Cls # thumb metacarpal base, intra-articular, Bennett 
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S250200 Closed fracture finger metacarpal base 
S250300 Closed fracture finger metacarpal shaft 
S250400 Closed fracture finger metacarpal neck 
S250500 Closed fracture finger metacarpal head 
S250600 Closed fracture finger metacarpal 
S250700 Closed fracture finger metacarpal, multiple 
S250800 Closed fracture of thumb metacarpal 
S250900 Cls # thumb metacarpal base, intra-articular, Rolando 
S250A00 Closed fracture thumb metacarpal shaft 
S250B00 Closed fracture thumb metacarpal neck 
S250C00 Closed fracture thumb metacarpal head 
S250x00 Closed fractures of multiple sites of unspecified metacarpus 
S250z00 Closed fracture of metacarpal bone(s) NOS 
S251.00 Open fracture of metacarpal bone(s) 
S251000 Open fracture of metacarpal bone(s), site unspecified 
S251100 Opn # thumb metacarpal base, intra-articular, Bennett 
S251200 Open fracture finger metacarpal base 
S251300 Open fracture finger metacarpal shaft 
S251400 Open fracture finger metacarpal neck 
S251500 Open fracture finger metacarpal head 
S251600 Open fracture finger metacarpal 
S251700 Open fracture finger metacarpal, multiple 
S251800 Open fracture of thumb metacarpal 
S251900 Opn # thumb metacarpal base, intra-articular, Rolando 
S251A00 Open fracture thumb metacarpal shaft 
S251B00 Open fracture thumb metacarpal neck 
S251C00 Open fracture thumb metacarpal head 
S251x00 Open fractures of multiple sites of unspecified metacarpus 
S251z00 Open fracture of metacarpal bone(s) NOS 
S252.00 Closed fracture sesamoid bone of hand 
S253.00 Open fracture sesamoid bone of hand 
S26..00 Fracture of one or more phalanges of hand 
S26..11 Finger fracture 
S26..12 Thumb fracture excluding base 
S260.00 Closed fracture of one or more phalanges of hand 
S260000 Closed fracture of phalanx or phalanges, unspecified 
S260100 Clsd # mid/prox phalanx/phalanges, unspecified part 
S260200 Cls # distal phalanx or phalanges, unspecified part 
S260300 Closed fracture thumb proximal phalanx 
S260400 Closed fracture thumb proximal phalanx, base 
S260500 Closed fracture thumb proximal phalanx, shaft 
S260600 Closed fracture thumb proximal phalanx, neck 
S260700 Closed fracture thumb proximal phalanx, head 
S260800 Closed fracture thumb distal phalanx 
S260900 Closed fracture thumb distal phalanx, base 
S260A00 Closed fracture thumb distal phalanx, shaft 
S260B00 Closed fracture thumb distal phalanx, tuft 
S260C00 Closed fracture thumb distal phalanx, mallet 
S260D00 Closed fracture finger proximal phalanx 
S260E00 Closed fracture finger proximal phalanx, base 
S260F00 Closed fracture finger proximal phalanx, shaft 
S260G00 Closed fracture finger proximal phalanx, neck 
S260H00 Closed fracture finger proximal phalanx, head 
S260J00 Closed fracture finger proximal phalanx, multiple 
S260K00 Closed fracture finger middle phalanx 
S260L00 Closed fracture finger middle phalanx, base 
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S260M00 Closed fracture finger middle phalanx, shaft 
S260N00 Closed fracture finger middle phalanx, neck 
S260P00 Closed fracture finger middle phalanx, head 
S260Q00 Closed fracture finger middle phalanx, multiple 
S260R00 Closed fracture finger distal phalanx 
S260S00 Closed fracture finger distal phalanx, base 
S260T00 Closed fracture finger distal phalanx, shaft 
S260U00 Closed fracture finger distal phalanx, tuft 
S260V00 Closed fracture finger distal phalanx, mallet 
S260W00 Closed fracture finger distal phalanx, multiple 
S260x00 Closed fractures of phalanx or phalanges, multiple sites 
S260z00 Closed fracture of one or more phalanges of hand NOS 
S261.00 Open fracture of one or more phalanges of hand 
S261000 Open fracture of phalanx or phalanges, unspecified 
S261100 Opn # mid/prox phalanx or phalanges, unspecified part 
S261200 Opn # distal phalanx or phalanges, unspecified part 
S261300 Open fracture thumb proximal phalanx 
S261400 Open fracture thumb proximal phalanx, base 
S261500 Open fracture thumb proximal phalanx, shaft 
S261600 Open fracture thumb proximal phalanx, neck 
S261700 Open fracture thumb proximal phalanx, head 
S261800 Open fracture thumb distal phalanx 
S261900 Open fracture thumb distal phalanx, base 
S261A00 Open fracture thumb distal phalanx, shaft 
S261B00 Open fracture thumb distal phalanx, tuft 
S261C00 Open fracture thumb distal phalanx, mallet 
S261D00 Open fracture finger proximal phalanx 
S261E00 Open fracture finger proximal phalanx, base 
S261F00 Open fracture finger proximal phalanx, shaft 
S261G00 Open fracture finger proximal phalanx, neck 
S261H00 Open fracture finger proximal phalanx, head 
S261J00 Open fracture finger proximal phalanx, multiple 
S261K00 Open fracture finger middle phalanx 
S261L00 Open fracture finger middle phalanx, base 
S261M00 Open fracture finger middle phalanx, shaft 
S261N00 Open fracture finger middle phalanx, neck 
S261P00 Open fracture finger middle phalanx, head 
S261Q00 Open fracture finger middle phalanx, multiple 
S261R00 Open fracture finger distal phalanx 
S261S00 Open fracture finger distal phalanx, base 
S261T00 Open fracture finger distal phalanx, shaft 
S261U00 Open fracture finger distal phalanx, tuft 
S261V00 Open fracture finger distal phalanx, mallet 
S261W00 Open fracture finger distal phalanx, multiple 
S261x00 Open fracture of phalanx or phalanges, multiple sites 
S261z00 Open fracture of one or more phalanges of hand NOS 
S262.00 Fracture of thumb 
S263.00 Fracture of other finger 
S264.00 Multiple fractures of fingers 
S26z.00 Fracture of one or more phalanges of hand NOS 
S27..00 Multiple fractures of hand bones 
S270.00 Closed multiple fractures of hand bones 
S271.00 Open multiple fractures of hand bones 
S27z.00 Multiple fractures of hand bones NOS 
S28..00 Ill-defined fractures of upper limb 
S28..11 Ill-defined fracture of arm 
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S280.00 Closed ill-defined fractures of upper limb 
S281.00 Open ill-defined fractures of upper limb 
S28z.00 Ill-defined fractures of upper limb NOS 
S29..00 Multiple # both upper limbs & upper limb with rib + sternum 
S29..11 Multiple fractures of arm 
S29..12 Multiple rib fractures 
S29..13 Multiple fractures of sternum 
S290.00 Closed multiple #upper limbs & upper limb with rib + sternum 
S291.00 Open multiple #upper limbs & upper limb with rib + sternum 
S292.00 Multiple fractures of clavicle, scapula and humerus 
S292000 Closed multiple fractures of clavicle, scapula and humerus 
S292100 Open multiple fractures of clavicle, scapula and humerus 
S293.00 Multiple fractures of forearm 
S294.00 Fractures involving multiple regions of both upper limbs 
S294000 Cl fractures involving multiple regions of both upper limbs 
S294100 Op fractures involving multiple regions of both upper limbs 
S29z.00 Multiple #upper limbs & upper limb with rib + sternum NOS 
S2A..00 Fracture of upper limb, level unspecified 
S2B..00 Fracture of bone of hand 
S2z..00 Fracture of upper limb NOS 
S3...00 Fracture of lower limb 
S3...11 Leg fracture 
S30..00 Fracture of neck of femur 
S30..11 Hip fracture 
S300.00 Closed fracture proximal femur, transcervical 
S300000 Cls # prox femur, intracapsular section, unspecified 
S300100 Closed fracture proximal femur, transepiphyseal 
S300200 Closed fracture proximal femur, midcervical section 
S300300 Closed fracture proximal femur, basicervical 
S300311 Closed fracture, base of neck of femur 
S300400 Closed fracture head of femur 
S300500 Cls # prox femur, subcapital, Garden grade unspec. 
S300600 Closed fracture proximal femur, subcapital, Garden grade I 
S300700 Closed fracture proximal femur, subcapital, Garden grade II 
S300800 Closed fracture proximal femur, subcapital, Garden grade III 
S300900 Closed fracture proximal femur, subcapital, Garden grade IV 
S300A00 Closed fracture of femur, upper epiphysis 
S300y00 Closed fracture proximal femur, other transcervical 
S300y11 Closed fracture of femur, subcapital 
S300z00 Closed fracture proximal femur, transcervical, NOS 
S301.00 Open fracture proximal femur, transcervical 
S301000 Opn # proximal femur, intracapsular section, unspecified 
S301100 Open fracture proximal femur, transepiphyseal 
S301200 Open fracture proximal femur, midcervical section 
S301300 Open fracture proximal femur, basicervical 
S301311 Open fracture base of neck of femur 
S301400 Open fracture head, femur 
S301500 Open fracture proximal femur,subcapital, Garden grade unspec 
S301600 Open fracture proximal femur,subcapital, Garden grade I 
S301700 Open fracture proximal femur,subcapital, Garden grade II 
S301800 Open fracture proximal femur,subcapital, Garden grade III 
S301900 Open fracture proximal femur,subcapital, Garden grade IV 
S301A00 Open fracture of femur, upper epiphysis 
S301y00 Open fracture proximal femur, other transcervical 
S301y11 Open fracture of femur, subcapital 
S301z00 Open fracture proximal femur, transcervical, NOS 
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S302.00 Closed fracture of proximal femur, pertrochanteric 
S302000 Cls # proximal femur, trochanteric section, unspecified 
S302011 Closed fracture of femur, greater trochanter 
S302012 Closed fracture of femur, lesser trochanter 
S302100 Closed fracture proximal femur, intertrochanteric, two part 
S302200 Closed fracture proximal femur, subtrochanteric 
S302300 Cls # proximal femur, intertrochanteric, comminuted 
S302400 Closed fracture of femur, intertrochanteric 
S302z00 Cls # of proximal femur, pertrochanteric section, NOS 
S303.00 Open fracture of proximal femur, pertrochanteric 
S303000 Open # of proximal femur, trochanteric section, unspecified 
S303011 Open fracture of femur, greater trochanter 
S303012 Open fracture of femur, lesser trochanter 
S303100 Open fracture proximal femur, intertrochanteric, two part 
S303200 Open fracture proximal femur, subtrochanteric 
S303300 Open fracture proximal femur, intertrochanteric, comminuted 
S303400 Open fracture of femur, intertrochanteric 
S303z00 Open fracture of proximal femur, pertrochanteric, NOS 
S304.00 Pertrochanteric fracture 
S305.00 Subtrochanteric fracture 
S30w.00 Closed fracture of unspecified proximal femur 
S30x.00 Open fracture of unspecified proximal femur 
S30y.00 Closed fracture of neck of femur NOS 
S30y.11 Hip fracture NOS 
S30z.00 Open fracture of neck of femur NOS 
S31..00 Other fracture of femur 
S310.00 Closed fracture of femur, shaft or unspecified part 
S310000 Closed fracture of femur, unspecified part 
S310011 Thigh fracture NOS 
S310012 Upper leg fracture NOS 
S310100 Closed fracture shaft of femur 
S310z00 Closed fracture of shaft or unspecified part, NOS 
S311.00 Open fracture of femur, shaft or unspecified part 
S311000 Open fracture of femur, unspecified part 
S311100 Open fracture shaft of femur 
S311z00 Open fracture of femur, shaft or unspecified part, NOS 
S312.00 Closed fracture distal femur 
S312.11 Closed fracture of femur, distal end 
S312000 Closed fracture of distal femur, unspecified 
S312100 Closed fracture of femoral condyle, unspecified 
S312200 Closed fracture of femur, lower epiphysis 
S312300 Closed fracture distal femur, supracondylar 
S312400 Closed fracture distal femur, medial condyle 
S312500 Closed fracture distal femur, lateral condyle 
S312600 Closed fracture distal femur, bicondylar (T-Y fracture) 
S312x00 Closed fracture distal femur, comminuted/intra-articular 
S312z00 Closed fracture of distal femur not otherwise specified 
S313.00 Open fracture distal femur 
S313.11 Open fracture of femur, distal end 
S313000 Open fracture distal femur, unspecified 
S313100 Open fracture of femoral condyle, unspecified 
S313200 Open fracture of femur, lower epiphysis 
S313300 Open fracture distal femur, supracondylar 
S313400 Open fracture distal femur, medial condyle 
S313500 Open fracture distal femur, lateral condyle 
S313600 Open fracture distal femur, bicondylar (T-Y fracture) 
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S313x00 Open fracture distal femur, comminuted/intra-articular 
S313z00 Open fracture of distal femur not otherwise specified 
S314.00 Fracture of shaft of femur 
S315.00 Fracture of lower end of femur 
S31z.00 Fracture of femur, NOS 
S32..00 Fracture of patella 
S32..11 #Knee-cap 
S320.00 Closed fracture of the patella 
S320000 Closed fracture patella, transverse 
S320100 Closed fracture patella, proximal pole 
S320200 Closed fracture patella, distal pole 
S320300 Closed fracture patella, vertical 
S320400 Closed fracture patella, comminuted (stellate) 
S321.00 Open fracture of the patella 
S321000 Open fracture patella, transverse 
S321100 Open fracture patella, proximal pole 
S321200 Open fracture patella, distal pole 
S321300 Open fracture patella, vertical 
S321400 Open fracture patella, comminuted (stellate) 
S32z.00 Fracture of patella, NOS 
S33..00 Fracture of tibia and fibula 
S330.00 Closed fracture of tibia and fibula, proximal 
S330000 Closed fracture of the proximal tibia 
S330011 Closed fracture of tibial condyles 
S330012 Closed fracture of tibial tuberosity 
S330100 Closed fracture proximal fibula 
S330200 Closed fracture of tibia and fibula, proximal 
S330300 Closed fracture proximal tibia, medial condyle (plateau) 
S330400 Closed fracture proximal tibia, lateral condyle (plateau) 
S330500 Closed fracture proximal tibia, bicondylar 
S330600 Closed fracture spine, tibia 
S330700 Closed fracture tubercle, tibia 
S330800 Closed fracture fibula, head 
S330900 Closed fracture fibula, neck 
S330z00 Closed fracture of tibia and fibula, proximal NOS 
S331.00 Open fracture of tibia and fibula, proximal 
S331000 Open fracture of the proximal tibia 
S331011 Open fracture of tibial condyles 
S331012 Open fracture of tibial tuberosity 
S331100 Open fracture proximal fibula 
S331200 Open fracture of tibia and fibula, proximal 
S331300 Open fracture proximal tibia, medial condyle (plateau) 
S331400 Open fracture proximal tibia, lateral condyle (plateau) 
S331500 Open fracture proximal tibia, bicondylar 
S331600 Open fracture spine, tibia 
S331700 Open fracture tubercle, tibia 
S331800 Open fracture fibula, head 
S331900 Open fracture fibula, neck 
S331A00 Open fracture tibial plateau 
S331z00 Open fracture of tibia and fibula, proximal NOS 
S332.00 Closed fracture of tibia/fibula, shaft 
S332000 Closed fracture shaft of tibia 
S332100 Closed fracture shaft of fibula 
S332200 Closed fracture of tibia and fibula, shaft 
S332z00 Closed fracture of tibia and fibula, shaft, NOS 
S333.00 Open fracture of tibia/fibula, shaft 
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S333000 Open fracture shaft of tibia 
S333100 Open fracture shaft of fibula 
S333200 Open fracture of tibia and fibula, shaft 
S333z00 Open fracture of tibia and fibula, shaft, NOS 
S334.00 Closed fracture distal tibia 
S334000 Closed fracture distal tibia, extra-articular 
S334100 Closed fracture distal tibia, intra-articular 
S335.00 Open fracture distal tibia 
S335000 Open fracture distal tibia, extra-articular 
S335100 Open fracture distal tibia, intra-articular 
S336.00 Fracture of upper end of tibia 
S336000 Fracture tibial plateau 
S337.00 Fracture of shaft of tibia 
S338.00 Fracture of lower end of tibia 
S339.00 Fracture of fibula alone 
S339000 Closed fracture of distal fibula 
S339100 Open fracture of distal fibula 
S33A.00 Fracture of tibia 
S33B.00 Open fracture of distal tibia and fibula 
S33C.00 Closed fracture of distal tibia and fibula 
S33x.00 Closed fracture of tibia and fibula, unspecified part, NOS 
S33x.11 Lower leg fracture NOS 
S33x000 Closed fracture of tibia, unspecified part, NOS 
S33x100 Closed fracture of fibula, unspecified part, NOS 
S33x200 Closed fracture of tibia and fibula, unspecified part 
S33xz00 Closed fracture of tibia and fibula, unspecified part, NOS 
S33y.00 Open fracture of tibia and fibula, unspecified part, NOS 
S33y000 Open fracture of tibia, unspecified part, NOS 
S33y100 Open fracture of fibula, unspecified part, NOS 
S33y200 Open fracture of tibia and fibula, unspecified part 
S33yz00 Open fracture of tibia and fibula, unspecified part, NOS 
S33z.00 Fracture of tibia and fibula, NOS 
S34..00 Fracture of ankle 
S340.00 Closed fracture ankle, medial malleolus 
S341.00 Open fracture ankle, medial malleolus 
S342.00 Closed fracture ankle, lateral malleolus 
S342000 Closed fracture ankle, lateral malleolus, low 
S342100 Closed fracture ankle, lateral malleolus, high 
S343.00 Open fracture ankle, lateral malleolus 
S343000 Open fracture ankle, lateral malleolus, low 
S343100 Open fracture ankle, lateral malleolus, high 
S344.00 Closed fracture ankle, bimalleolar 
S344.11 Dupuytren’s fracture, fibula 
S344.12 Pott’s fracture – ankle 
S344000 Closed fracture ankle, bimalleolar, low fibular fracture 
S344100 Closed fracture ankle, bimalleolar, high fibular fracture 
S345.00 Open fracture ankle, bimalleolar 
S345000 Open fracture ankle, bimalleolar, low fibular fracture 
S345100 Open fracture ankle, bimalleolar, high fibular fracture 
S346.00 Closed fracture ankle, trimalleolar 
S346000 Closed fracture ankle, trimalleolar, low fibular fracture 
S346100 Closed fracture ankle, trimalleolar, high fibular fracture 
S347.00 Open fracture ankle, trimalleolar 
S347000 Open fracture ankle, trimalleolar, low fibular fracture 
S347100 Open fracture ankle, trimalleolar, high fibular fracture 
S348.00 Fracture of medial malleolus 
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S349.00 Fracture of lateral malleolus 
S34x.00 Closed fracture ankle, unspecified 
S34y.00 Open fracture ankle, unspecified 
S34z.00 Fracture of ankle, NOS 
S35..00 Fracture of one or more tarsal and metatarsal bones 
S35..11 Metatarsal bone fracture 
S35..12 Tarsal bone fracture 
S350.00 Closed fracture of calcaneus 
S350.11 Heel bone fracture 
S350.12 Os calcis fracture 
S350000 Closed fracture calcaneus, extra-articular 
S350100 Closed fracture calcaneus, intra-articular 
S351.00 Open fracture of calcaneus 
S351000 Open fractures calcaneus, extra-articular 
S351100 Open fractures calcaneus, intra-articular 
S352.00 Closed fracture of other tarsal and metatarsal bones 
S352.11 March fracture 
S352000 Closed fracture of tarsal bone, unspecified 
S352100 Closed fracture of talus 
S352111 Closed fracture of astragalus 
S352200 Closed fracture navicular 
S352300 Closed fracture cuboid 
S352400 Closed fracture medial cuneiform 
S352500 Closed fracture intermediate cuneiform 
S352600 Closed fracture lateral cuneiform 
S352700 Closed fracture metatarsal 
S352800 Closed fracture talus, head 
S352900 Closed fracture talus, neck 
S352A00 Closed fracture talus, body 
S352B00 Closed fracture metatarsal base 
S352C00 Closed fracture metatarsal shaft 
S352D00 Closed fracture metatarsal neck 
S352E00 Closed fracture metatarsal head 
S352F00 Closed fracture metatarsal, multiple 
S352G00 Closed tarsal fractures, multiple 
S352H00 Closed fracture of cuneiforms 
S352J00 Closed fracture of base of fifth metatarsal 
S352z00 Closed fracture of one or more tarsal + metatarsal bones NOS 
S353.00 Open fracture of other tarsal and metatarsal bones 
S353000 Open fracture of tarsal bone, unspecified 
S353100 Open fracture of talus 
S353111 Open fracture of astragalus 
S353200 Open fracture navicular 
S353300 Open fracture cuboid 
S353400 Open fracture medial cuneiform 
S353500 Open fracture intermediate cuneiform 
S353600 Open fracture lateral cuneiform 
S353700 Open fracture metatarsal 
S353800 Open fracture talus, head 
S353900 Open fracture talus, neck 
S353A00 Open fracture talus, body 
S353B00 Open fracture metatarsal base 
S353C00 Open fracture metatarsal shaft 
S353D00 Open fracture metatarsal neck 
S353E00 Open fracture metatarsal head 
S353F00 Open fracture metatarsal, multiple 
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S353G00 Open tarsal fractures, multiple 
S353H00 Open fracture cuneiforms 
S353J00 Open fracture of base of fifth metatarsal 
S353z00 Open fracture of tarsal and metatarsal bones NOS 
S354.00 Fracture of calcaneus 
S355.00 Fracture of talus 
S356.00 Fracture of metatarsal bone 
S35z.00 Fracture of tarsal and metatarsal bones NOS 
S36..00 Fracture of one or more phalanges of foot 
S36..11 Toe fracture 
S360.00 Closed fracture of one or more phalanges of foot 
S360000 Closed fracture proximal phalanx, toe 
S360100 Closed fracture middle phalanx, toe 
S360200 Closed fracture distal phalanx, toe 
S360300 Closed fracture multiple phalanges, toe 
S361.00 Open fracture of one or more phalanges of foot 
S361000 Open fracture proximal phalanx, toe 
S361100 Open fracture middle phalanx, toe 
S361200 Open fracture distal phalanx, toe 
S361300 Open fracture multiple phalanges, toe 
S362.00 Fracture of great toe 
S362000 Closed fracture of great toe 
S362100 Open fracture of great toe 
S363.00 Fracture of other toe 
S36z.00 Fracture of one or more phalanges of foot NOS 
S37..00 Fracture of lower limb, level unspecified 
S370.00 Closed fracture of lower limb, level unspecified 
S371.00 Open fracture of lower limb, level unspecified 
S3X..00 Fracture of lower leg, part unspecified 
S3x..00 Other, multiple and ill-defined fractures of lower limb 
S3x0.00 Other, multiple and ill-defined closed fractures lower limb 
S3x1.00 Other, multiple and ill-defined open fractures of lower limb 
S3x2.00 Multiple fractures of femur 
S3x3.00 Multiple fractures of lower leg 
S3x4.00 Multiple fractures of foot 
S3xz.00 Other, multiple and ill-defined fractures of lower limb NOS 
S3y..00 Multiple #both legs, leg + arm ,leg + rib + sternum 
S3y0.00 Multiple closed #both legs, leg + arm, leg + rib + sternum 
S3y1.00 Multiple open #both legs, leg + arm, leg + rib + sternum 
S3yz.00 Multiple #both legs, leg + arm, leg + rib + sternum NOS 
S3z..00 Fracture of unspecified bones 
S3z..11 Fracture NOS 
S3z0.00 Closed fracture of bones, unspecified 
S3z0000 Greenstick fracture 
S3z1.00 Open fracture of bones, unspecified 
S3z2.00 Stress fracture 
S3zz.00 Fracture of bones NOS 
S4…13 Fracture dislocations and fracture subluxations 
S4A..00 Fracture-dislocation or subluxation shoulder 
S4A0.00 Closed fracture-dislocation shoulder 
S4A0000 Closed fracture-dislocation shoulder joint 
S4A0100 Closed fracture-dislocation acromio-clavicular joint 
S4A1.00 Open fracture-dislocation shoulder 
S4A1000 Open fracture-dislocation shoulder joint 
S4A1100 Open fracture-dislocation acromio-clavicular joint 
S4A2.00 Closed fracture-subluxation shoulder 
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S4A2000 Closed fracture-subluxation shoulder joint 
S4A2100 Closed fracture-subluxation acromio-clavicular joint 
S4A3.00 Open fracture-subluxation shoulder 
S4A3000 Open fracture-subluxation shoulder joint 
S4A3100 Open fracture-subluxation acromio-clavicular joint 
S4B..00 Fracture-dislocation or subluxation elbow 
S4B0.00 Closed fracture-dislocation elbow 
S4B0000 Closed fracture-dislocation elbow joint 
S4B0100 Closed fracture-dislocation superior radio-ulnar joint 
S4B1.00 Open fracture-dislocation elbow 
S4B1000 Open fracture-dislocation elbow joint 
S4B1100 Open fracture-dislocation superior radio-ulnar joint 
S4B2.00 Closed fracture-subluxation elbow 
S4B2000 Closed fracture-subluxation elbow joint 
S4B2100 Closed fracture-subluxation superior radio-ulnar joint 
S4B3.00 Open fracture-subluxation elbow 
S4B3000 Open fracture-subluxation elbow joint 
S4B3100 Open fracture-subluxation superior radio-ulnar joint 
S4C..00 Fracture-dislocation or subluxation of wrist 
S4C0.00 Closed fracture dislocation of wrist 
S4C0000 Closed fracture-dislocation distal radio-ulnar joint 
S4C0100 Closed fracture-dislocation radiocarpal joint 
S4C0200 Closed fracture-dislocation mid carpal 
S4C0300 Closed fracture-dislocation, carpometacarpal joint 
S4C0400 Closed fracture-dislocation lunate (volar) 
S4C0500 Closed fracture-dislocation peri-lunate (dorsal) 
S4C0600 Closed fracture-dislocation peri-lunate trans-scaphoid 
S4C0y00 Closed fracture-dislocation other carpal 
S4C1.00 Open fracture dislocation wrist 
S4C1000 Open fracture-dislocation, distal radio-ulnar joint 
S4C1100 Open fracture-dislocation radiocarpal joint 
S4C1200 Open fracture-dislocation mid carpal 
S4C1300 Open fracture-dislocation carpometacarpal joint 
S4C1400 Open fracture-dislocation lunate (volar) 
S4C1500 Open fracture-dislocation peri-lunate (dorsal) 
S4C1600 Open fracture-dislocation peri-lunate trans-scaphoid 
S4C1y00 Open fracture-dislocation other carpal 
S4C2.00 Closed fracture-subluxation of the wrist 
S4C2000 Closed fracture-subluxation, distal radio-ulnar jt 
S4C2100 Closed fracture-subluxation radiocarpal joint 
S4C2200 Closed fracture-subluxation mid carpal 
S4C2300 Closed fracture-subluxation, carpometacarpal joint 
S4C2400 Closed fracture-subluxation lunate (volar) 
S4C2500 Closed fracture-subluxation peri-lunate (dorsal) 
S4C2600 Closed fracture-subluxation peri-lunate trans-scaphoid 
S4C2y00 Closed fracture-subluxation other carpal 
S4C3.00 Open fracture-subluxation of the wrist 
S4C3000 Open fracture-subluxation, distal radio-ulnar joint 
S4C3100 Open fracture-subluxation radiocarpal joint 
S4C3200 Open fracture-subluxation mid carpal 
S4C3300 Open fracture-subluxation, carpometacarpal joint 
S4C3400 Open fracture-subluxation lunate (volar) 
S4C3500 Open fracture-subluxation peri-lunate (dorsal) 
S4C3600 Open fracture-subluxation peri-lunate trans-scaphoid 
S4C3y00 Open fracture-subluxation other carpal 
S4D..00 Fracture-dislocation/subluxation finger/thumb 
Appendices 
 399 
Table G.10  Continued. 
Read code Code description 
S4D0.00 Closed fracture-dislocation digit 
S4D0000 Closed fracture-dislocation digit, unspecified 
S4D0100 Closed fracture-dislocation, metacarpophalangeal joint 
S4D0200 Closed fracture-dislocation IPJ, unspecified 
S4D0300 Closed fracture-dislocation, distal interphalangeal joint 
S4D0400 Closed fracture-dislocation, proximal interphalangeal joint 
S4D0500 Closed fracture-dislocation, interphalangeal joint thumb 
S4D0600 Closed fracture-dislocation multiple digits 
S4D1.00 Open fracture-dislocation digit 
S4D1000 Open fracture-dislocation digit, unspecified 
S4D1100 Open fracture-dislocation, metacarpophalangeal joint 
S4D1200 Open fracture-dislocation IPJ, unspecified 
S4D1300 Open fracture-dislocation, distal interphalangeal joint 
S4D1400 Open fracture-dislocation, proximal interphalangeal joint 
S4D1500 Open fracture-dislocation, interphalangeal joint thumb 
S4D1600 Open fracture-dislocation multiple digits 
S4D2.00 Closed fracture-subluxation digit 
S4D2000 Closed fracture-subluxation digit, unspecified 
S4D2100 Closed fracture-subluxation, metacarpophalangeal joint 
S4D2200 Closed fracture-subluxation IPJ, unspecified 
S4D2300 Closed fracture-subluxation, distal interphalangeal joint 
S4D2400 Closed fracture-subluxation, proximal interphalangeal joint 
S4D2500 Closed fracture-subluxation, interphalangeal joint thumb 
S4D2600 Closed fracture-subluxation multiple digits 
S4D3.00 Open fracture-subluxation digit 
S4D3000 Open fracture-subluxation digit, unspecified 
S4D3100 Open fracture-subluxation, metacarpophalangeal joint 
S4D3200 Open fracture-subluxation IPJ, unspecified 
S4D3300 Open fracture-subluxation, distal interphalangeal joint 
S4D3400 Open fracture-subluxation, proximal interphalangeal joint 
S4D3500 Open fracture-subluxation, interphalangeal joint thumb 
S4D3600 Open fracture-subluxation multiple digits 
S4E..00 Fracture-dislocation or subluxation hip 
S4E0.00 Closed fracture-dislocation, hip joint 
S4E1.00 Open fracture-dislocation, hip joint 
S4E2.00 Closed fracture-subluxation, hip joint 
S4E3.00 Open fracture-subluxation, hip joint 
S4F..00 Fracture-dislocation or subluxation knee 
S4F0.00 Closed fracture-dislocation, knee joint 
S4F1.00 Open fracture-dislocation, knee joint 
S4F2.00 Closed fracture-subluxation, knee joint 
S4F3.00 Open fracture-subluxation, knee joint 
S4F4.00 Closed fracture-dislocation, 399atella-femoral joint 
S4F5.00 Open fracture-dislocation, 399atella-femoral joint 
S4F6.00 Closed fracture-subluxation, 399atella-femoral joint 
S4F7.00 Open fracture-subluxation, 399atella-femoral joint 
S4G..00 Fracture-dislocation or subluxation ankle 
S4G0.00 Closed fracture-dislocation, ankle joint 
S4G1.00 Open fracture-dislocation, ankle joint 
S4G2.00 Closed fracture-subluxation, ankle joint 
S4G3.00 Open fracture-subluxation, ankle joint 
S4H..00 Fracture-dislocation or subluxation foot 
S4H0.00 Closed fracture-dislocation foot 
S4H0000 Closed fracture-dislocation, subtalar joint 
S4H0100 Closed fracture-dislocation, midtarsal joint 
S4H0200 Closed fracture-dislocation, tarsometatarsal joint 
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Table G.10  Continued. 
Read code Code description 
S4H0400 Closed fracture-dislocation, IPJ, single toe 
S4H0600 Closed fracture-dislocation, IPJ, multiple toes 
S4H1.00 Open fracture-dislocation, foot 
S4H1000 Open fracture-dislocation, subtalar joint 
S4H1100 Open fracture-dislocation, midtarsal joint 
S4H1200 Open fracture-dislocation, tarsometatarsal joint 
S4H1300 Open fracture-dislocation, metatarsophalangeal joint, single 
S4H1400 Open fracture-dislocation, IPJ, single toe 
S4H1600 Open fracture-dislocation, IPJ, multiple toes 
S4H2.00 Closed fracture-subluxation, foot 
S4H2000 Closed fracture-subluxation, subtalar joint 
S4H2100 Closed fracture-subluxation, midtarsal joint 
S4H2200 Closed fracture-subluxation, tarsometatarsal joint 
S4H2400 Closed fracture-subluxation, IPJ, single toe 
S4H2600 Closed fracture-subluxation, IPJ, multiple toes 
S4H3.00 Open fracture-subluxation, foot 
S4H3000 Open fracture-subluxation, subtalar joint 
S4H3100 Open fracture-subluxation, midtarsal joint 
S4H3200 Open fracture-subluxation, tarsometatarsal joint 
S4H3300 Open fracture-subluxation, metatarsophalangeal joint, single 
S4H3400 Open fracture-subluxation, IPJ, single toe 
S4H3600 Open fracture-subluxation, IPJ, multiple toes 
S4J..00 Other fracture-dislocation or subluxation 
S4J0.00 Other closed fracture-dislocation 
S4J0000 Closed fracture-dislocation of sternum 
S4J0100 Closed fracture-dislocation of pelvis 
S4J1.00 Other open fracture-dislocation 
S4J1000 Open fracture-dislocation of sternum 
S4J1100 Open fracture-dislocation of pelvis 
S4J1200 Open fracture-dislocation sterno-clavicular joint, anterior 
S4J1300 Open fracture-dislocation sterno-clavicular joint, posterior 
S4J2.00 Other closed fracture-subluxation 
S4J2000 Closed fracture-subluxation of sternum 
S4J2100 Closed fracture-subluxation of pelvis 
S4J3.00 Other open fracture-subluxation 
S4J3000 Open fracture-subluxation of sternum 
S4J3100 Open fracture-subluxation of pelvis 
S4J3200 Open fracture-subluxation sterno-clavicular joint, anterior 
S4J3300 Open fracture-subluxation sterno-clavicular joint, posterior 
S6…00 Intracranial injury excluding those with skull fracture 
S6z..00 Intracranial injury, excluding those with skull fracture NOS 
SC00.00 Late effect of fracture of skull and face bones 
SC00.11 Late effect of face fracture 
SC00.12 Late effect of skull fracture 
SC01.00 Late effect of fracture of spine/trunk without cord lesion 
SC01000 Late effect of fracture of cervical vertebra 
SC01100 Late effect of fracture of thoracic vertebra 
SC01200 Late effect of fracture of lumbar vertebra 
SC02.00 Late effect of fracture of arm 
SC03.00 Late effect of fracture neck of femur 
SC04.00 Late effect of other fracture of leg 
SC05.00 Late effect of multiple and unspecified fracture of bones 
SC0X.00 Sequelae of other fracture of thorax and pelvis 
SC0z.11 Delayed union of fracture 
SC20.00 Late effect of intracranial injury without skull fracture 
SC3C000 Sequelae of fracture at wrist and hand level 
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Table G.10  Continued. 
Read code Code description 
SC3D400 Sequelae of fracture of femur 
SD92000 Fracture blister 
SP04A00 Fracture of bone autograft 
SP04C00 Fracture of bone allograft 
SP22400 Intra-operative fracture 
SR1..00 Fractures involving multiple body regions 
SR10.00 Fractures involving head with neck 
SR10000 Closed fractures involving head with neck 
SR10100 Open fractures involving head with neck 
SR11.00 Fractures involving thorax with lower back and pelvis 
SR12.00 Fractures involving multiple regions of one upper limb 
SR12000 Closed fractures involving multiple regions of one upp limb 
SR12100 Open fractures involving multiple regions of one upper limb 
SR13.00 Fractures involving multiple regions of one lower limb 
SR14.00 Fractures involving multiple regions of both lower limbs 
SR14000 Closd fractures involving multiple regions of both low limbs 
SR14100 Open fractures involving multiple regions both lower limbs 
SR15000 Cl fractures involving multiple regions upper with lower lmb 
SR15100 Open fracture 401nvolve multiple regions upper with lower lmb 
SR16000 Closed fracture inv thorax wth low back and pelvis and limbs 
SR16100 Open fracture inv thorax wth low back and pelvis and limbs 
SR1z.00 Multiple fractures, unspecified 
SR1z000 [X]Closed multiple fractures unspecified 
SR1z100 [X]Open multiple fractures unspecified 
Syu0300 [X]Fractures of other skull and facial bones 
Syu0400 [X]Fracture of skull and facial bones, part unspecified 
Syu1500 [X]Fracture of other specified cervical vertebra 
Syu1600 [X]Fracture of other parts of neck 
Syu2700 [X]Fracture of other parts of bony thorax 
Syu2800 [X]Fracture of bony thorax, part unspecified 
Syu4200 [X]Multiple fractures of clavicle, scapula and humerus 
Syu4300 [X]Fracture of other parts of shoulder and upper arm 
Syu4400 [X]Fracture of shoulder and upper arm, unspecified 
Syu5300 [X]Fracture of other parts of forearm 
Syu5400 [X]Fracture of forearm, unspecified 
Syu6300 [X]Fracture of other carpal bone(s) 
Syu6400 [X]Fracture of other metacarpal bone 
Syu6500 [X]Fracture of other & unspecified parts of wrist and hand 
Syu7200 [X]Fractures of other parts of femur 
Syu8300 [X]Fractures of other parts of lower leg 
Syu8D00 [X]Fracture of lower leg, part unspecified 
Syu9400 [X]Fracture of other tarsal bones 
SyuA200 [X]Fractures involving other combinations of body regions 
SyuBB00 [X]Fracture of unspecified body region 
SyuL100 [X]Sequelae of other fracture of thorax and pelvis 
SyuL400 [X]Sequelae of other fractures of lower limb 
TC7..00 Fracture, cause unspecified 
Zw01.00 [Q] Fractures involving the epiphyseal plate 
medcode description 
N331.00 Pathological fracture 
N331.13 Sponanteous fracture 
N331000 Pathological fracture of thoracic vertebra 
N331100 Pathological fracture of lumbar vertebra 
N331200 Postoophorectomy osteoporosis with pathological fracture 
N331300 Osteoporosis of disuse with pathological fracture 
N331400 Postsurgical malabsorption osteoporosis with path fracture 
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Table G.10  Continued. 
Read code Code description 
N331500 Drug-induced osteoporosis with pathological fracture 
N331600 Idiopathic osteoporosis with pathological fracture 
N331700 Fracture of bone in neoplastic disease 
N331800 Osteoporosis + pathological fracture lumbar vertebrae 
N331900 Osteoporosis + pathological fracture thoracic vertebrae 
N331A00 Osteoporosis + pathological fracture cervical vertebrae 
N331B00 Postmenopausal osteoporosis with pathological fracture 
N331C00 Pathological fracture of cervical vertebra 
N331M00 Fragility fracture due to unspecified osteoporosis 
N331M11 Minimal trauma fracture due to unspecified osteoporosis 
N331N00 Fragility fracture 
N331N11 Minimal trauma fracture 
N331y00 Other specified pathological fracture 
N331z00 Pathological fracture NOS 
Q202.00 Fracture of clavicle due to birth trauma 
Q203.11 Other fractures due to birth trauma 
Q203.12 Other birth fracture 
Q203000 Fracture of humerus due to birth trauma 
Q203100 Fracture of radius or ulna due to birth trauma 
Q203111 Birth fracture of radius 
Q203112 Birth fracture of ulna 
Q203200 Fracture of femur due to birth trauma 
Q203300 Fracture of tibia or fibula due to birth trauma 
Q203400 Fracture of skull due to birth trauma 
Q203y11 Fracture due to birth trauma NEC 
Q203y12 Fracture of nose due to birth trauma 
Q204100 Spine fracture due to birth trauma 
S0...00 Fracture of skull 
S00..00 Fracture of vault of skull 
S00..11 Frontal bone fracture 
S00..12 Parietal bone fracture 
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G.7.5 Identification of Read Codes Related to Failure to Thrive 
 
The following truncated search terms were used to identify Read codes related to 
failure to thrive: ‘thrive, ‘stunt’, ‘grow’, ‘weight’, ‘ftt’. Common code stems were used to 
identify additional relevant codes. A total of 17 relevant codes were identified. The final 
list of included codes is shown in Table G.11. 
 
Table G.11  Read codes related to failure to thrive. 
Read code Code description 
1621.11 Weight static 
1623.00 Weight decreasing 
1625.00 Abnormal weight loss 
1625.11 Abnormal weight loss - symptom 
1627.00 Unintentional weight loss 
1D1A.00 Complaining of weight loss 
22A6.00 O/E - Underweight 
22I2.00 O/E - failure to thrive 
22I5.00 O/E - lack of growth 
22IC.00 Physical growth is cause for concern 
R032.00 [D]Abnormal loss of weight 
R034100 [D]Failure to gain weight 
R034200 [D]Failure to thrive 
R034300 [D]Lack of growth 
R034800 [D]Underweight 
R034900 [D]Non-organic failure to thrive 
ZC2CE00 Dietary advice for failure to thrive 
 
 
 
G.7.6 Identification of Read Codes Related to Hypocalcaemia 
 
The following truncated search terms were used to identify Read codes related to 
hypocalcaemia: ‘hypocalc’, ‘calcium’. Common code stems were used to identify 
additional relevant codes. A total of 7 relevant codes were identified. The final list of 
included codes is shown in Table G.12. 
 
Table G.12  Read codes related to hypocalcaemia. 
Read code Code description 
C354000 Hypocalcaemia NEC 
C354600 Hypocalcaemic tetany 
Q444.00 Neonatal hypocalcaemia 
Q444100 Other neonatal hypocalcaemia 
Q444111 Hypocalcaemic tetany in newborn 
Q444z00 Neonatal hypocalcaemia NOS 
Qyu6200 [X]Other neonatal hypocalcaemia 
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G.7.7 Identification of Read Codes Related to Seizure or Tetany 
 
The following truncated search terms were used to identify Read codes related to 
seizure or tetany: ‘seizure’, ‘fit’, ‘convul’, ‘status’, ‘tetan’. Common code stems were 
used to identify additional relevant codes. A total of 49 relevant codes were identified. 
The final list of included codes is shown in Table G.13. 
 
Table G.13  Read codes related to seizure or tetany. 
Read code Code description 
1B63.00 Had a fit 
1B63.11 Fit - had one, symptom 
1B64.00 Had a convulsion 
1B64.11 Convulsion - symptom 
282..00 O/E - fit/convulsion 
282..11 O/E - a convulsion 
282..12 O/E - a fit 
282..13 O/E - a seizure 
2822.00 O/E - grand mal fit 
2823.00 O/E - petit mal fit 
2824.00 O/E - focal (Jacksonian) fit 
2824.11 O/E - Jacksonian fit 
2824.12 O/E - focal fit 
2825.00 O/E - psychomotor fit 
2828.00 Absence seizure 
282Z.00 O/E - fit/convulsion NOS 
F132z12 Myoclonic seizure 
F250200 Epileptic seizures - atonic 
F250300 Epileptic seizures - akinetic 
F251200 Epileptic seizures - clonic 
F251300 Epileptic seizures - myoclonic 
F251400 Epileptic seizures - tonic 
F251600 Grand mal seizure 
F252.00 Petit mal status 
F253.00 Grand mal status 
F253.11 Status epilepticus 
F254500 Complex partial epileptic seizure 
F255600 Simple partial epileptic seizure 
F25H.00 Generalised seizure 
F25X.00 Status epilepticus, unspecified 
F25y300 Complex partial status epilepticus 
Fyu5200 [X]Other status epilepticus 
Fyu5900 [X]Status epilepticus, unspecified 
Q480.00 Convulsions in newborn 
Q480.11 Fits in newborn 
Q480.12 Seizures in newborn 
R003.00 [D]Convulsions 
R003100 [D]Convulsions, infantile 
R003200 [D]Fit 
R003211 [D]Fit (in non epileptic) NOS 
R003y00 [D]Other specified convulsion 
R003z00 [D]Convulsion NOS 
R003z11 [D]Seizure NOS 
Ryu7100 [X]Other and unspecified convulsions 
C354600 Hypocalcaemic tetany 
Q444111 Hypocalcaemic tetany in newborn 
R017.00 [D]Tetany 
R017000 [D]Carpopedal spasm 
R017z00 [D]Tetany NOS 
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G.7.8 Identification of Read Codes Related to Numbness or Paraesthesia 
 
The following truncated search terms were used to identify Read codes related to 
numbness or paraesthesia: ‘numb’, ‘paraesthes’, ‘tingl’, ‘needle AND pin’. Common 
code stems were used to identify additional relevant codes. A total of 13 relevant codes 
were identified. The final list of included codes is shown in Table G.14. 
 
Table G.14  Read codes related to numbness or paraesthesia. 
Read code Code description 
1B41.00 Has pins and needles 
1B43.00 Has tingling sensation 
1B44.00 Has numbness 
1B44200 Numbness of limbs 
1B46.00 C/O paraesthesia 
1B47.00 Transient paraesthesia 
29B5.00 O/E - paraesthesia present 
29B5000 O/E - paraesthesia in hands 
2G2D.00 Numbness of hand 
G73y600 Acroparaesthesia - unspecified 
R020300 [D]Tingling of skin 
R020600 [D]Numbness 
R020700 [D]Paraesthesia 
 
 
 
 
G.7.9 Identification of Read Codes Related to Abnormal Gait 
 
The following truncated search term was used to identify Read codes related to 
abnormal gait: ‘gait’. Common code stems were used to identify additional relevant 
codes. A total of 5 relevant codes were identified. The final list of included codes is 
shown in Table G.15. 
 
Table G.15  Read codes related to abnormal gait. 
Read code Code description 
2995.00 O/E - waddling gait 
299Z.00 O/E - gait NOS 
R012.00 [D]Gait abnormality 
R012z00 [D]Gait abnormality NOS 
Ryu3200 [X]Other and unspecified abnormalities of gait and mobility 
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G.7.10 Identification of Read Codes Related to Muscle Weakness 
 
The following truncated search terms were used to identify Read codes related to 
muscle weakness: ‘weak’, ‘myopathy’, ‘musc’, ‘power’. Common code stems were used 
to identify additional relevant codes. A total of 5 relevant codes were identified. The 
final list of included codes is shown in Table G.16. 
 
Table G.16  Read codes related to muscle weakness. 
Read code Code description 
1B3..12 Weakness symptoms 
1B32.00 Weakness present 
2832.12 O/E - weakness 
29A2.00 O/E - muscle power reduced 
F397.00 Proximal myopathy 
 
 
 
 
 
G.7.11 Identification of Read Codes Related to Delay in Motor Development 
 
The following truncated search terms were used to identify Read codes related to delay 
in motor development: ‘motor’, ‘delay’, ‘development’’, ‘milestone’, ‘walk’, ‘sitting’, 
‘crawl’, ‘stand’, ‘roll’. Common code stems were used to identify additional relevant 
codes. A total of 8 relevant codes were identified. The final list of included codes is 
shown in Table G.17. 
 
Table G.17  Read codes related to delay in motor development. 
Read code Code description 
16G..00 Unable to stand 
22I3100 Not yet walking 
22I3200 Not yet sitting 
22I3300 Not yet standing 
Eu82.00 [X]Specific developmental disorder of motor function 
R034700 [D]Gross motor development delay 
R034711 [D]Gross motor skills development delay 
R034D00 [D]Motor delay 
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G.7.12 Identification of Read Codes Related to Cardiomyopathy 
 
The following truncated search term was used to identify Read codes related to 
cadiomyopathy: ‘cardiomyop’. Common code stems were used to identify additional 
relevant codes. A total of 11 relevant codes were identified. The final list of included 
codes is shown in Table G.18. 
 
Table G.18  Read codes related to cardiomyopathy 
Read code Code description 
G55..00 Cardiomyopathy 
G554.00 Other primary cardiomyopathies 
G554400 Primary dilated cardiomyopathy 
G554z00 Other primary cardiomyopathy NOS 
G557.00 Nutritional and metabolic cardiomyopathies 
G557z00 Nutritional and metabolic cardiomyopathy NOS 
G55y.00 Secondary cardiomyopathy NOS 
G55y.11 Secondary dilated cardiomyopathy 
G55z.00 Cardiomyopathy NOS 
Gyu5P00 [X]Other cardiomyopathies 
Gyu5S00 [X]Cardiomyopathy in nutritional diseases CE 
 
 
